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ABSTRACT 
The primary aim of this thesis was to increase understanding of the phenomenon of 
nicotine addiction. By combining cognitive, psychosocial, genetic and psycho- 
pharmacological data it was hoped we might achieve a more comprehensive 
understanding of models and mechanisms of smoking behaviour, and particularly the 
role of addiction and withdrawal in tobacco use and effect. The research also aimed to 
bridge the gap between psychology and pharmacology in the nicotine field. 
Experimental work conducted examined responses to nicotine withdrawal and 
reinstatement in humans in terms of mood and cognitive performance, and profiles 
personality and genetic characteristics that may influence the nicotine addiction 
phenomenon. The effect of noradrenergic drugs on tobacco dependence was also 
investigated, to examine how a2-adrenoceptor agonists can influence withdrawal. By 
generating a multidimensional tobacco "Addiction Index" score, it was possible to 
group smokers as addicted or non-addicted. Many of the chapters profile differences 
between these subgroups. For example, addicted smokers were significantly 
characterised by lower latency to first cigarette in the morning and accelerated 
reaction times following 24-hour smoking abstinence compared with non-addicted 
smokers. Addicted smokers were also more likely to report anxiety symptoms both as 
a personality trait and as a response to withdrawal than non-addicted smokers. 
Lofexidine, an a2-adrenoceptor agonist used successfully to manage opiate 
withdrawal; particularly the anxiety component, was shown to reduce overall severity 
of tobacco withdrawal symptoms and mitigate some of the performance deficits 
associated with tobacco withdrawal. Results indicate lofexidine could have a useful 
role either as an adjunct or alternative to nicotine replacement therapy. 
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Introduction 
Chapter I- Introduction to tobacco addiction 
1.1 Why study smoking? 
Chapter I 
Humans have used tobacco as a drug for approximately 2000 years. It is a native plant 
of the American continent, first introduced to Europe in the 15'h Century. Although 
almost always smoked, the way tobacco is used has changed with -time., In Britain, 
tobacco was smoked initially in pipes - particularly during the 16 th and 17 th Centuries. 
In the I 9th century cigars became the most popular means of smoking tobacco, with 
cigarettes becoming the most preferred method in the 20th Century. The use of 
tobacco in Britain peaked in the years of 1945 and 1946 after World War II. It has 
been declining steadily since 1948, with 1998 U. K. smoking prevalence figures of 
28% for men and 26% for women. There is some evidence that smoking prevalence is 
stabilising, although there is a worrying observed trend of increased prevalence 
figures in young women. 
Current thinking suggests that unless cessation rates improve in line with these 
increases, we could witness the first increase of smoking prevalence for several years. 
Most smokers are first exposed to tobacco as children, with many going on to become 
habitual smokers. The mechanisms of smoking initiation are generally accepted to be 
social forces from peers, siblings, parents and teachers; these are all likely to 
contribute to the determination of whether a child will become a regular smoker, i. e. 
at least one cigarette per week (Rowe, Chassin, Presson, Edwards & Sherman, 1992). 
Other risk factors including socio-economic status and educational achievement also 
predict childhood smoker status. However, this thesis will concentrate on aspects of 
smoking persistence rather than initiation. 
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Cigarette smoking causes considerable mortality and morbidity - approximately 
120,000 deaths each year in the UK. For example, in 1997 cigarette smoking 
accounted for 117,400 of the total of 628,000 deaths (Royat College of Physicians 
report, 2000). If these figures are representative, smoking contributes to I in 5 deaths 
in Britain. Although deaths related at least in part to smoking are due to a multitude of 
different conditions, three major disease states account for the majority of mortality: 
these are lung cancer, ischaernic heart disease and chronic obstructive pulmonary 
disease. Aside from these deaths, illness caused by smoking creates a major strain on 
the National Health Service, with many more non-fatal smoking-related hospital 
admissions and GP consultations on top of the 117,000 deaths. No other single 
avoidable cause of disease accounts for such a high proportion of deaths, hospital 
admissions or GP consultations. 
Many physicians regard cigarette smoking as the single most important public health 
problem in Britain. It is also estimated that the difference in expenditure in one year 
(1996-1997) in England between non-smokers and smokers in terms of health care 
costs is fl, 400 million. A further E328 million per year (based on 1991 figures) is 
suggested to be lost to the English economy as a whole due to smoking-related illness 
caused absence from work. Unfortunately there are no more recent figures than these 
regarding this feature of tobacco addiction, however it is likely that this total is now 
considerably higher. 
1.2 Psychopharmacology of nicotine 
Why people smoke is both a challenging psychopharmacological. problem as well as 
an issue of practical concern to health authorities. The pharmacology of nicotine is 
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now understood to be more complex than originally thought. Cigarette smoke is 
composed of volatile and particulate phases. Some 500 gaseous compounds including 
nitrogen, carbon monoxide (CO), carbon dioxide, ammonia, hydrogen cyanide and 
benzene have been identified in the volatile phase, which accounts for about 95% of 
the weight of cigarette smoke; the other 3500 compounds represent the 5% 
particulates (Ashton & Stepney, 1982). The most important particulate is nicotine. 
Other alkaloid particulates found in cigarette smoke include nornicotine, anatabine 
and anabasine. The particulate matter without its alkaloid and water content is called 
tar. Many carcinogens, including polynuclear aromatic hydrocarbons, -N-nitrosan-tines 
and aromatic amines have been identified in cigarette tar. 
It is the nicotine in tobacco that is accepted to be the major psychotropic substance, 
and is essentially responsible for the behavioural effects and addictive nature of 
smoking. Nicotine is a tertiary amine consisting of a pyridine and a pyrrolidine ring 
(left and right respectively in Figure 1.1). There are two stereoisomers of nicotine; 
(S)-nicotine is the active isomer that binds with nicotinic acetylcholine receptors 
(nAChRs), found mainly on cholinergic synapses, and is the naturally occurring 
alkaloid found in tobacco. During smoking, some racernisation takes place, and small 
quantities of (R)-nicotine, a weak agonist of cholinergic receptors, are found in 
cigarette smoke. 
Figure 1.1 Molecular structure of nicotine 
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When inhaled in cigarette smoke, nicotine is quickly and efficiently absorbed from 
the lungs. Once in the bloodstream, nicotine is quickly distributed throughout the 
body, reaching the brain in approximately 15 seconds, where it is temporarily 
concentrated (Russell & Feyerabend, 1978). Thus inhaled puffs of cigarette smoke 
produce intermittent highly concentrated boli of nicotine in the blood - this factor is 
important in determining the actions of nicotine, since similar doses given more 
slowly produces different results in non-human subjects (Armitage et al. 1969). 
Nicotine is primarily metabolised in the liver, with an elimination half-life of 
approximately 2 hours (Benowitz, 1988). There are marked individual differences in 
the rate of metabolism, and the rate appears increased in chronic smokers. The 
question whether this is purely association or some causal link exists has driven 
examinations of genetic differences in cytochrome P450; these are enzymes mainly 
responsible for nicotine metabolism. 
Some pharmacokinetic tolerance to nicotine develops in smokers, but 
pharmacodynamic tolerance is more important in -determining smoking behaviour. 
Pharmacodynamic tolerance develops unevenly in smokers, who become tolerant to 
the emetic and irritant effects of nicotine but still exhibit tachycardia, rise in blood 
pressure, peripheral vasoconstriction, and endocrine and metabolic responses to 
smoking. Some aspects of tolerance appear to decrease rapidly: in chronic smokers 
the first cigarette of the day elicits greater cardiovascular responses than later 
cigarettes, and many smokers say that they get the greatest hedonic effects from the 
first daily cigarette (Ashton & Stepney, 1982; Royal College of Physicians, Tobacco 
Advisory Group, 2000). 
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As stated previously, nicotine's primary pharmacological target is the nicotinic acetyl 
choline (ACh) receptor. The drug exerts a biphasic, dose-dependent 
stimulant/depressant action on these receptors at cholinergid synapses. ' When puffs of 
cigarette smoke are intermittently inhaled, the time/dose relationship of nicotine 
reaching the brain can be such as to produce either stimulant or depressant effects. 
The initial combination of nicotine with the receptor stimulates a response, but 
persistent occupation of the receptors and prolonged effects on the neuronal 
membrane may block further responses (Rowell & Duggan, 1998). The degree of 
stimulation versus block depends on the amount of nicotine present relative to the 
number of receptors available. In general, small doses of nicotine produce principally 
stimulant effects at synapses and larger doses produce mainly depressant effects. At a 
high enough dose, nicotine can block synaptic transmission completely. This is fatal. 
Thus, by varying factors such as the size of puff and depth of inhalation, a smoker can 
obtain predominantly inhibitory or predominantly excitatory effects, or a mixture of 
both, from one cigarette. The ease with which nicotine can produce rapid, reversible 
biphasic effects over a small dose range is probably a major factor determining and 
maintaining the popularity of the smoking habit, despite the well-publicised health 
risks (Ashton & Stepney, 1982). The variety of different effects of stimulation of 
nicotinic receptors may represent functions of the receptors at different locations, or 
different morphology of the receptors themselves. These effects are exerted on many 
brain systems including those involved in arousal, reward,, learning, memory and 
attention (Pornerleau & Pornerleau, 1989). 
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1.3 Nicotinic receptors 
Chapier I 
Nicotinic acetyl choline receptors (nAChRs) are pentamers composed of five 
homologous membrane-spanning subunits around a central ion-channel that have 
distinct but overlapping expression patterns in subsets of neurons. Two cc subunits and 
one each of 0, y and 8 subunits (with a change during development from y to F-) are 
arranged in the order (xy(x8D. The two cc subunits are the primary agonist binding 
subunits. Under normal conditions, opening of the ion channel results in an inward 
flux of Na' producing local depolarisation. After a brief period of being open, the 
nAChR goes through a series of cOnformational changes 'producing a desensitised 
state. In this configuration, the channel is closed to ions and is refractory to activation 
by agonist, although agonist can still bind to the receptor with low affinity. Low 
concentrations of agonist can push the receptor into the desensitised state without 
going through the open state (McGehee & Role, 1995). These properties have 
implications for the functional effects of nicotine during tobacco use. 
Studies using techniques such as in situ hybridization and molecular cloning have 
revealed that multiple subtypes of functional neuronal nAChRs can be formed from 
various combinations of nAChR sub-units, with evidence to suggest that four 
functionally distinct receptor sub-types exist. The majority of high affinity nAChRs in 
the brain comprise the c002 sub-type (Zoli et al., 1998), though there are other 
subtypes present (heteromeric 0 and homomeric 0). Recent reports have attempted 
to associate pharmacological studies detailing the behavioural effects of nicotine with 
molecular and anatomical properties of nAChRs (e. g. Picciotto et al. 2000). 
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There is some evidence that mutant mice bred without the 02-subunit fail to derive 
reinforcement from self-administered nicotine, demonstrated by significantly faster 
extinction compared with wild-type nuce (I icciotto et al. 1998). Further research 
shows serious problems associated with P2-subunit knockout n*e; the cognitive 
deficits associated with ageing appear to be greatly accelerated, and there is evidence 
of depleted numbers of pyramidal neurons and neocortical hypotrophy (Zoli et al. 
1999). It therefore appears that there is minimal, if any practical benefit achieved by 
targeting these nAChR sub-types, since the nicotinic system appears to suffer more 
generalised malfunctioning. 
In comparison to muscarinic receptors, neuronal nAChRs are expressed in relatively 
low density in the human brain. In addition, their pattern of distribution is relatively 
homogenous and is not restricted to the well-defined brain cholinergic pathways. 
Studies using chicks and rats have characterised the neuroanatomical distribution of 
the various nAChR subtypes in these species, but - there arejew studies cxa*ipg 
human nAChR distributions. 
Attempts to examine these details have focussed on ligand binding studies showing 
distribution of nicotinic receptors, and in situ hybridisation techniques showing 
distribution of nAChR subunit mRNA in the human brain. Breese et al. (1997) and 
Hellstrbm-Lindahl (1999) have concentrated on 0, a4,0,02 mRNA, with just one 
study examining 0 and 03 and 04 distribution in the post mortem human brain 
(Hellstr6m-Lindahl et al. 1998). High levels of [3H] nicotine binding is found in 
thalamus, caudate nucleus and substanstia nigra, with moderate density found in 
frontal cortex parietal cortex and low density found in occipital cortex, temporal 
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cortex, hippocampus and cerebellum (Adem et al., 1987; Nordberg et al., 1988 and 
Perry et al., 1992). 
Generally, exposure to agonists of a particular receptor produces down-regulation and 
exposure to antagonists produces receptor up-regulation, but this is not observed with 
nicotinic receptors. Research suggests that long-term exposure to nicotine results in 
increased numbers of nicotinic receptors in the brain of several species, including 
man. Post-mortem binding studies have shown increased [3H]nicotine and ACh 
binding sites in the brains of smokers compared to non-smokers with a dose 
dependent correlation observed between the number of cigarettes smoked and the 
increased number of binding sites (Benwell et al., 1988; Breese et al., 1997). 
It is proposed that the desensitisation and up-regulation of nAChRs following chronic 
nicotine exposure is the basis of tolerance to nicotine displayed by smokers as well as 
being influential in producing withdrawal symptoms on cessation of smoking 
(Benwell et al., 1988; Balfour & Fagerstrom, 1996; Dani & Heinemann, 1996). The 
rationale behind nAChR up-regulation is thought to lie in their rapid desensitisation 
and consequent inaction following chronic agonist exposure, putatively resulting in a 
deficit in cholinergic function, which is then counteracted by an increase in receptor 
number (Schwartz & Kellar, 1985; Rowell & Duggan, 1998; Reitstetter et al., 1999). 
There has been some imaging of nicotinic receptors with PET (Positron Emission 
Tomography) and SPECT (single photon emission computed tomography). These are 
both methods for imaging the regional distribution of radioactive tracers labelled with 
positron emitting radionuclides. These techniques have been successfully used to map 
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the binding and distribution of nicotinic receptors, allowing in vivo investigations. 
This is of considerable interest when examining involvement of these receptors in 
pathology of neuro-degenerative disorders like Alzheimer's and Parkinson's disease, 
and pathological conditions such schizophrenia, depression, epilepsy, and implication 
in neuropsychological processes such as learning and memory. It is hoped that studies 
of this nature may also provide insight into the neurobiology of nicotine addiction. 
1.4 Effects of nicotine on brain activity 
Electrophysiology studies have shown a variety of nicotine effects on brain activity. 
Small doses of intravenous nicotine or puffs of cigarette smoke introduced into the 
nostrils or lungs cause behavioural. and EEG (electroencephalogram) arousal in 
sleeping animals (Hall, 1970; Domino, 1979). An ACh antagonist, mecamylamine, 
can block these EEG changes (Stolerman et al. 1973). Electrocortical arousal caused 
by cigarette smoke or intravenous nicotine in humans is accompanied by increased 
output of ACh from the cortex (Armitage et al 1969). Both smoking and intermittent 
intravenous shots of nicotine can also increase the magnitude of cortical evoked 
potentials (Ashton et al. 1980; Knott 1989). 
Under certain conditions smoking and nicotine may decrease the level of arousal, 
providing further evidence for a biphasic action of the drug. Am-titage et al. (1969) 
showed that some doses could cause slowing of EEG activity and a fall in cortical 
ACh output in anaesthetised cats. Mangan & Golding (1978) demonstrated in human 
smokers that under conditions of mild stress, induced by white noise, smoking 
increased the amount of slow alpha activity in the EEG. Ashton et al. (1980) found 
that the effect of nicotine on the slow cortical evoked potential was dose-dependent, 
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with small doses causing a stimulant effect but larger doses producing a depressant 
effect. These experiments demonstrate that smoking can both decrease and increase 
arousal, at least partly through its effect on cholinergic arousal systems. 
There seems to be an interaction between dose, personality and environment that ý 
determines which effect predominates. Smokers can manipulate their nicotine dosage 
to obtain the desired effect in particular circumstances (Ashton & Watson, 1970; 
Ashton et al. 1974,1980; Armitage et al. 1968). Smokers themselves report that the 
subjective effects of smoking can be either stimulation or relaxation, and there is 
considerable evidence (e. g. Ashton & Stepney, 1982) that smokers self-regulate their 
nicotine intake when smoking cigarettes of different strength. 
1.5 Behavioural effects of nicotine 
1.5.1 Nicotine effects on cognition 
Although a large number of studies have examined the effects of smoking or nicotine 
on human cognitive performance, a number of issues need to be taken into 
consideration. Interpretation of these effects of nicotine depends on whether a study 
tests subjects who smoke under conditions of deprivation or non-deprivation. It is 
now understood that nicotine can reverse deprivation-induced impairments of mental 
performance (e. g. Heishman, Taylor & Henningfield, 1994), but true or absolute 
enhancement of performance can be demonstrated most effectivelY in non-deprived 
smokers or non-smokers (e. g. Heishman, 1998). These models of nicotine effect'are 
often referred to as the "resource" model, purporting absolute benefits of nicotine, and 
the "withdrawal reversal" model, contending that nicotine only has positive effects 
relative to the impairments caused by tobacco withdrawal. 
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1.5.1.1 Nicotine effects on psychomotor performance 
Chapter I 
In general, smoking or nicotine produces motor activation, such that locomotor 
activity in tolerant animals is increased (Clarke & Kumar, 1983), and in non-smoking 
humans, finger-tapping rate is increased (West & Jarvis, 1986; Perkins et al. 1990). 
Perkins et al. (1994) reported that lower nicotine doses increased and higher doses 
decreased finger-tapping rate. Perkins et al. (1994) explained their finding of 
decreased response rate at higher doses by suggesting that elevated doses of nicotine 
cause blockade of peripheral ganglia. 
Heishman & Henningfield (2000) argue that ganglionic blockade would be unlikely in 
the absence of overt signs of nicotine overdose. Heishman & Henningfield (2000) 
found that an 8 mg dose in nicotine gum impaired non-smokers performance on a 
'circular lights' motor coordination task. They explain both their own and Perkins et 
al. 's (1994) findings as being secondary to increased dysphoria observed with giving 
non-smokers high doses of nicotine. However, Foulds, Stapleton, Swettenham, Bell, 
McSorley & Russell (1996) found no effect of subcutaneous injections of 0.3mg or 
0.6mg nicotine on psychomotor performance in non-smokers. Perkins et al. (1994) 
also replicated earlier findings that finger-tapping rate is reliably increased by nicotine 
in overnight abstinent smokers. Research thus far therefore suggests nicotine has true 
positive effects on psychornotor perfonnance. 
1.5.1.2 Nicotine effects on attention 
Nicotine has been shown to accelerate reaction time in abstinent smokers during tests 
of focused attention. Bates, Mangan, Stough & Corballis (1995) showed that smoking 
decreased decision time in a choice reaction time task in 2-hour deprived smokers. 
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Houlihan, Pritchard & Robinson (1996) reported nicotine producing faster reaction 
times in visual and auditory "oddball" tasks in 12-hour deprived smokers. 
Furthermore, a study of non-smokers showed that subcutaneous nicotine increased the 
number of fast reaction times (but not accuracy) in an information processing task (Le 
Houezec, Halliday, Benowitz, Callaway, Naylor & Herzig, 1994) 
Nicotine has fewer robust effects on performance in tests of selective attention. It has 
been shown to reverse impairments on these tasks in deprived smokers (e. g. 
Heishman, 1994), but has few positive observed effects on non-smokers. The Stroop 
task (Stroop, 1935) is a classic test of distractibility. Studies using this task have 
examined abstinent smokers and non-smokers, and shown that nicotine either has no 
effect on performance (Foulds et al. 1996) or accelerated response time to both 
distracting and control stimuli (Perkins et al. 1994). 
Nicotine has been most convincingly shown to improve performance in tasks 
requiring vigilance and sustained attention, particularly in tests of rapid visual 
information processing (RVIP) (e. g. Wesnes & Warburton 1984; Koelega, 1993). It 
has been shown that nicotine improves RVIP accuracy in abstinent smokers both by 
subcutaneous injection (Foulds et al. 1996) and cigarette smoking (Gilbert, Estes & 
Welser, 1997). Smoking has also been shown to increase processing rate in a subject- 
paced version of the task (Baldinger, Hasenfratz & Battig, 1995). In an early study, 
Wesnes & Warburton (1984) found improved RVIP performance in non-smokers 
following nicotine tablet adn-dnistration. This has not been well replicated, although 
Foulds et al. (1996) reported faster reaction time and increased accuracy in non- 
smokers after subcutaneous nicotine. 
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Furthermore, nicotine has been shown to improve performance in non-smokers in a 
flight simulator (Mumenthaler, Taylor, O'Hara & Yesesage, 1998). In non-deprived 
smokers, subjects performing a driving simulation displayed decreased braking time 
and improved tracking following smoking. Warburton & Arnall (1994) reported that 
smoking a cigarette produced similar improvements in RVIP performance whether the 
smokers were deprived of nicotine for one or 12 hours, and similar results have been 
obtained using a nicotine patch (Warburton & Mancuso, 1998). 
The modicum of evidence regarding several absolute performance-enhancing effects 
of nicotine is broadly consistent with animal studies (Mirza & Stolerman, 1998; Levin 
& Simon, 1998). In a recent study, Hahn, Shoaib & Stolerman (2002) found that 
nicotine improved accuracy and reduced omission errors and reaction times in rats on 
a five-choice serial reaction time task. 
1.5.1.3 Nicotine effects on memory and learning 
Learning and memory are affected by the level of arousal and appear to involve 
cholinergic pathways. Nicotine and smoking have been shown to affect some learning 
and memory processes in animals and man. For example, Coleman & Flood (1987) 
reported that nicotine improved memory consolidation, and Alpern & Jackson (1978) 
observed complex dose-dependent biphasic effects of nicotine on a variety of stages 
of the memory process in mice. 
Armitage, Hall & Morrison (1968) found that nicotine could increase the rate of 
learning of reward or avoidance tasks in rats, depending on the dose and time after 
injection. In humans, the effects of smoking on learning and memory are complex, 
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dose-related and biphasic. Studies have shown that nicotine improved recognition 
memory in smokers abstaining overnight (Foulds et al. 1996; Perkins et al. 1994). 
Early studies suggest smoking improves selective attention and memory 
consolidation, while not affecting or slightly impairing initial learning (Andersson, 
1975; Mangan & Golding, 1978; 1983; Andersson & Hockey, 1977; Wesnes & 
Warburton, 1978; Williams, 1980; Ney et al. 1989). However, Rusted, Graupner & 
Warburton (1995) reported that smoking prior to list presentation enhanced word 
recall, whereas post-list smoking had no effect on intentional free recall. 
Studies examining non-smokers showed that nicotine improved recognition memory 
dose-dependently (Perkins et al. 1994), and enhanced response time but decreased 
accuracy in a digit recall task (Foulds et al. 1996; Heishman & Henningfield, 2000). 
Recent research suggests that the observed memory enhancements following nicotine 
may be a bi-product of the attentional improvements. This theory is supported by 
findings that'explicit effortful processing of material in the presence of nicotine is 
necessary for improved recall performance to be observed (Rusted, Graupner, 
Tennant & Warburton, 1998). 
1.5.2 Nicotine effects on mood and arousal 
Gross escalation of nicotine dosage does not occur in smokers. Since the rewarding 
effects of nicotine are probably derived from a combination of stimulant and 
depressant actions, and most smokers seek both these effects, they may be forced into 
maintaining a medium dosage, although addicted smokers are observed consurning 
between 10 and 80 cigarettes per day. This fine balance between stimulant and 
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sedative effects may contribute considerably to the tobacco habit. Subjects can obtain 
mild hedonic effects of the nicotine without the disruption of performance or after- 
effects that occur with other dependence-producing drugs. In fact, performance may 
be improved, as discussed above, and nicotine from cigarette smoke can be delivered 
in a controlled dosage to allow the subject to regulate his or her psychological comfort 
and performance in a way that is optimal in a range of environments (Ashton & 
Golding, 1989). 
Mangan & Golding (1978) present an arousal modulation theory of smoking. They 
broadly proposed that smoking is an activity that has the function of controlling 
arousal, i. e. the smoker smokes to increase arousal when bored or fatigued, and to 
reduce arousal when tense or stressed. Their theory is an attempt to integrate these 
paradoxical biphasic psychological effects; that smoking can lead to either increased 
cortical arousal or to reduced stress and emotional calming (Ashton & Golding, 
1989). 
The effects of nicotine on electroencephalography (EEG) profiles are discussed in 
section 1.4, however they provide evidence that smoking can lead to heightened 
arousal (e. g. Church, 1989). In contrast, smoking deprivation leads to changes 
indicative of reduced cortical arousal (Knott & Venables, 1977). Smoking produces 
an array of sympathornimetic changes leading to heightened arousal including 
increased heart rate, vasoconstriction, raised blood pressure and increased serum 
adrenaline (Herxheimer, 1967; Domino, 1973; Hill & Wynder, 1974). The 
improvements to cognitive performance discussed previously could also be 
interpreted as evidence of heightened arousal. 
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Several questionnaire studies examining motives for smoking havefound that many 
smokers report smoking for stimulation. These "stimulant" smokers report lighting up 
when they feel fatigued, bored or need to concentrate (Frith, 1971; Russell, Peto & 
Patel, 1974). 
Evidence also exists that smoking can reduce subjective feelings of stress. Reviewing 
the effects of smoking on emotion, Gilbert & Wesler (1989) concluded that "nicotine 
reduces anxiety and negative affect in chronic smokers". When viewing a stressful 
film, smokers' ratings of anxiety were significantly lower when they were allowed to 
smoke than when they were not (Heimstra, 1973). Ward, Green & Horn (1969) and 
Russell et al. (1974) performed questionnaire studies examining motivations for 
smoking, and one of the primary factors in the structures of both studies was for 
"sedative" smoking; i. e. smoking for stress or negative affect reduction. 
Approximately 80% of smokers report using cigarettes when they feel stressed or 
anxious (Russell et al. 1974; Warburton, 1988). 
Other research has failed to find mood-enhancing effects of smoking or nicotine. 
Meliska & Gilbert (1991) examined overnight abstinent smokers changes in mood 
ratings over a morning when they smoked either five medium-nicotine or five 
nicotine-free cigarettes. Of the 19 scales they utilised only "drowsiness" showed 
significant improvement; nicotine cigarettes reduced these ratings compared with 
nicotine-free cigarettes. 
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The arousal modulation theory suggests that these psychological changes (increased 
alertness, decreased negative affect) are interdependent, with cigarettes sometimes 
being used to acquire one effect or the other. Thus, stimulant smokers tend to report 
smoking in order to increase arousal, while sedative smokers generally smoke to 
reduce feelings of stress or anxiety. "Sedative smokers, who smoke under conditions 
of high arousal in order to decrease arousal; and stimulant smokers, who prefer to 
smoke under conditions of low arousal in order to increase arousal" (Suraway & Cox, 
1987) 
Nicotine can stimulate the release of many different neurotransmitters implicated in 
mood and arousal, including glutamate, GABA, ACh, dopamine, noradrenaline and 5- 
HT (Lu, Marks & Collins, 1999; Wonnacott, Irons & Rapier, 1989; Grady & Marks, 
1992; McGehee, Heath & Gelber, 1995; Marshall, Redfem & Wonnacott, 1997; Lu, 
Grady & Marks, 1998; Grady & Meinerz, 2001). Some of these effects potentially 
reduce activity in neuroanatornical structures associated with stress or anxiety (e. g. 
the locus coeruleus). Such an effect would tend to allay unpleasant subjective 
emotions such as anxiety, fear, frustration, and anger. Situations that give rise to these 
emotions have been shown to be those that increase the intensity of smoking in 
smokers. Schachter et al. (1977) noted an increase in the number of cigarettes under a 
high anxiety condition induced by electric shocks, and Mangan & Golding (1978) 
found an increase in the number and 'strength' of puffs when smokers were stressed 
by white noise. A similar relationship between stress and smoking intensity has been 
shown in questionnaire studies (e. g. Thomas, 1973). 
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Nicotine has been shown to attenuate the disruptive effects of stress on performance 
in several animal tests (e. g. Nelsen, 1978). Aggressive behaviour also appears to be 
modified by nicotine and smoking. Nicotine has been demonstrated to reduce 
aggressive behaviour in animals (e. g. Berntson et al. 1976), and Heimstra (1973) 
found that subjects allowed to smoke during a6 hour vigilance task did not increase 
their ratings of aggression while deprived-smokers and non-smokers did. 
Additionally, Dunn (1978) reported that smoking prevented the disruption in 
performance caused by frustration in a complex perceptual motor task, although it is 
unclear whether these were both simply common elements of the tobacco withdrawal 
syndrome. 
More recent research examining nicotine effects on anxiety and depression in both 
humans and animals suggests that the drug can be anxiolytic or anxiogenic depending 
on the anxiety model tested, the route of nicotine administration and the time course 
of administration (e. g. Picciotto, Brunzell & CaIdarone, 2002). It is suggested that the 
broad expression of nAChRs throughout the brain, the large variety of nAChR 
subtypes and ability of nicotine to both activate and desensitise nAChRs explains the 
paradoxical effects of nicotine on emotional state (Picciotto et al. 2002). 
Parrott (1998) challenges the view that arousal and emotional state are interdependent, 
citing psychological mood research (Mathews, 1990) showing that two distinct non- 
correlating factors emerge from standardised mood questionnaires; these were tense 
arousal (potentially representing negative affect) and energetic arousal (potentially 
representing positive affect). Parrott (1998) suggests it - is perfectly normal for 
individuals to feel mentally alert and relaxed, or tired and irritated for example. it may 
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therefore be the case that by affecting different neurotransmitters or nAChRs nicotine 
can produce an array of simultaneous mood effects. In terms of negative affect 
reduction, it seems most likely however that the belief that smoking improves mood 
develops from the repeated experience of mood worsening during periods of 
abstinence (via nicotine withdrawal), rather than from a consistent effect of smoking 
improving mood above baseline (non-smoker) levels (Pomerleau & Pomerleau, 
1990). 
1.6 Definitions of terms associated with addiction 
The terms "addiction" and "dependence" are essentially interchangeable in practice, 
and will be used interchangeably throughout this thesis. Under current definitions, 'the 
terms refer to "a situation in which a drug or stimulus has unreasonably come to 
control behaviour" (American Psychiatric Association, 1995). 
The prevalent view of drug dependence holds that repeated exposure to certain 
psychoactive substances leads to neuroadaptations. These initiate a cycle of increasing 
tolerance and increasing self-administration until an asymptote is eventually reached 
(Alexander & Hadaway, 1982). Interruption of this cycle, by withholding the drug or 
alternatively blocking its action causes disequilibria, resulting in characteristic signs 
and symptoms, called a withdrawal syndrome, which can be relieved by taking the 
drug again. These symptoms should be temporary because after a period of sustained 
abstinence the body should revert to a "normal", drug-free state (West & Gossop, 
1994). 
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In several ways, nicotine addiction fits this model very well. The development of 
smoking behaviour often follows a pattern of- initiation, followed by increased 
smoking, ultimately reaching a point where plasma nicotine levels are maintained (or 
"regulated") within characteristic lin-iits according to the individual (Russell & 
Feyerabend, 1978). Pornerleau et al. (1983b) propose that once inaugurated, these 
patterns of smoking are extremely resistant to change, and when interrupted result in a 
powerful desire to smoke, and withdrawal. 
Smoking to obtain nicotine meets standard diagnostic criteria for addiction. 
Comparable criteria for substance dependence in DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders, Version Four; American Psychiatric Association, 1995) 
and ICD-10 (International Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision; World Health Organisation, 1998) both readily 
characterise tobacco dependence. The ICD-10 features: Strong desire to use the drug 
(potentially "craving"), difficulty in controlling use (difficulty cutting down or 
quitting), spending time obtaining, using or recovering from effects (although readily 
available, smokers often have to spend time somewhere specifically for smoking). 
Other ICD-10 criteria are: use of drug is given higher priority than other activities or 
obligations (this is less applicable to smoking), continued use despite harmful 
consequences (most smokers are aware of the health risks, hence their desire to stop 
(Freeth, 1998)), tolerance (manifested by absence of nausea or dizziness on use), and 
withdrawal (relieving this syndrome is a major motive for persistence; see later 
section). Hughes, Gust & Pechacek (1987) suggest the majority of smokers meet 
diagnostic criteria for tobacco dependence. 
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Given what is known about tobacco, it is unsurprising that a majority of individuals 
who smoke are dependent on nicotine and have considerable difficulty reducing or 
curtailing use (Hughes et al. 1987). However, 5% to 10% of the smoking population, 
referred to as tobacco "chippers", smoke fewer than five cigarettes a day, and these 
smokers do not exhibit characteristic features of nicotine dependence (Shiffman, 
1989). This challenges traditional notions of drug dependence as an inevitable 
consequence of repeated exposures to an inherently addictive drug (Shiffman, 1991; 
Shiffman et al. 1994). 
1.7 Neurobiology of nicotine addiction 
Nicotine has reinforcing effects that have been demonstrated in animals. Specific 
doses enhance intracranial self-stimulation and animals will self-administer nicotine 
(Jarvik, 1967). In humans, smoking is reported to be pleasurable by nearly 90 percent 
of chronic smokers and has positive effects on mood, although it clearly does not 
produce a 'high' comparable with that of many other drugs of dependence. In addition 
it reduces pain and anxiety in stressful situations (Pomerleau et al. 1984). Hall & 
Turner (1972) demonstrated that nicotine increases the release of dopamine and 
noradrenaline from limbic areas and the hypothalamus in animals; these phenomena 
may be the basis for its rewarding effects. In addition, nicotine may interact with 
opioid reward systems (Karras & Kane, 1980), and smoking has been shown to 
increase plasma concentrations of beta-endorphin-beta-lipotrophin in humans 
(Pomerleau et al. 1983a). 
As discussed below, the dopamine system has been strongly implicated in nicotine 
addiction, but is not believed to be exclusively responsible for the behavioural effects 
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of nicotine. Animal studies involving microinjections to other brain structures have 
elicited behaviours associated with nicotine addiction (e. g. Iwamoto, 1990), though 
there may be indirect involvement of mesolimbic dopaminergic sites. Whether a 
unitary circuit mediates addictive behaviours observed with nicotine or whether 
multiple mechanisms exist via selective neuroanatomy has not been adequately 
addressed. It is also unclear whether actions of nicotine at a single high-affinity 
binding site can account for all its behavioural and addictive effects. 
1.7.1 'Doparnine hypothesis' of nicotine addiction 
Nicotine is a powerful reinforcer, which may be due to its indirect stimulation of 
dopamine release (Reavill, 1990). The discovery of nicotinic receptors in the ventral 
tegmental area (VTA) of the mid-brain, which activates the ascending mesolimbic 
doparnine system, was an important finding in understanding the neurobiology of 
nicotine addiction (Nisell et al., 1994a; 1994b). Small concentrations of nicotine, 
similar to those in the plasma of cigarette smokers, selectively enhance the release of 
dopamine in the nucleus accumbens in vitro (Rowell et al. 1987). Studies using 
microdialysis and voltarnmetry have reported similar effects in the nucleus accumbens 
in vivo after systemic adn-ýinistration of nicotine (Imperato et al. 1986; Brazell et al. 
1990). Doparnine is released when nicotine is infused directly into the nucleus 
accumbens (Mifsud et al. 1989). The receptors involved may correspond to the high- 
affinity binding site for nicotine, and the lack of tolerance to the effect suggests it may 
be relevant to the positive reinforcing and discriminative stimulus properties of 
nicotine. 
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All drugs of abuse appear to stimulate doparnine release in the shell area of the 
nucleus accumbens rather than the core (Pontied et al. 1996; 1998). Nicotinic 
receptors are located on both the terminal membranes in the nucleus accumbens and 
on the cell body membranes of the dopamine-secreting neurons in the mid-brain that 
innervate the nucleus (Clarke & Pert, 1985). There is evidence that responses to 
nicotine injections (either intravenous or subcutaneous) are predominantly mediated 
by the receptors located on the cell bodies in the mid-brain, although receptors on 
terminals may also contribute to resultant dopamine release (Benwell et al. 1993). 
Nicotine self-adrninistration in animals is significantly attenuated by doparnine 
antagonists (Corrigall & Coen, 1991) and by lesions of dopamine-containing neurons 
of the nucleus accumbens (Corrigall et al. 1992). As discussed previously, there is 
evidence that mice lacking the 02 subunit of the nicotine receptor are impaired in 
terms of both operant nicotine self-administration patterns and subsequent doparnine 
release. These findings are evidence that nicotine's action on dopamine pathways is a 
major contributor to nicotine self-administration. 
Addiction is widely accepted to be a result, in part, of chronic or repeated exposures 
to a drug. Therefore the ways in which brain responses are influenced by chronic 
exposure may be essential to understanding the neurobiology of addiction. Animal 
studies using in vivo microdialysis have suggested that repeated administration of 
amphetamine or cocaine results in sensitisation to their effects on dopamine release in 
the nucleus accumbens (Kalivas, et al. 1993). Robinson & Beffidge (1993) have 
postulated that this sensitisation may have a central role in the development of 
addiction; particularly that sensitisation of the pathway may facilitate the way in 
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which behaviours associated with obtaining the drug are learned, and with the process 
by which 'drug-liking' becomes 'drug-wanting'. The latter term may represent what is 
commonly referred to as "craving". 
Crucially, repeated injections of nicotine have also been demonstrated to result in 
sensitisation of effects on dopamine release in the nucleus accumbens (Benwell & 
Balfour, 1995). The mechanisms underlying this sensitisation response to repeated 
exposure are yet to be clearly defined. It would appear co-stimulation of the NMDA 
glutamatergic receptor is involved, since both the development and expression of the 
sensitised clopamine response are attenuated or abolished by the adn-ýinistration of 
NMDA receptor antagonists (Shoaib et al. 1994; Balfour et al. 1996). Co-stimulation 
of NMDA receptors has also been implicated in the mechanisms underlying 
sensitisation to other psychostimulant drugs of abuse, and is probably associated with 
an increase in the burst firing of neurons (Kalivas et al. 1993; Overton & Clark, 
1997). 
Neurochernically selective 6-hydroxydoparnine lesions of the mesolimbic doparnine 
system weaken both the self-administration and the locomotor activity produced by 
nicotine in rats. Doparnine receptor antagonists selective for the DI receptor can 
block place preference (a drug-seeking behaviour test technique) produced by 
nicotine, although this has not been demonstrated conclusively (Acquas et al. 1989). 
Microinjection studies show that the nucleus accumbens may also mediate other 
effects such as locomotor activation or depression (e. g. Welzl et al. 1990). Reavill & 
Stolerman (1990) found that nicotine increased locomotor activity when infused into 
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the ventral tegmental area; further evidence for the involvement of the mesolimbic 
dopamine system. 
The above research exan-ýining the role of mesolimbic dopan-ýine pathways in nicotine 
addiction are almost entirely based on animal studies. There is some circumstantial 
evidence that the conclusions also apply to the reinforcing effects of nicotine in 
tobacco smoke, in that administration of haloperidol, a dopamine antagonist, increases 
smoking in habitual smokers (Dawe et al. 1995). Furthermore, bromocriptine (a 
D2/D3 dopamine agonist) has been shown to reduce the mean duration of puffs, 
number of puffs and number of cigarettes smoked. Subjects receiving bromocriptine 
also reported less craving for cigarettes (Jarvik et al. 2000a). 
Mecarnylan-ýine blocks the effects of ACh at nicotinic receptors and also blocks the 
positive reinforcing effect of nicotine in humans and animals. Correlations have been 
reported between the ability of drugs to produce the nicotine discriminative stimulus 
(a behavioural science technique aiming to induce selective operant conditioning), 
and their action at the high-affinity binding site for [3 H]nicotine, although ligand- 
binding studies have not directly correlated the reinforcing effect with action at 
central nicotinic receptors. 
It is important to remember that tobacco-smoking habits are heterogeneous and that 
people smoke cigarettes at varying frequencies 'and in -different ways. Regular 
smoking results in the accumulation of nicotine in blood plasma during the 'smoking 
day'. The nicotine levels fall during sleep as the drug is metabolised and cleared from 
the body (e. g. Benowitz et al. 1987). Prolonged exposure to nicotine has been shown 
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to cause desensitisation of many of the neuronal nicotinic receptors. Pidoplichko et al. 
(1997) have demonstrated that plasma concentrations of nicotine commonly found in 
habitual smokers during the day are sufficient to desensitise nicotinic receptors on the 
mesolimbic dopamine neurons. As a result, the administration of a nicotine bolus no 
longer causes increased doparnine in the nucleus accumbens (Benwell et al. 1995). 
These findings create significant problems for the 'dopamine hypothesis' of nicotine 
addiction. They suggest that many smokers may continue smoking under conditions 
whereby nicotine is unlikely to stimulate the mesoliffibic dopan-ýine neurons, and that 
other neural mechanisms must presumably also contribute to the 'rewarding' 
properties of the drug that reinforce addiction. For those who smoke infrequently, 
significant peaks and troughs of nicotine levels may be observed (Russell, 1990). If 
nicotine concentration in the 'trough' falls below that required to desensitise the 
nicotinic receptors on mesolimbic doparnine neurones, each cigarette will be 
rewarded with increased dopan-ýine release. For these smokers, stimulation of 
doparnine release is likely to be the predominant mechanism underlying addiction to 
nicotine. 
Non-addicted smokers or chiPpers (q. v. ) may therefore receive a greater acute 
dopamine effect from tobacco smoking than addicted smokers. This would clearly 
present problems for a definitive dopamine hypothesis of tobacco dependence. The 
motivating factors for the two groups may therefore be very different 
psychopharmacologically. Potentially addicts generally smoke in order to avoid 




1.7.2 Noradrenaline and nicotine addiction 
Chapter I 
Nicotine has been shown to both increase and decrease noradrenergic activity. It is 
suggested that increased noradrenaline following nicotine adrninistration is partly 
responsible for the stimulant effects of the drug. Conversely, receptor desensitisation 
occurring on noradrenergic neurons may contribute to the subjective anxiolytic 
experience of smoking. 
It has been argued that receptor desensitisation may be the response that is reinforced 
in frequent or heavy smokers (Balfour & Fagerstr6m, 1996). For example, nicotinic 
receptors located on noradrenaline-secreting neurons are desensitised by nicotine 
concentrations comparable to those found in the plasma of many smokers (Benwell & 
Balfour, 1997). This may contribute to the tranquillising properties of tobacco smoke 
often reported by smokers exposed to environmental stressors. Since nicotine exerts 
its effects by acting at a family of nicotine receptors, it is possible that other neural 
responses, mediated by receptors more resistant to desensitisation may also play a role 
in nicotine addiction. 
Wonnacott (1990) describes animal studies that demonstrate an increase in high- 
affinity receptor density when they are chronically exposed to nicotine levels large 
enough to cause a desensitisation of catecholamine responses to the drug. This 
increased density seems to reflect a decreased turnover of the receptor complex 
(Marks et al. 1992; Peng et al. 1994), however the psychopharmacological 
significance of this effect remains unclear. It is unlikely that the increased receptor 
density accounts for the desensitisation to nicotine discussed above because up- 
regulation of the receptors is not observed with dosing regimens that elicit the 
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sensitised doparnine responses (Benwell & Balfour, 1985). The increase in receptor 
density may still be significant to the mechanisms underpinning nicotine addiction 
since they are also observed in brain tissue taken from humans who have been 
habitual smokers (e. g. Benwell et al. 1988). 
Bupropion, an atypical anti-depressant prescribed for aiding smoking cessation has 
both doparninergic and noradrenergic actions. Clonidine, an a2-adrenoceptor agonist 
has also been found to be effective in helping to quit smoking. The effects of these 
drugs in reducing noradrenergic activity may be reducing the intensity of the 
withdrawal syndrome, perhaps in a similar way to anti-noradrenergic treatments of 
opiate withdrawal (Gourlay & Benowitz 1995) (see section 1.7.2). 
If nicotine does have true caMng or anxiolytic effects, some of the above treatments 
may also replace the putative direct effects of nicotine on noradrenergic systems. 
However, most experimental work would predict the opposite effect. Animal studies 
using microdialysis demonstrate that nicotine administration into the cerebral 
aqueduct leads to dose-dependent increases in noradrenaline levels in the 
hypothalamus, resulting in increases in levels of stress hormones (Sharp & Matta, 
1993; Fu et al. 1997). Systemic administration of nicotine also results in increased 
levels of noradrenaline in the arnygdala and hippocampus (Fu et al. 1998), limbic 
structures known to regulate central mechanisms affecting stress hormone response 
(Feldman & Weidenfeld, 1996). Clarke & Reuben (1996) report that nAChRs that 
mediate noradrenaline release are pharmacologically distinct from those that mediate 
dopan-ýne release. 
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The locus coeruleus (LQ is a structure rich in noradrenaline-secreting neurons and 
implicated in fear and anxiety responses. Una et al. (1999) investigated nAChRs 
distribution in LC and found two types of neurons in this body expressed different 
receptor subtypes. Type A LC cells, that are small in size but have large nicotinic 
currents expressed 0 and 04 subunits. Type B cells, corresponding to the 
predominant noradrenergic projection neurons to the hippocampus, express P2, a4, a6 
and P3 subunits. Una et al. (1999) also found a5 and 0 subunits expressed in LC 
neurons. Their study suggests that nicotine can activate Type A and B cells with 
differential kinetic and desensitisation properties. This may explain some of the 
paradoxical effects of nicotine in terms of mood, arousal and withdrawal effects. 
Post-mortem studies demonstrate a relationship between chronic nicotine use and 
changes in noradrenergic neurobiology. Klimek et al. (2001) compared LC tissue 
radioligand binding in long-term smokers and non-smokers. They found that binding 
to a2-adrenoceptors was significantly lower along the axis of LCs of long-term 
smokers compared to non-smokers. They interpret their data as showing that long- 
term smoking down-regulates a2-adrenoceptors in the LC. They also comment that 
putative smoking-induced effects are widespread in the LC and not delimited to a 
specific sub-region, suggesting extensive effects of cigarette smoking on 
noradrenergic activity in the CNS. As the authors conclude, however, it is not possible 
to assert whether smoking actually causes these down-regulations in a2-adrenoceptors 
or whether a relative paucity of these receptors, possibly genetically mediated, 
predisposes individuals to tobacco addiction. 
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1.7.3 Chronic nicotine administration and 5-hydroxytryptamine 
Chapter I 
Anxiety is a withdrawal effect of nicotine abstinence, and believed to be mediated, at 
least in part, by 5-hydroxytryptamine systems. Animal studies suggest that chronic 
nicotine exposure causes repeated or prolonged reductions in demand for 5-HT in the 
hippocampus (Benwell & Balfour, 1979) by reducing the concentration and ability to 
synthesise 5-HT in appropriate terniinals in the structure (Benwell & Balfour, 1982; 
Ridley & Balfour, 1997). 
Human post-mortern studies have shown that habitual smoking is associated with a 
regionally-selective reduction in the concentration of 5-HT and its principal 
metabolite, 5-hydroxyindole acetic acid, in the hippocampus; this is not observed in a 
majority of the other areas of the brain that have been studied (e. g. Benwell, Balfour 
& Anderson, 1990). Comparing this with the animal data, it seems reasonable to 
suggest that nicotine in tobacco smoke mediates a reduction in formation and release 
of hippocampal 5-HT. 
Again, the consequences of these changes in hippocampal 5-HT elicited by nicotine 
remain to be determined. Studies have suggested that increased stimulation of 5-HT 
receptors in the hippocampus may be implicated in anxiety (Andrews et al. 1994), and 
it could be that this mechanism is involved in the decreases in anxiety consistently 
reported by smokers following tobacco use. Nicotine has reported anxiolytic 
properties in some tests (Brioni et al. 1994), although these findings have been 
contested (Balfour, Graham & Vale, 1986). If this hypothesis is correct, increases in 
receptor density could contribute to the symptoms often observed during the early 
stages of smoking cessation; i. e. acute tobacco withdrawal. Under conditions of initial 
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abstinence, hippocampal 5-HT release will no longer be suppressed, possibly resulting 
in feelings of anxiety. 
Other reports implicate occupation of the 5-HTIA receptor subtypes in the expression 
of the glucocorticoid receptors, which exert an inhibitory effect on pituitary-adrenal 
activity (SeckI & Fink, 1991); these are psychobiological mechanisms by which we 
cope with the stresses of everyday life (Benwell & Balfour, 1982). It can be argued 
therefore that effects of chronic nicotine on hippocampal 5-HT include attenuation of 
the mechanism that mediates adaptation to environmental stress, and upon acute 
cessation mediate certain tobacco withdrawal effects such as anxiety and depression 
(FagerstrOm & Schneider 1989). 
1.7.4 Nicotine addiction and other neurotransmitters 
As stated earlier, nAChRs are found on many neurons throughout the CNS. These 
pathways include many of the acetylcholine-secreting neurons found in the 
hippocampus and cortex. Nicotinic receptors are also found on terrninals that secrete 
the excitatory amino acid, glutamic acid, and the inhibitory amino acid, 
aminobutyric acid (GABA) (Wonnacott et al. 1990; McGehee et al. 1995; Lu et al. 
1998). The behavioural consequences of the action of nicotine on these neurons 
remain to be established. Stimulation of the receptor located on glutamate-secreting 
terminals facilitates release of the transmitter (McGehee et al. 1995). 
Stimulation of the NMDA receptors located on the doparnine-secreting neurons in the 
VTA results in increased burst firing of those neurons, and thus an enhanced 
doparnine response to nicotine (Balfour et al. 1998; Schilstr6m et al. 1998). It is well 
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accepted that the effects of nicotine on cholinergic neurons are implicated in increased 
arousal and attention sometimes associated with smoking (e. g. Balfour, 1984). 
Additionally, stimulatory effects of nicotine on acetylcholine and glutarnate secretion 
in the hippocampus and cerebral cortex may mediate the reported improved cognitive 
function (Balfour & Fagerstr6m, 1996). Smokers have long cited nicotine's apparent 
positive effects on cognition as a reason why they smoke. 
1.7.5 The tobacco withdrawal syndrome 
Cessation of smoking can give rise to a definite abstinence syndrome (Jaffe, 1980; 
Hatsukami et al. 1984). It cannot be labelled a "nicotine withdrawal syndrome" since 
it is difficult to demonstrate that it cannot occur through the loss of other aspects of 
smoking. Alternatively, it has not been demonstrated to occur with acute cessation of 
use of nicotine replacement products (e. g. nicotine gum). 
In keeping with the biphasic effects of nicotine, this syndrome shows characteristics 
of the withdrawal reaction from both stimulant and depressant drugs. Withdrawal 
effects include craving for tobacco, nausea, headache, constipation, restlessness, 
decreased psychomotor performance, increased appetite and weight, lethargy, 
depression, irritability, anxiety, restlessness, decreased cognitive and psychomotor 
performance, increased low frequency EEG activity, and fall in blood pressure and 
heart rate. The syndrome starts within 24 hours of smoking cessation and some 
symptoms may persist for many months. However, the severity is variable and some 
smokers can give up without difficulty. 
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Unsurprisingly, the severity of the withdrawal syndrome is related to the pre-cessation 
smoking levels and profiles, with more frequent and more dependent smokers 
experiencing relatively greater discomfort (West & Russell, 1985; Hughes & 
Hatsukami, 1986). The symptoms may be partially alleviated by nicotine replacement 
therapy (Russell et al. 1980; Pornerleau & Pornerleau, 1988; Gross & Stitzer, 1989), 
but the relapse rate of smokers advised to stop smoking for health reasons or attending 
anti-smoking clinics is high. 
Craving for tobacco is commonly increased under conditions of abstinence from 
smoking (Shiffman & Jarvik, 1976; Hughes & Hatsukami, 1986). There is little 
consensus regarding a definition of craving. An Expert Committee meeting on drug 
craving convened by the United Nations and World Health Organisation defined drug 
craving as "the desire to experience the effect(s) of a previously experienced 
psychoactive substance". This definition is considered to accurately describe 
phenomenon of drug craving in humans and can thus be clinically useful (Markou et 
al. 1993). 
Theories regarding cigarette cravings are consistent with general models of drug 
craving; they assume that urges and cravings represent subjectively experienced 
motivational states that are responsible for ongoing drug use in drug-dependent 
individuals, and precede and precipitate relapse episodes in addicts attempting 
abstinence (Shiffman, 1979; West & Schneider, 1987). Instruments such as the 
Questionnaire of Smoking Urges (Tiffany & Drobes, 1991) have been devised to 
characterise and quantify levels of tobacco craving. 
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The inclusion of "craving for tobacco" in the tobacco withdrawal syndrome is 
contentious, fundamentally because smokers crave tobacco when non-deprived, and 
even whilst smoking. The case is made for the inclusion of this symptom by evidence 
demonstrating these cravings are reduced by nicotine replacement (Russell et al. 
1993) and correlate with other elements of the syndrome (Zinser et al. 1992). Craving 
for tobacco is often regarded as the most important factor in the withdrawal 
syndrome, since it is the most predictive of subsequent relapse to smoking (West, 
Hajek & Belcher, 1989; Swan, Ward & Jack, 1996). 
Anxiety is a distressing negative emotional state that may have multiple components. 
Smokers' subjective ratings of anxiety are frequently increased following abstinence 
(Hughes & Hatsukami, 1986; Hughes, Higgins & Bickel, 1994). The nature of the 
abstinence is likely to be important to the validity of this symptom, as discussed 
below. Anxiety associated with acute tobacco withdrawal may be a direct result of the 
elimination of nicotine from the CNS. This may be due to consequent effects on 
neurotransn-titter systems that have adapted to an environment whereby the drug is 
regularly administered. This is likely to be experienced most severely by highly 
dependent smokers who have higher blood nicotine levels and -greater nicotine 
tolerance. Alternatively, psychological disturbances caused by changes in behaviour 
may mediate increases in anxiety. 
There is also ongoing debate as to whether anxiety should be included as a symptom 
in the withdrawal syndrome. West & Hajek (1997) propose that it should not, as they 
found that anxiety levels fall rather than rise among totally abstaining smokers (as 
opposed to those who might have had minor lapses). Other studies have reported an 
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initial elevation in reported anxiety after stopping smoking, but this is short-lived and 
followed by a reduction to below anxiety levels while smoking (Hughes et al. 1994). 
Furthermore, West & Hajek (1997) argue that increased anxiety observed in earlier 
studies on smoking cessation is a psychological response to the attempt to stop, which 
is worsened when that attempt is not wholly successful. 
1.8 Treating tobacco dependence 
There are a variety of different approaches to managing nicotine addiction. These can 
broadly be categorised as population interventions (advertising or educational 
campaigns, brief routine interventions by health-care professionals, over-the-counter 
products, etc. ) or individual interventions (intensive expert-delivered treatments). The 
two approaches overlap, and there are regular efforts made to adapt those 
interventions effective in the intensive treatment setting to the wider-reaching 
management strategies. For the purposes of this introduction, however, it is more 
appropriate to categorise methods of smoking management as either pharmacological 
or non-phannacological. 
1.8.1 Non-pharmacological treatments aiding smoking cessation 
Due to the scale of smoking prevalence, there is a need for interventions to reach large 
populations. Various interventions have been attempted, such as community-level 
poster, self-help and competition campaigns. More general self-help literature is 
available, updated to include current advice about nicotine-replacement therapy 
(NRT), and this is shown to be modestlY more effective than no intervention 
(Lancaster & Stead, 2000). Telephone help-lines have also been shown to be effective 
at improving quit rates (Zhu et al. 1996), as have brief advisory interventions by 
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healthcare professionals such as general practitioners or nursing staff (Cromwell et al. 
1997; Silagy & Ketteridge, 1999). Many of these generic non-pharmacological 
approaches are only effective in treating light smokers rather than more dependent 
smokers (e. g. Jackson et al. 1986). 
Smoking cessation clinics in the UK usually offer a combination of NRT and 
behavioural support. Importantly, well-organised intensive treatments are effective in 
helping even highly dependent smokers to stop smoking for a period of several weeks. 
The efficacy of intensive behavioural interventions is enhanced when an element of 
social support is prominent (West, Edwards & Hajek, 1998). Ways of designing, 
evaluating and implementing social support treatments on a larger scale could be an 
extremely cost-effective means of improving overall smoking cessation rates. 
Hypnosis and acupuncture are popular approaches to quitting smoking. Studies 
investigating hypnosis and acupuncture for smoking cessation have concluded that 
specific efficacy is lacking, but individuals may be helped by placebo or non-specific 
effects (Abbot et al. 1999; White & Rampes, 1999). 
1.8.2 Pharmacological treatments aiding smoking cessation 
NRT and the atypical antidepressant bupropion (Zyban@) are the only 
pharmacotherapies licensed in the UK to treat nicotine addiction. This is because 
these drugs have been reliably shown to improve cessation rates and have minimal 
side effects. Clonidine, an a2-adrenoceptor agonist, and mecarnylarnine, a non- 
competitive nAChR antagonist, have also been studied as treatments for smoking 
cessation either alone or as adjuncts to nicotine patches. 
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1.8.2.1 Nicotine replacement therapy (NRT) 
Chapter I 
The key difficulties acutely experienced by smokers attempting cessation seem to be 
attributable to the tobacco withdrawal syndrome. NRT essentially breaks the quitting 
process into two phases; in the first phase, quitters learn to cope without smoking 
behaviour and regular rapid boli of nicotine, while putatively protected from the worst 
withdrawal effects by moderate levels of nicotine afforded by NRT. Once this 
adaptation has developed, nicotine is gradually withdrawn completely. 
NRT alleviates withdrawal discomfort (Russell, 1990). In a recent review, West & 
Shiffman (2001) reviewed 27 studies investigating oral NRT device (gum, inhalator, 
tablet) effects on withdrawal symptoms and craving in abstinent smokers. They 
concluded that oral NRT reduces total withdrawal discomfort, and particularly anxiety 
and irritability. They found modest evidence for NRT effects on depressed mood and 
craving, although gum was less effective than other devices in reducing craving. 
Nicotine patches and nasal spray have also been demonstrated to mitigate withdrawal 
discomfort and the severity of craving/urges to smoke (Fagerstr6m et al 1993; 
Pickworth et al. 1996; Sutherland et al. 1992; Leischow et al. 1997). 
Although this comprises the main effect of NRT, other mechanisms may have a role, 
such as the provision of a coping mechanism, or possibly replacing some of the 
hypothetical positive effects of nicotine, such as increased alertness (West, 1992). 
NRT may also make early relapses to smoking in quitters less rewarding, and 
therefore less likely to trigger a full-scale relapse. A related possible mechanism could 
be deconditioning because the link between pharmacological reinforcement and 
smoking behaviour may weaken during abstinence accompanied by NRT use. 
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NRT can be administered via patches, gum, inhalators, nasal sprays, sub-lingual 
tablets and lozenges. These are available in different strengths and versions, and 
different products and potencies are indicated for different individual smokers. 
Irrespective of the particular device or product, NRT is reliably shown to help 
smokers quit. In a recent review, the overall odds ratio for abstinence with NRT 
compared to placebo was 1.73 (Silagy et al. 2000). In addition to enhancing early 
cessation, there is evidence that NRT also reduces early relapse (Stapleton et al. 
1995). 
Increasing dose seems to increase treatment efficacy, though the dose-response curve 
is shallow; for example, 4mg nicotine gum was shown to be more effective than 2mg 
gum in highly dependent smokers (e. g. Hughes et al. 1999b). Small but significant 
advantages have been demonstrated in 25mg over 15mg patches in sustained one-year 
abstinence rates (Tonnesen et al. 1999). 
1.8.2.2 Bupropion (Zyban@) 
The evaluation of use for antidepressants in smoking cessation pharmacotherapy 
(Covey et al. 2000) stems from the observed association between smoking, smoking 
cessation and depression (Breslau, Kilby & Andreski, 1993). Initial observations that 
depressed smokers administered the antidepressant bupropion experienced reduced 
craving for tobacco (Ferry & Burchette, 1994) led to larger trials examining the 
tolerability and efficacy of a sustained-release (SR) formulation of the drug as a 
smoking cessation agent (Hurt et al. 1997; Jorenby et al. 1999). 
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Bupropion SR has been consistently demonstrated to increase smoking cessation rates 
(Hughes, Stead & Lancaster, 2002) and decrease occurrence of withdrawal symptoms 
(Coleman, 2001). Its efficacy has also been reported in combination with both 
behavioural interventions (Hurt et al. 1997) and nicotine patches (Jorenby et al. 1999). 
Bupropion SR is currently prescribed to smokers who smoke more than 10-15 
cigarettes per day and who are highly motivated to stop; the treatment has proven 
efficacy with this group, nearly doubling the success of smoking cessation (Coleman, 
2001; Henningfield et al, 2000). 
Bupropion SR is primarily a selective dopamine and noradrenaline re-uptake 
inhibitor, and it is thought to exert its cessation-enhancing effects by increasing 
dopaminergic activity (Settle, 1993; Ascher et al. 1995). The drug is equally effective 
in assisting cessation in smokers with or without a past history of depression, 
suggesting that its efficacy is not due to its antidepressant effect (Hughes et al. 
1999a). Bupropion SR has been shown to mitigate increases in depression, difficulty 
concentrating and irritability following abstinence, and attenuate a decrease in 
positive affect (Shiffman et al. 2000). The drug is considered a useful option for 
smokers attempting to stop smoking for the first time, and in those who cannot 
tolerate NRT, those who prefer non-nicotine treatment, or those with whom NRT has 
failed (Hughes et al. 1999b). 
Aside from bupropion, several other antidepressants have been investigated in terms 
of efficacy as a smoking cessation aid. These include nortryptaline, doxepin, 
fluoxetine and moclobernide and show limited if any success (Benowitz & Wilson 
Peng, 2000). 
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1.8.2.3 Clonidine, mecamylamine and other pharmacotherapies 
Clonidine is an a2-noradrenergic agonist that suppresses sympathetic activity. It is an 
anti-hypertensive medication and has been used as a treatment of alcohol and opiate 
withdrawal (e. g. Gourlay & Benowitz, 1995; Gowing et al. 2002). Several early 
studies found that clonidine could also relieve craving for cigarettes and enhance 
smoking cessation (Ornish, Zisook & McAdams, 1988; Glassman et al. 1984). 
Prochazka et al. (1992) found that clonidine produced relief of withdrawal symptoms 
(anxiety and irritability) without finding enhanced quit rates. Gourlay & Benowitz 
(1995) report that both as pills and as a patch in low doses (0.2 - 0.4mg per day) 
clonidine increased smoking cessation in eight of nine trials. It has been 
recommended as a second-line therapy in US smoking cessation guidelines (Fiore, 
2000). 
Clonidine has more significant side effects (e. g. sedation, postural hypotension, dry 
mouth) and more dropouts due to side effects than NRT. The side effects clearly 
restrict its use and clinical effectiveness, and the drug's relevance to smoking 
cessation is clearly limited. 
Mecamylamine is a nicotine antagonist originally used to decrease cholinergic 
activity, and thus reduce blood pressure (Clarke, 1991). It does not specifically bind at 
nAChRs but blocks the associated ion channel; this may be why, in humans, it blocks 
the effects of nicotine but does not precipitate withdrawal symptoms (Clark, 199 1). 
Again however, side effects may limit the use of mecamylamine for smoking 
cessation. There are considerable gastro-intestinal effects, although these are less 
marked with lower doses. 
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Since smoking is often considered a means of reducing stress and anxiety (particularly 
by smokers) the potential efficacy of anti-anxiety drugs in smoking cessation has been 
investigated. Buspirone is associated with decreased nicotine withdrawal symptoms 
but efficacy has not been shown for smoking cessation (e. g. Covey et al. 2000). 
Naloxone and naltrexone, opioid antagonist drugs used extensivelY in treating alcohol 
and opiate addiction have been tested as smoking cessation aids. Results in terms of 
efficacy have been mixed (e. g. Covey et al. 2000). 
Lobeline, a nicotine-like alkaloid has also been used as a form of smoking cessation 
therapy (Benowitz & Wilson Peng, 2000). Silver acetate, which interacts with 
cigarette smoke to produce an aversive metallic taste, has been tested as a smoking 
deteffent but is not shown to be efficacious (Hyrnowitz et al. 1993). Glucose has also 
been identified as a potentially cheap and simple smoking cessation aid with modest 
efficacy. Studies have shown that chewing glucose tablets can reduce the desire to 
smoke during periods of cessation (West, 2001). 
1.9 Individual differences in smoking behaviour 
Despite increasing interest and research in the field of cigarette smoking during the 
1990s, the problem persists as to understanding why some people smoke and become 
nicotine dependent, others smoke as and when they feel like it with no discernible 
dependence, and others avoid smoking altogether. 
Approximately only 40% of people who experiment with tobacco -go on to smoke 
regularly. A popular theory as to why the other 60% escape addiction is that they have 
high innate sensitivity to nicotine and therefore experience the aversive effects on first 
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use more intensely, hence discouraging further experimentation (e. g. Silverstein et al. 
1982). By contrast, those with lower initial sensitivity to nicotine will experience 
fewer or less intense aversive side effects, and as a consequence will be more likely to 
continue smoking. 
Early self-administration is presumed to be maintained by social reinforcement, since 
the inception of smoking is usually an aversive experience. Following a certain 
"critical exposure" period, the social reinforcement is replaced by avoidance of 
nicotine withdrawal as the major motivator, signalling the development of 
dependence. Individual patterns will then emerge as each smoker's behavioural 
profile develops and stabilises, and these tend to be broadly categorised as "heavy" or 
"light" smokers. This rather arbitrary division is presented as purely dose-related, but 
implies that those who smoke more are highly nicotine dependent, have difficulty 
abstaining, are highly tolerant to nicotine and exhibit more withdrawal than light 
smokers on smoking cessation (Killen et al. 1988). 
1.9.1 Tobacco chippers 
Chippers (or non-addicted smokers) show no signs of withdrawal symptoms 
following overnight abstinence from smoking, and report being able to easily, and 
regularly abstain from tobacco for periods of a few days or longer (Shiffman, 1989). 
Interestingly, it has been shown that chippers' nicotine absorption per cigarette and 
nicotine elimination rates were similar to those of heavy smokers (Shiffman et al. 
1990; 1992; Brauer et al 1996). Chippers are less likely to smoke in order to relieve 
stress and to report an aversive response to their first ever cigarette, and also report 
having fewer smoking relatives (Shiffman, 1989; Kassel et al. 1994). 
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It is not clear what factors, if any, determine chipper status, and why this group is 
apparently protected from developing nicotine dependence, although there is evidence 
suggesting the group has a constitutionally reduced sensitivity to nicotine (Shiffman, 
1991) 
1.9.2 Models of nicotine tolerance 
Chronic tolerance is believed to develop in proportion to extent of nicotine exposure 
(Gurling, Grant & Dangl, 1985). This exposure model of tolerance purports that 
whether an individual smokes or not is due to constitutional factors (based on initial 
sensitivity to nicotine), but that degree of dependence is governed by environmental 
variables (social "support for smoking" determining amount of nicotine exposure). 
Although this theory demonstrates considerable face validity, it overlooks a number 
of important factors that may shape smoking behaviour: e. g. differences in individual 
brain architecture and biochemistry, including different cholinergic 
psychopharmacology and arousal effects, nicotine metabolism factors, etc. 
Recent critiques of the exposure model (e. g. Shiffman, 1991) have highlighted not 
only the theoretical shortcomings, but also the fact that the theory has achieved scant 
experimental support from the relevant human and animal research. Furthermore, it is 
practically and ethically extremely hard to determine the relationship between initial 
sensitivity to nicotine and tolerance. This is because appropriate research may involve 
administering the drug to nicotine-na7fve adolescents. However, paradigms have been 
developed for studying individual differences in sensitivity to nicotine (Pomerleau et 
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al. 1993b; Pomerleau, 1995) that offer the prospect of future genetic studies on human 
subjective and physiological responses to nicotine. 
Shiffman (1991) thus proceeded to propose a sensitivity model of tolerance, based on 
the theory that those individuals with a high initial sensitivity to nicotine not only 
derive greater aversive effects of the drug, but also greater reinforcement, and 
reinforcing effects (temporary improvements in affect and cognitive performance, 
amelioration of withdrawal symptoms). This is congruent with what is known about 
nicotine's psychopharmacological profile (see Section 1.7). In this theory, heavy 
smokers are hypothesised to be nicotine-sensitive individuals able to develop 
sufficient tolerance to the drug's aversive effects to sustain chronic use. When these 
individuals desist from smoking, they lose tolerance and suffer more intense 
withdrawal symptoms. 
It is suggested that non-smokers and occasional smokers develop from that group with 
low nicotine sensitivity, as they experience less intense effects, hence less 
reinforcement, and do not persist with the drug (in the case of non-smokers), or use it 
fundamentally in social situations (in the case of occasional smokers). This model 
proposes that constitutional factors determine the degree of dependence possible, and 
in so doing shape the consequent pattern of smoking. 
The sensitivity model is consistent with integrated models of tolerance (e. g. Poulos & 
Cappell, 199 1). These integrated models of tolerance described it as a set of bio- 
behavioural adaptations consisting of both learned or associative factors (conditioned 
or behavioural tolerance) and non-associative factors (phannacokinetic and 
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pharmacodynamic tolerance). This last group of factors addresses most of the 
problems with the exposure model, although arguably falls short of dealing with more 
complex neuropsychological variables. 
It also fails to address the problem of "chippers" (see Section 1.8.1). These are regular 
smokers who are not tobacco dependent (i. e. they demonstrate few, if any, withdrawal 
symptoms upon interruption of their smoking pattern) (Shiffman, 1989). Although 
this group is arguably a "highly social" group of "social smokers", it is unlikely that 
tolerance alone can fully explain their ability to stave off the addiction trap. 
1.9.3 Genetic influences on smoking 
In contrast to the progress in understanding the genetics of alcoholism, the genetics 
for biological bases of smoking behaviour are still unclear. Nonetheless, several 
studies suggest genetic factors play a considerable role in deterniining which 
individuals who begin to smoke will become persistent long-term smokers. Genetic 
influences on nicotine dependence have been suggested by studies that used inbred rat 
and mouse strains (Marks et al. 199 1). In recent years, human genomic research 
related to cigarette smoking has provided evidence for linkage of smoking behaviour 
to chromosomes 6,9 and 14 (Bergen et al. 1999). Although the addictive qualities of 
nicotine contribute to chronic smoking, some individuals appear more susceptible 
than others. Some previously addicted smokers are able to quit while others are not; 
and some people may experiment with cigarettes without becoming regular smokers. 
Heath & Madden's (1995) review presents results from national. twin surveys in 
Scandinavia and Australia from the 1960s to the early 1980s. They consistently report 
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that heritable factors explain variance affecting the probability of becoming a regular 
smoker ('initiation') and the risk that those who become regular smokers will become 
long-term persistent users ('persistence'). Increasing our understanding of genetic and 
environmental contributions to smoking initiation and persistence may enhance our 
ability to identify and prevent smoking in those most predisposed to becoming regular 
smokers, and improve cessation for persistent smokers. Linkage data indicate that the 
effects of genes on smoking behaviour are weak, or that gene alleles that influence 
smoking behaviour occur in onlY a small proportion of families. 
Twin studies support an important family environmental influence on initiation of 
smoking, and suggest an additional genetic influence (Boornsma et al. 1994; Heath & 
Madden, 1995). Findings of genetic influence on smoking persistence have been 
variable. Heath (1990) failed to find any evidence of genetic influences on persistence 
that were independent of the determinants of smoking initiation. However, data from 
a larger cohort found evidence for an important genetic influence on risk of smoking 
persistence in regular smokers that was independent of genetic influences on onset of 
smoking (Heath & Martin, 1993). Re-analysis of early twin studies in Scandinavia 
found evidence for substantial genetic influences on persistence that were unrelated to 
effects on onset (Medlund et al. 1977; Kaprio et al. 1978). A much weaker genetic 
effect was found in men than in women in the former study, although no interaction 
with gender was found in the latter (Heath et al. 1995; Heath & Madden, 1995). 
True et al. (1997) analysed twin data using a model allowing for both genetic and 
shared environmental effects on smoking initiation, which demonstrated accounts of 
50% and 30% of variance in risk respectively. However, this model solely allowed for 
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genetic effects on persistence in smoking among regular smokers, and this accounted 
for 70% of variance in risk. Therefore, findings to date suggest that there is stronger 
support for a genetic basis of smoking persistence than smoking initiation. 
1.9.3.1 Smoking behaviour and genetic differences in dopaminergic neurobiology 
Taking into consideration evidence suggesting the importance of doparninergic 
systems to addictive behaviour (Section 1.7.1), genes regulating its activity are likely 
to be involved in nicotine dependence and smoking behaviour. Among the five 
dopamine receptor subtypes investigated so far, the D 1, D2 and D3 subtypes are 
prevalent in the mesolimbic system and are most clearly implicated in the reinforcing 
effects of drugs (Clarke, 1998). 
There are few studies examining DRDI polymorphisms in relation to smoking 
behaviour. Comings et al. (1997) reported an association between homozygosity for 
either allele of a DdeI polymorphism (-A/G) and smoking, although the functional 
significance of this polymorphism is yet to be clarified. Duggirala et al. (1999) 
reported linkage of smoking behaviour to marker D5S1354 on chromosome 5q: this 
marker is located close to the genes for the DI dopamine receptor (DRD I). 
The TaqI A* polymorphism is the most extensively studied of the many DRD2 gene 
polymorphisms. Although thought not to be functional, TaqI Al allele is associated 
with reduced DRD2 availability in the striatum (Jonsson et al. 1999). Significant 
inverse associations have been reported between the prevalence of TaqI A* allele and 
the age of smoking onset and to the maximum period of time for which smokers were 
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have also been reported between smoking and DRD2 gene polymorphisms, in 
smoking incidence (Spitz et al. 1998; Yoshida et al. 2001), although these results are 
contested (Bierut et al. 2000). 
High densities of DRD3 are present in the nucleus accumbens (Arinami et al. 2000). 
Various polymorphisms have been identified, including the Ser9Gly polymorphism 
(Lannfelt et al. 1992). Associations have been reported between the homozygosity for 
the Ser9Gly polymorphism and both cocaine dependence (Comings et al. 1999) and 
opiate dependence (Duaux et al. 1998). Despite the variety of DRD3 polymorphisms, 
their association with smoking behaviour has not been examined. 
1.9.3.2 Smoking behaviour and genetic differences in personality via 
dopaminergic neurobiology 
Another route by which the dopamine system and smoking behaviour may be linked 
is via inherited personality traits, or genotypes encoding likely behavioural. 
characteristics resistant to change or environmental adjustment. Personality is the 
characteristic manner or style of an individual's behaviour as opposed to goals 
towards which it is directed (motivation), or the machinery of its execution (cognitive 
and motor skills). Gray (1973) argues that personality traits reflect motivational 
systems that evolved to increase adaptation to classes of stimuli associated with 
positive and negative reinforcement. Individual differences in personality thereby 
reflect variation in the sensitivity to such stimuli, and overall personality represents 
the relative strength of sensitivities to various stimulus classes. For example, 
impulsive people can be described as more sensitive to reward than to punishment, 
approaching rewarding situations even when punishers make restraint more 
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appropriate. Sensitivity ultimately means reactivity of the neurobiology associated 
with a motivational system (Depue & Collins, 1999). 
The majority of genetic research on personality involves self-report questionnaires. 
Responses to such questions are remarkably stable, even over several decades (Costa 
& McCrae, 1997). Questionnaires utilised include: the Revised NEO Personality 
Inventory (NEO-PI-R) (McCrae & Costa, 1997), Eysenck's Personality Inventory 
(EPI) (Eysenck & Eysenck, 1964), Cattell's 16 PF (Cattell, 1947), Cloninger's 
Temperament & Character Index (TCI) (formerly Tridimensional Personality 
Questionnaire, or TPQ) (Cloninger et al. 1993). All these self-report questionnaires 
reliably measure many of the same personality factors, especially the more robust 
categories of Novelty Seeking (extraversion, conscientiousness, sensation-seeking, 
psychoticism) and Harm Avoidance (neuroticism, anxiety-related traits). 
Cloninger's personality questionnaires were developed as tools to study the genetics 
of personality. The questionnaires draw on human and animal work to suggest that 
behaviour is mediated by certain neurotransmitters, which underlie three basic and 
largely heritable dimensions, called "Novelty Seeking", "Harm Avoidance" and 
"Reward Dependence". Novelty Seeking taps aspects of impulsiveness, curiosity (or 
exploratory behaviour in animals) and disorderliness. 
Smokers report higher Novelty Seeking scores than non-smokers (Pomerleau et al. 
1992). There are several sub-scales of Cloninger's Novelty Seeking trait. Of these, 
Impulsivity (impulsiveness) perhaps represents the strongest link to smoking 
behaviour. A high level of impulsivity has been equated with preferences for 
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immediate gratification, risky activities, novel sensations, and easier routes to self- 
gratification, as well as an inability to persist at a task and shorter reaction times (e. g. 
McCown et al. 1993). People with high levels of impulsivity are thought to be more 
likely to experiment with psychoactive drugs and possibly become regular users 
(Johnson et al. 1993; Logue, 1995). A study examining various scores on the 
Sensation-Seeking Scale (Zuckerman, 1971) found that smokers scored higher than 
non-smokers (Carton et al. 1994). There are many other studies reporting higher 
levels of impulsivity in smokers than in non-smokers (e. g. Williams, 1973; Golding et 
al. 1983; Zuckerman et al. 1990; Jenks, 1992; Mitchell, 1999). 
Novelty Seeking, the increased tendency to respond to novel and promising situations, 
is principally served by the mesolimbic dopamine system. Rewarding activities, 
including certain drugs such as nicotine, increase doparnine release or inhibit its re- 
uptake in the mesolimbic system (Schultz, 1997). Because of its critical role in the 
elicitation of euphoria in humans and exploratory approach behaviour in other 
animals (Cloninger, 1987), doparnine has been hypothesised as the main 
neuromodulator of Novelty Seeking. 
Associations have recently been reported between a specific genetic polymorphism 
and a specific personality trait. Ebstein et al. (1996) studied Novelty Seeking in 
normal volunteers and found an association with the 7-repeat allele of the DRD4 
exonic polymorphism. Similarly, Benjamin et al. (1996) reported population and 
familial associations between DRD4 gene polymorphisms and measures of Novelty 
Seeking. Ono et al. (1997) replicated this result in Japanese female students. These 
findings have been further replicated by some studies (Kuhn et al. 1999; Noble et al. 
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1999) and contradicted by others (Bau et al. 1999; Gelernter et al. 1997; Jonsson et al. 
1998; Sullivan et al. 1998). 
These initial studies examined the role of the exon III 48-bp repeat dopamine D4 
receptor polymorphism in personality. This gene has a highly polymorphic region in 
the third cytoplasmic loop that varies between 2 and 10 repeats in most populations 
and changes the length of the receptor protein (Lichter et al. 1993). Variants in the 
polymorphism are usually written "D4Y', where x represents the number of repeats. 
The doPamine D4.2, D4.4 and D4.7 receptor alleles occur the most frequently, but 
there is considerable variation in the distribution of alleles depending on ethnicity 
(Chang et al. 1996; Lichter et al. 1993). 
There is some evidence that the long (L) and short (S) alleles of this protein have 
moderate functional significance with L alleles demonstrating relatively lower affinity 
for dopamine (Asghari et al. 1994), although a more recent study presents 
contradictory evidence (Kazmi et al. 2000). Both the Benjamin et al. (1996) and 
Ebstein et al. (1996) studies suggested an association between Novelty Seeking and 
the L alleles of DRD4. 
An association between smoking behaviour and the DRD4 L allele has been reported 
for an African-American population (Shields et al. 1998). This study found that after 
smoking cessation counselling, none of the subjects with an L allele were abstinent at 
2 months compared with 35% of the subjects who were homozygous for the S allele. 
This association, however, was not reported in Caucasian subjects. This study also 
reports that subjects who had at least one L allele had higher risk of smoking, shorter 
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time to first cigarette in the morning and earlier age at smoking initiation. An 
association was also found between this polymorphism and opioid-dependence 
(Kotler et al. 1997; Li ct aL 1997), raising the possibility that D4 receptor genetics 
might have some generic influence on addiction. 
As stated, there is strong evidence of an association between the L allele and the 
Novelty Seeking personality trait (e. g. Ebstein et al. 1996; Benjamin et al. 1996). 
Since smokers showed higher Novelty Seeking rates than the general population 
(Pomerleau et al. 1992; Zuckerman et al. 1990), it is likely that the L allele is 
associated with smoking, concordant with Shields et al. 's (1998) reported findings 
with the African-American smokers. 
1.10 Aims of the current research 
The aims were to define addicted versus non-addicted smokers, and explore the role 
withdrawal may contribute to these differences by studying (a) mood and cognitive 
performance, (b) genes affecting doparninergic neurobiology, (c) psychosocial 
variables, and (d) withdrawal symptomatology. Finally, the (e) withdrawal-mediated 
involvement of noradrenergic systems in tobacco withdrawal was investigated. 
Using questionnaire data it was possible to derive a Nicotine Addiction Index, a 
composite score quantifying levels of nicotine dependence. This was subsequently 
investigated to reveal two distinct groups, labelled addicted and non-addicted 
smokers. 
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Differences in changes in mood and cognitive performance following nicotine 
withdrawal and reinstatement between addicted smokers and non-addicted smokers 
were examined. There is a large body of evidence supporting the existence of a sub- 
group of regular or habitual smokers dubbed "chippers" (Section 1.9.1), who seem 
able to tolerate prolonged periods of abstinence with no overt or reported withdrawal 
symptoms (e. g. Shiffman, 1989; 1991). One of the main aims of this PhD research 
was to elucidate why these individuals are able to regularly self-administer nicotine, a 
highly addictive drug, without developing dependence as in the majority of smokers 
consuming comparable levels of the substance. Some work has been done looking at 
possible relationships between psychosocial. or personality variables and chipper 
status, but with weak or inconclusive results (Kassel et al. 1994). 
Predictions 
It is hypothesised that withdrawing nicotine would cause a decline in mood and 
deterioration in cognitive performance in all smokers, but particularly the addicted 
smokers. Non-addicted smokers, effectively smokers demonstrating low tolerance and 
citing fewer addictive motivations for smoking) were not expected to show uniform 
impain-nents or significant effects of withdrawal. The addicted smoker group was 
expected to report greater withdrawal symptoms than other groups. It was predicted 
that there would be differences in responses to nicotine reinstatement between the two 
"types" of smoker. The addicted smokers were expected to demonstrate a 
considerable improvement in mood and cognitive performance following nicotine 
reinstatement, whereas the non-addicted smokers may have displayed some 
improvement, but not so marked. 
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DNA analysis was performed on experimental subjects. In recent years there has been 
some evidence that genetic predisposition to nicotine addiction or "addictiveness" 
may exist. In particular, polymorphic genes affecting dopaminergic function have 
been associated with variations in addictive behaviour or potential. Doparnine 
receptor sub-types D2, D3 and D4 were examined. Furthermore, DRD4 is a dopamine 
receptor believed to be associated with novelty-seeking behaviour. There is strong 
evidence that individuals' having a D4 L-allele genotype score consistently higher on 
Cloninger's Novelty Seeking trait than those with the other sub-type. It was predicted 
that addicted and non-addicted smokers would have consistently different dopamine 
receptor genotypes, with the former group possessing the L-allele. Smoking behaviour 
could be related to novelty-seeking, or related personality characteristics such as 
impulsivity. It was also hypothesised that addicted smokers will have higher Novelty 
Seeking scores than the other groups. 
Smoking behaviour and its relationship with personality and psychosocial variables 
per se was also examined. It is pertinent that there may be personality or social 
variables that can predict smoking behaviour, and these data may illuminate possible 
character or environmental differences between non-addicted and addicted smokers. 
Although Kassel et al. (1994) found only weak associations between smoker status 
and personality and psychosocial variables, their methodology and findings justify 
expansion of their research. It is possible that their modest findings were as a result of 
failure to measure enough variables, or by not examining interactions, or because of 
their subject sampling protocol. There are a number of previous studies suggesting 
that smoking motivation factors may predict severity of nicotine withdrawal 
symptoms, and thus level of dependence or addiction (e. g. West & Russell, 1985). 
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All the above studies utilised a control group of non-smokers, whether questionnaire, 
performance or DNA. It was hypothesised that there would be greater concordance 
between the non-smokers and non-addicted smokers on inter-session changes in most 
measures, as their psychological and psychopharmacological systems are arguably 
more sin-fflar (lower nicotine tolerance, less novelty-seeking personality 
characteristics, etc. ). 
Finally, noradrenergic involvement in tobacco withdrawal was investigated. The 
impact of lofexidine was compared with NRT on the tobacco withdrawal syndrome in 
a repeated measures study. Addicted smokers were assessed in terms of mood, 
cognitive performance, withdrawal symptoms and urges to smoke following 
withdrawal on four separate occasions. Lofexidine was expected to alleviate 
impairments and symptoms associated with tobacco withdrawal as effectively as NRT 
and better than placebo. 
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Chapter 2- Definition of addicted and non-addicted smokers 
2.1 Introduction 
Chapter 2 
Identifying what proportion of smokers is dependent is a complex question. Tobacco 
dependence can best be conceptualised as existing on a continuum rather than as a 
dichotomous variable (dependent vs. non-dependent), although a functional categoric 
division is useful in, for example, directing treatment. Difficulty abstaining and a 
perception of compulsion to smoke are central to the definition of nicotine 
dependence: this epitomises the lack of control viewed as fundamental to all 
dependence. There is evidence that degree of dependence, when defined as difficulty 
in abstaining, is closely related to frequency of smoking (Etter et al. 1999). 
A UK national statistics survey by Walker et al. (1998) found that 58% of current 
smokers state they would find it fairly or very difficult to abstain from smoking for 
only one day. Furthermore, Walker et al. (1998) state that those smoking 20 or more 
cigarettes a day are more likely to say it would be difficult than those smoking less 
than 10 a day (83% vs. 23%). Evaluating the proportion of non-dependent smokers is 
clearly related to definitions of both "dependence" and "a smoker". 
The tenn "chippers" was first used by Zinberg & Jacobsen (1976) to refer to opiate 
users who were capable of limiting and controlling their use of opiates as opposed to 
the common pattern of escalating and compulsive opiate use which many had come to 
associate with heroin users. They highlight what has now become a reliable axiom: 
that drugs which have strong dependence-producing qualities in many people do not 
necessarily produce dependence in all users (e. g. Powell, 1973). Following these early 
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studies examining non-dependent heroin users, it has been recognised that not all 
tobacco smokers progress to become highly dependent chain smokers. 
Shiffman was one of the first to systematically study the phenomenon of non- 
dependent smokers, and he also used the term "chippers" (Shiffman 1989). There is 
consensus in the literature that adults who consistently smoke five or fewer cigarettes 
per day, but who smoke at least four days a week over a long period (e. g. more than a 
year) are non-dependent. Walker et al. (1998) state that up to 20% of UK smokers 
report smoking fewer than five cigarettes a day, but it is unclear what proportion of 
these people are in a transitional phase of increasing or decreasing consumption. 
Many smokers preparing to quit decrease consumption prior to stopping, and this 
subgroup could confound the reliability of the statistics (e. g. Owen et al. 1995). It has 
been estimated that only about 5% of smokers are able to smoke without becoming 
addicted (Shiffman, 199 1). 
Initial studies of "chippers" compared them with heavy smokers (20-40 cigarettes per 
day). Light smokers (<20 per day) reported no signs of nicotine withdrawal after 
overnight abstinence and, in contrast to heavy smokers, also reported that they could 
regularly and easily abstain from tobacco for a period of a few days or longer 
(Shiffman, 1989). These findings confirmed that chippers were at the low end of the 
dependence continuum. However, it was also found that nicotine absorption per 
cigarette in the chippers and nicotine elimination rates were similar to those of heavy 
smokers (Shiffman, 1992). Chippers were less likely to smoke to relieve stress, less 
likely to report an aversive response to their first ever cigarette, and reported having 
fewer relatives who smoked (Shiffman, 1989). Hajek, West & Wilson (1995) 
57 
Addicted and non-addicted smokers Chapter 2 
compared very light smokers (consistently less than 6 cigarettes a day) with regular 
smokers in a cohort of women followed up for a year. This study found that very light 
smokers had higher educational attainment, more non-smoking relatives, but also 
more very light smokers among their relatives, lower neuroticism scores, and were 
less likely to state that they smoked in order to help them cope. 
Pomerleau et al. (1993b) suggest that vulnerability to nicotine dependence may be 
related to genetically based high initial sensitivity to nicotine; others present data 
purporting that gcnctic influcnccs on smoking bchaviour arc morc rclatcd to 
persistence (Heath & Madden, 1995). People who become highly dependent smokers 
have been found to have more pleasurable situations at their initial exposure to 
tobacco (Pomerleau, Pomerleau & Namenek, 1998). This may be perceived as 
contradicting Shiffman's (1989) findings that regular smokers recalled more 
unpleasant reactions to their first cigarette than chippers. Furthennore, research 
indicates that initial dizziness predicted increased likelihood of rapidly progressing to 
further smoking in children (Hirschman, Leventhal & Glynn, 1984). 
Shiffman (1989) found that chippers reported motivations to smoke were significantly 
different to those of regular smokers. Chippers scored considerably lower on the 
Addictive smoking factor of Horn's (Ikard et al. 1969) Reasons for Smoking scale, 
suggesting that internal cues characterising dependence were not responsible for 
initiating smoking behaviour in this subgroup. This scale is an early example of a 
questionnaire attempting to characterise the heterogenenity of smokers' motivations 
for smoking. This questionnaire presented a cluster of items measuring "addictive 
smoking", and yielded a factor recognisable as such. A similar attempt to classify 
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smokers by a factorial structure of motives was performed later (Russell et al. 1974), 
and again a recognisable "addiction" factor was elicited from their expanded 
questionnaire. Russell et al. (1974) proposed their factor structure as a tool for 
classifying smokers on a singular dimension of "nicotine addiction", rather than 
proposing a truly multi-factorial aetiology. 
Chronic nicotine tolerance is generally believed to be central to tobacco dependence 
(e. g. Pomerleau et al. 1993a). It has been shown to be present in both current smokers 
and ex-smokers, and a questionnaire has been devised and validated to quickly 
ascertain levels of physical dependence (Fagerstr6m, 1978). Data from studies 
investigating tolerance suggest that smoking immediately on waking may be the best 
indicator of dependence (Fagerstrbm, 1978; Kozlowski, 1981). Both chippers and 
their relatives who smoke have longer latency to smoke after waking, suggesting 
lower levels of tolerance relative to regular or dependent smokers (Shiffman, 1989; 
Shiffman et al. 1995) and a potential genetic involvement (Gurling et al, 1985). 
Chippers clearly smoke fewer cigarettes than dependent smokers (Shiffman, 1989) 
although whether this represents lower biological "need" for nicotine or another 
reason is unclear. 
Smokers have been shown to have less negative beliefs about smoking than non- 
smokers (Haddad & Malak, 2002; Panter & Reeve, 2002). Whether these reported 
attitudes are authentic or the outcome of cognitive dissonance (whereby beliefs are 
readjusted due to a conflict with an individual's behaviour) is a contentious issue. 
Chippers have been shown to have more positive smoking beliefs than non-smokers, 
but less than heavy smokers (Presson, Chassin & Sherman, 2002). 
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The current research included the development of a brief questionnaire measuring 
smokers' beliefs regarding 10 putative aspects of smoking (positive and negative) 
called the Smoking Beliefs Inventory. This was generated by "brainstorming" focus 
groups of smokers. 
The aim of this research was to accumulate a database of smokers and gain a 
comprehensive picture of the nature of their habit, and to develop an "Addiction 
Index" score quantifying levels of tobacco dependence. This composite score would 
comprise of summed, appropriately weighted numbers computed from reported levels 
of dependent motivations for smoking and nicotine tolerance. Using this Addiction 
Index, we aimed to investigate differences between dependent and non-dependent 
smokers. To this end, a questionnaire battery was compiled comprising several 
previously validated questionnaires about motivation for smoking, demographic data 
and questions about smoking behaviours, tobacco tolerance and smoking beliefs. 
The following hypotheses were investigated: 
I. that by generating an Addiction Index score, using tolerance and motivational 
self-report data to quantify levels of dependence, addicted and non-addicted 
subgroups of smokers can be identified and characterised. 
II. that subgroup status (addicted / non-addicted) would be associated with self- 
reported addiction to smoking, gender, being daytime rather than evening 
smoker, partner's smoking status, reported increased smoking when 
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consuming tea or coffee, increased smoking when consuming alcohol and 
parents knowledge of smoking behaviour. 
Ill. that greater levels of dependence would be positively correlated with reported 
number of cigarettes smoked, number of quit attempts and number of months 
being a smoker. 
IV. that greater levels of dependence would be negatively correlated with age 
smoking behaviour commenced and latency to first cigarette of the day. 
V. that greater levels of dependence would be positively correlated with 
agreement with positive belief statements about smoking. 
2.2 Method 
2.2.1 Design 
This was a cross-sectional self-report questionnaire-based study of smokers, detailing 
profiles of smoking-related motivations, behaviours and beliefs. The Smoking 
Questionnaire Battery (SQB) was a composite questionnaire constituting a short 
demographic section, questions regarding subjects' individual smoking behaviours 
and two validated questionnaires regarding motivations for smoking (Smoking 
Motivation Questionnaire - SMQ and Reasons for Smoking - RFS). Also included 
were questionnaires measuring estimated nicotine tolerance (Fagerstrom Tolerance 
Questionnaire, FTQ), and looking at beliefs about the mental and physical effects of 
smoking (Smoking Beliefs Inventory, SBI). 
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Also included in this booklet were questions regarding the subjects' willingness to 
participate in further experimental studies pertaining to smoking. Subjects were also 
asked to complete a psychosocial questionnaire booklet. This featured several 
extensive questionnaires regarding health-related behaviours, social support, 
perceived stress, psychological disturbance, etc. and is discussed in Chapter 5. 
2.2.2 Subjects 
Subjects (n=109) were recruited by means of posters around the University of Bristol 
campus advertising for smokers to come and complete a questionnaire battery for 
which they would be paid E5. They were also invited to take part in the mood & 
cognitive performance study (described in the Chapter 3). Respondents were 
primarily undergraduates and postgraduates at the University of Bristol, although 
members of the general public were also recruited via word of mouth. Subjects ages 
ranged from 16 to 54 (mean=23.3, SD=5.9): 49 male, 57 female. Three subjects chose 
not to state their gender. 
2.2.3 Questionnaires 
Reasons For Smoking (RFS) QuestionnairelHom-Waingrow scale (Ward, Green & 
Horn, 1969). This was one of the first questionnaires developed to ask people for 
reasons for their smoking. It is a 23-item self-report questionnaire, requiring a 
judgement by the respondent concerning the extent to which ("always", "frequently", 
64occasionally", "seldorif', "never) the behaviour was typical of their own. The 
response was registered for each item by circling the appropriate number on a 5-point 
Likert scale (I to 5). See Appendix 1. 
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Smoking Motivation Questionnaire (SMQ) (Russell, Peto & Patel, 1974). 
Chapter 2 
A 34-itern self-completion questionnaire based on smoking motive themes drawn 
from previous published work by McKennell (1970) and Ikard et al. (1969). Subjects 
were asked to respond in tenns of a four-point scale which was scored as follows: 
66not at all"=O, "a little"= 1, "quite a bit"=2, "very much so"=3. See Appendix 11. 
Fagerstrom Tolerance Questionnaire (FTQ) (Fagerstr6m, 1978). 
This 8-itern questionnaire was intended to measure physical dependence to nicotine. 
Subjects had free response to items 1,2,5 & 6; Item 3 was responded to by circling 
"always", "sometimes" or "never, and the remainder were responded to by circling 
"Yes", "No" or "Depends". See Appendix HI. 
Smoking Beliefs Inventory (SBI) (Hayward, unpublished) 
This 10-item questionnaire was generated in order to examine beliefs about smoking. 
It was generated from points made during brainstorming sessions of an informal focus 
group and presents several ideas about smoking that have been experimentally 
investigated. It makes positive and negative statements about putative general effects 
of smoking and asks subjects to rate how much they agree with the statements on a 
Likert-scale ("strongly disagree"=O, "slightly disagree"=I, "undecided"=2, "slightly 
agree"=3, and "strongly agree"=4). See Appendix IV. 
2.2.4 Procedure 
Smokers completed the Smoking Questionnaire Battery (SQB) in their own time, 
either at home or work, or in the Health Psychology Research Unit, University of 
Bristol. 
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2.3 Analyses 
Chapter 2 
Data were entered using Microsoft Access and analysed with SPSS Version 9.0 and 
BMDP. Principal components factor analysis was performed on the motivation 
questionnaires and analysis of variance was performed to verify the difference 
between the addicted and non-addicted subgroups. Pearson's Chi-square was used to 
test associations between subgroup status and variables with categoric data. 
Spearman's Rho was used to analyse correlation between Addiction Index scores and 
variables with continuous data. 
2.4 Results 
Results were based on data acquired from 103 subjects who had successfully 
completed the Smoking Questionnaire battery (six subjects were omitted from the 
analyses due to incomplete questionnaires). 
2.4.1 Calculating the Addiction Index and generating subgroups (addicted vs. 
non-addicted smokers) 
Individual factor analyses were performed on the questionnaires examining reasons 
for smoking, and factor scores computed for each subject. The Smoking Motivation 
Questionnaire (SMQ) and Reasons For Smoking (RFS) scale each yielded factor 
structures that were very similar to those found in the original paper. This included 
"addictive smoking" or "addiction" factors comparable to previous findings, and the 
factor scores of these were retained for use. 
Factor analysis of the RFS produced a five-factor structure. Factor I explained 
approximately 36% of the variance (Eigenvalue 8.22) and was labelled "Addiction" 
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(items relating to the compulsive or habitual aspects of smoking). The questionnaire 
items loading on the "Addiction" factor derived for the RFS by principal components 
analysis with varimax rotation were (factor loadings): 8 (0.87), 18 (0.75), 22 (0.73), 
13 (0.71), 10 (0.71), 20 (0.66), 5 (0.65), 15 (0.62), 3 (0.55) and 4 (0.54) (Table 2.1). 
The sample frequency of RFS "Addiction" factor scores was negatively skewed and 
ranged from 9 to 40 with a mean of 20.38 (SD 7.91) (Figure 2.1). Factor 2 explained 
approximately 11% of the variance (Eigenvalue 4.29) and was labelled "Negative 
affect reduction" (items pertaining to smoking in order to mitigate negative emotions). 
Factor 3 explained approximately 8% of the variance (Eigenvalue 1.84) and was 
labelled "Stimulation" (items pertaining to smoking in order to increase arousal or 
concentration). Factor 4 explained approximately 6% of the variance (Eigenvalue 
1.40) and was labelled "Pleasurable Relaxation" (items pertaining to smoking for its 
own sake or while relaxing). Factor 5 explained approximately 5% of the variance 
(Eigenvalue 1.26) and was labelled "Sensori-motoe' (items loading on this factor 
pertained to sensory aspects of smoking). 
Factor analysis of the SMQ produced a ten-factor structure. Factor I explained 
approximately 20% of the variance (Eigenvalue 6.27) and was labelled 
"Psychosocial" (items pertaining to the social aspects of smoking). Factor 2 explained 
approximately 11% of the variance (Eigenvalue 4.29) and was labelled "Stimulation" 
(items pertaining to smoking in order to increase arousal or concentration). Factor 3 
explained approximately 8% of the variance (Eigenvalue 2.83) and was labelled 
"Addiction" (items relating to the compulsive or habitual aspects of smoking). The 
questionnaire items loading on the "Addiction" factor derived for the SMQ by 
principal components analysis with varimax rotation were (factor loadings): 10 (0.81), 
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9 (0.74), 17 (0.66), and 31 (0.63) (Table 2.2). The sample frequency of SMQ 
"Addiction" factor scores was also negatively skewed and ranged from 0 to 13 with a 
mean of 4.26 (SD 2.8 1) (Figure 2.2). 
Factor 4 explained approximately 5% of the variance and was labelled "Sedative" 
(items loading on this factor pertained to smoking while relaxing). Factor 5 also 
explained approximately 5% of the variance and was labelled "Sensori-motor" (items 
loading on this factor pertained to sensory aspects of smoking). Factor 6 explained 
approximately 4% of the variance and was labelled "Automatic" (items loading on 
this factor pertained to sub-conscious smoking behaviours). The remaining factors 
were labelled "Postprandial", "Alcohol-associated", "Sharing" and "Oral"; these 
factors mainly had single items loading on them, and when combined accounted for 
10% of the variance. 
Totalled scores on the Fagerstrom Tolerance Questionnaire ranged from I to 9, with a 
mean of 3.9 (SD 1.98) (Figure 2.3). The FTQ is a powerful tool for identifying and 
diagnosing nicotine dependence, and Spearman's Rho demonstrated FrQ was 
significantly positively correlated with RFS "Addiction" factor (r--0.65, p<001,2- 
tailed) and with SMQ "Addiction" factor (r--0.52, p<001,2-tailed). 
The scores from the FTQ, "Addiction" factor scores from RFS and SMQ and the 
binary selection response to "would you say are you addicted to smoking? (Yes/No)" 
(self-reported addiction status) were considered important in the initial generation of a 
score quantifying a multi-source level of tobacco-dependence. Using and combining 
the data acquired using these questionnaire tools it was possible to formulate an 
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"addiction score" for each respondent. Scores from each component questionnaire 
were divided by their standard deviations in order to appropriately weight the items, 
and they were then summated to create a "composite addiction score". In this way it 
was possible to profile the sample in terms of how tobacco-dependent they were. 
o ADDICTION INDEX (composite addiction score) = addx 
* Reasons For Smoking "Addiction" Factor Score = RFSscx 
9 Smoking Motivation Questionnaire "Addiction" Factor Score = SMQscx 
* Fagerstrom Tolerance Questionnaire score = FTQx 
9 Self-reported addiction status = SRx 
Thus, each subject's Addiction Index was calculated by the following: 
addr RFSscx + smoscx + FTOx + SRx 
SD[RFSscxl SD[SMQscx) SD[FTQx) SD[SRx) 
This initial Addiction Index score ranged from 1.5 to 13.7 with a mean (SD) of 7.39 
(3.08). The resultant score distribution was normal (Gaussian), although negatively 
skewed (Figure 2.4). A median split was chosen to divide the addicted and non- 
addicted smoker groups. 
Many of the analyses performed when the groups were subdivided in this way 
indicated trends predicted by the experimental hypotheses, but with few significant 
results. Although there were several possible explanations for this (including the truth 
of the null hypotheses), it was likely that non-significant results were obtained due to 
the way subjects were allocated into their groups. 
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The model generating the Addiction Index was subsequently refined. Including 
subjects' own assessments of their addiction status (SRx) as an attempt to quantify 
nicotine addiction may not have been appropriate. It is likely that there will normally 
be considerable correlation between addicts' objective and subjective data regarding 
their status. However, not all addicts claim to be addicted, and likewise some non- 
dependent users will claim to be addicted to explain their behaviour. Although 
weighted, the SRx / SD(SRx) represented a considerable portion of the addx total. This 
was possibly responsible for non-addicts seeking to justify their smoking behaviour 
by defining themselves as tobacco-dependent, i. e. addicted. It was possibly also 
responsible for putting addicted smokers in denial of their addicted status in the non- 
addicted group. It was therefore decided to review the equation calculating Addiction 
Index without the subjective "are you addicted to smoking? " data, thus: 
addr RFSscx + smoscx + FTOx 
SD[RFSscx) SD[SMQscx) SD[FTQx) 
The new Addiction Index score ranged from 1.5 to 11.4 with a mean (SD) of 5.76 
(2.48). This changed the histogram profile of the sample. Although still negatively 
skewed, it showed a possible emergence of a bi-modal distribution (Figure 2.5). This 
distribution, because of the skewness, did not fail a test of normality and therefore 
cannot be formally labelled bi-modal. 
It was decided to define addicted and non-addicted groups by assun-dng Figure 2.5 
represented a true bi-modal distribution, with those subjects possessing an Addiction 
Index score of 8.00 or greater labelled "addicted". This yielded groups of 20 
"addicted" smokers and 83 "non-addicted" smokers from the 103 participants. To 
demonstrate meaningful dichotomy at the Addiction Index cutpoint of 8.0, the means 
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of the two groups were compared using a one-way analysis of variance and found to 
be significantly different (Fj 1,991=197.62, p<001). 
2.4.2 Demographic, behavioural and smoking belief differences between 
addicted and non-addicted smokers 
Following the factor analysis and generation of the Addiction Index scores, 
correlations and associations were performed to examine the relationships between 
the variables in the SQB (demographic, behavioural and beliefs) and the subgroup 
status or Addiction Index scores. Tables 2.3,2.4 and 2.5 present either means and 
standard deviations or relative percentages for addicted and non-addicted smokers for 
variables analysed in this section. 
2.4.2.1 Subgroup status (addicted vs. non-addicted) and association with 
demographic and behavioural variables 
Pearson Chi-square demonstrated that several SQB variables were associated with 
smoking group status. Addicted smoker status was associated with being male 
(x 2 =4.74, p<05). Self-reported addiction to smoking was associated with addicted 
smoker group status (Xý=8.65, p<01) (Figure 2.6). Parental awareness of participants 
smoking behaviour was associated with addicted smoker status ()? =6.34, p<05). 
Addicted smoker status was also associated with reported increased smoking when 
consuming tea or coffee ()? =10.24, p<001) (Figure 2.7), but not with reported 
increased smoking when consuming alcohol. 
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There was no significant association between smoker group status and mostly 
smoking in the daytime. Having a partner who smoked was not significantly 
associated with smoker group status. 
2.4.2.2 Correlation between demographic, behavioural and smoking 
beliefs and Addiction Index scores 
Spearman's Rho demonstrated that Addiction Index scores were positively correlated 
with number of cigarettes smoked each day (r--0.69, p<001, I-tailed), and that 
Addiction Index scores were positively correlated with number of months subjects 
had smoked (r--0.28, p<. Ol, I-tailed). No correlation was found between Addiction 
Index score and number of attempts to quit. 
Spearman's Rho also demonstrated that Addiction Index scores were negatively 
correlated with latency to first cigarette smoked after waking (r---0.65, p<. 001, I- 
tailed) (Figure 2.8). No correlation was found between Addiction Index score and age 
smoking behaviour commenced. 
Addiction Index scores were positively correlated with the following positive 
smoking beliefs as tested by Spearman's Rho: "smoking can help people relax" 
(r--0.38, p<001, I-tailed); "smoking can help people when they feel nervous or 
embarrassed" (r--0.17, p<05, I-tailed); "smoking improves concentration" (r--31, 
p<00 1,1 -tailed); "smoking is pleasurable" (r--0.3 1, p<00 I). 
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It should be noted that some of these significant associations and correlations might 
be explained by the fact that similar or related items included in the questions that 
contributed to the formulation of the Addiction Index score. 
2.5 Discussion 
These results suggest that the Smoking Questionnaire Battery administered was an 
effective tool for identifying levels of tobacco dependence. "Addiction" factor 
components derived from factor analyses of the RFS and SMQ were consistent with 
those indicated in the original reports. Using a composite model based on the data 
they provided and FrQ scores it was possible to establish an "Addiction Index" score 
representing an appropriate quantification of level of nicotine dependence. By 
profiling this sample's Addiction Index frequency data two groups of smokers were 
identified, labelled "addicted smokers" and "non-addicted smokers". "Addicted 
smoker" status was associated with being male, self-reporting addiction to smoking, 
parents knowledge that subject was a smoker, increased smoking when drinking tea or 
coffee. 
The Addiction Index score was positively correlated with number of cigarettes 
smoked per day, total number of months subject had been a smoker; and negatively 
correlated with latency to first cigarette after waking. The Addiction Index score was 
also positively correlated with believing that smoking can help people relax, can help 
people when they feel nervous or embarrassed, improves concentration and is 
pleasurable. The subgroups of addicted and non-addicted smokers were shown to 
possess good face validity and were functional in later chapters. Significant 
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differences between the subgroups' smoking behaviours, motivations and beliefs were 
demonstrated. 
The questions in the Smoking Questionnaire Battery are comprehensive in terms of 
asking people why they smoke, although some of the questionnaires used may be in 
need of updating. The principal components analysis performed on the RFS produced 
a five-factor structure comparable with the original Ikard et al. (1969) report. The 
current structure consisted of factor labelled "Addiction", "Negative affect reduction", 
"Stimulation", "Pleasurable relaxation" and "Sensori-motoe'. This factor structure 
was very similar to Ikard et al. (1969). The "Addiction" factor of the current study 
comprised the same questionnaire items in the original report, however this current 
analysis amalgamated the "Addictive" and "Habitual" factors of the original. In 
essence this does not present a theoretical difficulty, as it can be argued that the 
"Habitual" items effectively represent the behavioural. manifestation of the addiction. 
The "Addiction" factor of the current RFS analysis also included an item ("When I 
am trying to solve a problem, I light up a cigarette") in Ikard et al. 's (1969) 
"Reduction of negative affect" factor. This may have been an artefact, or perhaps an 
indication that smoking in order to alleviate stress may be correlated with nicotine 
dependence. it might be argued that this item is more relevant to stimulation smoking, 
but loaded very weakly on the "Stimulation" factor in the original report (-0.09), and 
only slightly more on the "Stimulation" factor in the current structure (0.26). It can be 
seen that the original and current factor structures are highly consistent, albeit that two 
factors have been combined in the present analysis. It was decided that factor scores 
from the RFS "Addiction" factor would be a valuable and effective tool in quantifying 
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nicotine dependence, as they cumulatively rate subjects' addiction- or dependence- 
based reasons for smoking. Hence they were used in the computation of the Addiction 
Index. 
The current SMQ analysis revealed a ten-factor structure. This was compared with 
Russell et al. 's (1974) six-factor structure. SMQ results were less consistent with 
original factor structure compared to the RFS, but still had many common factors and 
features of the original findings. The main six factors yielded here were highly similar 
to those of Russell et al. (1974); "Psychosocial", "Stimulation", "Addiction", 
"Sedative" (labelled "Indulgent" in the original structure), "Sensori-motoe' and 
"Automatic". Four particular items that would not load substantially on any of the 
main factors represented the remaining four factors. Two of these single-item factors 
loaded on the ma or factors found by Russell et al. (1974), while the other two were i 
not described by the original factor structure at all. 
Comparisons can readily be drawn between the original SMQ "Addictive smoking" 
factor (Russell et al. 1974) and the "Addiction" factor elicited in this current SMQ 
analysis. In both analyses, questionnaire items 9 (running out of cigarettes being 
unbearable), 10 (automatic smoking), 17 (aware of periods of not smoking) and 31 
(hunger to smoke following abstinence period) loaded on this factor. These were 
items Russell et al. (1974) had taken directly from the Ikard et al. (1969) report, and 
(as can be seen from Tables 2.1 and 2.2) these items loaded on the "Addiction" factor 
of the RFS. 
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Item 7 loaded on the "addiction" factor in the original analysis, but failed to reach the 
0.5 threshold in this study (0.48). Item 24 loaded unexpectedly in the original report 
(0.42), but not so markedly here (0.37). The two factor structures for the SMQ are 
somewhat consistent. Like the RFS, factor scores from the SMQ "Addiction" factor 
were considered to be a valuable and effective tool in quantifying nicotine 
dependence, since they cumulatively measure subjects' addiction- or dependence- 
based reasons for smoking. Hence they were also used in the computation of the 
Addiction Index. 
The general levels of nicotine tolerance in this sample were lower than those found in 
previous research. Mean FrQ scores in Fagerstr6m's (1978) original paper were 6.2 
and 7.2, compared with 3.9 in the current study. This difference is likely to be due to 
sample differences. FagerstrOm's (1978) subjects were clients at a smoking 
withdrawal clinic rather than predominantly undergraduates; they were also older and 
were heavier smokers than those in the current sample. The distribution of FTQ scores 
mirrors the negative skew distributions inferred by the "Addiction" factor scores of 
the SMQ and RFS. This was corroborated by the significant Spearman's correlations 
between FIQ and the two "Addiction" factors. This suggested that tolerance and 
addiction/dependence-based motivation to smoke were linked. These results are 
interpreted as suggesting that increased tolerance leads to increased addiction-based 
motivations to smoke. Hence FrQ scores were also used in the computation of the 
Addiction Index. 
Combining weighted scores derived from the "Addiction" factors of the RFS and 
SMQ and weighted total FrQ scores created the Addiction Index. This is the first 
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composite multi-source smoking-dependence scale of its kind. The frequency 
distribution was negatively skewed, probably due to the large number- of 
undergraduates in the sample. This may have meant the inclusion of a large number 
who have smoked for a relatively short time period and thus have not developed 
tobacco dependence or are in a transitional phase. Also, many students may be simply 
'social smokers'; i. e. having one or two cigarettes a day whilst out drinking with 
peers, etc. The emergence of a bi-modal distribution of addiction index scores 
represents an exciting finding in tobacco research. 
Although in essence nicotine dependence could be conceived as being on a 
continuum, it is shown here there are at least two definable subgroups of smokers in 
early adulthood. The relative sizes of the groups reflect the large sample skew better 
than the initial Addiction Index and median split division. 
It must be appreciated that what are termed "non-addicted smokers" in this research 
does not necessarily equate with "chippers". The latter refers to a group that not only 
has a sparse and erratic smoking style, but is also characterised by an absence of 
withdrawal symptoms in abstinence. At the time of this initial data collection, 
susceptibility to withdrawal and severity and profile of symptom data were not 
available, but these data are discussed in Chapter 6. It was assumed that the 
withdrawal profile would not necessarily be associated with pre-abstinent behaviour 
patterns (e. g. smoking less than five cigarettes per day) therefore the term "non- 
addiC'ted smoker" was used instead. 
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Furthermore, ascertaining true "non-dependence" requires evidence of stable regular 
low-level smoking over a considerable period. It may be that moderate levels of 
dependence coupled with reporting biases could lead to false categorisation. Smokers 
who have recently been trying to cut down, or who have recently started smoking and 
are just instantiating smoking behaviour patterns may also be erroneously categorised 
as "chippers" (Shiffman, 1989). These groups are in transitional phases, and therefore 
should not be called "chippers" in the true sense, rather "non-addicted smokers". This 
much more generic category can accommodate both "chippers" and low-level 
smokers in transitional phases of smoking behaviour. For investigative purposes of 
the research "non-addicted" is a functional category, although care must be taken 
drawing conclusions from data generated by this heterogeneous group. 
Removing subjects' self-reported "addiction status" from the Addiction Index 
computation was performed for reasons highlighted in the previous section. The 
disparity between objective and subjective assessments of addiction are borne out by 
the results, as 68% of the non-addicted smokers reported being addicted to smoking. 
This large figure may be partly due to ambiguity or subjectivity about the meaning of 
"addiction". Alternatively, less dependent smokers may be claiming to be in the grip 
of nicotine addiction as a means of reducing cognitive dissonance or 
obscuring/denying other reasons for smoking that may have a more internal locus of 
control. 
The addicted smokers group was predominantly male, whereas the non-addicted 
smokers were mainly female. This is broadly consistent with previous findings. 
Shiffman (1989) showed a trend to have greater proportions of males in the dependent 
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smokers group and more females in the chippers group. Subsequent research 
examining chippers has been heavily female-oriented since many studies used 
matched groups, and the apparent majority of chippers recruited are women (Kassel et 
al. 1994; Brauer, Hatsukami, Hanson & Shiffman, 1996). Furthermore, both Ward et 
al. (1969) and Russell et al. (1974) found trends for females to have lower (RFS and 
SMQ respectively) "Addiction" factor scores than males. Explanations for these 
differences are unclear, although previous research showed that males smoke more 
cigarettes, smoke cigarettes with higher tar and nicotine content, inhale more 
frequently and more deeply than females (Waingrow, Hom & Ikard, 1968). 
The addicted smoker group was associated with increased smoking when consuming 
caffeine. This is broadly consistent with previous research demonstrating a positive 
coffelation between caffeine and nicotine intake (Istvan & Matarazzo, 1984; Budney, 
Higgins, Hughes & Bickel, 1993). Addicted smokers may be deriving enhanced 
positive effects of smoking through concurrent caffeine use (Chait & Griffiths, 1983), 
or the use of caffeine may be increasing smoking frequency (Emurian, Ellis, Brady & 
Ray, 1982), possibly through accelerating nicotine metabolism (e. g. Tanda & 
Goldberg, 2000). Animal studies provide evidence of interaction effects of the two 
substances that may partly explain their commonly concurrent use. Chronic caffeine 
exposure has been shown to alter the subjective reinforcing effects of nicotine in rats, 
thus enhancing its addictive potential (e. g. Tanda & Goldberg, 2000). How these 
effects are brought about is unclear, although caffeine may increase the doparninergic 
action of nicotine (Shoiab, Swanner, Yasar & Goldberg, 1999). The coincidence of 
the two activities may be in part explained by environmental constraints and 
opportunities: e. g. break-times during a working day. 
77 
Addicted and non-addicted smokers Chapter 2 
Caffeine antagonises adenosine A2 receptors; stimulation of these receptors inhibits 
doparninergic activity as indicated by reductions in dopan-ýine receptor binding 
(Hillefors-Berglund et al. 1995) and increases in locomotor activation and conditioned 
place preference (Brockwell & Beninger, 1996). However, the association observed in 
the current study may be due to group differences in baseline tea and coffee 
consumption. Unfortunately these data were not acquired, so this explanation cannot 
be ruled out. 
No association was found between addiction group and increased smoking when 
consuming alcohol. All smokers reported increasing smoking when drinking. This is 
consistent with some previous research demonstrating a positive correlation between 
alcohol and nicotine intake (Istvan & Matarazzo, 1984; Schumann, Hapke, Rumpf, 
Meyer & John, 2001). As with caffeine and smoking, alcohol and tobacco are very 
often used concurrently. Again, animal studies offer some explanations as to why this 
might be. Reports have suggested that ethanol and nicotine produce combined effects 
on the mesolimbic dopamine pathway (Tizabi, Copeland, Louis & Taylor, 2002). This 
may explain why many heavy smokers also have high alcohol intakes (Istvan & 
Matarazzo, 1984), and why there is such a high incidence of smoking in alcoholics 
(e. g. Miller & Gold, 1998). 
This does not explain why non-addicted smokers should derive a high benefit from 
concurrent use of the drugs. It is possible that alcohol-induced disinhibition leads to 
increased smoking, or that environmental cues (e. g. sitting in a pub) may prime the 
behaviours. Although experimental and anecdotal evidence suggests people may 
experience heightened euphoria from using alcohol and nicotine together rather than 
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individually (Perkins, Sexton, DiMarco, Grobe, Scierka. & Stiller, 1995), human and 
animal work suggests that nicotine may counteract some of the cognitive performance 
deficits associated with alcohol intoxication (Kerr, Sherwood & Hindmarch, 1991; 
Gould, Collins & Wehner, 2001). Thus it may be that all smokers derive a variety of 
benefits from the stimulant effects of smoking when drinking alcohol. 
Addicted smoker status was not associated with smoking more during the daytime 
than the evening. This was not predicted, since Fagerstr6m (1978) showed that 
smokers who had higher nicotine tolerance were likely to smoke cigarettes during the 
daytime, particularly the morning, in order to boost plasma nicotine levels following 
overnight abstinence. This result is consistent with findings of other previous 
research, however. Shiffman (1989) showed no differences between chippers and 
dependent smokers in the distribution of smoking by time of day. This may be 
explained by the absence of chippers putatively fundamentally "social smoking"; if 
chippers or non-dependent smokers were simply social smokers a different temporal 
smoking pattern might be expected. However, Shiffman (1989) reported that chippers 
were as likely as dependent smokers to smoke alone, and no more likely to smoke 
when others are smoking. A similar explanation may account for the lack of 
association found between being an addicted smoker and having a partner who 
smoked. 
The association between addicted smokers and parents' awareness that subjects 
smoked was a novel result. The findings may reflect the difficulty of hiding a very 
frequent behaviour from people who have a close relationship with the subject. 
Alternatively the result may be an artefact of the subject sample, as it was 
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predominantly undergraduates who have relatively short smoking histories. The last 
point is supported by the observation that mean age was higher in the addicted 
smokers group. Furthermore, older smokers may be less motivated to hide their 
tobacco habits from their parents as the dynamic of that relationship changes. A final 
explanation could pivot on the parents' own smoking behaviour. This hypothesis is 
supported by previous results suggesting that chippers are less likely than dependent 
smokers to have parents that smoke (Shiffman, 1989; Presson, Chassin & Sherman, 
2002). Other research suggests that regular smokers are no more likely to have parents 
who smoke than chippers, but that close relatives of chippers are (if smokers) more 
likely to be chippers themselves (Kassel et al. 1994). This may mean that non- 
dependent smokers are less exposed to the smoking behaviours of their parents and 
are therefore less able to use their parents' habits as exoneration for their own. 
Unfortunately, parental smoking status data were not investigated by the SQB in the 
current study. 
A positive correlation was found between levels of tobacco dependence measured by 
Addiction Index scores and agreement with positive belief statements about smoking. 
These included the sedative, stimulant and hedonic putative effects of smoking. There 
are few previous studies regarding the relative smoking beliefs of dependent and non- 
dependent smokers. Haddad & Malak (2002) found that Jordanian students who 
smoked had more positive attitudes toward smoking than non-smokers, and disagreed 
with some of the criticisms against smoking. It is likely that general beliefs regarding 
the effects of smoking may reflect subjects' own motivations for smoking, or vice 
versa. Shiffman (1989) found that dependent smokers had significantly higher factor 
scores than chippers on the "Negative affect", "Stimulation" and "Indulgent" factors 
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on the SMQ. These are interpreted as manifestations of sedative, stimulant and 
hedonic beliefs about smoking respectively. Shiffman's (1989) findings suggest that 
current subjects were expressing beliefs that are actually held rather than behavioural 
justifications simply arising from cognitive dissonance. 
There are a number of methodological issues concerning this study. Unfortunately the 
cross-sectional sample yielded considerably more non-addicted smokers than addicted 
smokers. This was likely to have been due to the large number of undergraduates in 
the sample; they tended to have short smoking histories and/or smoking patterns 
structured by social patterns rather than tobacco dependence. It would have been 
preferable to improve the inclusiveness of the cross-section by recruiting more 
smokers from the general public. The Addiction Index could have been correlated 
with objective data regarding nicotine dependence (such as plasma nicotine levels, 
cue-reactivity or withdrawal sensitivity) by way of validating the scores generated. 
The SQB, although extensive, omitted several important questions. 
Acquiring data regarding subjects' baseline alcohol and caffeine intake would have 
allowed more focused and confident interpretation of results regarding concurrent use 
of these substances with tobacco. Details regarding the subjects' fan-dly history of 
smoking would also have been useful. It is possible family history data may have 
discriminated between the addicted and non-addicted groups in its own right, or may 
have interacted with other items to be an important covariant in the analyses. 
Using smoking motivation and nicotine tolerance self-report data, it was possible to 
create a tobacco Addiction Index scale from this sample of smokers. The resulting 
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profile allowed the sample to be split into groups labelled "addicted smokers" and 
"non-addicted smokers". In contrast to non-addicted smokers, addicted smokers were 
characteristically male, professed addiction to smoking, smoked more when 
consurning caffeine, and had parents who were aware of their habit. Disregarding the 
grouping, high scores on the Addiction Index were correlated with 1) smoking more 
cigarettes, 2) smoking sooner after waking, 3) having been a smoker for longer, and 
4) having stronger positive beliefs about smoking. The generation of a functional 
multi-source tobacco dependence scale was critical to the subsequent studies. Once 
this was achieved, through frequency modelling and later re-evaluation two valid 
subgroups were derived based on smoking dependency status. The Addiction Index 
scale and "addicted"/"non-addicted" groupings are used throughout the rest of this 
research. In future this Addiction Index scale could chart the progression of smokers 
behaviour over time to identify whether individuals transmigrate between the two 
functional groups, and if so, how long it takes for this transition to occur. 
82 
Addicted and non-addicted smokers Chapter 2 
Figure 2.1 Graph showing frequencies of subjects' Smoking Motivation 
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Figure 2.2 Graph showing frequencies of subJects' Reasons For Smoking 
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Figure 2.3 Cvraph showing frequencies of subjects' Fagerstr6m Tolerance 
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Figure 2.5 Graph showing frequencies of subjects' final Addiction Index 
scores not incorporating self-assessment of addiction status, and 
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Figure 2.6 Graph showing frequency of "yes" and "no" responses to SQB 
item asking "would you say you are addicted to smoking? " by 
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Figure 2.7 Graph showing frequency of "yes" and "no" responses to SQB 
item asking "do you rind that you smoke more when you are 








Figure 2.8 Scatterplot showing correlation between Addiction Index score 

































Addicted and non-addicted smokers 
Table 2.1 Items loading on the Reasons For Smoking scale "Addiction" 
factor 
Chapter 2 
ITEM RFS ITEM FACTOR LOADING 
NUMBER 
8 1 smoke cigarettes automatically without even 0.87 
being aware of it 
18 When I have run out of cigarettes I find it almost 0.75 
unbearable until I can get them 
22 1 do not feel contented for long unless I am 0.73 
smoking a cigarette 
13 Between cigarettes, I get a craving that only a 0.71 
cigarette can satisfy 
10 1 get a real gnawing hunger for a cigarette when 1 0.71 
haven't smoked for a while 
20 1 smoke cigarettes from habit, without even 0.66 
wanting the one I'm smoking 
5 1 am very much aware of the fact when I am not 0.65 
smoking a cigarette 
15 1 light up a cigarette without realising I still have 0.62 
one burning in the ashtray 
3 When I am trying to solve a problem, I light up a 0.55 
cigarette 
4 When I smoke a cigarette, part of the enjoyment is 0.54 
watching the smoke as I exhale it 
Table 2.2 Items loading on the Smoking Motivation Questionnaire 
"Addiction" factor 
ITEM SMQ ITEM FACTOR LOADING 
NUMBER 
10 1 smoke automatically without even being aware 0.81 
of it 
9 When I run out of cigarettes I find it almost 0.74 
unbearable until I can get them 
17 1 am very much aware of the fact when I am not 0.66 
moking 
31 1 get a real gnawing hunger to smoke when 1 0.63 
haven't smoked for a while 
87 
Addicted and non-addicted smokers Chapter 2 
Table 2.3 Mean and standard deviations of "Addiction" factor scores and 
responses to specific demographic and smoking behaviour 
questions in the Smoking Questionnaire Battery for addicted and 
non-addicted smoker groups 
roup G uroup NON-ADDICTED ADDICTED Item 
SMOKERS SMOKERS 
Niean (SD) age (years) 24.51 (13.04) 28.67 (17.58) 
Mean (SD) age when started 15.94 (2.21) 14.67 (4.39) 
smoking (years) 
Mean (SD) number of cigarettes 5.91 (11.30) 20.40 (6.39) 
smoked per day** 
Mean (SD) latency to first 243.51 (203.02) 18.48 (14.43) 
cigaretteof the day (minutes)** 
Mean (SD) number of attempts 1.44(2.06) 1.15(l. 49) 
to quit smoking 
Mean (SD) SMQ "Addiction" 3.37(l. 99) 7.86(2.69) 
factor score* 
Mean (SD) RFS "Addiction" 17.86 (5.80) 30.14 (8.22) 
factor score* 
Mean (SD) FrQ total score* 3.19(l. 40) 6.29(l. 93) 
*These scores were used in generating the Addiction Index score to create the groups 
"These questions were asked in categoric form in the FTQ 
Table 2.4 Percentage responding affirmatively to specific demographic and 
smoking behaviour questions in the Smoking Questionnaire 
Battery for addicted and non-addicted smoker groups 
NON-ADDICTED ADDICTED Item 
SMOKERS SMOKERS 
Percentage who "would say 67.9 100 
they are addicted to smoking" 
Percentage of male participants 65 38 
in the group 
Percentage whose parents know 58.8 89.5 
they smoke 
Percentage who smoke more in 15.6 25 
the daytime than evening 
Percentage who smoke more 50.6 90 
when they drink coffee/tea 
Percentage who smoke more 96.3 95 
when they drink alcohol 
Percentage who smoke more 8.6 15 
when they drink soft drinks 
Percentage of subjects with 56.9 70 
partners who smoke (if they had 
partners) 
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Table 2.5 Mean and standard deviations of agreement scores (range 0- 4) 
for addicted and non-addicted smoker groups on items in the 
Smoking Beliefs Inventory 
NON-ADDICTED ADDICTED 
SMOKERS SMOKERS 
Mean (SD) agreement to 3.12(0.80) 3.48(0.98) 
.1 smoking can help people relax" 
(0-4) 
Mean (SD) agreement to 2.89(l. 30) 2.38(l. 40) 
"smoking is a dirty habit" (04) 
Mean (SD) agreement to 3.02(0.79) 3.24(l. 00) 
61 
smoking can help people when 
they feel nervous or embarrassed" 
(04) 
Mean (SD) agreement to 1.89(l. 20) 2.38(l. 02) 
6. smoking improves 
concentration" (0-4) 
Mean (SD) agreement to 3.49(0.91) 3.38(l. 12) 
11 smoking does more harm than 
good" (0-4) 
Mean (SD) agreement to 1.16(l. 05) 1.33(l. 11) 
46 smoking improves memory" (0- 
4) 
Mean (SD) agreement to 3.60(l. 06) 3.38(l. 43) 
"children should be discouraged 
from smoking" (0-4) 
Mean (SD) agreement to 2.63(l. 11) 2.00(l. 34) 
61 smoking is a nuisance" (0-4) 
Mean (SD) agreement to 3.20(0.84) 3.24(1.14) 
"smoking is pleasurable" (0-4) 
Mean (SD) agreement to 3.89(0.55) 3.19(l. 36) 
"smoking can kill" (0-4) 
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Chapter 3- Mood and cognitive performance changes in nicotine 
withdrawal and subsequent reinstatement in addicted and non- 
addicted smokers 
3.1 Introduction 
A variety of negative changes in psychological state or function occur when 
dependent smokers abstain from smoking. This has been conceptualised as the 
tobacco withdrawal syndrome, and is described in DSM-IV. The syndrome includes 
symptoms such as craving for tobacco, irritability, restlessness and impairment on 
tasks requiring concentration (e. g. Hatsukami, Hughes & Pickens, 1985). This latter 
symptom is based on a large number of studies demonstrating that smokers do more 
poorly on some tasks when deprived of cigarettes as compared to a non-deprived 
smoking group (Wesnes & Warburton, 1983b). 
Tobacco withdrawal has been demonstrated to cause impairments in cognitive 
function, although these are not uniform across different measures. Heimstra et al. 
(1980) reported performance deficits on a psychomotor task following 24-hour 
cigarette deprivation. Other research has shown that tobacco deprivation had no effect 
or impaired performance on simple tasks (e. g. vigilance) (Elgerot, 1976; 1978) and 
had no effect or enhanced performance on complex tasks (e. g. mental arithmetic) 
(Myrsten, Elgerot & Edgren, 1977). Snyder & Henningfield (1989) reported that 
smokers who abstained from tobacco for 12 hours performed more poorly on a variety 
of cognitive tasks than they did under ad libitum smoking conditions. Snyder, Davis 
90 
Mood and cognition in withdrawal and reinstatement Chapter 3 
& Henningfield (1989) reported that tobacco deprivation significantly increased 
response latencies on five and decreased accuracy on two cognitive performance tests. 
The impairments peaked at 24-48 hours before returning toward baseline (non- 
deprived) levels. Snyder et al. (1989) also showed that these impairments were 
partially reversed after I hour of resumption of smoking, with all impairments 
returning to baseline levels within 24 hours of resumption of smoking. 
Abstinence from tobacco is associated with negative changes in mood in dependent 
smokers, hence the inclusion of symptoms such as irritability, anxiety and impatience 
in the withdrawal syndrome. Shiffman et al. (1995) reported that dependent smokers 
experience decreased arousal and increased mood disturbance, such as lowered 
hedonic tone, when withdrawn from tobacco. 
Previous studies suggest that smoking motivation factors may predict severity of 
nicotine withdrawal symptoms, and thus level of dependence or addiction (e. g. West 
& Russell, 1985). There is evidence of a sub-group of regular or habitual smokers - 
called "chippers" - who seem able to tolerate prolonged periods of abstinence with no 
overt or reported withdrawal symptoms (Shiffman, 1989). It is still unclear what 
mechanism allows these individuals to regularly self-administer nicotine -a highly 
addictive drug - without developing dependence as in the majority of smokers 
consuming comparable levels of the substance. Shiffman et al. (1995) examined the 
differences between chippers and dependent smokers during 48-hour periods of either 
smoking or abstinence. They found that chippers showed no changes in tobacco 
withdrawal, either in terms of self-report ratings of withdrawal symptoms or cognitive 
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performance, whereas dependent smokers task performance was slower when in 
abstinent conditions. Controversially, their overall results were conceptualised as 
demonstrating nicotine enhancing performance rather than withdrawal-mediated 
impairments. 
The aim of this study was to examine possible differences in changes of mood and 
cognitive performance, following nicotine withdrawal and reinstatement, between 
addicted smokers and non-addicted smokers. The predicted impairments to cognitive 
performance are indices of acute psychopharmacological changes and markers of 
withdrawal in their own right. Two hypotheses were examined: 
I. that addicted smokers will be more negatively affected by 24-hour nicotine 
withdrawal in terms of mood and cognitive performance compared with non- 
addicted smokers. 
Ii. that nicotine reinstatement will positively affect mood and cognitive 
performance of addicted smokers more greatly than non-addicted smokers. 
3.2 Method 
3.2.1 Design 
The study was a mixed design investigating three groups (N=75) comprising non- 
smokers (n=25), addicted smokers (n=10), and non-addicted smokers (n=40), as 
defined in Chapter 2. Subjects completed computer-based mood scales and cognitive 
tasks in three different sessions ("Baseline", "Withdrawn" and "Reinstated"). Fifty- 
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nine smokers who completed the Smoking Questionnaire Battery (see Chapter 2) did 
not participate in this experiment. 
The smokers were grouped as 'addicted' or 'non-addicted' following the completion 
of all questionnaires and performance trials. Grouping was achieved by computing the 
"Addiction Index" for each smoker, as described in Chapter 2. 
3.2.2 Subjects 
Subjects were recruited from a database at the Health Psychology Research Unit, 
University of Bristol. Recruitment posters placed in University departments, e-mails 
to student mailing lists and verbal communication, supplemented this database. The 
majority of subjects completing the Smoking Questionnaire Battery (n=109) were 
undergraduate or post-graduate students. The remaining subjects were recruited from 
outside the University. From this initial screening 50 smokers took part in this study. 
Non-smokers (n=25) were recruited in a similar manner to smokers. Non-smokers did 
not complete the Smoking Questionnaire Battery and were not breathalysed prior to 
the "withdrawn" session, as it was considered unnecessary. Subjects were paid E50, 
except non-smokers who received E30 since they were not paid for the inconvenience 
and discomfort of abstinence. 
3.2.3 Questionnaires 
Withdrawal Symptoms Checklist (WSC; Hughes & Hatsukan-ý, 1986) and 
Questionnaire of Smoking Urges (QSU; Tiffany & Drobes, 1991) were administered 
to subjects as part of the procedure. Due to the large amount of data this study 
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generated this chapter concentrates on the cognitive perfonnance and visual analogue 
mood scale data. Data from the WSC and QSU questionnaires are presented and 
discussed in Chapter 6. 
3.2.5 Computer tasks 
The computer test battery was derived from Broadbent's (1984; et al. 1984) human 
performance measurement system. Duration was the same for all experimental 
sessions. Tasks were always in the same order (with self-report mood scales at the 
beginning and end, and the eight cognitive performance tasks between), although 
target stimuli or data sets were changed for each of the sessions. The tests used are 
listed and briefly described below. These particular tests have been extensively used 
and validated (e. g. Smith, Wilson, Glue & Nutt, 1992). 
Mood I 
Subjects rated their current mood on 18 consecutively presented bi-polar visual 
analogue scales. These scales consisted of a horizontal line with extremes of emotion 
at either end (e. g. DEPRESSED and ELATED), and a short vertical bisect which 
subjects moved using the left and right keys on the control box to indicate on the scale 
how they felt at that moment. Each of the 18 items in the mood scales generated a 
score between I and 5 1. These items factorised onto three scales. Factor I (Alertness), 
Factor 2 (Hedonic Tone) and Factor 3 (Anxiety) were examined. See Appendix V. 
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Simple reaction time 
Subjects were presented with 5 minutes of trials on this task. In this task a frame of a 
box was displayed in the centre of the screen and at varying intervals (from 1-8 
seconds) a target square appeared inside the box. As soon as participants detected the 
square, they were required to press the response key marked SPACE using the 
forefinger of their dominant hand only. Reaction times below 200 milliseconds or 
greater than 750 milliseconds were eliminated from the raw data. See Appendix VI. 
Focused attention 
Subjects were presented with ten practice trials followed by 5 blocks of 64 trials 
(approximate duration of 6 minutes) on this task. In this task, target letters ('A' or 
'B') appeared in the centre of the screen. Participants responded to the target in the 
centre of the screen as quickly and accurately as possible, ignoring any distracters. 
Warning crosses were presented on the screen for 500 ms, before being replaced by 
the target letter. The central target letter was either accompanied by 1) nothing, 2) 
asterisks, 3) letters that are the same as the target or 4) letters that are different from 
the target. See Appendix VH. 
Categotic searchl divided attention 
Subjects were presented with ten practice trials followed by 5 blocks of 64 trials 
(approximate duration of 6 minutes) on this task. Two crosses were presented for 500 
ms either in the near location, or further towards the left and right extremes of the 
screen. The target letter then appeared in place of one of these crosses. In 50% of 
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trials the target letter 'A' or 'B' is presented alone, and in 50% of trials it is presented 
with a distracter (single digit). See Appendix VIII. 
Psychomotor (5-choice) 
This task lasted 5 minutes, and provided a measure of both speed and accuracy of 
movement to a choice of targets. Subjects were presented with five LED buttons 
arranged in a regular pentagon shape, with a sixth in the centre. They were required to 
switch each button off by pressing it as soon as it lit up. Only one button would be lit 
at any one time, and extinguishing a peripheral button would light the central one, and 
vice versa. See Appendix IX. 
Repeated digits detection R VIPI vigilance task 
This visual cognitive vigilance task measures the ability to detect targets at irregular 
intervals. In this task lasting 5 minutes, participants were shown successive 
presentations of three digit numbers in the centre of the screen at the rate of 100 per 
minute. Each three-digit number usually differed from the one immediately preceding 
it, with one out of the three digits being replaced with a different digit (e. g. 463,563, 
562). Eight times per minute the same three-digit number will be presented on 
successive trials. Participants were required to detect and respond to these repetitions 
as quickly as possible by pressing a key. See Appendix X. 
Mood2 
Subjects repeated the visual analogue mood scales presented at the start of the battery. 
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3.2.4 Procedure 
Chapter 3 
Subjects were given written information and consent was obtained. They were 
required to attend the Health Psychology Research Unit (HPRU) on a minimum of 
two occasions. Four sessions of computer-administered cognitive tasks were to be 
completed - Familiarisation, Baseline, Withdrawn and Reinstated. The latter two 
sessions were always performed consecutively. 
Familiarisation 
All subjects completed this 20-minute session prior to Baseline. This session 
consisted of shortened versions of the tasks utilised in the experimental sessions. On 
completion, subjects were invited to ask questions, and investigators checked data to 
ensure tasks were being performed correctly. 
Baseline 
Subjects attended the HPRU at 9.00 am, having been instructed to: 
a) Smoke as they normally would both in the previous evening and in the morning 
before attending the Unit. 
b) Refrain from excessive alcohol intake (>4 units) during the previous evening. 
c) Consume normal caffeine intake before attending the Unit, up to 20 minutes prior 
to arrival. 
d) Have a typical sleep pattern during the preceding night. 
e) Not exercise vigorously in the morning before attending the Unit. 
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9.00am. On arrival, subjects were shown to a booth and asked to complete the 
Baseline Session Pre-test Questionnaire. This booklet contained questions 
regarding eating, drinking and smoking behaviour in the last 24 hours, a 
Withdrawal Symptoms Checklist, and Tiffany & Drobes (1991) Questionnaire 
of Smoking Urges. These data are discussed in Chapter 6. 
9.10am. Participants were asked to supply a DNA sample (see Chapter 4). 
9.15am. Subjects then performed the full version of the battery of computer tasks. 
This took approximately 50 minutes. 
10.10am. Participants reminded of their appointment for the next session and of their 
abstinence requirements for that stage. 
10.15am. Subjects left HPRU- 
Withdrawn 
Subjects attended the HPRU at 9.00 am, having been instructed to: 
a) Smoke nothing in the preceding 24 hours before attending the Unit, and follow the 
conditions b) to e) as for the Baseline session. 
9.00am. On arrival, subjects were breathalysed using a carbon monoxide breathalyser. 
If <10 PPM (parts per million) CO count, then abstinence was assumed and 
the procedure was continued. Subjects were also asked to report if they had 
lapsed (smoked) during the abstinence period. These details were recorded. 
9.05am. Subjects completed the Withdrawn Session Pre-test Questionnaire (see 
Chapter 6). 
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9.15am. Subjects then performed the full version of the battery of computer tasks. 
This took approximately 50 minutes. 
10.10am. Upon completion of the computer tests by all participants in the laboratory, 
subjects were informed they had an hour before the final session. They were 
issued with ashtrays and advised that they could smoke at least I cigarette 
during the next 45 minutes. Participants smoked between I and 5 cigarettes in 
this period. During this hour, subjects were administered Cloninger's (1992) 
Temperament & Character Inventory (see Chapter 4). No caffeine or eating 
was permitted during this period, and subjects generally passed time reading. 
After 45 minutes, subjects were asked to extinguish any cigarettes and relax. 
Once the hour break was concluded, the next session commenced; 
10.55am. Subjects were asked to extinguish any cigarettes and relax. 
11.10am. Next session commenced. 
Reinstated 
11.10am. Subjects then completed the Reinstated Session Pre-test Questionnaire. This 
booklet consisted of questions regarding eating, drinking and smoking 
behaviour in the last hour, a withdrawal symptoms checklist, Tiffany & 
Drobes (1991) Questionnaire of Smoking Urges. Subjects then performed the 
full version of the battery of computer tasks. This took approximately 50 
minutes. 
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3.2.6 Statistical analysis 
Chapter 3 
Mood data was factorised to give scores on three axes (alertness, hedonic tone and 
anxiety). 
Statistical analyses were performed using BMDP (Bio-Mathematics Data Processing, 
Release 7) statistical software package. Univariate analyses of variance (ANOVA) 
with Tukey post-hoc tests were performed on the change scores. 
Correcting for multiple comparisons in the Focused Attention and Categoric Search 
tasks, since both tests examined large numbers of variables, was considered but not 
performed as it was deemed inappropriate. Although many statistical tests were 
performed in the analyses of both tasks, the precise variables tended to be highly 
correlated components of either accuracy or reaction time on the global cognitive 
attributes measured. Correcting for multiple comparisons would have therefore 
increased the likelihood of Type Il error. 
3.3 Results 
3.3.1 Effects of withdrawal on mood and cognitive performance 
Change scores were created for all variables in each cognitive test and mood rating by 
subtracting Baseline session scores from Withdrawn session scores. The mean change 
scores were then compared across the three groups (non-smokers, non-addicted 
smokers and addicted smokers). 
An overview of the observed effects of tobacco withdrawal is shown in Table 3.1. 
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3.3.1.1 Mood 
Chapter 3 
Neither Alertness or Hedonic Tone changes between Baseline and Withdrawn 
sessions were significantly different between the groups in either pre-test or post-test 
ratings. 
Pre-test Anxiety change scores from Baseline to Withdrawn session did not differ 
significantly between the subject groups. Post-test Anxiety factor change scores were 
significantly different according to group (F(2,72)=3.99, p<025). Addicted smokers 
reported increased post-test Anxiety following withdrawal, whereas the non-addicted 
smokers' Anxiety ratings decreased from baseline (see Figure 3.1). Non-smokers 
reported feeling slightly greater post-performance Anxiety in their second session. 
Lower scores on this factor indicated higher ratings on the mood scale items 
measuring Anxiety (relaxed-excited, troubled-tranquil, tense-calm). Tukey post-hoc 
analysis demonstrated that addicted smokers had significantly different changes in 
Anxiety to non-addicted smokers (p<05), and a non-significant trend for greater 
increases in Anxiety than non-smokers (p< 10) - 
3.3.1.2 Cognitive Performance 
3.3.1.2.1 Simple reaction time task 
No significant group effects were yielded from analysis of variance on change scores 
(Withdrawn minus Baseline) for this simple reaction time task. 
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3.3.1.2.2 Focused attention task 
Chapter 3 
A non-significant trend was observed for the groups to show different changes in 
accuracy responding to targets presented alone or with asterisks (F(2,721=2.99, 
p<06). Non-smokers change scores showed increased accuracy, while addicted and 
non-addicted smokers change scores showed decreased accuracy in the Withdrawn 
session (Figure 3.2). Tukey post-hoc analysis showed significant differences between 
non-addicted smokers and non-smokers change scores (p<05). 
3.3.1.2.3 Categoric search task 
Change scores in the number of long responses (lapses) on the categoric search task 
following withdrawal were significantly different according to group (F[2,721=4.86, 
p<025). All groups showed a reduction in number of long responses from Baseline to 
Withdrawn sessions (Figure 3.3). The addicted smokers had a greater reduction in 
number of long responses than non-addicted smokers following withdrawal (Tukey 
post-hoc analysis, p<01). 
Non-smokers became faster at encoding new information between Baseline and 
Withdrawn conditions whereas both groups of smokers, particularly the addicted 
group, became slower (F[2,72)=3.45, p<05) (Figure 3.4). Tukey analysis showed 
non-significant trend differences between non-smokers and both the addicted smokers 
and non-addicted smokers (both p< 10). 
All three groups became faster responding to targets presented alone or with asterisks 
in the categoric search task in the Withdrawn session, with addicted smokers and non- 
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smokers demonstrating greater acceleration of reaction time than non-addicted 
smokers (FJ2,721=4.66, p<025) (Figure 3.5). Tukey post-hoc analysis showed non- 
addicted smokers differed from non-smokers (p<. 05) and from addicted smokers as a 
non-significant trend (p< 10). 
3.3.1.2.4 Five-choice serial reaction time (psychomotor) task 
No significant group effects were yielded from analysis of variance on change scores 
(Withdrawn minus Baseline) for this psychomotor task. 
3.3.1.2.5 Repeated digits RVIP / Vigilance task 
A non-significant trend was observed for group effects on changes following 
withdrawal in 'number of hits' (correct response to targets) on the repeated digits 
vigilance/RVIP task (F12,72)=2.57, p<10). All three groups demonstrated decreases 
in the number of 'hits' in the Withdrawn session compared to Baseline. The addicted 
smoker group was most affected, with a mean of approximately one less 'hit' (Figure 
3.6). Tukey post-hoc test showed a non-significant trend of difference between 
addicted smokers and non-smokers (p< 10). 
3.3.2 Effects of nicotine reinstatement following 24-hour withdrawal on mood 
and cognitive performance. 
An overview of the observed effects of tobacco reinstatement is shown in Table 3.2. 
Change scores were created for all variables in each cognitive test and mood rating by 
subtracting Withdrawn session scores from Reinstated session scores. The mean 
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change scores were then compared across the three groups (non-smokers, non- 
addicted smokers and addicted smokers). 
3.3.2.1 Mood 
A non-significant trend for group effects on changes in pre-test Alertness from 
Withdrawn session to Reinstatement session was observed (F(2,721=2.61, p<10). 
Both smoking groups rated their pre-test Alertness higher in the Reinstatement 
session than in the Withdrawal session, whereas non-smokers rated their alertness 
lower in their final session (Figure 3-7). Tukey post-hoc analyses showed a non- 
significant difference between non-smokers and non-addicted smokers (p< 10). 
A significant group effect was shown on changes in post-test Alertness following 
reinstatement (F(2,72)=5.23, p<. 01). Both smoking groups rated their post-test 
Alertness higher in the Reinstatement session than in the Withdrawn session, whereas 
non-smokers rated their alertness lower in their final session (Figure 3.8). Tukey post- 
hoc analyses showed differences between non-smokers and non-addicted smokers 
(p<01), and a non-significant trend difference between non-smokers and addicted 
smokers (p< 10). 
Pre-test Hedonic Tone change scores (from Withdrawn to Reinstatement session) did 
not differ significantly between the subject groups. Group effects were shown on 
post-test Hedonic Tone changes following reinstatement (F[2,721=3.88, p<025). 
Both smoking groups reported improved Hedonic Tone in the Reinstated session, 
whereas non-smokers reported decreased Hedonic Tone in their final session (Figure 
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3.9). Differences between non-smokers and non-addicted smokers were significant 
(Tukey post-hoc analysis, p<. 05). 
Pre-test Anxiety change scores (from Withdrawn to Reinstatement -session) did not 
differ significantly between the subject groups. A non-significant trend was observed 
for group effects on changes in ratings of post-test Anxiety following reinstatement 
(F[2,72)=2.49, p<10). Non-smokers and non-addicted smokers showed a slight 
increase in post-test Anxiety from withdrawal session to reinstated session. Addicted 
smokers demonstrated a large decrease in post-test Anxiety after reinstatement 
(Figure 3.10). Tukey post-hoc analysis showed a non-significant difference between 
addicted and non-addicted smokers (p< 10). 
3.3.2.2 Cognitive Performance 
3.3.2.2.1 Simple reaction time task 
A significant group effect was demonstrated on total mean reaction time changes from 
Withdrawn session to Reinstated session in the simple reaction time task 
(F(2,72)=7.12, p<01). All three groups became slower in the Reinstated session, 
although Tukey post-hoc analysis showed the non-smokers reaction times decelerate 
more than both the non-addicted smokers (p<. Ol) and (as a non-significant trend, 
p< 10) addicted smokers (Figure 3.11). 
3.3.2.2.2 Focused attention task 
No significant results were yielded from analysis of variance on differential changes 
following reinstatement on these groups for this task. It would therefore appear that 
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reinstatement following 24-hour nicotine withdrawal does not affect focused 
attention. 
3.3.2.2.3 Categoric search task 
Group effects were shown for changes following reinstatement on reaction time taken 
to encode new information in the categoric search task (F(2,721=5.36, p<01). The 
smoking groups both became faster at encoding new information following 
reinstatement, whereas the non-smokers became slower in their final session (Figure 
3.12). Tukey post-hoc analyses showed non-smokers differed from both non-addicted 
smokers (p<. O 1), and non-significantly from addicted smokers (p< 10). 
A non-significant trend for group effects was observed on changes following 
reinstatement on reaction time responding to targets presented alone or with asterisk 
in the categoric search task (F j 2,72 1 =2.45, p< 10). All three groups became faster on 
these trials in the Reinstated session compared with Withdrawn session, but smokers 
(especially non-addicted) demonstrated the greatest improvement (Figure 3.13). All 
Tukey post-hoc comparisons were not significant. 
3.3.2.2.4 Five-choice serial reaction time (psychomotor) task 
No significant group effects were shown on changes following reinstatement for this 
task. It would therefore appear that reinstatement following 24-hour nicotine 
withdrawal does not affect psychornotor performance, as measured by the 5-choice 
serial reaction time task. 
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3.3.2.2.5 Repeated digits detection task 
Chapter 3 
No significant group effects were shown on changes following reinstatement for this 
task. It would therefore appear that reinstatement following 24-hour nicotine 
withdrawal does not affect vigilance or RVIP, as measured by the repeated digits 
detection task. 
3.4 Discussion 
Acute 24-hour abstinence from smoking was shown to have a variety of effects on 
cognitive function and negatively affect mood. Subsequent reinstatement through 45 
minutes of ad libitum smoking improved mood and cognitive performance, and in 
some cases reversed some of the withdrawal-induced deficits. Mood of addicted 
smokers was more adversely affected by tobacco withdrawal than the non-addicted 
group, demonstrated by a trend toward greater increases for addicted smokers than the 
non-addicted group in post-test Anxiety following withdrawal. There was a trend for 
reinstatement to cause greater reductions in post-test Anxiety in addicted smokers 
compared to non-addicted smokers, 
Addicted smokers cognitive performance was somewhat more enhanced than the non- 
addicted smokers following withdrawal. Lapses (long response times) on the 
categoric search task were significantly reduced by withdrawal in the addicted 
smokers compared with non-addicted smokers. A trend was observed for addicted 
smokers to be more accurate following withdrawal than non-addicted smokers on 
categoric search trials with neutral or no distracters. Few variables were differentially 
affected by reinstatement according to smoking group. Non-addicted smokers 
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experienced more accelerated reaction times on categoric search trials with neutral or 
no distracters. 
In terms of cognitive performance, nicotine withdrawal through 24-hour abstinence 
from smoking produced a variety of effects. There was a trend for smokers to perform 
less accurately in withdrawal on trials in the focused attention task. This contrasts 
with Snyder et al. 's (1989) findings, as they reported withdrawal affecting reaction 
time rather than accuracy on simple tasks. All subjects experienced fewer attentional 
lapses (long reaction times) in the categoric search task in the Withdrawn session. 
This was not predicted by the hypotheses, since lapses indicate loss of concentration, 
which was expected to occur, particularly in the addicted smokers. This finding is 
difficult to explain, but may indicate that addicted smokers were more focused on 
completing the tasks than other groups, perhaps in order to smoke as soon as possible. 
Alternatively the findings may reflect that addicted smokers were aware they needed 
to concentrate in order to compensate. 
All smokers became slower at encoding new information on the categoric search task 
in withdrawal. This is concordant with the findings of Snyder et al. (1989) using a 
comparable task (two-letter search), who showed that reaction times significantly 
slowed following 24-hour abstinence. Conversely, present data show smokers' 
reaction times were accelerated by withdrawal in categoric search trials where either 
no distracter or a neutral distracter was present. Comparing these findings with 
Snyder et al. (1989) is problematic since many more detailed and specific variables 
were generated by the current task. 
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There was a trend for smokers' performance on the vigilance/RVIP task to be 
impaired by withdrawal. This is consistent with previous findings (Snyder et al. 1989; 
Heimstra, 1980), and demonstrates the concentration difficulties described in the 
tobacco withdrawal syndrome. Snyder et al. (1989) used a serial subtraction/addiction 
task to test vigilance, and found that smokers' accuracy and response time was 
adversely affected by withdrawal. 
Addicted and non-addicted smokers demonstrated few clear differences in terms of 
cognitive response to withdrawal. There was a trend for addicted smokers to show 
more accelerated response times than non-addicted smokers in categoric search trials 
where either no distracter or a neutral distracter was present. This result is difficult to 
explain, and contrasts with the findings of Shiffman et al. (1995), who showed that 
dependent smokers response times become slower in withdrawal on mathematics and 
logic tasks, whereas chippers response times are unaffected. Although non-significant, 
there was a trend that the vigilance of addicted smokers was more impaired than that 
of non-addicted smokers following withdrawal. Although vigilance/RVIP was not 
investigated explicitly by Shiffman et al. (1995), this finding would be expected if the 
principles demonstrated by their tasks generalised to other aspects of cognitive 
performance requiring attention and/or concentration. 
Withdrawal had few effects on measures of smokers' mood. Post-test Anxiety was 
increased by 24-hour abstinence in the addicted smokers group. This increase was not 
found in the non-addicted smokers or non-smokers. Anxiety is a symptom of the 
tobacco withdrawal syndrome described in DSM-IV, and current findings parallel 
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those of previous research. Hughes & Hatukami (1986) found that abstinent smokers 
self-reported higher levels of anxiety than when they were non-deprived. Current 
findings are also broadly concordant with Shiffman et al. (1995), who showed that 
chippers "mood disturbance" was unaltered by withdrawal, but that dependent 
smokers "mood disturbance" was increased. Their "mood disturbance" factor featured 
several items that could be described as measuring anxiety. It is theoretically possible 
that addicted smokers are inherently more anxious than non-addicted smokers 
(discussed in Chapter 5) even prior to the onset of smoking, and these differences may 
re-emerge following abstinence. It is interesting that post-test and not pre-test Anxiety 
was affected by abstinence; perhaps addicted smokers felt their cognitive performance 
had been significantly worsened by withdrawal and were anxious primarily for that 
reason. 
Tobacco-withdrawn smokers' cognitive performance was generally enhanced by 45 
minutes of ad libitum smoking. Non-smokers simple reaction times were greatly 
increased in the third (Reinstated) session, whereas both smoking groups (although 
also increased) were much less decelerated/slowed. The non-smoker finding could be 
explained in terms of fatigue, with nicotine potentially demonstrating some protective 
efficacy against fatigue or boredom effects in the smokers. Similar results were 
yielded by the categoric search task, where non-smokers became slower encoding 
new information in their third session whilst all smokers became faster following 
reinstatement. This was the only specific cognitive performance variable that was 
shown to be both impaired by withdrawal and enhanced by reinstatement. 
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These findings are concordant with Snyder et al. (1989), who found that reaction 
times on all the cognitive tasks they examined were improved following tobacco 
reinstatement. This may reflect reductions in cholinergic function caused by 
abstinence, which are returned to baseline levels through reinstatement (e. g. Rezvani 
Levin, 2001). 
A trend was observed for non-addicted smokers reaction times to be more greatly 
accelerated following reinstatement than addicted smokers (and non-smokers) in 
categoric search trials with a neutral or absent distracter. These trials may be sensitive 
to learning effects since all subjects had progressively accelerated responses with each 
session. These findings suggest that non-addicted smokers derived greater cognitive 
facilitation from ad libitum smoking than addicted smokers on these task trials. Such a 
finding implies a direct effect of tobacco rather than a reversal of withdrawal effects. 
Shiffman et al. (1995) did not examine differential reinstatement effects on cognitive 
performance of chippers and dependent smokers, but their results suggested that 
cognitive performance was improved by nicotine rather than worsened by withdrawal. 
However, Shiffman et al. (1995) did not show improvement of cognitive performance 
in chippers through smoking. The contrast with current findings may be due to the 
important differences in typology between "chippers" and "non-addicted smokers". 
"Chippers" are a stable non-dependent group whereas "non-addicted smokers" is a 
rather non-specific category. The latter group may contain individuals who are simply 
in transitional stages of smoking behaviour, and therefore may be in transitional levels 
of nicotine dependence. 
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Reinstatement was shown to have several effects on mood. Following ad libitum 
smoking, all smokers rated their post-test Alertness and (non-significantly) pre-test 
Alertness higher than when tobacco withdrawn. This finding is concordant with some 
previous research showing that acute smoking increases subjective arousal (Parrott, 
1995b), although other studies have not replicated this effect (Shiffman et al. 2002). 
However, these previous studies did not have such an extensive withdrawal period 
prior to acute smoking, making direct comparison difficult. Reinstated smokers also 
experienced increases in post-test Hedonic Tone, demonstrating a marked 
improvement in mood following the removal of withdrawal. 
Although direct comparison is problematic due to differences in methodology, these 
findings are broadly consistent with previous research where smokers rated 
themselves as happier and more sociable after smoking (Warburton, 1994). However, 
whether or not nicotine has a direct effect on mood and cognitive performance in 
humans or whether the majority or all its observed effects are a result of factors such 
as withdrawal reversal is a highly contentious area (e. g. Heishman, 1998; Waters & 
Sutton, 2000). 
A trend was observed for addicted smokers to rate their post-test Anxiety lower 
following reinstatement, compared to small increases in non-addicted smokers and 
non-smokers. This is consistent with some previous research, although Kassel & 
Shiffman (1997) suggest that nicotine's effects on anxiety may be mediated through 
its cognitive effects. They reported that when smokers are presented with a benign 
distracter task, smoking might improve attentional focus. Therefore, these smokers 
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are less distracted by internal and external stimuli that may promote anxiety. This 
explanation does not adequately explain the findings of the current study, since only 
the addicted smokers experienced a reduction in Anxiety, whilst both smoking groups 
experienced modest improvements in cognitive task performance following 
reinstatement. 
There are a number of potential issues that need addressing in this study. Greater 
numbers of subjects in the addicted smokers group would have added power to the 
statistical analyses. This could have resulted in several non-significant trends 
becoming significant effects, and may have elicited significant withdrawal effects on 
more variables. Secondly, although expired breath CO is a convenient way of testing 
whether a smoker has complied with the abstinence protocol, it is not infallible. 
Plasma nicotine or salivary cotinine levels with individual baseline measures would 
provide a more robust verification of abstinence. 
Although this study examined a control group of non-smokers, future designs should 
look into administering nicotine to the non-smokers, or by having further groups of 
smoking participants who were not abstinent. This would have engendered further 
ethical and/or methodological issues, but may have clarified whether effects found in 
the Reinstatement condition were due to withdrawal reversal or any absolute effect of 
nicotine on mood or cognition. The 24-hour abstinence period was chosen since 
withdrawal symptoms are generally at their most severe at this time (Snyder et al. 
1989). It would also be desirable to examine several different abstinence epochs; this 
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would allow analysis of the time-course of withdrawal, and any further differences 
therewith between addicted and non-addicted smokers. 
The present study provides a profile of addicted and non-addicted smokers mood and 
cognitive responses to smoking abstinence and reinstatement. 24-hour tobacco 
withdrawal caused increased Anxiety in addicted smokers, but caused both positive 
and negative effects on cognitive performance; addicted smokers often performed 
better in the Withdrawn session. Reinstatement through 45 minutes ad libitum 
smoking increased Alertness and Hedonic Tone, while addicted smokers also 
demonstrated modest reductions in Anxiety. Non-addicted smokers derived apparent 
cognitive facilitation from nicotine on the categoric search task. The study suggests 
that addicted and non-addicted smokers are not well characterised by differences in 
their cognitive performance responses to nicotine withdrawal and reinstatement, 
although anxiety (a symptom of the tobacco withdrawal syndrome) may critically 
discriminate these groups. 
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Figure 3.1 Graph showing different changes in post-test Anxiety scores 
following abstinence for the three groups. Data are pi-cscrited its 
mean change scores (n=75-, non-smokcrs n=25, non-addicted smokers 
n=40, addicted smokers n=10), and error bars denote ± standard error 
of the mean (S. E. ). Chanore scores were COMPLIted by sLibtracting 
Baseline (non-deprived) session scores from Withdrawn (24-hoLir 
abstinence) session scores. Addicted smokers differed to non-addicted 
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Figure 3.2 Graph showing different changes in accuracy responding to 
targets presented alone or with asterisks in the focused attention 
task following abstinence for the three groups. (Foi- details see 
legend to Figme 3.1. Non-addicted smokei-, dil'I'ei-ed to non-sniokei-s, r-I Ir 
p<. 05). 
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Figure 3.3 Graph showing different changes in number of lapses (responses 
>10OOms) in the categoric search task following abstinence for the 
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Figure 3.4 Graph showing different changes in speed of encoding new 
information in the categoric search task following abstinence for 
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Graph showing different changes in reaction time responding to 
targets presented alone or with asterisks in the categoric search 
task following abstinence for the three groups. (Foi- clctýdl. s sec 
le(micl to Figui-e 3.1. Non-addicled smokei-s difTei-ed I'mm iioii- I L- 
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Figure 3.6 Graph showing different changes in 'number of' hits' on the 
repeated digits vigilance/RVIP task following abstinence for the 
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Figure 3.7 Graph showing different changes in pre-test Alertness scores 
following reinstatement for the three groups. Data are I)resented as 
mean chanore scores (n=75, non-smokers n=25, non-addicted sniokers 
n=40, addicted smokers n= 10), and error bars denote ± standard error 
of the rnean (S. E. ). Change scores were cornpLited by sLihtracting 
Withdrawn (24-hour abstinence) session scores froni Reinstatcnient 
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Figure 3.8 Graph showing different changes in post-test Alertness scores 
following reinstatement for the three groups. (Foi- details see legend 
to Figure 3.7. Non-addicted sinokei-s dit'let-ed to non-sniokers, p<. O I). 
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Figure 3.9 Graph showing different changes in post-test Hedonic Tone scores 
following reinstatement for the three groups. (For details see Icoend C_ 
to Figure 3.7. Non-addicted smokers difTered to non-smokers, p<. 05). 
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Graph showing different changes in post-test Anxiety scores 
following reinstatement for the three groups. (Foi- details see legend 














Figure 3.11 Graph showing different changes in mean total reaction time in the 
simple reaction time task following reinstatement for the three 
groups. (For details see legend to H-Ure 3.7. Non-addicted smokers 
differed to non-smok-ers, p<. O I 
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Figure 3.12 Graph showing different changes in speed of encoding new 
information in the categoric search task following reinstatement 
for the three groups. (For details see Ic,,, end to FigLire 3.7. Non- 
















Figure 3.13 Graph showing different changes in speed of encoding new 
information in the categoric search task following reinstatement 
for the three groups. (Foi- details see leoend to Fi,, Lii-c 3.7). 
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Table 3.1 Summary of changes (relative to controls) in the mood and 
cognitive performance battery from the Baseline (non-deprived) to 
Withdrawn (24-hour abstinence) session in the smoking groups. 
T=increase (or improvement), J=decrease (or decrement), Tj=some 
variables improved, others impaired, --+=no change. 
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Table 3.2 Summary of changes (relative to controls) in the mood and 
cognitive performance battery from the Withdrawn (24-hour 
abstinence) to Reinstated (post-45-minute ad libitum smoking) 
session in the smoking groups. T=increase (or improvement), 
TT=many variables improved, J=decrease (or decrement), -+=no 
change. *Although SRT performance was impaired for smokers 
following reinstatement, the increases in reaction times were less than 
those for non-smokers, suggesting an anti-fatiguing effect of smoking. 
`_ý GROUP 7 NON-ADDICTED ADDICTED SMOKERS 
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Chapter 4- Dopamine receptor genetics, novelty-seeking personality 
types and smoking behaviour 
4.1 Introduction 
Smoking induces feelings of pleasure in those who are regular tobacco users, as most 
drugs subject to abuse increase hedonic tone. The nicotine in tobacco smoke is 
believed to be responsible for these effects. Doparnine, a major neurotransmitter of 
the central nervous system, is thought to be involved in the mesolimbic reward 
pathway (Wise & Rompre, 1989; Koob, 1992; Di Chiara, 1999). Nicotinic receptors 
have been identified on the doparninergic cell bodies, and stimulation of these 
receptors by nicotine has been shown to cause an increase in release of doparnine in 
the nucleus accumbens (Pontieri et al, 1996). This structure is an integral part of the 
ascending mesolimbic system. 
Increasing evidence suggests that polymorphisms; of the dopaminergic system genes 
may be linked to susceptibility to a variety of conditions including alcoholism (Blum 
et al. 1990), polysubstance abuse (Smith et al. 1992), cocaine addiction (Noble et al. 
1993) and pathological gambling (Comings et al. 1996b). Whilst environmental 
factors may be important determinants of smoking, the results of association, family 
and twin studies suggest that initiation and maintenance of smoking also involves 
hereditary factors (Hughes et al. 1986; Heath et al. 1995; Carmelli et al. 1992). 
Due to the likely involvement of the mesolimbic doparnine system in nicotine 
addiction, several studies have examined dopamine receptor polymorphisms, in 
relation to this condition. Studies looking at Caucasian populations in the United 
125 
Dopamine receptor genotypes Chapter 4 
States have shown a relationship between either the DRD2*A I or the *B I allele and 
genetic predisposition to smoking behaviour (Noble et al. 1994; Comings et al. 1996a; 
Spitz et al. 1998), although this association was not confirmed in a United Kingdom 
population (Singleton et al. 1998). A study of Japanese found different results again, 
with smoking behaviour shown to be associated with DRD2*A2 (homozygous) 
genotype (Yoshida et al. 2001). Other studies have found no linkage between DRD2 
and smoking (e. g. Bicrut et al. 2000). 
DRD3 receptor genetics have also been implicated in addictive behaviour, with 
associations demonstrated between homozygosity and both cocaine dependence 
(Comings et al. 1999) and opiate dependence (Duaux et al. 1998). To date, no studies 
have examined the association between DRD3 polymorphisms and smoking 
behaviour. 
An association between smoking behaviour and the DRD4 exon III L allele 
polymorphism has been reported for an African-American population (Shields et al. 
1998). This study found that after smoking cessation counselling, individuals with the 
L allele were much less likely to be abstinent at 2 months compared with subjects 
who were homozygous for the S allele. This association, however, was not found in 
Caucasian subjects. Shields et al. (1998) also report that subjects who had at least one 
L allele had higher risk of smoking, shorter time to first cigarette in the morning and 
earlier age at smoking initiation. Associations have also been found between the 
DRD4 L allcle polymorphism and opiate dependence (Kotler et al. 1997; Li et al. 
1997), suggesting that D4 receptor genetics may have some basic influence on 
addiction per se. 
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The doparnine system and smoking behaviour may be linked via inherited personality 
traits. Gray (1973) purported that personality traits reflect motivational systems that 
evolved to increase adaptation to classes of stimuli associated with positive and 
negative reinforcement. Personality questionnaires have been developed (e. g. Tri- 
dimensional Personality Questionnaire (TPQ) (Cloninger, 1987) and Temperament & 
Character Index (TCI) (Cloninger et al. 1993)) as tools to study the genetics of 
personality, and these have been widely used. These questionnaires draw on human 
and animal work to suggest that behaviour is mediated by certain neurotransmitters, 
which underlie three basic heritable dimensions. 
The temperament dimension 'Novelty Seeking' (NS) draws on aspects of 
impulsiveness, curiosity (or exploratory behaviour) and disorderliness, and is believed 
to reflect dopaminergic function. impulsivity (a sub-scale of NS) perhaps represents 
the strongest link to smoking behaviour. People with high levels of impulsivity are 
thought to be more likely to experiment with psychoactive drugs and possibly become 
regular users (Johnson et al. 1993; Logue, 1995). Various studies report higher levels 
of impulsivity in smokers than non-smokers (Williams, 1973; Golding et al. 1983; 
Zuckerman et al. 1990; Jenks, 1992; Mitchell, 1999). 
There is strong evidence of an association between the DRD4 L allele and 
Cloninger's NS personality trait (e. g. Ebstein et al. 1996; Benjamin et al. 1996). Since 
smokers showed higher NS rates than the general population (e. g. Pomerleau et al. 
1992; Zuckerman et al. 1990), it is likely that the L allele is associated with smoking, 
concordant with Shields et al. 's (1998) findings in African-Americans. 
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The current study investigated the inter-relationship between personality traits, 
DRD2, D3 and D4 genetic polymorphisms, and smoking behaviour. 
Three experimental hypotheses were tested: 
1. that addicted smokers will be more likely than non-addicted smokers to 
possess the *Al polymorphism for DRD2 TaqIA, and possess homozygous 
DRD3 Ball genes. Furthermore, all smokers will be more likely to possess the 
DRD2*A I and homozygous DRD3 genotypes than non-smokers. 
II. that there is an association between Novelty Seeking and DRD4 exon III 
polymorphism, with those subjects scoring higher on the Novelty Seeking 
scale more likely to possess the L allele of this gene. 
III. that addicted smokers will be more likely to possess the DRD4 L allele 
compared with non-addicted smokers, and that together high Novelty Seeking 




This was a between subjects comparison of three groups (non-smokers, addicted 
smokers and non-addicted smokers) using Cloninger's (1993) Temperament & 
Character Inventory and genotyping polymorphisms of D2 (DRD2 TaqIA), D3 
(DRD3 Ball) and D4 (DRD4 exon IH) dopamine receptors. 
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4.2.2 Subjects 
Chapter 4 
Subjects (N=77) participated as part of the mood and cognitive performance study 
presented in Chapter 3. The participants were categorised as non-smokers (n=25), 
addicted smokers (n=10) and non-addicted smokers (n=42). Two participants 
provided a DNA sample, but quit the study prior to completion. A full description of 
the subject sample and recruitment information is included in Chapters 2 and 3. 
4.2.3 Materials 
Cloninger's (1993) Temperament & Character Inventory (TCI) was used to measure 
Novelty Seeking. This is a 240-item true-false self-report questionnaire, taking 
approximately 45 minutes to complete. It was administered as a pen-and-paper 
questionnaire, with written instructions. Seven dimensions of personality were 
derived: the original three Tridimensional Personality Questionnaire scales (or 
"temperaments") of Novelty Seeking, Harm Avoidance and Reward Dependence 
(Cloninger et al. 1994) and a fourth dimension, Persistence. Three "character" 
dimensions were also derived: Self-directedness, Cooperativeness and Self- 
transcendence. The TO also measured 25 more specific traits that define the 
temperament and character dimensions: these are presented as sub-scales of each. The 
full questionnaire can be seen in Appendix XI. 
DNA was collected using buccal DNA collection kits. Each of these comprised of a 
barcode-labelled stoppered plastic test tube containing 10ml saline and a pack of 10 
buccal stick swabs. Each swab was used and placed into the solution: when all 10 
were completed the tube was sealed and stored at room temperature, out of direct 
light. 
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4.2.4 Procedure 
Chapter 4 
All participants gave informed written consent, and were notified which genes would 
be examined. The consent form is included in Appendix XII. 
Once all samples for all subjects were collected, these were sent to Dr David Ball at 
The Social Genetic and Developmental Psychiatry Research Centre laboratory at the 
Institute of Psychiatry, Denmark Hill, London. Here the DNA was extracted from the 
cheek cell material contained in the buccal swabs and the doparnine receptor 
polymorphisms of the participants' genotypes were characterised. A laboratory 
technician blind to subjects' identities carried out PCR amplification. 
Buccal cells collected in the oral swabs were pelleted and lysed in 3. OmI of cell lysis 
solution. The crude DNA extract was deproteinated with 300gg of proteinase K for 2 
hours at 55'C, and an additional 30011g of proteinase K were added for overnight 
digestion. RNA was digested by adding 60gg of Rnase A for 30 minutes at 37'C. 
Protein from the DNA extract was removed with I. On-d of protein precipitation 
solution after centrifuging at 2000 xg for 10 minutes, washed in 70% ethanol, briefly 
air-dried, and resuspended in TLE (10 mM Tris-HCI, 0.1 mM EDTA, pH 7.4) buffer. 
DRD2 analysis 
DRD2*A genotypes were determined by means of PCR using sense (5'- 
CCGTCGACCCTTCCTGAGTGTCATCA-3') and antisense (5'-CCGTCGACGGC 
TGGCCAAGTTGTCTA-3') oligonucleotide primers (Noble et al. 1994). The 
resulting PCR products were digested with TaqI, followed by electrophoretic 
separation on 3% agarose gels. 
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DRD3 analysis 
Chapter 4 
Baff restriction fragment length polymorphism at the first exon was performed 
according to the method described by Lannfelt et al. (1992). The primers used for 
DNA amplification were 5-GCTCTATCTCCAACTCTCACA-3' and 5- 
AAGTCTACTCACCTCCAGGTA-3'. PCR reaction contained 150ng genomic DNA, 
2U Taq polymerase, Ix Taq polymerase buffer, 0.5jtM each primer, I OOgM dATP, 
dCTP, dGTP, dTTP, 0.01% gelatin in a total volume of 501A. Samples were heated to 
95'C for 6 minutes to denature DNA. Thirty-five cycles were performed according to 
the following steps: 92'C for I minute, 56'C for I minute, 72*C for I minute, 
followed by a final extension of 7 minutes. 
The PCR products were subsequently digested with MscI restriction enzyme 
(isoschizomer of Ball) for 2 hours and the digested products were analysed on a 3% 
agarose gel. This polymorphism revealed a2 allele system, allele I was 304 bp in 
length, allele 2 consisted of two fragments of 206 and 98 bp in length. Two constant 
bands at III and 47 bp were present. 
DRD4 analysis 
The DNA region containing the 48 base pair repeat in exon III of the DRD4 gene was 
amplified using primers D4-3 (5'-GCGACTACGTGGTCTACTCG-3') and D4-12 
(5'-GGTCTGCGGTGGAGTCTG-3'). PCR conditions were chosen according to the 
method by Lichter et al. (1993) with the exception that the initial denaturing step was 
extended to 5 minutes. PCR fragments were separated in 15% polyacrylamide gels 
(acrylamide: bisacrylamide = 49: 1) containing 1x TBE and visualised by silver 
staining (Budowle et al. 1991). 
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4.3. Results 
4.3.1 DRD2*A Taql Polymorphism 
Chapter 4 
The DNA encoding for DRD2*A presents 2 alleles. These genes are either 
homozygous (both alleles being the same) or heterozygous (different alleles). The 
sample (N=73, DRD2 data unobtainable for 4 subjects) contained all three possible 
genotypes: Al/Al (n=5,6.8%), AIIA2 (n=24,32.9%) and A2/A2 (n=44,60.3%), see 
Figure 4.1. Thus 29 subjects (39.7%) possessed the Al allele (see Figure 4.2). The 
difference in distribution of the DRD2*A genotype among addicted smokers, non- 
addicted smokers and non-smokers (see Table 4.1) was non-significant as determined 
by the chi-square test (Fisher Exact used due to low observed cell counts). It was 
observed that participants who smoked (regardless of addiction status) were more 
likely to have the A2/A2 genotype, although this was not statistically significant 
(Table 4.2, Figure 4.3). 
4.3.2 DRD3 BaII Polymorphism 
The DNA encoding for DRD3 BaII presents 2 alleles. These genes are either 
homozygous or heterozygous. The sample (N=7 1, DRD3 data unobtainable for 6 
subjects) contained all three possible genotypes: 1-1 (n=29,40.8%), 1-2 (n=35, 
49.3%) and 2-2 (n=7,9.9%) (Figure 4.4). Thus 36 subjects (50.7%) possessed 
homozygous DRD3 BaII genes. The difference in distribution of the DRD3 BaII 
genotypes among addicted smokers, non-addicted smokers and non-smokers (see 
Table 4.3) was non-significant as determined by the Pearson chi-square test. Results 
were non-significant both when the sample was clustered by the three genotypes and 
when homozygous subjects were compared with heterozygous subjects. It was 
observed that participants who smoked (regardless of addiction status) were more 
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likely to possess a hornozygous DRD3 Baff genotype, although this was not 
statistically significant (Table 4.4, Figure 4.5). 
4.3.3 DRD4 exon III Polymorphism and Novelty Seeking 
The DNA encoding for DRD4 exon HI presents with 2 alleles. These genes are either 
homozygous or heterozygous. The sample (N=77) contained 10 different DRD4 
genotypes (Figure 4.6), whereby the most conunon alleles are the D4.2, D4.4 and 
D4.7 polymorphisms, (Table 4.5). Subjects homozygous for the D4.4 alleles represent 
the largest portion of the variations, followed by those heterozygous for D4.4 and 
D4.7 alleles. Subjects were divided into two groups: L allele (D4.7 or D4.8) present 
(n=24,3 1% of sample), and L allele absent (n=53,69% of sample) (Figure 4.7). 
Five (50%) of the addicted smokers possessed the L allele for DRD4, compared with 
only twelve (29%) of the non-addicted smokers and seven (28%) of the non-smokers 
(Figure 4.8). The association between possession of DRD4 L allele and smoking 
group was not significant when examined using Pearson chi-square. 
The relationship between scores of Novelty Seeking (NS) and its sub-scales and the 
presence of the L allele of DRD4 was investigated. NS and its component subscale 
means were higher when the L allele was present (Table 4.6). Two subjects did not 
complete TCI questionnaires, hence the reduction in group sizes. The subjects 
possessing the L allele had significantly greater NS scores (FJ 1,73)=4.26, p<05) than 
those lacking the L allele. Of the sub-scales, Impulsivity demonstrated significantly 
higher scores with the presence of L allele (F(1,731=5.74, p<025), and 
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Disorderliness showed a non-significant trend for the L allele present group to have 
higher scores (F ( 1,73 1 =3.42, p=. 068). 
Addicted smokers score higher on NS and all its sub-scales (particularly 
Impulsiveness) compared to non-addicted smokers, with non-smokers being lower 
than all smokers (see Table 4.7). Analyses of variance with Tukey post-hoc analyses 
were performed to examine the differences between the groups. Novelty Seeking was 
shown to differ according to smoking group (F(2,721=7.97, p<001). Both addicted 
smokers (p<001) and non-addicted smokers (p<025) had significantly higher NS 
scores than non-smokers. 
Impulsiveness subscale was shown to differ according to smoking group 
(F(2,721=7.98, p<001). Both addicted smokers (p<001) and non-addicted smokers 
(p<025) had significantly higher Impulsiveness scores than non-smokers. There was 
also a trend for addicted smokers to have higher Impulsiveness scores than non- 
addicted smokers, which marginally failed to reach significance (p=. 057) (Figures 4.9 
and 4.10). Extravagance (F[2,72)=5.08, p<01) and Disorderliness (F[2,721=5.21t 
p<01) were also both shown to differ according to smoking group; in both subscales 
both addicted (p<. 025) and non-addicted (p<05) smokers had higher scores than non- 
smokers. 
4.4 Discussion 
The results of this study demonstrated non-significant trends for associations between 
polymorphisms, of D2, D3 or D4 doparnine receptors and smoking behaviour. 
Furthermore, significant relationships were found between the DRD4 L allele and NS 
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personality trait, with subjects possessing the L allele shown to have higher NS, 
particularly higher Impulsivity. It was also shown that NS scores differed between 
groups with different smoking behaviours. Addicted smokers and non-addicted 
smokers had significantly higher NS than non-smokers; again particularly in the 
Impulsivity subscale, but also shown in the Extravagance and Disorderliness 
subscales. A trend for addicted smokers to demonstrate higher Impulsivity than non- 
addicted smokers narrowly failed to reach significance. It is argued that DRD4 
polymorphism is likely to be indirectly linked to smoking behaviour via novelty 
seeking personality traits. 
No association was observed between the DRD2*A Taql genotypes and smoking 
behaviour. This finding supports Bierut et al. 's (2000) study showing no linkage 
between DRD2*A polymorphism and smoking behaviour. The incidence distribution 
of the three DRD2*A genotypes was comparable with previous research (e. g. Spitz et 
al. 1998; Wu et al. 2000). The findings here do not replicate those suggesting 
DRD2*AI allelic association with smoking found in several previous studies (e. g. 
Spitz et al. 1998), however there was a non-significant trend for subjects with the 
A2/A2 genotype to be current smokers, regardless of addiction status. This result 
supports findings of Yoshida et al. (2001), who showed an association between "ever- 
smokers" and the homozygous A2 genotype in Japanese subjects. This association in 
the current research may have become significant if a larger number of subjects had 
been genotyped. Most studies in this field being discussed analysed in excess of three 
hundred people, whereas the current study only genotyped seventy-seven. 
There was also no significant association between homozygous DRD3 BaII genotypes 
and smoking behaviour. Although no previous research has examined the association 
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between DRD3 polymorphisms and smoking behaviour, past studies have shown 
associations between homozygosity of the Ball variant and opioid and cocaine 
dependence (Duaux et al. 1998; Comings et al. 1999). The incidence distribution of 
the three DRD3 Ball genotypes was comparable with previous research (e. g. Duaux et 
al. 1998). The current research shows a slight trend for current smokers to be more 
likely to possess the homozygous genotype than the non-smokers. Given that 
susceptibility to drug addiction is polygenic and with major environmental factors 
(Cadoret et al. 1986), it has been suggested that individual genes rarely contribute 
more than 2% of the variance of a given trait (Comings et al. 1998). With these 
statistical levels, it further adds to the importance of having large samples when 
analysing genetic psychiatric data. If larger numbers had been tested in the current 
study, it is possible that BaII homozygosity would have been significantly associated 
with smoking status. 
DRD4 exon III polymorphisms, were significantly related to Novelty Seeking 
personality trait scores, which is turn was highly associated with smoking status. The 
findings provide moderate support for the findings of Shields et al. (1998), who 
observed an association between possession of the L allele (D4.7 or D4.8) and 
smoking behaviour. The incidence of the various genotypes was consistent with 
previous research (Van Tol et al. 1992; Ebstein et al. 1996). The mean Novelty 
Seeking score for the sample was 23.5, which is higher than previous studies (e. g. 
Cloninger et al. 1993; Herbst et al. 2000; Richter et al. 1999). This may be a result of 
using a student sample rather than the general population samples used in earlier 
studies. Furthermore, two-thirds of the current sample were smokers (smokers 
normally comprise approximately one third of the population). Non-smokers mean 
NS (20.4) was closer to those previously reported. 
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The results show that those with the L-allele had significantly higher NS scores than 
those without the allele. This finding replicates the Ebstein et al. (1996) and Benjamin 
et al. (1996) studies. For example, Ebstein et al. (1996) found those who had the 7- 
repeat allele (D4.7) present had higher mean NS scores than those without the 7- 
repeat allele. It appears that Impulsiveness contributes critically to this difference, as 
the current results show it is the most significantly increased subscale associated with 
presence of the L allele. Previous studies have not examined the association between 
the NS subscales and DRD4 polymorphism. 
Doparnine receptors expressed by the D4.7 or D4.8 alleles have a lower relative 
affinity for doparnine than those expressed by shorter alleles (Asghari et al. 1994). It 
may be that individuals with these alleles are self-medicating for a lower general 
dopaminergic function by behaving in such a way as to promote dopan-ýine release. It 
is possible that individuals possessing the L-allele are prone to novelty seeking 
because they derive the most noticeable reward from activities that increase 
dopan-ýinergic activity. Another possibility is that individuals are attempting to boost 
doparnine levels in a way to modulate affect. 
The addicted smokers had higher mean scores of NS and all its subscales than the 
non-addicted smokers, although only the Impulsiveness subscale was statistically 
significantly different between the groups. These results are consistent with previous 
research showing that regular smokers are more impulsive than non-smokers (e. g. 
Carton et al. 1994; Mitchell, 1999). A number of theories could explain this finding. 
The lack of impulse control may mean that once smoking behaviour is initiated and 
patterns of drug use are developing, impulsive individuals may find restraint harder, 
thus escalating their use more quickly and developing tolerance. This could result in 
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rapid development of dependence. Alternatively, the sensitivity to nicotine's 
rewarding z effects and impulsive behavioural tendencies could be related, or even 
simultaneous manifestations of a particular dopaminergic function profile. 
The Exploratory sub-scale may be more salient to smoking initiation, which is not 
believed to be prone to genetic influence (Heath & Madden, 1995). This could explain 
why there is little difference between the addicted and non-addicted smokers on this 
factor. It is possible therefore that smoking behaviour is related to novelty seeking in 
a'multi-factorial way, with smoking persistence mediated by Impulsiveness and 
smoking initiation mediated by Exploratory factors. These theories provide 
considerable scope for further research, requiring a detailed examination of the 
relationship between smoking behaviours and novelty seeking personality types. 
Addicted smokers were statistically no more likely to possess the DRD4 L-allele than 
non-addicted smokers. However, in the addicted smokers group there are as many 
individuals with the L-allele as without. This is not the case in the non-addicted 
group, with only about a third possessing the L-allele. Although the DRD4 L-allele 
does not explain the variance between 'addicted' and 'non-addicted' based on the 
criteria used in this series of studies, the greater incidence of the L-allele in the 
'addicted smokers' group may be important. An interesting associative triangle is 
emerging, comprising DRD4 exon HI genotype, personality and tobacco dependence. 
Susceptibility to nicotine dependence may be a direct result of D4.7/D4.8 receptor 
expression, as the resultant lowered dopamine affinity promotes behaviours that will 
stimulate doparnine release. Results obtained here suggest it may be that the observed 
relationship between DRD4 genotypes and smoking behaviour is indirect. 
Conceivably, the DRD4 genotype might well predict or determine novelty-seeking 
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personality traits (Ebstein et al. 1996; Benjamin et al. 1996). The impulsiveness 
element (measured in the NS trait) is a risk factor or source of predisposition for 
nicotine addiction (e. g. Mitchell, 1999). Clearly the relationship between dopan-ýine 
and addiction needs considerable further investigation, in order to tease out specific 
relationships. It is argued from these results that possessing the L-allele genotype for 
DRD4 exon III is significantly associated, either directly or indirectly, with being both 
a novelty-seeker and a tobacco addict. 
Caution is required drawing conclusions from this data due to the small number of 
addicted smokers in the sample. Power calculations demonstrate that there would 
need to be six more addicted smokers at this level of association to show a statistically 
significant effect. Furthermore, it is understood that the definition of addicted and 
non-addicted smoker is not definitive, and may have resulted in some subjects being 
incorrectly categorised. Caution is also required generalising these results due to the 
sampling method, although the sample was representative of a Caucasian student 
population. 
In conclusion, these findings suggest a moderate role for dopamine receptor genetics 
in relation to smoking behaviour, although greater numbers of subjects may have 
elicited more significant results. DRD2*A TaqI and DRD3 BaII polymorphisms have 
a limited, if any, role in nicotine addiction. DRD4 exon HI polymorphisms may have 
a more salient influence on smoking behaviour, with L alleles (134.7 and D4.8) shown 
to be associated with higher scores on Cloninger's (1993) Novelty Seeking. NS, 
particularly the Impulsiveness subscale, was higher in smokers than non-smokers, and 
highest in the addicted smokers. The results suggest that possession of DRD4 L allele 
indirectly increases an individual's susceptibility to nicotine dependence. 
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Table 4.1 Distribution of DRD2*A Taql genotypes In relation to snwk-Ing 
Statu& 
DR 2*A Taql GENOTYPE 




0(0%) 3(30%) 7(70%) 
Non-addicted 
smkcrs (n=39) M 




2(8%) 10(42%) Il (50,11e) 
Table 4.2 Distribution or hornozygous DRD2*A2 TaqI genotypes in relation 
to smoking status (addicted and non-addictedw-s. non-smokers). 
110MOZYGOUS A2 ALLEL E DRD2*A TaqI GENOTYPE 
S%IOKFR STATUS Not Prew-ent Present 
SfWkcrs (all) 17(35%) 32(65%) 
(n--49) 





Table 4.3 Distribution or DRD3 Ball genot) pes In relation to smk-ing status. 
D RD3 Ball GENOTYPE 
511 KVR STA ýTVS 1.1 i 1-2 2-2 
Addicted smkcrs 5(56%) 4(44%) 0(0%) 
(n=10) 
m-iddGed 1508%) 19(49%) 5(13%) 
s=kcrs (n=39) ok e V 
On-smokcrs N on-12W 
, 
91 9(39%) 12(52%) 2(9%) 
( n 4) 
Table 4A DIstribution or homz)gous DRD3 Ball genotypes In relation to 
Sn1oking status (addicted and non-addicted vs. non-snwkers). 
110. %IOZVGOUS DRD3 Ball GENOTYPE 
. 
'""OKER %-rAlrl'% Not Prewnt Pmwnt 
Smokers (all) 23(48%) 25 (n 
(n=48i 
1-1. mkcrs 12(52%) 11(48%) 
(n=23) 
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Table 4.5 Total incidence of DRD4 exon III allelic polymorphisms 
Chapter 4 
D4.2 D4.3 D4.4 D4.5 D4.7 D4.8 
No. of 
subjects 18(23%) 11 (14%) 66 (86%) 1(1.3%) 21(27%) 4(5%) 
presenting 
M 
Table 4.6 Mean Novelty Seeking (and subscale) scores in relation to presence 
of DRD4 exon III L-allele (D4.7 or D4.8) 








ABSENT 22.6 ± 5.9 7.3 ± 2.1 3.8 ± 2.2 6.0 ± 2.5 5.4± 1.9 
(n=5 1) 
PRESENT 25.6 ± 6.3* 7.7 ± 1.9 5.2 ± 2.4** 6.5 ± 2.2 6.3 ± 2.1 
(n=24) 
Absent versus present: * significance p<. 05 ** significance p<025 
Table 4.7 Mean Novelty Seeking (and subscale) scores for non-smokers, 
addicted and non-addicted smokers 
Smoking Group Novelty Seeking Sub-scale 1 Sub-scale 2 Sub-scale 3 Sub-scale 4 
(Exploratory) (Impulsiveness) (Fxtravagance) (Disorderliness) 
ADDICTED 
SMOKERS 28.6 ± 5.2' 7.8 ± 1.6 6.3 ± 1.9 c 7.6± 1.4 b 6.9± 1.5 b 
(n=9) 
NON- 




SMOKERS 20.4 ± 5.1b c 7.4 ± 1.9 3.1 ± 2.2 b, c 5.1 ± 2.5 a, b 4.8 ± 1.9a, b 
(n=25) 
Differences between Smoking Groups: significance p<05, significance p<025, significance 
P<001 
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Chapter 5- Psychosocial differences between addicted and non- 
addicted smokers 
5.1 Introduction 
In Britain, approximately 28% of men and 26% of women are regular smokers 
(Omnibus Survey, 1997). Many smokers commence the behaviour aged 12-15, with 
adult prevalence peaking in the 20-24 age bracket (Department of Health Bulletin, 
1998). There is a paucity of contemporary research investigating personality and 
psychosocial variables that might discriminate or predict smoking behaviour. The 
initiation of smoking has been attributed to environmental factors such as peer group 
pressure and adult modelling (Eysenck, 1980; Presti et al. 1992; Rowe et al. 1992), 
although theories of smoking persistence have focused on the relationship between 
smoking behaviour and psychoactive effects. This conceptualises personality 
interacting with internal and external environmental factors to produce motivational 
conditions conducive to smoking (Eysenck, 1980). 
Previous research reports that 90% of smokers meet DSM-III criteria for tobacco 
dependence (Hughes, Gust & Pechacek, 1987), and that 90% of adolescents who 
smoke as few as 3 or 4 cigarettes progress to complete dependence (Russell, 1990). 
For these reasons, nicotine has come to be regarded as an addictive substance. 
Smoking behaviour has been explained in terms other than dependence; people may 
smoke in order to obtain positive reinforcing effects of nicotine, possibly including 
enhancement of cognitive performance (Wesnes & Warburton, 1983b). The latter 
theory is contentious since a tobacco withdrawal syndrome has been demonstrated, 
which impairs cognitive performance (Snyder, Davis & Henningfield, 1989). 
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It has also been theorised that smoking and other drug use is associated with levels of 
ability to cope effectively with stress. The stress-coping model of addiction proposes 
that in the absence of more effective or appropriate coping strategies, individuals use 
drugs as a means of coping with stress (Alexander & Hadaway, 1982; Wills & 
Shiffman, 1985). These theories purport a role for perceived stress, coping abilities 
and strategies, and social support in drug use, although it has been argued that the 
persistent cycle of withdrawal in habitual smoking itself causes stress (Parrott, 2000). 
If this is the case, smoking is conceivably the solution to a problem of its own 
creation. Parrott & Kaye (1999) reported that abstinent smokers experienced greater 
daily stress and cognitive failures (absent-n-tindedness) than non-abstinent smokers, 
which may be a direct result of the tobacco withdrawal syndrome or due to the 
removal of a stress-reducing or attention-enhancing agent (i. e. nicotine). 
Smokers could conceivably be using tobacco as a pharmacological coping strategy in 
the absence of other stress buffers (e. g. social support) that may be less risky or 
physically damaging than smoking. The presence of interactions between stress and 
social support in smokers is not well researched; although studies have shown that 
successful quitting is associated with higher levels of support (e. g. West, McEwen, 
Bolling & Owen, 2001; Carlson, Goodey, Hahn Bennett, Taenzer & Koopmans, 
2002). Specific support, such as from a spouse/partner, has not been shown to be 
associated with smoker/non-smoker status (Rehm, Fichter & Elton, 1993). 
Dependent smoking is associated with major depression and anxiety disorders 
(Covey, Glassman & Stetner, 1998; Bergen & Caporaso, 1999; Degenhart, Hall & 
Lynskey, 2001). These associations or comorbidity is interesting, and research into 
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the relationship between smoking behaviour and affective psychiatric disorders is 
growing. For example, smokers may be using tobacco to self-medicate their mood 
problems. Altematively, it might be that the perpetual diurnal cycle of withdrawal and 
reinstatement leads to increased anxiety and dysphoria (West & Hajek, 1997). 
There is evidence that habitual smoking could cause reductions in 5-HT release in the 
hippocampus (Benwell, Balfour & Anderson, 1990). As studies have shown that 
increased stimulation of 5-HTIA receptors in the hippocampus may be implicated in 
anxiety (Andrews et al. 1994), it is possible smokers are benefiting from nicotine- 
induced reductions in hippocampal 5-HT, thus phannacologically reducing baseline 
levels of anxiety. This is concordant with human studies suggesting that 'nicotine 
reduces anxiety and negative affect in chronic smokers' (Gilbert & Wesler, 1989). 
A number of prospective studies support the theory that smokers may be using 
nicotine to reduce anxiety. Several of these have reported associations between 
anxious, aggressive, depression-prone and generally neurotic personality traits in 
childhood and the tendency to take up smoking later in life (Brown et al. 1996; Cherry 
& Kiernan, 1978; Kandel & Davies, 1986; Seltzer & Oechsli, 1985). Alternatively, 
dysphoric individuals being less able to quit may explain this association. Anda et al. 
(1990) reported that depressed smokers were 40% less likely to quit compared with 
non-depressed smokers. Furthermore, Covey et al. (1990) reported that smokers with 
a history of depression experienced more severe withdrawal symptoms (especially 
depressed mood and difficulty concentrating) than the group without such a history. 
Persistent depressive symptoms are shown to be prospective predictors of increased 
cigarette use across time, after controlling for baseline levels of smoking (Windle & 
149 
Psychosocial differences Chapter 5 
Windle, 2001). Proponents of this 'self-medication' hypothesis suggest that many of 
the negative affective symptoms associated with the tobacco withdrawal syndrome 
represent the unmasking of psychopathology that had been controlled by smoking 
(Goldstein, 1987; Hughes & Hatsukarni, 1987). 
Smoking has been reported to be associated with a variety of negative health-related 
behaviours. There is a well-documented positive association between alcohol 
consumption and smoking (e. g. Shiffman & Balabanis, 1995), as well as associations 
between smoking and both physical inactivity (Wankel & Sefton, 1994) and 
unhealthy diet (Dallongueville, Mar6caux & Fruchart, 1998). These associations are a 
major concern since evidence suggests that the risk of mortality elevates with 
increasing numbers of unhealthy behaviours (Wingard, Berkman & Brand, 1982). 
Furthermore, smokers are shown to have more limited expectations of health, 
perceived lower effectiveness of health-promoting behaviours and more situational 
motivations to engage in negative health behaviours (Chamberlain & O'Neill, 1998). 
"Chippers", or non-dependent regular smokers (Shiffman, 1989) have also received 
little psychosocial profiling. Kassel, Shiffman, Gnys, Paty & Zettler-Segal (1994) 
found no differences between chippers and dependent smokers in terms of perceived 
stress, coping or social support. However, as the authors themselves pointed out, their 
dependent smokers group may have been unrepresentative since they were closely 
matched to the chippers group and featured an unusually high proportion of females, 
and a low average cigarette nicotine yield. Kassel et al. (1994) reported dependent 
smokers having modest personality differences to chippers, with higher impulsivity 
and lower self-control. 
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The current study aims to identify whether there are particular psychosocial markers 
that could potentially discriminate addicted from non-addicted smokers. Since 
psychosocial measures can be subtle and highly sensitive, a battery of several 
instruments was used to maximise the scope of the study. Although it is difficult to 
attribute causality (in terms of both existence and direction) between smoker status 
and many of these variables, understanding that the associations exist may provide 
useful indications of groups particularly at risk of developing tobacco dependence. 
The following hypotheses were tested: 
I. that psychosocial profiles of smokers and non-smokers would differ 
significantly; particularly that smokers would have greater perceived stress, 
psychological disturbance, prevalence of cognitive failures, and have lower 
social support, health values and expectancies. 
11. that psychosocial profiles of addicted and non-addicted smokers would differ 
significantly; particularly that addicted smokers would have greater 




This between subjects design examined the psychosocial profiles of addicted smoker 
(n=10), non-addicted smoker (n=39) and non-smoker (n=25) groups. Details 
regarding the grouping of subjects are described in Chapter 2. Instruments measured 
subjects' health-related behaviours, social support, loneliness, self-esteem, internal 
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and external control, life events, perceived stress, health values and expectancies, 
cognitive failures, psychological and somatic well-being and physical symptoms. 
5.2.2 Subjects 
Subjects (N=74) age ranged from 18 to 54 (mean 24.5), 35 males, 39 females. Fifty- 
two subjects (70%) participated as part of the mood and cognitive performance study 
presented in Chapter 3. Twenty-two subjects (30%) were recruited only for the 
questionnaire study detailed in Chapter 2. Twelve questionnaire booklets were 
incomplete, however all completed individual instruments were included in analyses. 
A full description of the subject sample and recruitment information is included in 
Chapters 2 and 3. 
5.2.3 Measures 
Demographics 
These data (sex, age, etc. ) were cross-referenced from the Smoking Questionnaire 
Battery discussed in Chapter 2. 
Psychosocial Questionnaire Measures 
The following instruments were administered as a large questionnaire booklet. Copies 
of these questionnaires may be seen in Appendix XIII. 
a) Health Related Behaviours: Cohen et al (1991) 
This questionnaire contained 27 items covering eating, sleeping, drinking, smoking 
and exercise behaviours. Response scales often differed according to each item. 
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b) Interpersonal Support Evaluation List (ISEL) 
Social support was measured by the ISEL (Cohen and Hoberman, 1983), a 40-itern 
questionnaire relating to perceived level of current support; each item was scored on a 
4-point scale. Four subscales were derived: Tangible support (the availability of 
material help), Appraised support (someone available to talk to), Belonging 
(availability of someone to do things with), and Self-esteem support (positive 
comparison of oneself to others). These subscales were also totalled to yield an 
overall ISEL score, covering all areas of social support in general life. Cohen et al. 
(1985) calculated an internal reliability (Alpha coefficient) of . 88 to . 90. 
c) Social Network Index (SNI): Berkman (1984) 
This 12-item questionnaire was split into 3 sections. Section la) and Section 3 were 
answered by circling yes/no, while the other questions were responded to on a 5-point 
Likert-type scale. This yielded a total SNI score indicating size and frequency of 
respondents social network. 
d) University of California Loneliness Scale (UCLA): Russell, Peplau and 
Ferguson (1978) 
This 20-item questionnaire measured frequency of feelings of loneliness. Subjects 
responded on a 5-point Likert-scale (O=never, I=almost never, 2=sometimes, 3=fairly 
often, 4=very often). These items yielded a total loneliness score. 
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e) Seýf-esteem scale (SE): Fleming and Watts (1981) 
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This was a 14-item questionnaire on which subjects responded using a 6-point Likert- 
type scale (1= I agree very much", to 6= "I disagree very much"). This yielded a 
total Self-Esteem score. 
J) Social Reaction Inventory (SRI) 
Control over non-job life was measured by two scales from The Social Reaction 
Inventory (Paulhus, 1983), consisting of 10 items per scale, scored on a 6-point 
response scale. The questionnaire asked respondents to state how they 'usually feel', 
implying an ongoing state. Responses were scored in these two main areas, Control 
over interpersonal relationships, and Control over personal life. The two scales were 
also summated to yield an overall score. Alpha coefficients for reliability are reported 
as . 75 and . 77 respectively, and the convergent validity for both scales fell between 
. 30 and . 37. Paulhus (1983) reported that the correlates of each scale were largely 
independent, and showed good discriminant validity. 
g) Life Events List 
This was a modified version of the Life Events Scale (Cohen, Tyrell & Smith, 1993), 
which measured both positive and negative life events, and also provided a total 
score, which was a composite of the two subscales. It consisted of a 24-itern scale 
ascertaining whether specific life events have occurred during the past 12 months. 
h) Perceived Stress Scale (PSS) 
This 14-itern questionnaire was developed by Cohen et al (1983), and measured the 
degree to which subjects find their lives overloading, unpredictable and 
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uncontrollable. Participants were also asked questions about their current levels of 
experienced stress. Responses were made using a 5-point Likert-type scale (0 = never, 
I =almost never, 2=sometimes, 3=fairly often and 4=very often). 
i) Health Promotion Scale 
This questionnaire was devised by Bausell (1986), and consists of 19 health-related 
questions. These cover eating habits, health checkups i. e. visits to the doctor and 
dentist to exercising, alcohol consumption, smoking and sleep patterns. Subjects 
respond by circling 'yes' or 'no' to each question. 
Health Orientation Scale 
This 50-itern questionnaire (Snell, Johnson, Lloyd & Hoover, 1991) measures several 
subscales of psychological tendencies associated with health. These include Health 
consciousness, Health anxiety, Health confidence, Motivation not to be unhealthy, 
Motivation to be healthy, Health Internal Locus of Control, Health External Locus of 
Control and Health Status. Subjects respond to each question on a 5-point Likert scale 
(I=not at all characteristic of me, 2=slightly characteristic of me, 3=somewhat 
characteristic of me, 4=moderately characteristic of me and 5=very characteristic of 
me). 
k) Cognitive Failures Questionnaire 
Devised by Broadbent, Cooper, Fitzgerald and Parkes (1982), this 25-item 
questionnaire measures lapses of memory whilst undertaking tasks (e. g. forgetting 
appointments). Subjects respond to each question on a 5-point Likert scale (O=never, 
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I=very rarely, 2=occasionally, 3=quite often and 4=very often) by circling how often 
each cognitive failure occurs. 
1) Middlesex Hospital Questionnaire 
This adapted version of the original MHQ (Crown-Crisp Experiential Index; Crown & 
Crisp, 1979) was based on that used by Broadbent et al. (1984). The questionnaire 
featured 28 items, and responses were registered using a 3-point scale (typically 
O=never, I=sometimes, 2=often). Respondents were asked to consider each item in 
the context of "during the last six weeks". The MHQ generated four scores for various 
kinds of symptoms: Anxiety, Obsessional Symptoms, Somatic Symptoms and 
Depression, as well as a somewhat different short scale of Obsessional Personality. 
m) Cohen and Hoberman Inventory of Physical Symptoms (CHIPS) 
This scale was devised by Cohen and Hoberman (1983), and consisted of 12 
statements related to physical symptoms. Subjects were required to indicate how 
much each physical symptom had bothered or distressed them during the last month. 
Responses were made using 5-point Likert-type scales (O=not at all, I=a little bit, 2= 
moderately, 3= quite a bit and 4= extremely). A total score was obtained by 
sununing frequency responses across the range (i. e. I to 48). Previous studies 
conducted by Cohen and Hoberman (1983), using student populations have found the 
intemal reliability to be 0.88 (Cronbachs alpha). 
n) Symptom Checklist 
This questionnaire was in two parts. Part I presented respondents with 27 common 
physical symptoms with checkboxes next to them. Participants were asked to tick the 
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boxes of any symptoms they were currently experiencing. Part 2 asked subjects to 
indicate which, if any, prescribed drugs or multivitamins, etc. they were currently 
taking. 
5.2.4 Procedure 
Subjects were given Psychosocial Questionnaire Booklets at first face-to-face contact 
with researchers, and asked to answer the questions in their own time. Subjects 
reported taking approximately 40 minutes to complete the booklet. 
5.2.5 Statistical analyses 
The main effect of group on the numerous subscales and factors of the various 
instruments examined were analysed using univariate analysis of variance (ANOVA). 
Specific differences between the three groups were examined using the Tukey post- 
hoc test. Statistics were performed using the Statistical Package for Social Sciences 
version 9.0. Correction for multiple comparisons was considered unnecessary since 
each component was analysed in its own right, and many of the instruments would 
yield highly correlated results. 
5.3 Results 
The psychosocial differences between smokers and non-smokers are examined in 
Section 5.3.1, while Section 5.3.2 presents differences between the two smoking 
groups. The relationship between levels of tobacco dependence and levels of 
psychological disturbance is presented in Section 5.3.3. 
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5.3.1 Psychosocial differences between smokers and non-smokers 
Results are reported where there were significant main effects of group, and Tukey 
post-hoc analyses demonstrated significant differences between non-smokers and both 
groups of smokers. Mean scores for each group on the different psychosocial 
variables are reported in Table 5.1. 
No significant differences were observed between smokers and non-smokers in 
variables pertaining to health-related behaviours, perceived levels of social support, 
individuals' loneliness, levels of self-esteem, measures of internal and external 
control, life events, psychological and somatic well-being or total number of current 
physical symptoms. 
5.3.1.1 Perceived Stress 
Scores on the Perceived Stress Scale were affected by group (F[2,701=3.30, p<05). 
Tukey post-hoc analysis showed non-significant trends for non-smokers to have lower 
perceived stress than both addicted and non-addicted smokers (both p<10) (Figure 
5.1). 
5.3.1.2 Health values and expectancies 
Several variables on the Health Orientation Scale demonstrated group effects. 'Health 
Confidence' factor scores were significantly affected by group (F(2,701=6.80, p<01). 
Tukey post-hoc analysis demonstrated that non-smokers had significantly higher 
'Health Confidence' scores than both addicted smokers (p<05) and non-addicted 
smokers (p<. O I) (see Figure 5.2). 
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'Motivation to not be unhealthy' factor scores were different between the groups 
(F12,71)=12.73, p<001). Tukey post-hoc analysis demonstrated that non-smokers 
had significantly higher 'Motivation to not be unhealthy' factor scores than both 
addicted and non-addicted smokers (both p<001) (Figure 5.3). 
'Motivation to be healthy' factor scores were also different between the groups 
(F f 2,7 11 =9.93, p<. 00 1). Tukey post-hoc analysis demonstrated that non-smokers had 
significantly higher 'Motivation to be healthy' factor scores than both addicted 
smokers (p<. O I) and non-addicted smokers (p<. 001) (Figure 5.4). 
5.3.1.3 Cognitive failures 
The prevalence of cognitive failures (total CFQ score) was significantly affected by 
group (F(2,69)=4.93, p<01). Tukey post-hoc analysis showed that non-smokers had 
fewer cognitive failures than addicted smokers (p<. 025) and non-addicted smokers 
(p<05) (Figure 5.5). 
5.3.2 Psychosocial differences between addicted and non-addicted smokers 
Results are reported where there were significant main effects of group, and Tukey 
post-hoc analyses demonstrated significant differences between non-addicted smokers 
and addicted smokers. Mean scores for each group on the different psychosocial 
variables are reported in Table 5.1. 
No significant differences were observed between addicted smokers and non-addicted 
smokers in variables pertaining to health-related behaviours, perceived levels of social 
support, individuals' loneliness, levels of self-esteem, measures of internal and 
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external control, life events, perceived stress, health values and expectancies or total 
number of current physical symptoms. 
5.3.2.1 Psychological and somatic well-being 
Two factors on the Middlesex Hospital Questionnaire demonstrated group effects. 
Anxiety factor scores were significantly affected by group (F(2,671=4.05, p<025). 
Tukey post-hoc analysis demonstrated that addicted smokers had significantly higher 
Anxiety scores than non-addicted smokers and non-smokers (both p<. 05) (see Figure 
5.6). 
Depression factor scores were also different between the groups (F12,691=4.63, 
p<025). Tukey post-hoc analysis demonstrated that addicted smokers had 
significantly higher Depression scores than both non-addicted smokers and non- 
smokers (both p<05) (Figure 5.7). 
5.3.3 Levels of tobacco dependence and psychosocial correlates 
Adjunctive to the result that Depression and Anxiety subscales of the MHQ differ 
between addicted and non-addicted smoker groups, the associative relationship 
between these subscale factor scores and level of tobacco dependence was 
investigated. Spearman's Rho correlation was used to examine the association 
between Anxiety and Depression factor scores and Addiction Index scores. 
Frequency analysis identified a single Depression factor score outlier that was 
removed prior to correlation analysis. Depression factor scores were positively 
correlated with Addiction Index scores (r--3.89, p<. Ol; 2-tailed) (Figure 5.8). Anxiety 
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factor scores were not correlated with Addiction Index scores (r--O. 157, p=0.29; 2- 
tailed). 
5.4 Discussion 
The major findings of this study were that smokers have greater perceived stress and 
cognitive failures than non-smokers. Smokers had significantly lower motivation 
toward healthy behaviours and to avoid unhealthy behaviours, and had lower 
confidence in their health than non-smokers. Addicted smokers reported more 
psychological disturbance, particularly greater anxiety and depression than non- 
addicted smokers. Furthermore, levels of tobacco dependence were positively 
correlated with depression. 
As predicted, there were significant psychosocial differences between smokers and 
non-smokers. The observed trend for non-smokers to report lower perceived stress 
than both smoking groups is not consistent with the findings of Kassel et al. (1994), 
who reported no differences in levels of perceived stress between non-smokers, 
regular smokers and chippers. The current results suggest that smokers have greater 
perceived stress than non-smokers, although the existence or direction of causality 
cannot be inferred. Smokers may be self-medicating in order to reduce perceived 
stress levels (Wills & Shiffman, 1985). 
The current findings are concordant with the theories and findings of Parrott (2000; 
1995a; 1995b; Parrott & Kaye, 1999), who has consistently found higher baseline 
stress levels in smokers than non-smokers. Parrott (2000) explains these results not in 
terms of a pre-morbid condition or greater objective stress, but as an effect of 
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smoking; i. e. a stress-inducing persistent cycle of withdrawal and reinstatement. 
Current findings do not entirely support this theory, since it would predict there to be 
differences in perceived stress between addicted and non-addicted smokers, a finding 
not observed. In order to clarify this issue, prospective research should look at 
perceived stress levels before and after initiation of smoking behaviour. 
Smokers, particularly the addicted group, reported having more prevalent cognitive 
failures than non-smokers. Although no directly comparable previous research has 
been carried out, Parrott & Kaye (1999) found that abstinent smokers had more 
cognitive failures than non-abstinent smokers over the course of a normal day, 
although non-abstinent smokers did not differ from non-smokers. Parrott & Kaye 
(1999) interpret their findings as support for the deprivation reversal model of tobacco 
use. Following from this, cognitive failures (or absent-mindedness) may be an indirect 
measure of withdrawal. In the case of the current findings, the differences between 
smokers and non-smokers may reflect episodes of acute tobacco withdrawal 
throughout the day, leading to attentional. deficits (Snyder, Davis & Henningfield, 
1989) that manifest as perceived cognitive failures or absent-mindedness. These may 
even act as internal/cognitive cues to initiate smoking behaviour. Alternatively the 
cognitive failures may not be related to acute episodes of withdrawal. Smokers might 
be self-medicating in an attempt to improve poor baseline cognitive perfon-nance. 
Smokers and non-smokers were shown to have different health value and health 
orientation profiles. Smokers were more anxious and less confident about their health 
than non-smokers. This is broadly consistent with Chamberlain & O'Neill's (1998) 
findings that smokers had lower expectations of health and lower perceived 
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effectiveness of health-promoting behaviours. Furthermore, they were less motivated 
to be healthy and less motivated not to be unhealthy. This is consistent with 
Chamberlain & O'Neill's (1998) results showing that smokers report greater 
situational pressures to engage in negative health behaviours. These findings 
demonstrate to some degree that smokers were aware that their smoking compron-dses 
their health. Furthermore, they may be reacting to the cognitive dissonance created by 
their smoking behaviour by devaluing both health-promoting behaviour and their own 
health per se. 
No differences were shown between smokers and non-smokers in terms of perceived 
social support. These findings are consistent with Kassel et al. (1994), who showed no 
differences between smokers and non-smokers in the amount of social support 
experienced. This has implications for the stress-coping model of smoking (Wills & 
Shiffman, 1985), as it suggests that levels of non-drug stress buffering are comparable 
between non-smokers and smokers. It seems less likely therefore that smokers are 
making up for shortfalls in alternative sources of coping or support by using tobacco. 
Perceived social support is viewed as a more sensitive indicator of its stress-buffering 
effects than objective existence of the resource (Blazer, 1982). This is because the 
appraisal of stress is based on a person's beliefs about available support as opposed to 
its actual availabilitY (Cohen et al. 1985). 
Psychological disturbance such as symptoms of anxiety, depression, somatic 
complaints and obsessive behaviour were not shown to differ significantly between 
smokers and non-smokers. This finding was unexpected, since previous research 
suggests smokers tend to be more anxious (West & Hajek, 1997; Parrott, 1999) and 
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more depressed (Degenhart et al. 2001) than non-smokers. As discussed later 
however, group differences were teased out, as addicted smokers had greater anxiety 
and depressive symptoms than both non-addicted smokers and non-smokers. The 
cited previous research above utilised large samples where presence of nicotine 
dependence was estimated at 55-87% (Woody, Cottler & Cacciola, 1993), whereas 
only 33% of the current sample was designated as dependent. Differences in 
categorization, contrasts used and relative proportions of dependent tobacco users are 
therefore presented as explanations for these findings. 
There were few psychosocial variables that statistically significantly differed between 
addicted and non-addicted smokers, however those that did were highly salient and 
interesting. No differences were observed between addicted and non-addicted 
smokers in terms of perceived stress. This finding is consistent with those of Kassel et 
al. (1994) as presented earlier, but is not consistent with Shiffman (1989). Shiffman 
(1989) found that dependent smokers had higher levels of subjective stress as 
measured by the Perceived Stress Scale than chippers. Of course, current results are 
not directly comparable with Shiffman's studies as chippers are likely to be a subset 
rather than a synonym of non-addicted smokers. The non-addicted smokers group in 
the current study may have contained some moderately dependent smokers or even 
dependent smokers who were under-reporting their addictive status in previous 
smoking-related questionnaires. 
Furthermore, there were no differences between addicted and non-addicted smokers 
levels of perceived social support. As above, this is consistent with the findings of 
Kassel et al. (1994), who reported that the amount of social support experienced did 
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not discriminate chippers from regular smokers. Shiffman (1989) however, found that 
chippers had significantly higher total perceived support demonstrated by higher total 
ISEL scores than dependent smokers. 
The current findings suggest that stress and coping variables are not relevant to non- 
addicted smokers absence of (or protection from) tobacco dependence. It does not 
support the theory that dependent smokers feel the "need" to smoke more than their 
non-dependent counterparts as they perceive greater stress and have less appropriate 
coping strategies. Again, it might be argued that the heterogeneity of the non-addicted 
smokers group and the small number of addicted smokers may be masking important 
differences in these variables. 
Addicted and non-addicted smokers differed significantly on two factors of 
psychological disturbance measured by the MHQ. Addicted smokers had higher 
Anxiety and Depression symptoms than non-addicted smokers. This is consistent with 
previous research showing that tobacco dependence is associated with anxiety and 
affective disorders (e. g. Covey et al. 1998). 
These current findings are particularly interesting since they show non-smoker and 
non-addicted smoker groups with almost identical means and variance, but with the 
addicted smokers demonstrating considerably higher scores. Unfortunately, the 
existence and direction of a causal relationship between anxious and depressive 
symptoms and tobacco dependence cannot be elucidated by these results. It is possible 
that smokers are becoming tobacco dependent through self-medicating their pre- 
morbid mood disorder(s). Alternatively, the cycle of withdrawal and reinstatement 
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that characterises nicotine dependence may be either directly or indirectly generating 
more depressive or anxious episodes. Evidence for both phenomena exist (Windle & 
Windle, 2001; Brown et a]. 1996; Parrott, 2000), and it is possible that both 
mechanisms could be acting in tandem, which would offer further explanation why 
nicotine is a drug that is considered disproportionately difficult to give up. 
There was a positive correlation between level of tobacco dependence and prevalence 
of depressive symptoms on the MHQ, strengthening the validity of the association 
discussed in the previous paragraph. This observed relationship between dysphoria 
and nicotine addiction is clearly important. Windle & Windle (2001) found that 
serious and persistent depressive symptoms were prospective predictors of increased 
cigarette use across time, after controlling for baseline measures. More prospective 
studies should attempt to replicate these findings, so it can be identified if adolescents 
with even mild affective disorders are at increased risk of tobacco dependence. 
Greater numbers of subjects in the addicted smokers group would have been 
desirable, as this would possibly have made some of the trends significant and 
elucidated further psychosocial differences between the three groups. One important 
factor missing from the psychosocial profile generated in this research was socio- 
economic status. This has been shown to be associated with smoking (Chamberlain & 
O'Neill, 1998), levels of social support (Turner & Marino, 1994) and psychological 
distress and depression (Ulbrich, Warheit & Zinunerman, 1989). It would have been 
useful to add socio-economic status as a covariate when performing the analyses to 
ensure that relationships between the three groups were independent of other 
commonly associated factors. 
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The findings presented in this chapter suggest that smokers generally experienced 
greater perceived stress and reported more cognitive failures than non-smokers, 
possibly reflecting either baseline psychological differences or feedback from the 
cycle of withdrawal and reinstatement associated with the tobacco withdrawal 
syndrome. Smokers also have different health orientations to non-smokers, 
characterised by greater anxiety about health, lower health confidence and 
motivations to be healthy. Addicted smokers were shown to have more anxious and 
depressive symptoms than non-addicted smokers. Prospective studies should be 
undertaken to clarify the relationship between affective disorders and tobacco 
dependence, as this may elucidate the existence or direction of causality in the 
association. This could allow groups at particular risk of depression and anxiety, or 
addiction to smoking, to be targeted and informed or treated. 
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Figure 5.1 Error-bar graph showing mean scores on the Perceived Stress 
Scale for non-smokers, addicted and non-addicted smokers. Error 
bars represent ±2 standard errors of the group mean scores (n=74; 
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Figure 5.2 Error-bar graph showing mean 'Health Confidence' factor scores 
(from Health Orientation Scale) for non-smokers, addicted and 
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Figure 5.3 Error-bar graph showing mean 'Motivation to not be unhealthy' 
factor scores (from Health Orientation Scale) for non-smokers, 
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Figure 5.4 Error-bar graph showing mean 'Motivation to be healthy' factor 
scores (from Health Orientation Scale) for non-smokers, addicted 
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Figure 5.5 Error-bar graph showing mean Cognitive Failure Quest ormaire 
scores for non-smokers, addicted and non-addicted smokers. (For 
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Figure 5.6 Error-bar graph showing mean Middlesex Hospital Questionnaire 
Anxiety factor scores for non-smokers, addicted and non-addicted 
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Figure 5.7 Error-bar graph showing mean Middlesex Hospital Questionnaire 
Depression factor scores for non-smokers, addicted and non- 





.27.0 0 Cc$ 
a 6.0 








N 1; 37 275 
ADDICTED SMOKERS NON-ADDICTED SMOKERS NON-SMOKERS 
GROUP 
Figure 5.8 Scatterplot showing relationship between level of tobacco 
dependence (Addiction Index score) and MHQ Depression factor 
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Table 5.1 Psychosocial scores for non-smokers, addicted and non-addicted 









ISEL - Appraised support 33.50 (6.04) 32.38 (5.42) 32.46 (3.75) 0.20 
ISEL - Tangible support 31. 
iO (4.94) 32.15 (4.79) 33.52 (3.12) 0.88 
ISEL - Self-esteem support 28.80 (4.37) 29.30 (4.45) 31.91 (2-91) 3.64* 
ISEL - Belonging 33.60 (3.98) 33.10 (4.66) 34.50 (3.12) 0.85 
ISEL - Total score 127.70 (16.53) 127.59 (16.82) 132.82 (9.76) 0.91 
SNI - Total score 9.56(l. 81) 10.36 (3.13) 9.31(2.80) 0.97 
UCLA Loneliness 26.40 (12.29) 28.78 (12.97) 26.04 (12.66) 0.39 
Self-Esteem 59.20 (15.76) 57.67 (13.50) 63.52 (11.06) 1.42 
SRI - Control (Personal) 30.30 (8.17) 31.79 (5.07) 35.25 (5.31) 3.86* 
SRI 7 Control (Interpers. ) 32.20 (9.04) 31.82 (7.85) 34.08 (7.03) 0.66 
Life Events (Negative) 3.90(2.33) 2.97(2.85) 2.00(l. 66) 2.45 
Life'Events (Positive) 1.60(0.97) 1.69(l. 52) 1.56(l. 16) 0.08 
Life Events (Total) 5.50(2.07) 4.67(3.56) 3.56(2.33) 1.77 
Perceived Stress Scale 27.90 (8.14) 25.24 (8.13) 20.76 (8.73) 3.30* 
HOS - Health Confidence 13.10 (3.21) 13.67 (3.88) 17.08 (4.20) 6.80*** 
HOS - Health Anxiety 12.00 (4.08) 12.38 (4.33) 9.58(3.91) 3.47* 




Motiv. Unhealthy 11.70 (4.03) 13.31 (4.16) 18.44 (5.13) 12.72*** 
HOS - Health Consc'ness 15.80 (3.33) 15.90 (3.07) 18.04 (4.42) 2.30 
Cognitive Failures Q'naire 49.90 (11.87) 44.37 (13.83) 36.08 (12.00) 4.93** 
MHQ - Anxiety 6.50(2.84) 4.00(2.65) 3.91(2.45) 
4.05* 
MHQ - Somatic symptoms 5.10(2.81) 3.86(2.04) 4.20 (T29) 1.20 
MHQ - Depression 8.00(l. 15) 6.24(2.05) 5.96(l. 72) 4.63* 
MHQ - Obsessive sympts. 3.10(l. 37) 2.68(l. 62) 2.56(l. 66) 0.41 
MHQ - Obsessive Pers'ty 2.00(l. 25) 2.00(l. 13) 2.64(l. 25) 2.36 
CHIPS - Physical sympts. 6.40(6.98) 6.50(5.34) 5.64(5.47) 
0.18 
Symptoms Checklist Total 3.56(4.07) 4.29(2.84) 2.36(2.29) 3.34* 
treatment df=2, error degrees of freedom are variable (between 66 and 7 1) 
significant at p<05 level, **- significant at p<. O I level, ***- significant at p<. 001 level 
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Chapter 6- Craving and withdrawal symptoms after 24-hour 
abstinence and the effect of reinstatement through ad Ubitum 
smoking 
6.1 Introduction 
Nicotine is regarded as a powerfully addictive substance. Traditional models of drug 
dependence and drug motivation have accorded withdrawal a central role in 
motivating addictive drug use and relapse (Isbell & White, 1953; Seevers, 1962; 
Wikler 1973). Despite withdrawal symptoms not being a universal consequence of 
abstinence, most smokers experience withdrawal symptoms and tobacco cravings on 
cessation (Hatsukarni et al. 1985; Shiffman, 1979). The mechanisms by which 
abstinence from smoking induces withdrawal symptoms are not well understood. 
Withdrawal phenomena may be due to pharmacological dependence on nicotine 
similar to dependence observed with other drugs of abuse (Shiffman, 1979; 
Hatsukarni, Hughes & Pickens, 1985). 
The severity of the withdrawal syndrome is variable, with some smokers appearing to 
suffer very little, while others experience distressing symptoms. It would be expected 
for heavier smokers to experience greater withdrawal discomfort: however, usual 
daily cigarette consumption has not been reliably shown to predict severity of 
withdrawal. Studies have shown that smokers with a high pre-abstinence nicotine 
intake experience the greatest discomfort (Bums, 1969; West & Russell, 1985). 
Hughes & Hatsukami (1986) and Pornerleau et al. (1983b) both reported that subjects 
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who were, more tolerant had more withdrawal discomfort. The latter results are 
consistent with earlier theories (e. g. Kalant, LeBlanc & Gibbins, 1971) postulating 
that tolerance and withdrawal develop concomitantly because they are both 
manifestations of the development of physical dependence. Hughes & Hatsukami 
I 
(1986) also found that withdrawal effects were initially the opposite of nicotine 
effects, then decreased towards baseline; a "rebound" phenomenon consistent with 
opiate/sedative type dependence. Perhaps most saliently, administration of nicotine 
relieves tobacco withdrawal (e. g. Hughes et al. 1984; Hughes & Hatsukarni, 1985). 
Shiffman (1979) purports that dose dependency is so characteristic of withdrawal 
syndromes from other substances that establishing this effect for tobacco would be an 
important step in understanding nicotine dependence. Seven symptoms have been 
collated and termed tobacco withdrawal in DSM-IV: craving for tobacco, irritability, 
anxiety, difficulty concentrating, restlessness, headaches, drowsiness, and 
gastrointestinal tract disturbances. Shiffman (1979) reports that the onset of 
withdrawal prompts smoking, deters attempts to stop smoking, reduces cessation 
success and causes relapse to smoking. 
Various studies have described tobacco withdrawal phenomena, although the validity 
and generalisability of these reports is contentious. Many of these studies relied on 
self-reported symptoms that may have been more dependent on subjectivity, although 
others have also utilised objective measures (Hughes & Hatsukami, 1986). 
Nonetheless, several laboratory experiments have demonstrated objective changes 
analogous with self-reported withdrawal symptoms. Concerns exist regarding a 
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66 rationalisation bias" whereby abstinent smokers exaggerate withdrawal symptoms in 
order to rationalise their (actual or potential) inability to quit. 
DSM-IV incorporates increased anxiety as one of the nicotine withdrawal symptoms. 
Most studies report a transient increase in anxiety during abstinence (Hughes, Higgins 
& Bickel, 1994). West & Hajek (1997) showed that 24-hour abstinence produced no 
increased anxiety, and argued that it is not a robust element of the tobacco withdrawal 
syndrome. Some studies show a decrease in anxiety below pre-cessation levels after 
several weeks of abstinence (Gross & Stitzer, 1989). Population studies present data 
that smokers report higher anxiety levels than individuals who have never smoked or 
ex-smokers (Jarvis, 1994). 
Aside from craving, daytime sleepiness, difficulty sleeping at night and irritability 
(which may impact on sleep patterns) are the most frequently reported symptoms of 
tobacco withdrawal, occurring in up to 70% of those who stop smoking (Hatsukami et 
A 1985; 1988). Hughes & Hatsukami (1986), stated that more than half of their 
sample reported decreased adequacy of sleep and decreased time asleep. Prosise et al. 
(1994) report significant increases in number of relative arousals, sleep stage changes 
and awakenings during smoking cessation. Hughes, Higgins & Hatsukami (1990) 
claim that abstinence appears to increase the number of awakenings and the amount 
of REM sleep, although these effects cannot be categorically ascribed to nicotine 
deprivation. This suggests that changes in sleep or sleep-associated variables may be a 
core problem in smoking cessation. 
175 
Craving and withdrawal symptoms Chapter 6 
West & Schneider (1987) describe craving as "potentially the most important feature 
of cigarette withdrawal", however there is little consensus concerning a definition of 
craving. The United Nations International Drug Control Programme (UNDCP) and 
World Health Organisation (WHO) jointly presented a definition of drug craving as 
"the desire to experience the effect(s) of a previously experienced psychoactive 
substance', '. , It is widely accepted that craving contributes significantly to the 
development and maintenance of drug dependence. The DSM-IV states that craving is 
"likely to be experienced by most if not all individuals with substance dependence". 
Shiffman (2000) argues that it currently seems most useful to regard craving as a 
subjective motivational state. 
Craving is thus considered analogous to emotions, and to have motivational 
significance for an individual. It is also considered analogous to hunger, as both 
craving and hunger are subjectively experienced as a need for something to be 
ingested (Kassel & Shiffman, 1992). Modem conceptions of craving often incorporate 
cognitive concepts such as cognitive labelling, outcome expectancy and cognitive 
processing (Tiffany, 1999). These models posit that craving is a non-automatic 
process (and therefore not simply emotional or motivational) that requires mental 
effort and is limited by a person's cognitive ability (Tiffany, 1999). Hughes & 
Hatsukarni (1986) stated that 62% of their sample reported increased cravings for 
tobacco after abstinence. They included craving in their measures of withdrawal, as 
they were using DSM-111 criteria. However, due to accounts that smokers report 
craving even during smoking, this item was eliminated from the tobacco withdrawal 
syndrome detailed in DSM-IV. It has been subsequently argued that the incidence of 
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craving whilst smoking may be more due to procedural issues than to true 
unreliability of subjective experience (Jarvik et al. 2000b). 
Under conditions of deprivation, smokers report cravings for tobacco that generally 
translate into smoking, and increased levels of deprivation typically lead to stronger 
cravings (Payne et al. 1996). Cravings for cigarettes are commonly reported as 
motivators or precursors to actual use (Marlatt & Gordon, 1985), and are typically 
initiated by a variety of internal (emotions, thoughts) and external (situational) cues 
(Abrams et al. 1987; Niaura et al. 1992,1998; Shiffman et al. 1996). Cravings reliably 
predict relapse to cigarettes (Killen & Fortman, 1997; Shiffman et al. 1997) and 
precipitate lapses following abstinence (Shiffman et al. 1996). Early research found 
no difference in craving between light and heavy smokers following 48-hour 
abstinence (Gritz & Jarvik, 1973). 
Since it is accepted as a subjective state, self-report measures dominate assessment 
and measuring of craving. Although other measurement modalities have been 
suggested, these measures often lack specificity as they are under control of numerous 
other influences. Shiffman (2000) purports that although objective measures of 
craving might be developed in future, subjective self-report appears to be the only 
viable current option. As with other reported withdrawal symptoms, this presents its 
own problems, such as interpretation of the questions and/or terms used, social 
demand and self-deception, but these are partially overcome by use of repeated 
measures designs since these issues will often control for themselves. 
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Tiffany & Drobes (1991) Questionnaire of Smoking Urges is an example of a multi- 
dimensional subjective self-report tool measuring cravings for smoking. Its two-factor 
structure allows subjects to rate their desire to smoke based on expected positive 
reward and appetitive desire to smoke (positive reinforcement), and removal of 
withdrawal and/or negative affect (negative reinforcement). 
Tobacco "chippers" are characterised as regular but non-dependent smokers, and have 
been shown to exhibit no significant signs or symptoms of withdrawal after overnight 
abstinence (Shiffman, 1989). This is consistent with reports that claim that chippers 
easily and voluntarily abstain from smoking for a day or more each week. The 
behaviour of this group challenges conventional notions regarding addiction and its 
causes, as chippers chronically expose themselves to an addictive drug yet show no 
evidence of dependence. Chippers may have low nicotine tolerance, hence the 
absence of a withdrawal syndrome. This is likely to assist this group in avoiding 
tobacco dependence, although little else is known about the factors defining these 
individuals and protecting them from developing addiction to smoking. 
The current study aimed to demonstrate that 24-hour abstinence from tobacco would 
cause subjects to rate withdrawal symptoms and urges to smoke significantly greater 
than when non-deprived, and that these would be reversed by 45 minutes of ad 
libitum smoking. It was predicted these effects would be more marked in addicted 
smokers than non-addicted smokers. This could provide a useful way of 
characterising the presence or level of nicotine dependence. 
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Hypotheses: 
I. that 24-hour abstinence will increase urges to smoke and reported severity of 
withdrawal symptoms in all smoking subjects. 
11. that overall changes of withdrawal symptom ratings between baseline and 
withdrawn sessions will be correlated with nicotine dependence as indicated 
by addiction index scores. 
III. that smoking urges measured by the QSU would be greater in withdrawn 
sessions in the addicted smokers group than in the non-addicted smokers. 
IV. that reinstatement through 45 minutes of ad libitum smoking will significantly 
reduce withdrawal symptoms and urges to smoke in all smoking subjects. 
V. that overall changes of withdrawal symptom ratings between withdrawn and 
reinstated sessions will be correlated with nicotine dependence as indicated by 
addiction index scores. 
VI. that smoking urges measured by the QSU would be more reduced by 
reinstatement in the addicted smokers than the non-addicted smokers group. 
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This was a between subjects comparison of three groups (addicted smokers, non- 
addicted smokers and non-smoker controls) using a Withdrawal Symptoms Checklist 
based on Hughes & Hatsukami (1986), and Tiffany & Drobes (1991) Questionnaire of 
Smoking Urges. 
6.2.2 Subjects 
Subjects (N=75) participated as part of the mood and cognitive performance study 
presented in Chapter 3. The participants were categorised as non-smokers (n=25), 
addicted smokers (n=10) and non-addicted smokers (n=40). A full description of the 
subject sample and recruitment information is included in Chapters 2 and I 
6.2.3 Questionnaires 
Withdrawal Symptoms Checklist (WSC) 
This is a fifteen-item checklist based on the Hughes & Hatsukarni (1986) study on 
tobacco withdrawal. It features eight items taken from the DSM-Ill symptom list for 
the tobacco withdrawal syndrome, plus further items added by the authors. It presents 
each item (craving for tobacco, irritability, etc. ) with 4 checkboxes labelled 0 to 3. 
O=not present, l=n-ffld, 2=moderate, 3=severe. See Appendix XIV. 
Questionnaire of Smoking Urges (QSU) 
This is a 32-item questionnaire developed and validated by Tiffany & Drobes (1991). 
Subjects are presented with positive or negative statements regarding urge to smoke. 
0 
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Subjects were asked to indicate on a Likert-type scale how strongly they agree or 
disagreed with each statement. Each item was scored on a scale of I (strongly 
disagree) to 7 (strongly agree). See Appendix XV. 
6.2.4 Procedure 
Subjects were fully briefed on the procedure prior to starting, and were informed of 
their rights and requirements. Subjects were required to attend the Health Psychology 
Research Unit on a minimum of two occasions. Three sessions were completed: 
Baseline, Withdrawn and Reinstated. The latter 2 sessions were always perfonned 
consecutively. 
Baseline 
Subjects attended the HPRU at 9.00 am, having been instructed to: 
a) Smoke as they normally would both in the previous evening and in the morning 
before attending the Unit. 
b) Refrain from excessive alcohol intake (>4 units) during the previous evening. 
c) Consume normal caffeine intake before attending the Unit, up to 20 minutes prior 
to arrival. 
d) Have a typical sleep pattern during the preceding night. 
e) Not exercise vigorously in the morning before attending the Unit. 
On arrival, subjects were shown to a booth and asked to complete the Baseline 
Session Pre-test Questionnaire. This booklet contained questions regarding eating, 
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drinking and smoking behaviour in the last 24 hours, a Withdrawal Symptoms 
Checklist, and Tiffany & Drobes (1991) Questionnaire of Smoking Urges. 
Withdrawn 
Subjects attended the HPRU at 9.00 am, having been instructed to: 
a) Smoke nothing in the preceding 24 hours before attending the Unit, and follow the 
conditions b) to e) from the Baseline session. 
On arrival at the Unit, subjects were breathalysed using a carbon monoxide 
breathalyser to ascertain whether they had complied with the 24-hour abstinence 
protocol. If the breathalyser registered less than 10 PPM (parts per million) CO count, 
the subject was allowed to continue with the experiment. Subjects were also asked to 
report if they had smoked during the designated abstinence period. These details were 
recorded. 
Subjects were shown to their testing booth and asked to complete the Withdrawn 
Session Pre-test Questionnaire (see Section 6.2.4). This booklet consisted of questions 
regarding eating, drinking and smoking behaviour in the last 24 hours, a withdrawal 
symptoms checklist, Tiffany & Drobes (1991) Questionnaire of Smoking Urges. 
Upon completion of the computer tests by all participants in the laboratory, subjects 
were informed they had an hour before the final session. They were issued with 
ashtrays and advised that they could smoke at least 1 cigarette during the next 45 
minutes. Subjects smoked between I and 5 cigarettes. During this hour "break", 
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subjects were administered Cloninger et al. 's (1993) Temperament & Character 
Inventory (see Chapter 4). No caffeine or eating was permitted during this period, and 
subjects generally passed time reading. After 45 minutes, subjects were asked to 
extinguish any cigarettes and relax. The final fifteen minutes were smoke-free in 
order to avoid direct cognitive effects of nicotine. Once the hour break was 
concluded, the next session commenced. 
Reinstated 
Subjects then completed the Reinstated Session Pre-test Questionnaire. This booklet 
consisted of questions regarding eating, drinking and smoking behaviour in the last 
hour, a withdrawal symptoms checklist, Tiffany & Drobes (1991) Questionnaire of 
Smoking Urges. Once these were completed, subjects were asked to leave their 
booklets open on the final page, which was a response sheet for the Free Recall 
memory task. 
6.3 Results 
6.3.1 Effects of abstinence on smokers' withdrawal symptom ratings 
Baseline session total WSC ratings were compared with the withdrawn session total 
WSC ratings using repeated measures analysis of variance. Smoking group was the 
between-subjects factor. Mean WSC ratings for the groups in each session are shown 
in Table 6.1. 
There was a significant interaction between WSC total ratings and smoking group 
(F(2,681=7.88, p<001). Tukey post-hoc analysis showed that both addicted and non- 
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addicted smokers increased their ratings in withdrawal relative to non-smokers (both 
contrasts p<001) (see Figure 6.1, Table 6.2). No significant differences were shown 
between the two groups of smokers. 
Further analyses were performed on individual WSC items ratings (see Table 6.1) to 
identify symptom differences between the addicted and non-addicted smoker groups. 
Baseline and withdrawn sessions were compared, using repeated measures analysis of 
variance with Tukey post-hoc analysis. A significant interaction effect between 
session-and smoking group was shown for craving for tobacco (F(2,70)=11.21, 
p<001). Tukey post-hoc analysis demonstrated addicted smokers reported greater 
increases in craving for tobacco than non-addicted smokers in withdrawn sessions 
compared to baseline (p<. 025) (Figure 6.2, Table 6.3). 
6.3.2 Relationship between withdrawal sensitivity and tobacco dependence 
Change scores were computed to present how total withdrawal symptornatology had 
changed from Baseline (non-deprived) to Withdrawn session (post-24-hour 
abstinence), i. e. Withdrawn WSC total minus Baseline WSC total. Change scores 
were also computed for the individual items in WSC (Withdrawn WSC item minus 
Baseline WSC item). Data from non-smokers were excluded from these analyses. 
Since the data was non-parametric, a series of Spearman's Rho analyses was used to 
investigate correlations between addiction index scores and withdrawal change scores. 
Significance levels were I-tailed due to the predicted directionality of the correlations. 
Addiction index correlated positively with total WSC change score (r--0.282, p<05 I- 
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tailed). This showed that subjects with higher addiction scores experienced greater 
increases in the overall withdrawal symptoms measured (Figure 6.3). 
Addiction index correlated positively with individual WSC change scores for the 
"restlessness" (r--0.255, p<05 I-tailed) and "sleep disturbance" (r--0.274, p<05 I- 
tailed) symptoms. This showed that subjects with higher addiction scores experienced 
greater increases in these symptoms following 24-hour withdrawal. 
6.3.3 Differences between addicted and non-addicted smokers urges to smoke 
following 24-hour abstinence 
Baseline session QSU Factor I scores were compared with the withdrawn session 
QSU Factor I scores using repeated measures analysis of variance. Smoking group 
was the between-subjects factor. Non-smokers were excluded from these analyses. 
All smoking subjects were shown to increase QSU Factor 1 (urges relating to positive 
reinforcement) scores following 24-hour withdrawal (FII, 48)=44.76, p<001), 
however there was no interaction between smoking group and these scores. Although 
addicted smokers rated their Factor 1 urges to smoke in withdrawal higher than non- 
addicted smokers, this difference was not significant (Table 6.4, Figure 6.4). 
Although all smokers had increased QSU Factor 2 (urges relating to negative 
reinforcement) scores following 24-hour withdrawal (Fj 1,48)=29.56, p<. 001), there 
was no interaction between smoking group and these scores. Addicted smokers rated 
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their Factor 2 urges to smoke much higher in withdrawal than non-addicted smokers, 
however this difference was not significant (Table 6.5, Figure 6.4). 
Although the QSU was not shown to discriminate between the addicted and non- 
addicted groups, it is relevant to and affected by levels of dependence. Change scores 
were computed to characterise the difference between baseline session and withdrawn 
session for both QSU Factors (Withdrawn QSU Factor I scores minus Baseline QSU 
Factor I scores, and same for Factor 2). These change scores were then correlated 
with Addiction Index scores using Spearman's Rho. Significance levels were Wailed 
due to the predicted directionality of the correlations. Although there was no 
significant correlation for Factor I change scores, levels of nicotine dependence 
(Addiction Index) were positively correlated with urges to smoke relating to negative 
reinforcement (Factor 2 change scores) (r--0.245, p<05 I-tailed; see Figure 6.5. ). 
6.3.4 Effects of reinstatement on smokers' withdrawal symptom ratings 
Withdrawn session total WSC ratings were compared with the Reinstated session total 
WSC ratings using repeated measures analysis of variance. Smoking group was the 
between-subjects factor, and Baseline session WSC ratings were included as a 
covariate in the analysis to act as a quantitative predictor. 
There was a significant interaction between WSC total ratings and smoking group 
(F(2,67)=4.87, p<025). Pairwise comparisons of means showed that both addicted 
and non-addicted smokers increased their ratings in withdrawal relative to non- 
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smokers (both contrasts p<001) (see Figure 6.6, Table 6.2). No significant differences 
were shown between the two groups of smokers. 
Further analyses were performed on individual WSC items ratings (see Table 6.1) to 
identify symptom differences between the addicted and non-addicted smoker groups. 
Withdrawn and reinstated sessions were compared, using repeated measures analysis 
of variance with Tukey post-hoc analysis. No significant interactions between session 
and smoking group were shown for any of the individual WSC items, demonstrating 
that no particular withdrawal symptom is differentially affected by reinstatement 
between addicted and non-addicted smokers. 
0.3.5 Relationship between reinstatement sensitivity and tobacco dependence 
Change scores were computed to present how total withdrawal symptornatology had 
changed following reinstatement (i. e. Withdrawn (post-24-hour abstinence) WSC 
scores minus Reinstated (post-45-minute ad libitum smoking) WSC scores. Change 
scores were also computed in the same way for the individual items in the WSC. Data 
from non-smokers were excluded from these analyses. Since the data was non- 
parametric, a series of Spearman's Rho analyses was used to investigate correlations 
between Addiction Index scores and withdrawal change scores. 
Addiction Index correlated negatively with total WSC change score (r---0.27, p<05 I- 
tailed) showing that subjects with higher addiction scores (tobacco dependence) 
experienced greater reductions in the overall withdrawal symptoms measured 
following 45 minutes of ad libitum smoking (Figure 6.7). 
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Addiction Index correlated negatively with individual WSC change scores for craving 
for tobacco symptoms (r---0.317, p<025 1-tailed) showing that subjects with higher 
addiction scores experienced greater reductions in craving following 45 minutes of ad 
libitum smoking. 
6.3.6, Differences between addicted and non-addicted smokers urges to smoke 
:I:, following reinstatement 
Withdrawn session QSU Factor I scores were compared with the reinstated session 
QSU Factor I scores using repeated measures analysis of variance. Smoking group 
was the between-subjects factor. This analysis was repeated with Factor 2 scores. 
Baseline Factor scores were used as a covariate in the analysis to act as a quantitative 
predictor. Non-smokers were excluded from these analyses. 
Although all smoking subjects were shown to have reduced QSU Factor I scores 
following reinstatement (increased primary intention and appetitive desire to smoke) 
(F I 1,47)=34.28, p<001), there was no significant interaction between smoking group 
and Factor I scores. Thus although following reinstatement non-addicted smokers 
reduced their ratings of Factor I urges to smoke more than addicted smokers, this 
difference was not significant (Table 6.4, Figure 6.4). 
Similarly, although all smoking subjects were shown to have reduced QSU Factor 2 
scores following reinstatement (decreased desire to alleviate withdrawal and reduce 
negative affect through smoking) (FJ 1,48)=4.5, p<05), there was no significant 
interaction between smoking group and Factor 2 scores. Thus, although following 
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reinstatement, addicted smokers reduced their Factor 2 scores more than non-addicted 
smokers, this difference was not significant (Table 6.5, Figure 6.4). 
Change scores were computed to characterise the difference between withdrawn 
session and reinstated session for both QSU Factors (Reinstated QSU Factor I scores 
minus Withdrawn QSU Factor I scores, and same for Factor 2). These change scores 
were then correlated with Addiction Index scores using Spearman's Rho, to examine 
whether the impact of reinstatement on smoking urges was related to level of 
dependence. There were no significant correlations for higher levels of nicotine 
dependence (Addiction Index) with Factor I or Factor 2 change scores quantifying 
reinstatement from 45-minutes ad libitum smoking. 
6.2 Discussion 
Acute 24-hour abstinence from smoking was shown to bring about an array of 
symptoms concordant with previous formulations of the tobacco withdrawal 
syndrome (e. g. Hughes & Hatsukami, 1986). Furthermore it was shown that addicted 
smokers reported greater "craving for tobacco" than non-addicted smokers, and that 
higher levels of tobacco dependence were correlated with larger increases in 
withdrawal symptornatology (especially "restlessness" and "sleep disturbance"). All 
smokers were observed to increase their ratings of urges to smoke relating to both 
positive and negative reinforcement (see Figure 6.4), with the latter motivation being 
more greatly increased in those with higher levels of tobacco dependence as measured 
by Addiction Index scores (p<05). 
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Ad libitum smoking for 45 minutes (reinstatement) was shown to reverse many of 
these withdrawal effects; all smokers' total withdrawal symptoms were reduced, with 
more tobacco dependent smokers showing the greatest reductions in symptornatology 
(Particularly "craving for tobacco"). Reinstatement also elicited significant reductions 
in smokers urges to smoke pertaining to both positive and negative reinforcement, and 
these reductions were independent of levels of tobacco dependence and smoker sub- 
group. 
The Withdrawal Symptoms Checklist (adapted from Hughes & Hatsukami, 1986) was 
shown to be a sensitive tool for measuring levels of tobacco withdrawal. All smokers 
reported significant increases in total withdrawal symptom severity, concordant with 
Hughes & Hatsukarni's (1986) findings. No differences were shown between addicted 
and non-addicted smokers in the total symptom severity response to withdrawal. This 
finding is not in accord with Shiffman (1989), whose chippers showed significantly 
fewer symptoms than dependent smokers after overnight abstinence. This indicates 
tangible differences between "'chippers" and "non-addicted smokers". The latter group 
is clearly less stringent and includes smokers with moderate levels of tobacco 
dependence. These individuals are likely to experience significant withdrawal 
symptoms. 
Individual WSC items were examined in order to elucidate withdrawal symptoms that 
could discriminate addicted and non-addicted smoker groups. "Craving for tobacco" 
was more increased by withdrawal in the addicted smokers than the non-addicted 
smokers. This finding is concordant with Shiffman (1989), who reported that "Desire 
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to Smoke" (a factor on the Shiffman & Jarvik (1976) withdrawal scale) was 
significantly greater in dependent smokers than chippers following overnight 
abstinence. These findings support the grouping methodology used in this research 
(see Chapter 2). However, it is possible that a contingent of the non-addicted group 
may be moderately tobacco dependent, or may go on to develop greater dependence. 
When dependence is quantified on a continuous scale (Addiction Index, see Chapter 
2), it was demonstrated that higher scores were correlated with greater increases in 
symptom severity (total WSC ratings) following abstinence. These findings support 
previous research showing a similar correlation between "Dependent" factor scores on 
Russell et al. 's (1974) Smoking Motivation Questionnaire (SMQ) and overall 
withdrawal severity (West & Russell, 1985). Of the individual WSC items examined, 
"sleep disturbance" and "restlessness" ratings were positively correlated with 
Addiction Index. These findings are interesting, as they suggest that when nicotine 
levels are lowered through abstinence, dependent smokers have trouble relaxing or 
it switching off'. Results of previous studies are consistent with the finding that 
dependent smokers have disturbed sleep following abstinence (e. g. Hughes & 
Hatsukami, 1986; Prosise et al. 1994), and rate restlessness as increased (Hughes & 
Hatsukami, 1986). 
West & Russell (1985) showed no correlation between "restlessness" ratings and 
"Dependent" factor scores on the SMQ. Closer observation of their results showed 
they used 2-tailed Speannan's Rho to analyse their correlations. If West & Russell's 
(1985) hypotheses had been directional they could have used a I-tailed test, and the 
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correlation (r--0.30) would have been significant at the p<05 level. Current results 
clearly demonstrate a relationship between levels of dependence with severity of 
withdrawal symptoms experienced, although the precise nature of the association is 
unclear. 
Smokers rate their urges to smoke measured by the QSU as significantly increased 
following 24-hour abstinence. Both Factor 1 scores (primary intention and appetitive 
desire to smoke, or positive reinforcement) and Factor 2 scores (avoidance of 
withdrawal effects and negative affect, or negative reinforcement) were higher in the 
withdrawn session than the baseline (non-deprived) session. These results are 
consistent with previous research. Tiffany & Drobes (1991) showed smokers QSU 
scores on both factors increased incrementally following abstinence periods of 0,1 
and 6 hours. Willner, Hardman & Eaton (1995) showed a similar increase following 
abstinence periods of between 4 and 14 hours. 
The smoker sub-groups were not significantly differentially affected in terms of 
increase of QSU ratings on either factor. It can be seen however that addicted smokers 
were rating their urges to smoke higher than non-addicted smokers on both factors. 
Davies, Willner & Morgan (2000) compared chippers and dependent smokers QSU 
ratings in response to smoking cues. They found that chippers Factor I scores, but not 
Factor 2 scores, were elevated by cues. This difference was not found in dependent 
smokers. Exposure to relevant cues and an appropriate period of abstinence are two 
methods of eliciting craving. If the effects of abstinence on smoking urges can be 
compared with effects of cue-exposure, Davies et al. 's (2000) findings are analogous 
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to the current results. Davies et al. (2000) showed that chippers had increased QSU 
smoking urges relating to positive reinforcement following cue-exposure, and little 
increase in urges relating to negative reinforcement. They also showed that both types 
of urges were significantly increased by cue-exposure in regular smokers. The current 
study broadly supports their findings, and the failure to achieve significance may be 
due to differences between "chippers" (used by Davies et al. 2000) and "non-addicted 
smokers" (used in the current research). It was shown that urges of non-addicted 
smokers pertain to positive rather than negative reinforcement, as these motivations 
(QSU Factor 1) are the most greatly increased by abstinence and reduced by 
reinstatement. 
Another result in the current study that supports those of Davies et al. (2000) is that 
higher tobacco dependence (Addiction Index scores) was correlated with greater 
increases in Factor 2 scores (negative reinforcement) following abstinence. 
Furthermore, this is concordant with the theory that negative reinforcement is a 
defining feature of substance dependence (Piasecki et al. 2000), and reduced 
sensitivity to this aspect may be protecting chippers from developing greater tobacco 
dependence. However, the existence of causal relationships cannot be automatically 
inferred from correlation data. Low levels of tobacco dependence or tolerance may 
explain why negative reinforcement is less important in non-addicted smokers or 
chippers. 
Smokers' total severity of withdrawal symptoms was significantly reduced by 45 
minutes of ad libitum smoking. These findings are concordant with those of Shiffman 
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(1989), who compared abstinent smokers before and after a single cigarette and found 
that reinstatement caused significant reductions in psychological withdrawal 
symptoms. Addicted and non-addicted smokers did not differ in their 
symptornatological response to reinstatement, since both groups rated total 
withdrawal significantly lower after smoking. 
This contrasts with Shiffman's (1989) findings that chippers are not significantly 
subjectively affected by smoking following overnight abstinence. In non-addicted 
smokers studied in the current research, withdrawal symptoms increase following 
abstinence and decrease following reinstatement. In chippers, Shiffman (1989) only 
showed small increases and decreases in symptoms following abstinence then 
reinstatement; this further exemplifies the difference between chippers and non- 
addicted smokers discussed previously. The significant effects of reinstatement on 
withdrawal symptoms would be predicted since non-addicted smokers reported 
significantly increased withdrawal symptoms following abstinence. In contrast with 
the response to withdrawal, no individual symptoms differentiated addicted and non- 
addicted smokers in response to reinstatement, although there was a non-significant 
trend for addicted smokers to report greater reductions in "craving for tobacco". This 
finding is broadly consistent with Shiffman (1989), who reported a trend for greater 
decreases in "desire to smoke" in dependent smokers compared to chippers after one 
cigarette. 
Higher levels of tobacco dependence were correlated with both greater reductions in 
total withdrawal symptoms and greater reductions in "craving for tobacco" following 
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reinstatement. These results are interpreted as showing that high-dependence smokers 
experienced greater increases in withdrawal, craving in particular, following 
abstinence. Ergo they were experiencing greater reductions in symptoms after 
reinstatement, as their symptoms returned to approximately baseline levels. These 
results are broadly consistent with theories that levels of dependence will predict 
severity of withdrawal (Wikler, 1973). High levels of tobacco dependence may reflect 
more pronounced neuro-adaptation or a greater constitutional need for nicotine (Royal 
College of Physicians, 2000). Both these phenomena can easily be related to tobacco 
withdrawal, since more neuro-adaptation or higher nicotine tolerance would mean 
greater psychopharmacological repercussions during periods of abstinence. This is 
because homeostatic adaptations caused by chronic nicotine exposure would suddenly 
be inappropriate for the abstinent state. 
Smokers rated their urges to smoke significantly lower following reinstatement than 
in withdrawal. This occurred in items relating to both positive reinforcement (primary 
intention and appetitive desire to smoke) and negative reinforcement (avoidance of 
withdrawal symptoms and negative affect). There was a non-significant trend for ad 
libitum smoking to cause greater reductions in items relating to positive reinforcement 
in the non-addicted than addicted smokers. This can be explained by the similar levels 
of urges relating to positive reinforcement reported by both groups during the 
withdrawn session, whilst the baseline and reinstatement session ratings were lower 
for the non-addicted group. 
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Although no comparison data is available showing effects of withdrawal and 
reinstatement on QSU measures, Shiffman (1989) showed a reduction in "desire to 
smoke" in both chippers and dependent smokers following reinstatement. Current 
results showed a non-significant trend for rating changes from withdrawal to 
reinstatement in urges to smoke relating to negative reinforcement to correlate with 
levels of tobacco dependence. This correlation was significant when examining the 
negative reinforcement change from baseline to withdrawn sessions, but did not 
achieve significance in this comparison perhaps due to greater variation in the ratings 
on Factor 2 items in the reinstatement session. 
Although the functional smoker subgroups used in this study were shown to be valid 
and discriminatory, it may have been more useful to split the smoker sample into 
three subgroups rather than two. Chippers (see Chapter 2) could have been examined 
in their own right whilst moderately addicted smokers could have been studied as a 
separate subgroup. The small number of addicted smokers may also have contributed 
to smaller effects and less discriminatory or statistical power in the study. Although 
45 minutes of ad libitum smoking was likely to have been enough to achieve 
reinstatement for most subjects, some highly dependent smokers may not have 
reinstated nicotine levels to baseline through a lack of time, or by smoking fewer 
cigarettes than they actually desired (i. e. saving cigarettes for another time). 
This study demonstrated that 24-hour abstinence from smoking increased ratings of 
withdrawal in all smokers, and that smokers who were more dependent had greater 
increases in tobacco craving, restlessness and sleep disturbance. Although all urges to 
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smoke were increased by withdrawal in all smokers, urges relating to positive 
reinforcement were most increased in non-addicted smokers, whereas addicted 
smokers reported greater increases in urges relating to negative reinforcement All 
these effects were reversed by reinstatement, with addicted smokers deriving greater 
relief from tobacco craving than non-addicted smokers. The findings provide insight 
into particular problems that might be encountered when abstaining from smoking 
according to levels of tobacco dependence. This may be useful in targeting specific 
clinical smoking cessation advice for particular types of smokers. 
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Figure 6.1 C, raph showing mean total WSC ratings of the three groups during 
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Figure 6.3 Scatterplot showing relationship between Addiction Index score 
and change in total WSC ratings (baseline to withdrawn) in 
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Figure 6.4 Graph showing addicted and non-addicted smokers QSU Factor I 
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Figure 6.5 Scatterplot showing relationship between Addiction Index score 
and change in QSU Factor 2 score (baseline to withdrawn) in 
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Figure 6.6 Graph showing mean total WSC ratings of' the three subJect 
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Figure 6.7 Scatterplot showing relationship between Addiction Index score 
and change in total WSC ratings (withdrawn to reinstated) in 
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Table 6.1 Mean (standard deviation) withdrawal symptom ratings of 
addicted smokers, non-addicted smokers and non-smokers in the 
three test sessions. 
WSC ITEM GROUP BASELINE WITHDRAWN REINSTATED 
CRAVING AD. 0.67(0.71) 2.23(l. 09) 0.22(0.44) 
FOR NON-AD. 0.48(0.68) 1.45(0.99) 0.40(0.71) 
TOBACCO NON-SM. 0.00(0.00) <0.01 (0.20) <0.01 (0.20) 
IRRITABILITY AD. 0.44(0.53) 0.89(0.93) 0.33(0.50) 
NON-AD. 0.60(0.74) 0.85(0.86) 0.58(0.75) 
NON-SM. 0.42(0.58) <0.01 (0.20) 0.01(0.28) 
ANXIETY AD. 0.33(0.71) 1.11(0.78) 0.44(0.73) 
NON-AD. 0.53(0.75) 0.63 (0. ýO) 0.40(0.63) 
NON-SM. 0.33 (0.56) 0.16(0.37) 0.16(0.47) 
DIFFICULTY AD. ' 0.89(0.78) 0.67(0.50) 0.56(0.73) 
CONCENTRATING NON-AD. 0.95(0.88) 0.98(0.83) 0.63(0.67) 
NON-SM. 0.58(0.72) 0.32(0.48) 0.24(0.52) 
RESTLESSNESS AD. 0.67(0.71) 1.56(l. 01) 0.56(0.53) 
NON-AD. 0.83(0.78) 0.97(0.84) 0.78(0.83) 
NON-SM. 0.29(0.55) 0.16(0.47) 0.20(0.50) 
HEADACHES AD. 0.11(0.33) 0.22(0.44) 0.11(0.33) 
NON-AD. 0.23(0.58) 0.35(0.77) 0.18(0.50) 
NON-SM. 0.33(0.76) 0.16(0.37) 0.01(0.28) 
DROWSINESS AD. 1.11(l. 05) 0.78(0.97) 0.78(0.67) 
_ NON-AD. 1.08(0.89) 1.03(l. 07) 0.85(0.77) 
NON-SM. 0.58(0.78) 0.40(0.58) 0.16(0.37) 
GASTROINTESTINAL AD. 0.11(0.33) 0.00(0.00) 0.44(l. 01) 
TRACT NON-AD. 0.20(0.56) 0.28(0.72) 0.01(0.35) 
DISTURBANCE NON-SM. 0.25(0.61) 0.01(0.28) 0.00(0.00) 
IMPATIENCE AD. 0.67(0.50) 0.78(0.67) 0.67(0.71) 
NON-AD. 0.70(0.72) 0.95(t. 04) 0.78(0.73) 
NON-SM. 0.33(0.56) 0.12(0.33) 0.12(0.33) 
SOMATIC AD. 0.33(0.71) 0.22(0.67) 0.11(0.33) 
COMPLAINTS NON-AD. 0.15(0.36) 0.20(0.56) <0.01 (0.16) 
NON-SM. 0.01(0.28) 0.20(0.58) 0.12(0.44) 
INCREASED AF 0.33(l. 00) 5.67(0.71) 0.00(0.00) 
EATING NON-AD. 0.35(0.70) 0.70(0.79) 0.18(0.50) 
NON-SM. 0.01(0.28) 0.00(0.00) <0.01 (0.20) 
HUNGER AD. 0.78(0.97) 0.89(0.78) 0.67(0.71) 
NON-AD. 0.60(0.78) 0.60(0.84) 0.68(0.92) 
NON-SM. 0.17(0.48) 0.00(0.00) 0.40(0.65) 
UNUSUAL ALCOHOL AD. 0.11(0.33) 0.33(0.71) 0.00(0.00) 
INTAKE NON-AD. 0.25(0.71) 0.26(0.68) 0.10(0.38) 
NON-SM. 0.13(0.35) 0.00(0.00) 0.00(0.00) 
UNUSUAL CAFFEINE AD. 0.44(0.53) 0.56(l. 13) 0.11(0.33) 
INTAKE NON-AD. 0.15(0.53) 0.30(0.61) 0.13(0.46) 
NON-SM. 0.17(0.64) 0.12(0.44) 0.12(0.44) 
SLEEP AD. 0.56(0.53) 0.89(0.93) 0.22(0.44) 
DISTURBANCE NON-AD. 0.38(0.70) 0.70(0.97) 0.28(0.51) 
NON-SM. 0.33(0.70) 0.24(0.44) 0.24(0.52) 
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MEAN SD) TOTAL WSC RATINGS 
BASELINE WITHDRAWN REINSTATED 
7.56(4.33) 11.78 (5.04) 5.22(3.03) 
7.45(5.17) 9.79(6.53) 6.03(4.67) 
6.36(4.15) 2.04(2.59) 2.0(2.97) 
Table 6.3 Mean "Craving for Tobacco" WSC ratings for the three groups in 







MEAN (SD) "CRAVING FOR TOBACC O" WSC RATINGS 
BASELINE WITHDRAWN REINSTATED 
0.67(0.71) 2.22(l. 09) 0.22(0.44) 
0.48(0.68) 1.45(0.99) 0.4(0.71) 
0.0(0.0) 0.0(0 - 2) 0.0(0.2) 
Table 6.4 Mean QSU Factor 1 scores (positive reinforcement) for the two 
smoking groups in the three experimental sessions 
MEAN (SD) QSU FACTOR I SCORES 
BASELINE WITHDRAWN REINSTATED 
ADDICTED -21.5 (19.74) -0.9 (17.15) -23.1(22.65) SMOKERS 
NON-ADDICTED -27.53 (14.65) -0.71(16.93) -30.23 (14.15) SMOKERS 
Table 6.5 Mean QSU Factor 2 scores (negative reinforcement) for the two 
smoking groups in the three experimental sessions 
MEAN (SD) QSU FACTOR 2 SCORES 
BASELINE WITHDRAWN REINSTATED 
ADDICTED 
SMOKERS 
29.4 (11.57) 44.2 (16.57) 27.9 (13.08) 
NON-ADDICTED 
SMOKERS 
24.68 (11.26) 34.75 (15.04) 25.7 (11.01) I 
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Chapter 7- The effects of lofexidine and nicotine on cognitive 
performance deficits and withdrawal symptoms associated with the 
tobacco withdrawal syndrome 
7.1 Introduction 
Nicotine deprivation has been shown to cause impaired cognitive function (Wesnes & 
Warburton, 1984; Snyder, Davis & Heningfield, 1989; Parrott & Winder 1989), and 
reinstatement has been shown to reverse these effects, both by smoking (e. g. 
Houlihan, Pritchard & Robinson, 1996) and by nicotine replacement therapy (e. g. 
Foulds et al. 1996). These phenomena were investigated in Chapter 3. Symptoms such 
as difficulty concentrating have been ascribed to the tobacco withdrawal syndrome 
associated with abstinence in addicted smokers. While the underlYing mechanisms of 
nicotine withdrawal are not well understood, it is believed that lowered mood, anxiety 
and altered central noradrenergic function are major components of a withdrawal 
syndrome. 
Nicotine is one of several drugs (e. g. alcohol, opiates) that can give rise to a 
withdrawal syndrome during periods of abstinence. Withdrawal from opiates is 
associated with hyperactivity of afferent noradrenergic cells in the locus coeruleus 
(Redmond, Hwang & Gold, 1977) thought to contribute to the anxiety component of 
the withdrawal syndrome (Weiss, Ciccocioppo, Parsons, Katner, Liu, Zorilla, Valdez, 
Ben-Shahar, Angeletti & Richter, 2001). a2-adrenoceptor agonists (e. g. clonidine or 
lofexidine) attenuate this "noradrenergic st=7 (Brunning et al. 1986). Although 
atypical anxiolytics, clonidine and lofexidine have been used successfully to treat the 
opiate withdrawal syndrome (Gold, Redmond & Kleber, 1978; Strang, Beam & 
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Gossop, 1999), blocking signs and symptoms indicating anxiety including 
apprehension and irritability (Uhde, Redmond & Kleber, 1980). 
Anxiety is commonly associated with withdrawal from a variety of addictive 
substances (e. g. Stewart & Kushner, 2001; Weiss et al. 2001). The locus coeruleus (a 
brain area rich in ct2-adrenoceptors) is implicated in fear and anxiety responses to 
stimuli, mediated by noradrenaline. Many of the autonomic and psychological 
manifestations of withdrawal (i. e. sweating, tachycardia, elevated blood pressure) are 
similar to the exacerbation of anxiety in patients with panic disorder. Uhde et al. 
(1980) suggest that it is the panic-anxious component of the opioid abstinence 
syndrome that is most effectively treated by clonidine. Clonidine has also been 
reported to reduce anxiety in humans and ameliorate anxiety in non-addicted patients 
(Aghajanian, 1978; Svensson & Strombom, 1977). 
(x2-receptors can be located both pre- and post-synaptically, with stimulation of each 
having different effects. Fortuitously, pre- versus post-synaptic mode of action can be 
determined by the dose of an (x2-agonist. At low doses (e. g. 0.2mg clonidine) pre- 
synaptic autoreceptors such as those in the locus coeruleus are stimulated, attenuating 
neuronal firing and the release of noradrenaline from terminals (Svensson, Bunney & 
Aghajanian, 1975; Ong, BaH & Vaughn, 1991). At higher doses post-synaptic actions 
are triggered, boosting noradrenergic function (Amsten & Goldman-Rakic, 1985; 
Amsten & Cai, 1993). ec2-adrenoceptor agonists have sedative side effects (Uhde et 
al. 1984). 
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There have been a number of studies examining clonidine and its impact on nicotine 
withdrawal. Several of these have found that clonidine can indeed mitigate some of 
the problems associated with tobacco withdrawal. Prochazka et al. (1992) found that 
clonidine administered transdermally to abstinent smokers reduced some withdrawal 
symptoms (anxiety and irritability), but did not improve rates of long-term smoking 
cessation. Ornish et al. (1988) examined the effects of transdermal clonidine on the 
withdrawal symptoms associated with smoking cessation over six days. They found 
that craving, anxiety and irritability were reduced by clonidine. Other studies suggest 
that clonidine does not ameliorate tobacco withdrawal (e. g. McGee & Murray 1989). 
There is little research on the effects of (x2-agonists on withdrawal-induced cognitive 
performance deficits, although (x2-adrenoceptors are also known to play a role in 
cognitive performance. The locus coeruleus noradrenergic system is associated with 
consolidation and learning (Crow, 1968; Kety, 1970), selective attention (Mason & 
Iversen, 1979) and prefrontal cognitive processing (e. g. Arnsten & Goldman-Rakic, 
1985; Sahakian, Coull & Hodges, 1994). Low doses of clonidine have been 
demonstrated to selectively impair cognitive performance in humans and animals 
(Arnsten & Goldman-Rakic, 1985; Frith, Dowdy, Ferrier & Crow, 1985). The 
findings are consistent with the theory that noradrenaline is involved in preventing 
people from becoming distracted by irrelevant stimuli. 
Low doses of clonidine have also been shown to impair performance on a focused 
attention task (Smith & Nutt, 1996) and a rapid visual infon-nation processing task 
(Coull et al. 1995). This is contrasted with findings that idazoxan (an (x2-antagonist) 
improved performance on a categoric search task (Smith et al. 1992a). Clark, Geffen 
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& Geffen (1989) however reported that clonidine reduced errors on the Posner covert 
orientation of attention task (Posner, 1980). These studies therefore suggest that (X2- 
agonists broaden the focus of attention, whereas enhanced noradrenergic function (as 
induced by ec2-antagonists or opiate withdrawal) narrows the focus of attention. 
There may be common ground among withdrawal syndromes associated with many 
drugs of dependence in terms of psychopharmacology and behavioural effects. The 
importance of anxiety both as a baseline discriminator and as a differentially 
prominent withdrawal symptom justifies looking further at the effects of this class of 
drug on the tobacco withdrawal syndrome. Although clonidine effects on tobacco 
withdrawal have been investigated, lofexidine has fewer side effects and promotes 
less hypotension (Gerra et al. 2001), and therefore may ultimately have more clinical 
significance. Examination of the impact of lofexidine on tobacco withdrawal may also 
improve our understanding of this withdrawal syndrome as well as offer increased 
pharmacotherapeutic options in terms of treating nicotine dependence. If lofexidine 
can ameliorate nicotine withdrawal in a similar way to opiate withdrawal, it is 
important to establish whether different symptoms are differentially affected. 
Cognitive tasks demonstrating sensitivity to effects of tobacco withdrawal and 
reinstatement in Chapter 3 were chosen for use in this study. These were a focused 
attention task, categoric search task, and rapid visual information processing task. 
In order to clearly present all the findings of this study, the current chapter splits 
following the Method section to present the mood and cognitive performance results 
and discussion (7A), followed by the withdrawal questionnaire symptornatology 
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results and discussion (713). These will be surnmarised with a general discussion at the 
close of the chapter. 
Hypotheses (7A): 
that 24-hour nicotine withdrawal will result in performance decrements on 
cognitive tasks, including reduced accuracy and increased reaction times on 
trials of the focused attention and categoric search tasks, and fewer hits on the 
repeated digits vigilance/RVIP task). 
11. that 24-hour nicotine withdrawal will affect visual analogue scale ratings of 
mood, reducing alertness and hedonic tone, and increasing anxiety. 
111. that NRT (Nicorette@ inhalator) will reverse these withdrawal-induced mood 
and performance decrements more effectively than placebo. 
IV. that lofexidine will reverse withdrawal-induced mood and performance 
decrements where impaired attention or increased anxiety is fundamental, 
better than placebo and as effectively as NRT. 
Hypotheses (7B): 
V. that 24-hour nicotine withdrawal will increase subjects' self-report ratings of 
withdrawal symptoms. 
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VI. that 24-hour nicotine withdrawal will increase subjects' ratings of urges to 
smoke (particularly on Factor 2 scores on QSU). 
VII. that 24-hour nicotine withdrawal will negatively affect acute mood states 
measured bY POMS. 
VIII. that NRT (NicoretteD inhalator) will reverse these nicotine withdrawal 
symptoms, urges to smoke and negative mood states more effectively than 
placebo. 
IX. that lofexidine will reverse nicotine withdrawal symptoms, urges to smoke and 
negative mood states better than placebo and as effectively as NRT. 
7.2 Method 
7.2.1 Design 
This study was a double-blind placebo-controlled pseudo-randomised repeated 
measures design with the following conditions: lofexidine capsule, placebo capsule, 
nicotine inhalator and placebo inhalator. Performance measures used were Broadbent 
et al. 's (1989) focused attention and categoric search tasks (measuring accuracy and 
reaction time variables), and repeated digits vigilance / rapid visual information 
processing (RVIP) task (measuring hits, false alarms and reaction times). Pre- and 
post-test mood measures were also taken using visual analogue scales (measuring 
alertness, hedonic tone and anxiety). See Appendices V, VII, VIII and X for full 
descriptions of the variables. Questionnaires administered were Withdrawal 
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Symptoms Checklist, Other Withdrawal Symptoms checklist, Questionnaire of 
Smoking Urges and Profile of Mood States. These are described in Section 7.2.3. 
Participants attended two experimental weeks that were normally consecutive. One 
was a 'nicotine week' consisting of a Baseline Session (Monday), Placebo Session 
(Tuesday or Friday) and Drug Session (Friday or Tuesday). Another was a 'lofexidine 
week' also consisting of a Baseline Session (Monday), Placebo Session (Tuesday or 
Friday) and Drug Session (Friday or Tuesday). All subjects performed all sessions: 
those who received placebo on Tuesday received drug on Friday, and vice versa. This 
was counterbalanced to control for order effects, as was order of nicotine/lofexidine 
week. 
The United Bristol Healthcare Trust granted ethical approval for this study. 
7.2.2 Subjects 
Twelve addicted smokers (6 male, 6 female) were recruited from student sources via 
posters around the University campus and mail-shots on various e-mail lists. Ages 
ranged from 19-45, mean=24.4 (SD 7.7). Smokers' addiction status was assessed 
using the Fagerstrom Tolerance Questionnaire (FTQ) described in Chapter 2. 
Smokers scoring 4 or higher on the FTQ and smoking 15 or more cigarettes per day 
were considered addicted and accepted on the study. These participants later 
completed the SQB (see Chapter 2), and all were found to have an Addiction Index 
score higher than 8.0 (mean=10.4, SD 1.12), and could therefore be classed as 
addicted smokers using the same criteria previously utilised in the thesis. 
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7.2.3 Questionnaires 
Chapter 7 
A pre-test questionnaire (PTQ) booklet was compiled and used in a similar way to 
that described in Chapter 6. This pre-test questionnaire (PTQ) features a short 
questionnaire asking for details of food, alcohol and tobacco consumption over the 
previous 24 hours (see Appendix XVI); it also includes The Profile of Mood States 
(POMS), WSC and QSU (see Chapter 6) and Other Withdrawal Symptoms (OWS). 
Questionnaire data will be described in section 7B. 
Withdrawal Symptoms Checklist (WSQ 
This is a fifteen-item checklist based on the Hughes & Hatsukami (1986) study on 
tobacco withdrawal. It features eight items taken from the DSM-III symptom list for 
the tobacco withdrawal syndrome, plus further items added by the authors. It presents 
each item (craving for tobacco, irritability, etc. ) with 4 check-boxes labelled 0 to 3. 
O=not present, I=mild, 2=moderate, 3=severe. See Appendix XIV. 
Other Withdrawal Symptoms (OWS) 
This is a twenty-item checklist based on the withdrawal symptoms reported in opiate 
withdrawal likely to be associated with noradrenaline (Strang, Beam & Gossop, 
1999). Each item is presented with a 10-point Likert-type scale with ratings from 0 
(not present) through to 9 (severe). See Appendix XVIL 
Questionnaire of Smoking Urges (QSU) 
This is a 32-item questionnaire developed and validated by Tiffany & Drobes (1991). 
Subjects are presented with positive or negative statements regarding urge to smoke. 
Subjects were asked to indicate on a Likert-type scale how strongly they agree or 
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disagreed with each statement. Each item was scored on a scale of I (strongly 
disagree) to 7 (strongly agree). See Appendix XV. 
Profile of Mood States 
The mono-polar POMS questionnaire (McNair et al. 197 1; 198 1) was utilised to 
examine acute mood states. This was used in conjunction with the pre- and post-test 
mood scales included in the computer task battery. The POMS is a 65-item 
questionnaire asking subjects to rate a mood state (e. g. sad, angry, lively) on a 5-point 
Likert-type scale (O=Not at all, through to 4=Extremely). See Appendix XVIII. 
7.2.4 Materials 
Lofexidine was administered as a 0.2mg tablet, which has been previously used 
safely. Tablets were placed inside lactulose capsules, randomised by a third party and 
placed in labelled grip-bags. Placebo in this trial was a comparable lactulose capsule. 
Nicotine was administered via a Nicorette@ inhalator device. This is a plastic tube- 
shaped mouthpiece containing a NicoretteO cartridge containing 10mg nicotine and 
menthol flavouring. Subjects were instructed to use these in a particular way; i. e. by 
taking eight "puffs" on the inhalator. Subjects were asked to inhale deeply through the 
inhalator, and warned that there is far more resistance than with normal cigarettes. 
The placebo version of these devices was the same except the cartridge was altered: 
the polythene pellet within was removed and replaced with a Swan slimline filter tip 
bent double. Both placebo and drug cartridges were treated with a drop of Olbas oil 
tincture overnight prior to use. This was to mask taste and aroma differences between 
nicotine and placebo. 
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At appropriate times, subjects were breathalysed in order to check whether they had 
successfully abstained from smoking for the previous 24 hours. This was done using a 
MicroMedical MicroCO carbon monoxide breathalyser. A count of less than 10 parts 
per million was accepted as proof that the subject had abstained and could continue 
with the trial. 
7.7.5 Computer tasks 
The tasks were chosen from those described in Chapter 3 showing marked impact of 
nicotine withdrawal, and were administered using Amstrad PCs running DOS. 
Mood - Visual analogue mood scales 
Subjective mood is assessed using 18 computerised visual analogue mood scales. 
These 18 scales were presented successively. Ultimately these are factor scored and 
yield scores for three measures: anxiety, hedonic tone and alertness. See Appendix V 
for a full description. 
Performance tests 
Focused attention task 
Participants were presented with ten practice trials followed by W blocks of 64 trials. 
In each block there were equal numbers of 'near' or 'far' conditions, 'A' or V 
responses and equal numbers of the four distracter conditions. The nature of the 
previous trial was also controlled. See Appendix VII f6r a full description of this task. 
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Categoric search task 
Chapter 7 
The number of 'near' and 'far' stimuli, 'A' and V responses, and distracter and 
blank conditions were controlled. Half of the trials lead to compatible responses (i. e., 
the letter A on the left side of the screen, or letter B on the right). The nature of the 
preceding trial was also controlled. In other respects (practice, number of trials, etc. ) 
the task is identical to the focused attention task. See Appendix VIII for a full 
description of this task. 
Repeated digits detection (R VIPIvigilance) task 
This visual cognitive vigilance task measures the ability to detect targets at irregular 
intervals. In this task lasting 5 minutes, participants were shown successive 
presentations of three digit numbers in the centre of the screen at the rate of 100 per 
minute. Each three-digit number usually differed from the one immediately preceding 
it, with one out of the three digits being replaced with a different digit (e. g. 463,563, 
562). Eight times per minute the same three-digit number will be presented on 
successive trials. Participants were required to detect and respond to these repetitions 
as quickly as possible by pressing a key. See Appendix X. 
7.2.6 Procedure 
The experimental week procedure can be observed as a timetable in Table 7.1. 
Familiarisation 
This session was performed at any time prior to the commencement of the first week 
of the study. On arrival at the Psychology Research Unit, participants were issued 
with standardised verbal instructions. 
214 
Lofexidine and nicotine effects Chapter 7 
Subjects were asked to read the information sheet (see Appendix XIX) and gave 
written consent regarding participation (see Appendix XX). Once complete they were 
asked to perform a shortened 15-minute version of the computer test battery. When 
finished, subjects completed a Smoking Questionnaire Battery (see Chapter 2). 
Baseline 
This session tested participants under normal, non-abstinent conditions. Each subject 
performed this session at the start of each experimental week (nicotine and 
lofexidine). It commenced Monday at 9.00 a. m., with subjects asked to smoke 
normally prior to arrival. 
9.00 a. m. Pre-Test Questionnaire booklets (see Appendix XVI) completed. 
9.1 Oa. m. Computer test battery performed. 
Experimental session 
Both experimental weeks featured drug and placebo condition experimental sessions, 
which were randomly allocated to Tuesday and Friday. These conditions were single- 
blind in the nicotine week and double-blind in lofexidine week. 
9.00 a. m. Pre-Test Questionnaire booklets (see Appendix XVI) completed. 
9.05 a. m. Subjects breathalysed using the MicroCO. 
9.10 a. m. Computer test battery performed. 
9.30 a. m. Subjects remain in booths for I hour break (resting). 
9.32 a. m. (Lofexidine week) - Subjects administered lofexidine or lactulose 
capsule and 200ml water and instructed to swallow the capsule 
immediately. 
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10.10 a. m. (Nicotine week) - Subjects administered nicotine or placebo inhalator. 
Subjects were instructed to familiarise themselves with the airflow 
resistance of the device then to take 8 'puffs' on the device; 'puff' 
being defined as breathing in through the inhalator straight into their 
lungs for as long as was comfortable. Subjects told to take normal 
breaths between 'puffs'. 
10.20 a. m. (Lofexidine week) - Subjects' blood pressure taken. 
10.30 a. m. Pre-Test Questionnaire booklets (see Appendix XVI) completed. 
10.35 a. m. Computer test battery repeated. 
11.00 a. m. (Friday, second week) - Subjects completed documentation and 
informed when they would receive their remuneration, then thanked 
and debriefed. 
SECTION 7A 
7A. 1. Statistical analyses 
Analysing the lofexidine and nicotine study weeks as two separate 2x2 (drug versus 
placebo, pre-treatment versus post-treatment) factorial repeated measures analyses of 
variance was considered. Although this method had increased power relative to the 
analysis method ultimately used and removed the need for conservative Bonferroni 
corrections, there were several good reasons why the W model was rejected in this 
instance. To merely investigate the nicotine or lofexidine effects, using the W model 
might have been preferable, however we were also interested in withdrawal effects; 
i. e. a direct comparison between baseline and pre-treatment session means. We were 
also interested in explicit placebo effects. These extra comparisons fall outside the 
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standard remit of the W factorial design. Furthermore, the validity of baseline data 
as covariates in the 2x2 model is questionable. Since both the pre-treatment 
(withdrawn) and post-treatment (inhalator/capsule) states were very different to 
normal non-deprived baseline conditions, the inclusion of the latter in the model may 
lack statistical and theoretical relevance. 
Analysis using the 2x2 factorial method was carried out in order to contrast with the 
single-factor model finally chosen. Many of the results observed were highly 
comparable between the two methods. For example, the lofexidine effect of 
increasing time taken to encode new information in the Focused Attention task 
(section 7A. 2.1.1.2.2) showed similar findings using the W ANOVA (Ff 1,101=14.7, 
p<005). Other effects, however, were not corroborated by the alternative analysis, 
probably due to the direct involvement of placebo effects in the model. For example 
the nicotine effect of reducing the Eriksen effect in the Focused Attention task 
(section 7A. 2.1.1.2.2) was not found using the W ANOVA (F [ 1,10 1 =2.3, p=O. 16). 
To minimise the likelihood of Type II errors, and for the reasons outlined in the 
previous paragraph, the W factorial analysis was not utilised in the global analyses 
of data in this chapter. The same rationale was also applied to analyses in Section 7B. 
Repeated measures analysis of variance was carried out on the performance data using 
SPSS 9.0 statistical package. All 10 sessions were compared with each other as 10 
levels of the same variable: Time. Using this model allowed us to explicitly 
investigate the effects of withdrawal by comparing baseline with pre-treatment 
(abstinent) sessions, and placebo effects by comparing pre-placebo and post-placebo 
sessions. Due to the large number of comparisons, session means contrasts were 
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examined using Bonferroni correction for multiple comparisons. Mood data was 
factorised to give scores on three axes (alertness, hedonic tone and anxiety). Order 
effects were not formally examined due to the randomised cross-over structure of the 
design. 
Further correction for multiple comparisons in the Focused Attention and Categoric 
Search tasks, since both tests examined large numbers of variables, was considered 
but not performed as it was deemed inappropriate. Although many statistical tests 
were performed in the analyses of both tasks, the precise variables tended to be highly 
correlated components of either accuracy or reaction time on the global cognitive 
attributes measured. Correcting for multiple comparisons would have therefore 
increased the likelihood of Type H error. 
7A. 2. Results 
7A. 2.1. Cognitive Performance 
An overview of the effects of withdrawal, and subsequent effects of lofexidine, 
nicotine and placebo on accuracy and reaction time on the three cognitive 
performance tasks can be observed in Table 7.2. 
7A. 2.1.1. Focused Attention Task 
This task measures 46 different variables: of these, 12 showed a significant effect of 
session: 10 of these were discrete accuracy variables and two were derived reaction 
time-based variables. 
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7A. 2.1.1.1. Accuracy (F. A. T. ) 
Chapter 7 
7A. 2.1.1.1.1. Withdrawal effect: comparison of baseline (non-deprived) 
session with pre-drug/pre-placebo 
Subjects' accuracy on several variables in the focused attention task was impaired in 
withdrawn sessions. 
Repeated measures analysis of variance indicated reduced accuracy in responding to 
targets presented alone or with an asterisk (F[9,99)=3.11, p<002), with pre-drug 
nicotine sessions less accurate than nicotine baseline (p<05) and pre-placebo 
lofexidine sessions less accurate than lofexidine baseline (p<05) (see Table 7.3, 
Figure 7.1). Reduced accuracy can be seen in all sessions compared to baseline. These 
effects did not survive Bonferroni correction for multiple comparisons. 
The Eriksen effect (spatial interference) on accuracy of responses was affected by 
session as revealed by ANOVA (F[9,99)=2.24, p<05). Subjects were less prone to 
spatial interference effects on accuracy when abstinent, as significant differences were 
found between nicotine week baseline and the pre-drug session (p<. 025). These 
effects did not survive Bonferroni correction for multiple comparisons. No significant 
withdrawal effects are demonstrated in the lofexidine week. 
Accuracy was also affected by session when the target was presented with 
disagreeing stimuli (e. g. if 'A' was the target, the distracters, were 'B') in the 'near' 
position (F(9,991=2.94, p<01). Both pre-placebo (p<05) and post-placebo (p<01) 
sessions showed greater impact of near disagreeing distracters than in lofexidine 
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baseline, as accuracy in the latter sessions was lower. These effects did not survive 
Bonferroni correction for multiple comparisons. 
Accuracy of response when a target was repeated from previous trial (e. g. 'A' 
followed by 'A') was also shown to be significantly affected by session 
(F(9,99)=3.77, p<001). Greater accuracy was observed in the lofexidine baseline 
session than a withdrawn (pre-placebo) session (p<025). This effect did not survive 
Bonferroni correction. Furthermore, accuracy of response when a target was 
alternated from previous trial (e. g. 'B' when previous trial was 'A') also 
demonstrated a significant session effect (F(9,991=2.84, p<01). Mean accuracy is 
significantly lower in the pre-placebo (p<05) lofexidine session compared to 
lofexidine baseline (see Figure 7.2 and Table 7.4). This effect survived Bonferroni 
correction for multiple comparisons. 
Response accuracy was significantly affected by session when asterisks were 
presented in the 'near' position with the target (F19,991=2.41, p<025). Accuracy was 
shown to be lower in the pre-drug session (p<. 025) compared to baseline in the 
nicotine week. These effects did not survive Bonferroni coffection for multiple 
comparisons. 
Presenting disagreeing stimuli in the 'near' location to the target has an effect of 
decreasing accuracy. This effect differed between sessions as shown by repeated 
measures ANOVA (F[9,991=2.52, p<025). The impairing effect of 'near'-placed 
distracters; was significantly greater in the baseline session than the pre-drug session 
(p<025). This effect did not survive Bonferroni correction for multiple comparisons. 
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Variables pertaining to accuracy on the focused attention task were shown to be not 
sensitive to effects of lofexidine in 24-hour tobacco withdrawn subjects. This was 
investigated using repeated measures analysis of variance to exan-dne main effects of 
Gsession', and Bonferroni corrected multiple comparisons of estimated marginal 
means. No post-lofexidine sessions differed significantly from the pre-lofexidine 
sessions. 
7A. 2.1.1.1.3. Nicotine effect 
Variables pertaining to accuracy on the focused attention task were shown to be not 
sensitive to effects of nicotine in 24-hour tobacco withdrawn subjects. This was 
investigated using repeated measures analysis of variance to examine main effects of 
'session', and Bonferroni corrected multiple comparisons of estimated marginal 
means. No post-nicotine sessions differed significantly from the pre-nicotine sessions. 
7A. 2.1.1.2. Reaction time (F. A. T. ) 
7A. 2.1.1.2.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Variables pertaining to reaction times on the focused attention task were shown to be 
not sensitive to 24-hour abstinence from tobacco using repeated measures analYsis of 
variance to investigate main effects of 'session', and Bonferroni corrected multiple 
comparisons of estimated marginal means. No withdrawn sessions differed 
significantly from the respective baseline sessions. 
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Subjects' reaction times on the focused attention task were impaired by lofexidine. 
Analysis of variance showed that mean time taken to encode a new response (Z time 
respon ing to targets alternating from previous trial minus I time responding to 
ýt targets repeating from previous trial) was affected by session (F(9,99)=1.97, p<05). 
Scores on this variable shows that lofexidine increases the amount of time taken to 
encode a new response on the focused attention task (post-lofexidine session differs to 
pre-lofexidine session (p<. 005)). See Figure 7.3 and Table 7.5. This effect did not 
survive Bonferroni correction for multiple comparisons. 
7A. 2.1.1.2.3. Nicotine effect 
ANOVA showed a main effect of session on spatial interference (Eriksen effect) 
(F[9,991=2.29, p<025). The Eriksen effect was reduced by the adn-ýnistration of 
nicotine. Prc-nicotinc and post-nicotinc session means differed significantly (p<. 025), 
although this effect did not survive Bonferroni correction for multiple comparisons. 
7A. 2.1.2. Categoric Search Task 
This task examined 44 variables on the Broadbent (1989) categoric search task. 
Fourteen of these variables showed a significant effect of session when examined 
using repeated measures analysis of variance, including 4 variables regarding 
accuracy and 10 reaction time variables. 
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7A. 2.1.2.1. Accuracy (C. S. T. ) 
7A. 2.1.2.1.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Chapter 7 
Subjects' accuracy on several variables in the categoric search task was impaired in 
withdrawn sessions. 
Analysis of variance (repeated measures) showed a main effect of session on mean 
accuracy responding to targets presented in the same location as the previous trial 
(F[9,991=2.00, p<05). Lofexidine week baseline was more accurate than both the 
pre-placebo and pre-drug sessions during that week (both p<05). These differences 
did not survive Bonferroni correction for multiple comparisons. 
Mean accuracy on trials where targets are in blank (no distracter), 'far' position, 
incompatible (e. g. target presentation on left, correct response key on right) conditions 
were shown by ANOVA to be subject to a main effect of session (F[9,99)=1.99, 
p<05). Accuracy is significantly higher in the baseline sessions than in the withdrawn 
sessions, shown by differences between baseline and pre-drug session in the nicotine 
week (p<025). Similar differences were also shown between baseline and both pre- 
drug (p<01) and pre-placebo (p<05) sessions in the lofexidine week. These effects 
did not survive Bonferroni correction for multiple comparisons. 
7A. 2.1.2.1.2. Lofexidine effect 
Lofexidine improves accuracy on the categoric search task. Effects were observed in 
mean accuracy responding to targets in blank (no distracter), 'far' and 'incompatible' 
conditions (F19,991=1.99, p<05). Subjects' responses to these trials were more 
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accurate after the administration of lofexidine, as pre-lofexidine means are lower than 
post-lofexidine (p<05). This effect did not survive Bonferroni correction for multiple 
comparisons. 
7A. 2.1.2.1.3. Nicotine effect 
As with the focused attention task, variables pertaining to accuracy on the categoric 
search task were shown to be not sensitive to effects of nicotine in 24-hour tobacco 
withdrawn subjects. This was investigated using repeated measures analysis of 
variance to examine main effects of 'session, and Bonferroni corrected multiple 
comparisons of estimated marginal means. No post-nicotine sessions differed 
significantly from the pre-nicotine sessions. 
7A. 2.1.2.2. Reaction time (C. S. T. ) 
7A. 2.1.2.2.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Subjects' reaction times on several variables in the categoric search task were 
improved in withdrawn sessions. 
Mean reaction time responding to trials where targets were presented in the same 
location as the previous trial was significantly different according to session 
(Fj 9,99 1 =3.23, p<O 1). Response times were significantly slower in baseline than pre- 
placebo session (p<05) in the lofexidine week. This effect did not survive Bonferroni 
correction for multiple comparisons. 
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Analysis of variance revealed a main effect of session on mean reaction time to trials 
when the target is repeated from the previous trial (e. g. target was 'A' in both current 
and previous trial) (F(9,991=3.27, p<01). Baseline reaction times on these trials are 
significantly slower than pre-placebo session (p<025) in the lofexidine week (Figure 
7.4 and Table 7.6). These effects did not survive Bonferroni correction for multiple 
comparisons. 
Mean reaction time in trials where the target was presented with a distracter in the 
'far' and 'incompatible' position was shown to be significantly affected by session 
(F[9,991=3.79, p<001). In the lofexidine week response times were significantly 
slower in baseline sessions than in pre-placebo session (p<05). Mean reaction times 
on trials where a distracter was present in the 'near' and 'incompatible' conditions 
was also significantly affected by session (F(9,99)=2.10, p<05). Response times 
were slower in baseline sessions than in withdrawal; with significant differences 
observed between baseline and pre-placebo sessions (p<05) in the lofexidine week. 
These effects did not survive Bonfeffoni correction for multiple comparisons. 
7A. 2.1.2.2.2. Lofexidine effect 
Lofexidine improved reaction time performance on several variables of the categoric 
search task. Analysis of variance showed an effect of lofexidine on the changes 
caused to mean reaction time by presenting targets with irrelevant stimuli (digits), in 
the 'far' and 'compatible' condition (F[9,99)=2.27, p<025). Comparisons showed 
the slowing effect on response times caused by irrelevant stimuli was significantly 
less in the post-lofexidine session compared with the pre-lofexidine session (p<05), 
although this effect did not survive Bonferroni correction (Figure 7.5 and Table 7.7). 
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Lofexidine effects were also observed on mean reaction time to trials where the target 
is presented with a distracter, in the 'far' and 'incompatible' position (F[9,99)=3.79, 
p<001). Subjects' response times are significantly faster in this condition after the 
administration of lofexidine, as pre-lofexidine and post-lofexidine sessions differed 
(p<05). This effect did not survive Bonferroni correction for multiple comparisons. 
Placebo effects (significant differences between pre-placebo and post-placebo 
sessions) were found on the mean reaction time when the target category is repeated 
from previous to current trial (i. e. 'A' followed by 'A') (F[9,99)=3.27, p<01). 
Reaction times in this condition were faster following placebo capsule (pre-placebo 
versus post-placebo, p<05). This effect did not survive Bonferroni correction. 
7A. 2.1.2.2.3. Nicotine effect 
Nicotine improved subjects' reaction times on certain variables in the categoric search 
task. ANOVA showed nicotine effects on mean reaction time to targets presented in 
the same location as the previous trial (F[9,991=3.23, p<01). Subjects' response 
times are significantly faster in the post-nicotine session compared to the pre-nicotine 
session (p<. 05) (Figure 7.6 and Table 7.8), although this effect did not survive 
Bonferroni coffection. 
Nicotine effects were also demonstrated on mean reaction time when targets are 
repeated from previous trial (F[9,99)=3.27, p<. 01). Response times were 
significantly faster in this condition in post-nicotine sessions compared with pre- 
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nicotine (p<05). These effects did not survive Bonferroni correction for multiple 
comparisons. 
Placebo effects during the nicotine week were demonstrated using analysis of 
variance on several variables. Mean reaction time when the target was repeated from 
previous trial (F19,99)=3.27, p<01); reaction times were faster post-placebo 
compared with pre-placebo session (p<05, after Bonferroni correction). Mean 
reaction time when targets were presented in a different location to the previous trial 
(F[9,991=2.11, p<05) ; reaction times were faster post-placebo compared with pre- 
placebo session (p<. 001, after Bonferroni correction). Mean reaction time when 
targets were presented alone (F(9,991=2.75, p<01); reaction times were faster post- 
placebo compared with pre-placebo session (p<. 001, after Bonferroni correction). 
Mean reaction time responding to targets presented in the same location as the 
previous trial (F[9,991=3.23, p<01); reaction times were faster post-placebo 
compared with pre-placebo session (p<. 025, this effect did not survive Bonferroni 
correction). 
Mean reaction times where targets are in 'blank' (no distracter), 'far' and 
'incompatible' (correct response key on opposite side to target) trials (F(9,991=2.35, 
p<025) ; reaction times were faster post-placebo compared with pre-placebo session 
(p<025, after Bonferroni correction). Mean reaction time where targets were 
presented with a distracter, in the 'far' and 'incompatible' position (F(9,99)=3.79, 
P<001); reaction times were faster post-placebo compared with pre-placebo session 
(p<. O I, after Bonferroni correction). Mean reaction times to trials where a distracter is 
present, in the 'far' and 'compatible' condition (F[9,99)=2.30, p<025); reaction 
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times were faster post-placebo compared with pre-placebo session (p<. Ol, this effect 
did not survive Bonferroni correction). 
7A. 2.1.3. Repeated digits RVIP/vigiIance task 
Two of the three global variables (mean total reaction time of responses, total number 
of 'hits' - correctly responding to a target 'repeat') measured by this task 
demonstrated a significant effect of session. The number of 'false alarms' (responses 
to non-targets) was not sensitive to session. 
7A. 2.1.3.1. Accuracy (RVIP) 
7A. 2.1.3.1.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Repeated measures analysis of variance showed a main effect of session on mean total 
number of hits on this task (F[9,99)=3.12, p<01). Significantly more 'hits' were 
achieved in the baseline session than pre-drug session (p<05) in the nicotine week. In 
the lofexidine week, significantly more 'hits' were made in the baseline session than 
in the pre-placebo session (p<025). These effects do not survive Bonferroni 
correction for multiple comparisons. 
7A. 2.1.3.1.2. Lofexidine effect 
Variables pertaining to accuracy on the repeated digits vigilance/RVIP task were 
shown to be not sensitive to effects of lofexidine in 24-hour tobacco withdrawn 
subjects. This was investigated using repeated measures analysis of variance to 
examine main effects of 'session', and Bonferroni corrected multiple comparisons of 
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estimated marginal means. No post-lofexidine sessions differed significantly from the 
pre-lofexidine sessions. No effects of placebo capsule were observed. 
7A. 2.1.3.1.3. Nicotine effect 
Variables pertaining to accuracy on the repeated digits vigilance/RVIP task were 
shown -to be not sensitive to effects of nicotine in 24-hour tobacco withdrawn 
subjects. This was investigated using repeated measures analysis of variance to 
examine main effects of 'session', and Bonferroni corrected multiple comparisons of 
estimated marginal means. No post-nicotine sessions differed significantly from the 
pre-nicotine sessions. 
Analysis of variance demonstrated a placebo effect during the nicotine week on mean 
total number of hits (F[9,991=3.12, p<01). There was a greater number of 'hits' in 
the pre-placebo session than in the post-placebo session (p<001, this marginally did 
not survive Bonferroni correction) (Figure 7.7 and Table 7.9). 
7A. 2.1.3.2. Reaction time (RVIP) 
7A. 2.1.3.2.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Withdrawal improves subjects' reaction times on this task. Repeated measures 
analysis of variance showed a main effect of session on total mean reaction time of 
responses on this task (F[9,99)=2.94, p<. 005). Reaction time was significantly slower 
in the baseline session than the pre-drug session (p<. 05) in the nicotine week. In the 
lofexidine week, reaction time was significantly slower in the baseline session 
compared to pre-placebo (p<05). These effects do not survive Bonferroni correction. 
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7A. 2.1.3.2.2. Lofexidine effect 
Chapter 7 
Variables pertaining to reaction time on the repeated digits vigilance/RVIP task were 
shown -to be not sensitive to effects of lofexidine 
in 24-hour tobacco withdrawn 
subjects. This was investigated using repeated measures analysis of variance to 
examine main effects of 'session', and Bonferroni corrected multiple comparisons of 
estimated marginal means. No post-lofexidine sessions differed significantly from the 
pre-lofexidine sessions. No effects of placebo capsule were observed. 
7A. 2.1.3.2.3. Nicotine effect 
Variables pertaining to reaction time on the repeated digits vigilance/RVIP task were 
shown to be not sensitive to effects of nicotine in 24-hour tobacco withdrawn 
subjects. This was investigated using repeated measures analysis of variance to 
examine main effects of 'session', and Bonferroni corrected multiple comparisons of 
estimated marginal means. No post-nicotine sessions differed significantly from the 
pre-nicotine sessions. 
Repeated measures analysis of variance showed a placebo effect on total mean 
reaction times of responses on this task (F(9,99)=2.94, p<005). Faster reaction times 
were shown in the post-placebo session compared with pre-placebo (p<01). This 
effect did not survive Bonferroni correction for multiple comparisons. 
7A. 2.2. Mood 
7A. 2.2.1. Alertness 
Scores on this scale indicate general feelings of arousal, with high scores indicating 
greater alertness, and low scores expressing reduced alertness. 
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7A. 2.2.1.1 Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Pre-test alertness was affected by session as revealed by repeated measures analysis of 
variance (F[9,99)=2.79, p<01). Pre-test alertness was rated significantly lower in 
pre-placebo (p<. O I) and pre-drug (p<025) sessions than baseline in the nicotine week 
(see Figure 7.8 and Table 7.10). These effects did not survive Bonferroni correction 
for multiple comparisons. 
Post-test alertness was affected by session as revealed by repeated measures analysis 
of variance (F19,99)=2.3, p<025). Post-test alertness was rated significantly lower in 
pre-placebo (p<. Ol) and pre-drug (p<. 025) sessions than baseline in the nicotine 
week. These effects did not survive Bonferroni correction for multiple comparisons. 
There were no changes in alertness from pre- to post-test compared between baseline 
and withdrawn (pre-placebo and pre-drug) sessions in both nicotine and lofexidine 
weeks. 
7A. 2.2.1.2. Lofexidine effect 
Repeated measures analyses of pre-test alertness and post-test alertness showed no 
lofexidine effects, as means did not differ significantly between pre-lofexidine and 
post-lofexidine sessions. No lofexidine placebo effects on pre-test alertness or post- 
test alertness were observed. 
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Alertness change scores between pre-test ratings in the pre-treatment session and 
post-test ratings in the post-treatment session were computed for lofexidine and 
placebo days. No significant differences were observed. 
7A. 2.2.1.3. Nicotine effect 
Repeated measures analyses of pre-test alertness showed no nicotine effects, as means 
did not differ significantly between pre-nicotine and post-nicotine sessions. No 
nicotine placebo effects on pre-test alertness were observed. 
Subjects rated their post-test alertness higher after administration of nicotine as shown 
by analysis of variance (p<025), comparing pre-nicotine session with post-nicotine 
session (Figure 7.9, Table 7.11). Subjects also rated their post-test alertness 
significantly higher after administration of placebo inhalator as shown by analysis of 
variance, comparing pre-nicotine session with post-nicotine session (p<025). These 
effects did not survive Bonferroni correction for multiple comparisons. 
Alertness change scores between pre-test ratings in the pre-treatment session and 
post-test ratings in the post-treatment session were computed for nicotine and placebo 
days. No significant differences were observed. 
7A. 2.2.2. Hedonic tone 
Higher ratings of hedonic tone indicate increased levels of positive affect and 
contentedness, whereas lower scores indicate negative attributes such as unhappiness 
and irritation. 
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7A. 2.2.2.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
Pre-test hedonic tone was affected by session as revealed by repeated measures 
analysis of variance (F[9,991=2.64, p<01). Pre-test hedonic tone was rated 
significantly lower than baseline in pre-placebo (p<05) and pre-drug (p<05) sessions 
in the lofexidine week (Figure 7.10 and Table 7.12), but this effect did not survive 
Bonferroni correction. A non-significant trend was observed for pre-test hedonic tone 
to also be rated lower than baseline in pre-placebo and pre-drug sessions in the 
nicotine week. 
Post-test hedonic tone was affected by session as revealed by repeated measures 
analysis of variance (F[9,991=2.16, p<05). Post-test hedonic tone is rated 
significantly lower than baseline in pre-placebo (p<025) and pre-drug (p<05) 
sessions in the nicotine week, but these effects did not survive Bonferroni correction. 
Changes in hedonic tone from pre- to post-test were not significantly affected by 
session. 
7A. 2.2.2.2. Lofexidine effect 
Repeated measures analyses of pre-test hedonic tone and post-test hedonic tone 
showed no lofexidine effects, as means did not differ significantly between pre- 
lofexidine and post-lofexidine sessions. No lofexidine placebo effects on pre-test 
hedonic tone or post-test hedonic tone were observed. 
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Alertness, change scores between pre-test ratings in the pre-treatment session and 
post-test ratings in the post-treatment session were computed for lofexidine and 
placebo days. No significant differences were observed. 
7A. 2.2.2.3. Nicotine effect 
Repeated measures analyses of pre-test hedonic tone showed no nicotine effects, as 
means did not differ significantly between pre-nicotine and post-nicotine sessions. No 
nicotine placebo effects on pre-test hedonic tone were observed. 
A non-significant trend was observed for subjects to rate their post-test hedonic tone 
higher in post-nicotine session compared with pre-nicotine session. 
Subjects rated their post-test hedonic tone higher after administration of placebo 
inhalator as shown by (p<. Ol) comparing pre-placebo with post-placebo session 
(Figure 7.11 and Table 7.13), but this effect did not survive B onferroni correction. 
Hedonic tone change scores between pre-test ratings in the pre-treatment session and 
post-test ratings in the post-treatment session were computed for nicotine and placebo 
days. No significant differences were observed 
7A. 2.2.3. Anxiety 
High scores on this scale indicate low anxiety, and vice versa (see Figure 7.12). 
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7A. 2.2.3.1. Withdrawal effect: comparison of baseline with pre-drug/ 
pre-placebo 
No significant withdrawal effects were indicated by analyses on visual analogue 
anxiety scales, although analysis of variance suggested a non-significant trend effect 
of session was emerging (F(9,991=1.8, p<075). 
Analysis of variance revealed that post-test ratings of anxiety were not significantly 
affected by session. 
Changes in anxiety from pre- to post-test were not significantly affected by session. 
7A. 2.2.3.2. Lofexidine effect 
A repeated measures analysis of pre-test anxiety showed no lofexidine effect. Means 
did not differ significantly between pre-lofexidine and post-lofexidine sessions. No 
lofexidine placebo effects on pre-test anxiety were observed. 
Ratings of post-test anxiety showed no lofexidine or placebo effect. Means did not 
differ significantly between pre-lofexidine and post-lofexidine sessions. Figure 7.12 
shows mean post-test anxiety scores during the lofexidine week as an error-bar plot. 
The session means can also be viewed in Table 7.14. 
Anxiety change scores between pre-test ratings in the pre-treatment session and post- 
test ratings in the post-treatment session were computed for lofexidine and placebo 
days. No significant differences were observed. 
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7A. 2-2.3-3. Nicotine cffect 
Chapter 7 
A repeated measures analysis of prc-test anxiety showed no nicotine effect. Means did 
not differ significantly between pre-nicotinc and post-nicotinc sessions. No nicotine 
placebo effects on pre-test anxiety were observed. 
Repeated measures analyses of variance on post-test anxiety showed no lofcxidine 
effCcL Means do not differ significantly between pre-lofcxidinc and post-lofcxidinc 
sessions. No lofexidinc placebo effects on post-tcst anxiety were observed. 
Anxiety change scores between prc-tcst ratings in the prc-treatuicrit session and post- 
test ratings in the post-treatment smion were computed for nicotinc and placebo 
daYs. No significant differences were observed. 
7A. 3. Discussion (Section 7A) 
'Me results above show that acute 24-hour tobacco abstinence has a variety Of cffccts 
on cognitive pcrformance and mood. These impairmcnts, arc afIected in different ways 
by nicotine and lofcxidinc, and performance tasks are not significantly affected by the 
different drugs in the same way. Withdrawal is shown to reduce response accuracy on 
all three cognitive pcrformance tasks, whereas the Wects on reaction time arc 
'equivocal. Lofcxidinc improved accuracy and reaction time performance on the 
catcgOric search task but had little impact on the other tcsm while nicotine improved 
reaction time variables on the focu%cd attention and categoric search tasks. 
%rithdrawal reduced subjective ratings of alertness and hedonic tonc. Lofcxidinc did 
not affect subjective mood ratingsý but participants reported higher alertness and a 
trend toward higher hcdonic tonc following nicotine. 
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Cognitive performance 
Chapter 7 
As predicted, withdrawal was shown to cause reductions in accuracy in the focused 
attention task, the categoric search task and the RVIP task. Conversely, nicotine 
withdrawal improved subjects' reaction times on the latter two tasks. These findings 
are not consistent with previous research, as Snyder, Davis & Heningfield (1989) 
showed that reaction times on attentional. tasks were worsened by withdrawal and that 
accuracy was less affected. It may be that withdrawal induced a different performance 
style or strategy, or that withdrawn individuals during this study intentionally changed 
the equilibrium between speed and accuracy (i. e. performing tasks faster in order to 
smoke sooner). 
Withdrawal was shown to reduce accuracy on focused attention task trials where 
either discordant or concordant distracter stimuli were presented 'near' to the target. 
This effect can be contrasted with differences in far-field stimuli, since the Eriksen 
effect (the relative interference effect of near-field distracters compared to far-field) 
was greater when subjects were in withdrawal. The finding that near-field non-targets 
were more distracting than far-field distracters suggests that the focus of attention had 
become narrowed by withdrawal. 
Narrowing of the focus of attention is a phenomenon associated with increased frontal 
noradrenergic function. This theory is supported by cognitive performance studies 
using a2-antagonists; Smith et al. (1992a) showed that chronic idazoxan (an a2- 
antagonist causing increased levels of frontal noradrenaline) administration improved 
attentional performance as measured by the place repetition effect. Their subjects 
responded more quickly to targets presented in the same location as the previous trial 
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than one presented at a different location, suggesting a narrowing of focus of attention 
(Coull, 1994). The current results are also concordant with theories that withdrawal 
results in increased noradrenergic activity in the locus coeruleus (e. g. Redmond et al. 
1977). 
Withdrawal significantly reduced accuracy on focused attention task trials where the 
target was presented alone or with a neutral distracter. A similar withdrawal effect 
was observed on trials where targets are alternated from the previous trial. These 
kinds of errors may be due to transient changes in mood such as increased 
impulsiveness or impatience. As described in Chapter 4, impulsiveness is an 
established personality trait of dependent smokers (Mitchell, 1999) that may be 
intensified in conditions of withdrawal. Earlier research in the tobacco withdrawal 
syndrome (e. g. Hughes & Hatsukami, 1986) and DSM-IV cite "impatience" as a 
reliable symptom. 
Subjects also performed less accurately in withdrawal on trials where the target was 
repeated from a previous trial. Together these results indicate a non-specific accuracy 
impairment, possibly explained by motor interference, or a more random, less 
attentive response style. To support this, it was shown that no reaction time variables 
on this task were affected by withdrawal. The trade-off between accuracy and reaction 
time associated with task performance appeared to change when in a state of 
withdrawal. Subjects were aware they would be able to smoke once the session was 
complete, therefore they may have been deliberately accelerating their performance, 
thus making more effors. 
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Accuracy and reaction time variables on the categoric search task were also sensitive 
to effects of 24-hour abstinence. Withdrawal impaired accuracy on trials where targets 
were presented alone, trials where targets were presented in the same location as the 
previous trial, and trials where targets were presented in a different location from the 
previous trial. The latter two results suggest that withdrawal does not differentially 
impair performance based on place repetition effects. This poses theoretical 
difficulties for a solely noradrenergic account of cognitive deficits associated with 
tobacco withdrawal. If withdrawal induced changes in noradrenergic function similar 
to a2-antagonists, significant place repetition effects would be predicted (Smith et al. 
1992a). However, if subjects were responding randon-fly or impulsively, selective 
effects on place repetition may have been lost in a general accuracy deficit. 
Withdrawal effects were also seen when targets were presented with no distracter, in 
the 'far' position, with the correct response key in the 'incompatible' position. This 
may be attributable to impulsive responding, hitting the response key on the same side 
as the stimulus. Alternatively, it may again reflect a more random or less attentive 
response style. 
Reaction time variables were more affected than accuracy by withdrawal in the 
categoric search task. Many reaction times were faster following 24-hour withdrawal. 
Again, subjects could be responding more quickly and therefore less accurately, 
reflecting either mood-based withdrawal symptoms such as impatience (see Section 
7B) or a conscious attempt to finish tasks sooner in order to be able to smoke sooner. 
Interestingly, whereas reaction times on this task were faster in withdrawal than 
baseline (non-deprived), they were not affected on the focused attention task. If this 
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were singularly a result of changes in response style, the tasks would probably have 
been affected in similar ways. 
Withdrawal effects were observed on variables measuring accuracy and response 
times on the repeated digits RVIP/vigilance task. Performance in terms of the number 
of 'hits' achieved during the task was worse than baseline following withdrawal in 
both weeks. This is consistent with previous studies; Sommese & Patterson (1995) 
found that tobacco abstinence adversely affected vigilance in airline pilots who 
smoked. 
Lofexidine increased the time taken to encode a new response on the focused 
attention task, but improved accuracy and reaction time on the categoric search task. 
No lofexidine effect was observed on the RVIP task. Smith & Nutt (1996) reported 
clonidine having an adverse effect on sustained focused attention, which is analogous 
with the findings here. 
In contrast, the relative improvement in categoric search task performance following 
lofexidine suggests that different attentional. mechanisms are employed, possibly in a 
similar way to the Posner covert orientation of attention task (Posner, 1980). For 
example, reaction times were quicker on trials where targets were presented in the 
'far' and 'incompatible' conditions with distracters following lofexidine. This may 
signal one of the direct effects of (x2-agonists, a reduction in the interference of 
irrelevant stimuli. This would therefore be consistent with other work demonstrating 
ct2-agonists broadening the focus of attention (Clark, Geffen & Geffen, 1989). If 
withdrawal does lead to increased frontal noradrenergic activity, and this mediates the 
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associated cognitive impairments, lofexidine (that reduces noradrenergic function) 
can to some extent reverse these deficits. 
Nicotine adn-ýinistration reduced the Eriksen effect (spatial interference) on the 
focused attention task and improved reaction time on the categoric search task, but 
had no effect on the RVIP task. The beneficial effects of nicotine on attention in 
abstinent smokers are well documented, with administration shown to improve 
decision time on a choice reaction test (Bates et al. 1995) and improve reaction time 
in visual and auditory odd-ball tasks (Houlihan, Pritchard & Robinson, 1996). It is 
interesting that withdrawal increased spatial interference on the focused attention task 
whereas nicotine reduced it. Research in future could focus on whether the Eriksen 
effect is directly affected by nicotine, i. e. determine whether absolute effects can be 
observed in non-deprived smokers or non-smokers. The improvements following 
nicotine seen in the categoric search task are also consistent with previous research 
(Perkins et al. 1996). 
The failure of nicotine to elicit effects on the RVIP task examined here is puzzling. 
Previous research has shown nicotine improves performance on RVIP tasks both via 
smoking (Wesnes & Warburton, 1983a; Gilbert, Estes & Welser, 1997) and NRT 
(Jones et al. 1992; Foulds et al. 1996; Mancuso et al. 1999). An insufficient dose is 
one possible reason for the lack of nicotine effect. Previous research indicates that one 
"puff' of an inhalator provides 13pg of nicotine at room temperature (Schneider et al. 
1996). Although Schneider et al. (1996) state that this is based on shallow "puffing" 
rather than the deep inhalation used by participants in this research, it is still highly 
likely that blood levels of nicotine achieved were well below those attained by a 
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single cigarette. Mancuso et al. (1999) found improvements in RVIP performance 
after very small doses of nicotine administered via patch, although their levels were 
still likely to be higher than those attained in the current study. Different results may 
have been found if subjects had been allowed to use the inhalators ad libitum for (e. g. ) 
a twentY-minute period. 
Marked placebo effects were observed during the nicotine weeks. The placebo 
inhalator improved subjects' reaction times without affecting accuracy on the 
categoric search task. Placebo effects per se are well documented (Lasagna et al. 
1954), and there is evidence that placebo NRT has considerable effects (Davies, 
Willner, James & Morgan, in press). It is interesting that the main placebo effect is 
analogous to the actual nicotine effect. This may be explained in terms of using the 
inhalator, simulating smoking. This contrasts with lofexidine, which is taken as a 
tablet (and is a novel substance rather than the desired drug). Simply performing the 
motor activity associated with delivering the drug of addiction could simulate 
neurochernical changes similar to actually obtaining the drug. Similar effects to this 
have been shown with other addictive substances, with sensory cues eliciting 
increased doparninergic (reward) function (Schultz, 2001). 
Mood 
Withdrawal caused negative changes in mood, as predicted in the hypotheses. 24-hour 
abstinence from nicotine resulted in subjects rating their alertness and hedonic tone 
lower than when they were non-deprived. Tobacco withdrawal effects on alertness 
found here are consistent with previous research (e. g. Prosise et al, 1994), as 
drowsiness and daytime sleepiness are established symptoms of the syndrome. 
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Hedonic tone was also negatively affected by withdrawal. This is likely to be because 
the hedonic tone factor incorporated items such as 'sociability' and 'happiness'. 
Subjects increased irritability and negative affect were expressed on these scales, 
which is also consistent with previous formulations of withdrawal symptornatology 
(e. g. Hughes & Hatsukami, 1986). 
Anxiety ratings were not significantly affected by 24-hour smoking abstinence, which 
was not predicted. A non-significant trend was observed, however, for subjects to 
register greater anxiety in the withdrawn sessions compared to baseline (non- 
deprived). Increased anxiety is a reliably demonstrated symptom of tobacco 
withdrawal (e. g. Hughes & Hatsukami, 1986; Hughes, 1992). It is possible these 
results failed to reach significance due to the structure of the Anxiety factor including 
less salient mood states. If specific individual items such as "Relaxed - Anxious" had 
been used, significance may have been reached. 
Lofexidine failed to affect visual analogue mood ratings. It was expected that 
lofexidine would reduce anxiety and possibly reduce alertness, due its sedative side 
effect. These results differ to previous research, which has shown another a2-agonist 
(clonidine) to effectively reduce anxiety in tobacco-withdrawn smokers (Ornish et al. 
1988; Prochazka et al. 1992). Although both pre- and post-test anxiety was rated 
lower following lofexidine, it failed to reach statistical significance, perhaps for the 
reasons outlined above. Alternatively, it may be that a single one-off dose may not 
have the anxiolytic efficacy of repeated exposures over a longer period (as utilised in 
the above studies). 
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Nicotine was shown to increase alertness, although the placebo inhalator elicited 
similar effects. This is consistent with previous findings, which found nicotine gum 
and smoking to increase ratings of arousal (Warburton et al. 1988; O'Neill & Parrott, 
1992). Increased alertness may not be a direct effect of nicotine, a theory supported by 
the placebo effects. These may implicate the arousing effects of using the inhalator, or 
reflect neurochemical changes associated with smoking cues experienced by using the 
oral device (Schultz, 2001). 
Methodological changes could be made to improve the study. Testing a larger number 
of subjects may have elicited more significant effects, and allowed more confident 
interpretation of results. It is clear that the impact of lofexidine and nicotine on both 
mood and cognitive performance in this design was limited. It would be useful to 
know whether the reason for this was insufficient doses of the two substances. This 
could be addressed by testing more subjects using higher doses; e. g. 0.4mg lofexidine 
and, most importantly, 20 minutes ad libitum use of the Nicorette(D inhalator. This 
would provide levels of nicotine more analogous to smoking a cigarette (Schneider et 
al, 1996). It would have provided a useful variable if subjects had been asked to 
indicate whether they believed they had received placebo or drug in the post- 
administration sessions, so that expectancy effects could have been measured and 
possibly statistically controlled for. 
There may have been important data lost in the way the mood factors were structures, 
perhaps through the inclusion of less salient mood states in each category. Since 
tobacco-withdrawn smokers are impatient, they may not have moved the cursor into 
its most appropriate or accurate position on the mood scales. Using pen-and-paper 
244 
Lofexidine and nicotine effects Chapter 7 
visual analogue scales may have been more appropriate. Furthermore, there are 
ongoing debates as to the precision or suitability of bi-polar mood scales as opposed 
to uni-polar scales. Bi-polar scales assume that the words given are genuine opposites 
in 'mood space', rather than antonyms as heuristics of psychological state. 
Tobacco withdrawal was shown to impair cognitive performance and cause negative 
changes in mood states. Lofexidine and nicotine can reverse some of these deficits, 
though they seem to affect different aspects to each other. Withdrawal reduced 
accuracy on the focused attention, vigilance/RVIP and categoric search tasks. 
Reaction times were often faster in withdrawal sessions, and these changes were 
either a direct neuropsychological result of withdrawal, or subjects were intentionally 
performing with a faster (and less accurate) strategy in order to be able to smoke 
sooner. Lofexidine improved subjects' accuracy and reduced the impact of distracters 
on reaction times in the categoric search task, but had no positive effect on 
performance in the focused attention or RVIP task. Nicotine was shown to improve 
reaction times on the focused attention task and categoric search task, although the 
latter also showed many placebo effects. Contrary to previous work, nicotine did not 
affect performance on the RVIP task. Visual analogue ratings of alertness and hedonic 
tone were reduced following 24-hour tobacco withdrawal. Lofexidine made no impact 
on these ratings, whereas nicotine significantly increased ratings of alertness and 
hedonic tone. Even at the low levels used here, nicotine still appeared to be effective 
at reducing withdrawal-induced mood deficits, while lofexidine might be examined in 
tandem with nicotine in terms of cognitive deficit reversal. 
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SECTION 7B 
713-1. Statistical analyses 
Chapter 7 
See section 7A. 1. for rationale rejecting using W factorial ANOVA model. Repeated 
measures analysis of variance was carried out on the performance data using SPSS 9.0 
statistical package. Due to the large number of comparisons, session means contrasts 
were examined using Bonferroni correction for multiple comparisons. WSC and OWS 
data were analysed both as summed totals and appropriate individual items from each 
questionnaire. QSU data was reduced to factor scores based on the original Tiffany & 
Drobes (1991) two-factor structure. POMS data was also reduced to factor scores, 
yielding measures of Anger, 'Vigour', 'Tension', 'Confusion', Depression and 
Fatigue. 
7B. 2. Results 
7B. 2.1. Withdrawal Symptoms Checklist 
Withdrawal symptoms ratings on the WSC were totalled to give a total severity of 
tobacco withdrawal score. These were examined using repeated measures analysis of 
variance with Bonferroni correction for multiple comparisons. The most sensitive 
items (as indicated by Hughes & Hatsukarni, 1986) and those most likely to indicate 
acute drug effects were also examined individually. 
7B. 2.1.1. Withdrawal effects on WSC scores 
Total WSC scores were analysed and a main effect of session was demonstrated 
(F[9,99]=9.92, p<001). Both pre-placebo (p<01) and pre-drug (p<05) (i. e. 
withdrawn) sessions had higher WSC totals than baseline (non-deprived) in the 
nicotine week. Similarly, pre-placebo (p<01) and pre-drug (p<01) sessions had 
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higher WSC totals than baseline in the lofexidine week (Figure 7.13 and Table 7.15). 
These effects survived Bonfeffoni correction for multiple comparisons. 
'Craving for tobacco' demonstrated a main effect of session (F[9,99]=15.16, p<01), 
with pre-placebo (p<001) and pre-drug (p<. 001) sessions significantly higher than 
baseline in the nicotine week. Pre-drug (p<01) and pre-placebo (p<001) sessions 
were significantly higher than baseline in the lofexidine week (these significance 
levels were using Bonferroni correction for multiple comparisons). 'Anxiety' WSC 
ratings were also affected by session (F[9,991=3.03, p<01), with pre-placebo session 
mean ratings in the nicotine week significantly higher than baseline (p<05, after 
Bonferroni correction). 'Impatience' was affected by session as revealed by analysis 
of variance (F[9,99]=8.49, p<001). After Bonferroni correction, ratings were 
significantly higher than baseline in pre-placebo (p<001) and pre-drug (p<05) 
sessions in the nicotine week. 'Impatience' was also rated higher than baseline in pre- 
drug sessions (p<05) and pre-placebo sessions (p<05) in the lofexidine week, after 
Bonferroni correction. 
7B. 2.1.2. Lofexidine effects on WSC scores 
Post-lofexidine session WSC totals were significantly lower than pre-lofexidine 
means (p<. 025) (Figure 7.13). There was a non-significant trend (p=. 054) for 
'Craving for tobacco' to be lower in the post-lofexidine session than pre-lofexidine. 
'Anxiety' was lower in the post-lofexidine session than pre-lofexidine (p<05) (Figure 
7.14). Subjects' ratings of 'impatience' were lower in the post-lofexidine session than 
pre-lofexidine (p<01). None of the above effects survived Bonferroni correction for 
multiple comparisons. 
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7B. 2.1.3. Nicotine effects on WSC scores 
Chapter 7 
When total WSC scores were compared between the sessions using repeated measures 
analysis of variance, there was no significant difference between pre-nicotine and 
post-nicotine sessions, with or without Bonferroni correction. However, nicotine 
effects could be observed when WSC items were analysed individually. 'Craving for 
tobacco' was significantly reduced by the administration of nicotine (pre-nicotine 
versus post-nicotine, p<01). This effect narrowly failed to survive Bonferroni 
correction (p=. 069). There was also a significant effect of placebo on 'craving for 
tobacco' during the nicotine week (pre-placebo v post-placebo session, p<05). A 
non-significant trend was observed (p=. 053) for subjects to rate 'anxiety' lower 
following administration of nicotine (pre- vs. post-nicotine sessions). Subjects rated 
'impatience' lower following administration of the placebo inhalator (p<05). These 
effects did not survive Bonferroni correction for multiple comparisons. 
7B. 2.2. Other Withdrawal Symptorm 
Withdrawal symptoms ratings on the OWS were totalled to give a total of opiate-like 
withdrawal score. These were examined using repeated measures analysis of variance 
with Bonferroni correction for multiple comparisons. The most appropriate items on 
the OWS, reflecting those indicating noradrenergic involvement (as indicated by 
various sources including Hughes & Hatsukami, 1986) were also examined 
individually. Appropriate individual items with significant effects of withdrawal, 
lofexidine or nicotine action are reported. 
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7B. 2.2.1. ' Withdrawal effects on OWS scores 
Total OWS ratings differed according to session as revealed by repeated measures 
analysis of variance (F[9,99]=5.29, p<001). Withdrawal effects were observed as pre- 
placebo OWS were significantly higher than baseline totals in the lofexidine week 
(p<05, after Bonferroni correction for multiple comparisons). Pre-placebo (p<01) 
and pre-drug (p<05) sessions had significantly higher OWS totals than baseline in the 
nicotine week. In the lofexidine week, total OWS were significantly higher in pre- 
drug (p<01) or pre-placebo (p<001) sessions than in baseline. Aside from the latter 
contrast, these effects did not survive Bonferroni correction. 
Scores of 'Excessive yawning' were affected by session (F[9,99]=2.66, p<01). 
Withdrawal effect was demonstrated by significantly higher than baseline scores in 
pre-drug sessions (p<. 05) in the nicotine week; and by significantly higher than 
baseline scores in pre-placebo sessions (p<05) in the lofexidine week. 'Trouble 
getting to sleep' ratings were also significantly affected by session (F[9,99]=3.36, 
p<001), and was rated higher in the pre-drug session than the baseline in the 
lofexidine week (p<01). 'Runny nose' was significantly affected by session 
(F[9,99]=2.07, p<05). Pre-drug ratings were significantly higher than baseline in the 
nicotine week (p<05), although the nicotine week baseline was significantly lower 
(p<05) than the lofexidine week baseline. These effects did not survive Bonferroni 
correction for multiple comparisons. 
'Excessive sweating' was also demonstrated to be affected by session (F[9,991=2.00, 
p<05). Ratings were significantly higher than baseline in pre-placebo sessions in both 
the nicotine week (p<. 05) and lofexidine week (p<05). Feeling 'tense and jittery' was 
249 
Lofexidine and nicotine effects Chapter 7 
sensitive to session effects (F[9,99]=3.32, p<001), with ratings being significantly 
higher than baseline in the pre-placebo (p<01) and pre-drug (p<05) sessions in the 
nicotine week. In the lofexidine week, ratings were significantly higher in both the 
pre-drug (p<05) and pre-placebo (p<05) session than in baseline. A main effect of 
session on mean ratings of 'watery eyes' (F[9,99]=2.43, p<025) was found. Subjects 
rated 'watery eyes' significantly higher following withdrawal than in the baselines, as 
differences between baseline and pre-placebo ratings in the nicotine week (p<05), 
and between baseline and pre-drug sessions in the lofexidine week (p<01) 
demonstrated. These effects did not survive Bonferroni correction for multiple 
comparisons. 
'Fitful sleep' (F[9,99]=3.1 1, p<-O 1), 'bothered by noises' (F[9,99]=2.72, p<O 1) and 
'skin clammy and damp' (F[9,99]=2.33, p<05) were further items with ratings 
significantly affected by session. These showed various profiles of differences 
between baseline and withdrawal during the two experimental weeks. In all cases, 
ratings of these symptoms were significantly higher during the withdrawn sessions 
compared to baseline. These effects do not survive Bonferroni correction for multiple 
comparisons. 
7B. 2.2.2. Lofexidine effects on OWS scores 
Subjects OWS totals were significantly lower following lofexidine administration 
(mean total OWS pre- versus post-lofexidine, p<05). OWS were also significantly 
reduced by placebo capsule (pre-placebo versus post-placebo, p<05). These effects 
did not survive Bonferroni correction for multiple comparisons. 
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Lofexidine caused no significant changes in the individual OWS items. Lofexidine 
placebo was related to a reduction in ratings of 'excessive sweating' by significant 
differences between pre- and post-placebo means (p<05). 
7B. 2.2.3. Nicotine effects on OWS scores 
Nicotine administration significantly lowered subjects total OWS ratings (pre- versus 
post-nicotine, p<025). This effect did not survive Bonferroni correction for multiple 
comparisons. 
Mean ratings of 'runny nose' were significantly lower in post-nicotine session 
compared with pre-nicotine (p<. 05). The effect did not survive Bonferroni correction 
for multiple comparisons. 
There was also a placebo effect during the nicotine week on subjects ratings of 'tense 
and jittery' feelings, as post-placebo mean ratings were significantly lower than pre- 
placebo ratings (p<05). These effects did not survive Bonferroni correction for 
multiple comparisons. 
7B. 2.3. Combining and contrasting WSC and OWS scores 
Withdrawal symptoms total scores were computed for each subject for each session 
by totalling items on both the WSC and OWS. These were then analysed using SPSS 
repeated measures analysis of variance, with Bonferroni correction for multiple 
compansons. 
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WSC/OWS combined total scores were rated higher in all sessions after 24-hour 
withdrawal compared to baseline (Table 7.15). Repeated measures analysis of 
variance revealed a main effect of session (F[9,99]=7.57, p<001), with WSC/OWS 
totals significantly higher than baseline in the pre-placebo session (p<. 05, after 
Bonferroni correction) in the nicotine week. This effect was repeated during the 
lofexidine week, as pre-placebo (p<. Ol) and pre-drug sessions (p<05) had higher 
total withdrawal (WSC/OWS) than baseline. All these contrasts survived Bonferroni 
correction. 
The relationship between OWS and WSC was demonstrated by comparing line graphs 
of mean total responses for the two questionnaires across the sessions (Figure 7.14). 
Furthermore, session means for the WSC and OWS were compared using Spearman's 
Rho correlation (see Table 7.16), with some sessions correlating significantly. 
7B. 2.4. Questionnaire of Smoking Urges (QSU) 
The original Tiffany & Drobes (1991) two-factor structure was utilised, as this sample 
was too small to reliably perform a novel principal components analysis. Factor 
scores were created for Factor I (appetitive desire to smoke) and Factor 2 (seeking 
withdrawal reversal) for each subject (n=12) in each session (10). A repeated 
measures analysis of variance was then performed. The means for each session can be 
viewed in tables 7.17 (Factor 1) and 7.18 (Factor 2). 
Analysis of variance revealed a main effect of session for Factor I scores 
(F[9,99]= 18.13, p<00 1) and Factor 2 scores (F[9,99]= 10.23, p<00 1). 
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7B. 2.4.1. Withdrawal effects on QSU 
Chapter 7 
Baseline mean Factor I scores were shown to differ significantly from both pre- 
placebo (p<001) and pre-drug (p<001) scores in the nicotine week. In the lofexidine 
week, Factor I scores differed significantly between baseline and both pre-drug 
(p<001) and pre-placebo'(p<. 001) sessions. QSU Factor 1 scores were much lower in 
baseline sessions than withdrawn sessions (Table 7.17), showing that subjects' 
appetitive desire to smoke was greater after 24-hour abstinence than when they were 
non-deprived. 
A similar effect was observed for Factor 2. Baseline mean Factor 2 scores were 
shown to differ significantly from both pre-placebo (p<001) and pre-drug (p<001) 
scores in the nicotine week. In the lofexidine week, Factor 2 scores differed 
significantly between baseline and both pre-drug (p<. Ol) and pre-placebo (p<. Ol) 
sessions. QSU Factor 2 scores were much lower in baseline sessions than withdrawn 
sessions (Table 7.18), showing that subjects' urges to smoke in order to alleviate 
perceived withdrawal symptoms was greater after 24-hour abstinence than when they 
were non-deprived. 
7B. 2.4.2. Lofexidine effects on QSU scores 
Factor I scores were significantly reduced following lofexidine (pre-lofexidine versus 
post-lofexidine sessions p<05), although this effect did not survive Bonferroni 
correction. No significant effect of lofexidine was demonstrated in Factor 2 scores. 
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7B. 2.4.3. Nicotine effects on QSU scores 
Although nicotine administration reduced QSU scores, there were no significant 
effects on either Factor, with or without Bonferroni correction. 
7B. 2.5. Profile Of Mood States (uni-polar) 
POMS responses generate scores on five factors: Anger, 'Tension', Depression, 
'Vigour', Fatigue and 'Confusion'. Significant main effects of session were observed 
on the factor scores for 'Tension' (F[9,81]=2.92, p<005) (Table 7.19), 'Vigour' 
(F[9,81]=2.69, p<01) (Table 7.20) and 'Confusion' (F[9,81]=3.88, p<. 001) (Table 
7.21). 
7B. 2.5.1. Effect of 24-hour nicotine withdrawal on POMS 
'Confusion' factor scores were significantly higher than baseline in both pre-placebo 
(p<01) and pre-drug (p<05) sessions in the nicotine week. In the lofexidine week 
pre-drug session (p<05) 'Confusion' scores were higher than baseline. These effects 
did not survive Bonferroni correction. 
Tigour' mean scores were lower than baseline in the pre-drug session in the nicotine 
week (p<05). This effect did not survive Bonferroni correction for multiple 
comparisons. 
'Tcnsion' factor scorcs wcrc significantly highcr in both prc-placebo (p<05) and pre- 
drug (p<01) sessions in the nicotine week. In the lofexidine the pre-drug session 
'Confusion' factor scores were higher than baseline (p<. 05). These effects did not 
survive Bonferroni correction. 
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7B. 2.5.2. Effect of lofexidine administration on POMS 
Lofexidine administration had no significant effect on 'Confusion' factor scores 
(comparing pre- and post-lofexidine means). 
'Vigour' factor scores were rated much lower following the administration of 
lofexidine, as pre- and post-lofexidine sessions were significantly different (p<05). 
This effect did not survive Bonferroni correction. 
'Tension' factor scores were significantly lower following lofexidine adn-ýinistration 
(pre- versus post-lofexidine session, p<05). This effect did not survive Bonferroni 
correction for multiple comparisons. 
7B. 2.5.3. Effect of nicotine adn-tinistration on POMS 
The administration of nicotine had no significant effect on subjects' ratings of 
'Confusion', 'Vigour' or 'Tension'. Nicotine placebo significantly reduced 'Tension' 
factor scores (pre-placebo versus post-placebo session, p<05), although this did not 
survive Bonferroni correction. 
7B. 3. Discussion (Section 7B) 
Acute 24-hour abstinence from smoking was shown to induce an array of 
characteristic withdrawal symptoms (tobacco withdrawal syndrome), as measured by 
a Withdrawal Symptoms Checklist. These are concordant with previous findings (e. g. 
Hughes & Hatsukami, 1986), and the similar response pattern with a checklist of 
opiate-like withdrawal symptoms suggests tobacco withdrawal may have 
noradrenergic components. Withdrawal also reliably increased cravings and urges to 
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smoke (measured by Questionnaire of Smoking Urges; Tiffany & Drobes, 1991), and 
caused negative changes in mood state (reduced 'Vigour' scores, increased 'Tension' 
and 'Confusion' scores on the Profile of Mood States; McNair et al. 1971,198 1). An 
oral dose of 0.2mg lofexidine reduced urges to smoke and POMS scores on 'Tension' 
and 'Vigour' factors. It also reduced severity ratings of withdrawal symptoms on both 
WSC and OWS, particularly anxiety, impatience and excessive sweating. Its effects 
are more marked than nicotine, which (by this dose and means of administration) has 
not been shown to affect urges to smoke measured by QSU or significantly alter 
POMS acute mood states in 24-hour nicotine withdrawn subjects. However, the 
nicotine inhalator was found to reduce craving for tobacco and runny nose better than 
placebo measured using the WSC and OWS respectively. 
Withdrawal symptoms following 24-hour abstinence from smoking were rated 
significantly higher than baseline (non-deprived), as predicted. Totals on WSC and 
OWS were greater following withdrawal than in the baseline sessions. Items that are 
robust symptoms of the tobacco withdrawal syndrome such as 'craving for tobacco', 
'anxiety' and 'impatience' were rated higher following withdrawal. This finding is 
consistent with previous research using the WSC (Hughes & Hatsukami, 1986). 
Withdrawal clearly affected subjects' sleep quality, as 'trouble getting to sleep', 
'fitful sleep' and 'excessive yawning' (inter-related OWS items) were all rated higher 
in withdrawn sessions. Interestingly, subjects rated OWS items 'runny nose', 'watery 
eyes', 'excessive sweating' and 'skin clammy and damp' higher following 
withdrawal. These symptoms are strongly associated with the excessive frontal 
noradrenergic activity typical of opiate withdrawal (Strang, Beam & Gossop, 1999). 
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This would support the theory that nicotine withdrawal produces similar increases in 
noradrenaline to opiate withdrawal, albeit less severe. Altematively these symptoms 
may be secondary, perhaps associated with insufficient sleep. 
Smoking urges, as measures by Tiffany & Drobes (1991) questionnaire were 
markedly increased as a result of 24-hour abstinence. Using the authors' original 2- 
factor structure, the results indicate that withdrawal increased both Factor I (primary 
intention and desire to smoke, and anticipated pleasure) and Factor 2 (anticipation of 
relief from negative affect and withdrawal) scores. These results are consistent with 
Tiffany & Drobes (1991) and subsequent validations (e. g. Morgan, Davies & Willner, 
1999). Although Tiffany & Drobes (1991) studied a general public sample, it was 
demonstrated that the original factor structure could be appropriately applied to this 
mainly student sample. 
'Confusion', 'Vigour' and "Tension" were factors of the Profile of Mood Sates 
(McNair et al. 1971; 1981) that were significantly affected by 24-hour abstinence. 
Subjects rated items on the 'Confusion' factor significantly higher than the 
appropriate baseline session in three of the four withdrawn sessions. Subjects may 
have rated salient items (e. g. 'muddled' and 'bewildered') highly during withdrawal 
to express their perceived difficulty concentrating or attentional. problems (Hughes & 
Hatsukami, 1986; Snyder, Davis & Heningfield, 1989). Items loading on the 
'Tension' factor were also rated higher in three of the four withdrawn sessions 
comparative to baseline. This is likely to reflect withdrawal symptoms such as 
impatience, anxiety and irritability (e. g. Hughes & Hatsukami, 1986). 'Vigour' factor 
effects were less reliable, as just one withdrawn session was significantly lower than 
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baseline, although factor scores were lower than baseline in all sessions. This may be 
related to sleep disturbance, or reduced feelings of general arousal directly due to 
nicotine withdrawal. The latter explanation is supported, since if subjects were 
suffering from tiredness Fatigue ratings would have been significantly higher 
following withdrawal. 
The administration of lofexidine caused acute changes in severity ratings of 
withdrawal symptoms. WSC totals were significantly lower in the post-lofexidine 
session compared with pre-lofexidine, suggesting that lofexidine has a generally 
alleviating effect on tobacco withdrawal symptoms measured by this instrument. This 
is a novel finding, but is consistent with studies showing that the lofexidine analogue 0 
clonidine can ameliorate tobacco withdrawal (Prochazka et al. 1992). Total OWS 
scores were also significantly reduced by lofexidine; these items were included to 
measure more defined noradrenergic withdrawal effects. It was expected that OWS 
would be more affected by lofexidine than WSC, which was not shown. Furthermore, 
the fact that placebo was as effective at reducing total OWS as lofexidine may 
indicate that nicotine withdrawal is only moderately mediated by noradrenaline. 
Although only a trend, WSC item 'craving for tobacco' was rated lower following 
lofexidine. This may have reached significance had there been greater numbers of 
subjects. This finding is important; as it suggests that lofexidine could be used to 
ameliorate tobacco withdrawal pharmacotherapeutically in those attempting to quit. 
This result is comparable to the equivocal findings of studies examining clonidine and 
craving for tobacco (e. g. Ornish et al. 1988, showed a reduction in craving; Murray et 
al. 1989, showed no reduction). Other WSC items also rated lower following 
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lofexidine were 'impatience' and 'anxiety'. Alleviation of anxiety is a robust effect of 
this dose of lofexidine (Aghajanian, 1978; Uhde et al. 1980), and other a2-agonists 
have been shown to reduce the anxiety component of tobacco withdrawal (e. g. 
Prochazka et al. 1992). The observed reduction of impatience may be a secondary 
effect of the amelioration of anxiety or the sedative side effect. 
Subjects rated items loading on Factor I (primary intention and desire, or positive 
reinforcement) of the QSU significantly lower after administration of lofexidine. 
Reductions in scores on Factor 2 (withdrawal-removal motivation, or negative 
reinforcement) following lofexidine were expected but not observed. When 
considered in conjunction with the trend of lofexidine reducing 'craving for tobacco', 
it seems that the drug somehow decreases the positive reinforcement urges to smoke 
rather than perceived withdrawal alleviation. This result is difficult to explain in the 
context of withdrawal symptom amelioration effected by lofexidine in this study, and 
the similar effects of clonidine on withdrawal symptoms in previous studies (e. g. 
Prochazka et al. 1992). This finding may have implications for the QSU, as it suggests 
that the 2-factor structure does not adequately define the items in the instrument. 
Perhaps Factor 2 includes too many items not directly relating to "withdrawal- 
removal" motivations. An alternative explanation is that the actual symptoms 
experienced are not the same as those expected to be relieved by smoking. This idea 
requires further investigation, since it would change the conceptualisation of the 
tobacco withdrawal syndrome. 
'Vigour' and 'Tension' POMS factors were significantly affected by lofexidine. 
Subjects' ratings of 'Vigour' items were reduced by the administration of lofexidine. 
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This is likely to reflect the sedative side effects of the drug (e. g. Akhurst, 1999). 
'Tension' factor scores were also reduced by lofexidine. This result was ascribable to 
the anxiolytic and/or sedative effects of lofexidine, reducing ratings of items such as 
'nervous' and 'uneasy'. This provides further evidence for lofexidine targeting the 
dpanic-anxious' component of a withdrawal syndrome (Uhde et al. 1980). The 
sedative side effects of lofexidine are less prominent than with clonidine, but may be 
problematic if attempting to use the drug to assist smoking cessation either by itself or 
as an adjunct to NRT. Clinical trials would need to be run to establish whether 
individuals in nicotine withdrawal could become tolerant to the sedative effects. 
OWS total scores were lower following the administration of nicotine, and this effect 
was not observed with the placebo inhalator. Individual WSC items were sensitive to 
the effects of nicotine, although total WSC scores were not significantly altered. 
'Craving for tobacco' was significantly lower following nicotine administration, and 
there was a non-significant trend for subjects to rate 'anxiety' lower after receiving 
nicotine. This is consistent with previous research (e. g. West & Shiffman, 2001). 
Placebo inhalator significantly reduced ratings on 'craving for tobacco' and 
'impatience' items. Administration of nicotine also reduced subjects' ratings of the 
OWS item 'runny nose'. This may be a genuine withdrawal reversal effect, or 
possibly the afleviation effect of nicotine on anxiety and irritability combined with the 
trigen-ýinal nerve stimulation effected by the menthol had misled subjects into thinking 
their noses were less runny. 
QSU scores on both Factors were unaffected by nicotine, contrary to predictions. This 
is not consistent with other research that suggests NRT can reduce QSU ratings (Allen 
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et al. 2000). This again suggests that the dose of nicotine delivered by eight puffs on 
the inhalator was too low to have a measurable effect. Nicotine was shown to have no 
statistically significant effect on POMS factor scores. This finding was not predicted, 
and is inconsistent with previous studies (e. g. Hughes et al. 1984). This may again 
reflect too low a dose of nicotine to achieve reliable effects. There was a placebo 
effect on 'Tension' factor scores, with subjects rating their "Tension" lower 
following the non-nicotine inhalator. This is explained in terms of subjects simulating 
smoking behaviour, with the cues leading to neurochemical and mood changes 
analogous to actually receiving the drug (Scultz, 2001). 
This study demonstrated that 24-hour smoking abstinence caused an increase in 
ratings of withdrawal measured using two symptom checklists (WSC and OWS) that 
generally correlated with each other. Abstinence also led to higher ratings of urge to 
smoke (measured by QSU) and increased ratings on POMS 'Confusion' and 
'Tension' factors, and reduced ratings on POMS 'Vigour' factor. Lofexidine 
administered to withdrawn subjects reduced severity ratings of withdrawal symptoms, 
reduced appetitive urges and primary intention to smoke, and reduced POMS 
'Vigour' and 'Tension' scores. Nicotine also reduced severitY ratings of withdrawal 
symptoms, but did not affect urges to smoke measured by the QSU. NRT also failed 
to alter any POMS factor scores. Although both substances mitigated withdrawal 
effects and tobacco craving, they appeared to affect different aspects of the syndrome. 
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GENERAL DISCUSSION 
7.3. General Discussion 
Chaptcr 7 
The results of sections 7A and 7B present a case for further investigation of the 
effects of lofexidine on nicotine withdrawal. 24-hour abstinence from smoking was 
shown to cause impairments in cognitive performance, adversely affect mood and 
increase urges to smoke. 
The administration of lofexidine improved specific aspects of withdrawal-impaired 
cognitive performance, but did not affect mood states measured by visual analogue 
scales, including performance-related Anxiety. However, other mood measures used 
showed significant reductions in anxiety ffension'), illustrating the value of utilising 
more than one mood measure instrument. Alertness ('Vigour') variables and severity 
ratings of withdrawal symptoms were also reduced following lofexidine. Positive 
reinforcement (appetitive) urges to smoke were reduced following lofexidine 
administration, although urges pertaining to negative reinforcement (anticipation of 
relief from withdrawal effects) were not affected. NRT improved some reaction time 
variables of cognitive performance, and significantly increased alertness measured by 
visual analogue scales. Again, the VAS mood data was inconsistent with the Likert 
(POMS) mood data, as these were unaffected by nicotine administration. Nicotine 
was also shown to reduce withdrawal symptoms induced by 24-hour abstinence. 
Both nicotine and lofexidine were shown to reverse some of the effects of withdrawal 
on the mood and questionnaire data. There was moderate overlapping of the 
individual cognitive performance variables affected by the three conditions. In the 
context of the withdrawal relief afforded by both lofexidine and NRT as demonstrated 
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by the WSC and OWS, the cognitive performance findings are confusing. There are 
several potential explanations of these various anomalies. It could be that the 
improvements in cognitive performance following lofexidine or nicotine 
administration are not actually a result of withdrawal reversal, but a psychological 
response to a novel behaviour or mental state. 
The weak effects of both substances may suggest that the doses (particularly nicotine) 
used in this study were too low. The inhalator method of NRT was chosen primarily 
because it is the most analogous to smoking, with similar kinaesthetic qualities and 
motor actions required. The actual nicotine dose administered by eight puffs of an 
inhalator was unknown and subject to individual variation, but was likely to have 
been very low. This dose was estimated from the information provided with the 
Nicorette(D device. Future studies should use a longer period of ad libitum use to 
allow subjects to freely increase their plasma nicotine. Using a higher dose of 
lofexidine may also have elicited greater effects, although this is more problematic. In 
lofexidine-naYve individuals it is possible that 0.4mg may act post-synaptically, 
increasing noradrenergic function. If tobacco withdrawal symptoms are in some way 
related to increased noradrenergic activity (perhaps in the locus coeruleus) then 
lofexidine acting post-synaptically could exacerbate the relevant phenomena rather 
than attenuate them. 
The moderate reversal of cognitive performance decrements and the reduction in 
withdrawal symptoms and smoking urges associated with lofexidine represents an 
interesting and exciting development in tobacco withdrawal research. Although 
similar work has been undertaken with clonidine (Prochazka et al. 1992), lofexidine 
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has fewer hypotensive and sedative side effects (Gerra et al. 2001). The results 
presented in this chapter state a case for further investigation of the effects of 
lofexidine on nicotine withdrawal. Future studies should examine lofexidine and NRT 
concurrently as possible adjunctive pharmacotherapy. These findings also support a 
contribution of noradrenaline to the tobacco withdrawal syndrome. 
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Figure 7.1 Graph showing mean accuracy of responses to targets presented 
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Figure 7.2 Graph showing mean accuracy of responses to targets alternating 
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Figure 7.4 Graph showing mean reaction time on trials in the categoric 
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Figure 7.5 Graph showing mean adjustment to reaction time caused by 
presentation of distracters in 'far' and 'compatible' conditions in 
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Figure 7.6 Graph showing mean reaction time to trials where target is 
presented in the same location as the previous trial in categoric 
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Figure 7.7 Graph showing mean total number of 'hits' on repeated digits 
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Figure 7.8 Graph showing mean pre-test alertness ratings (visual analogue) 
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Figure 7.9 Graph showing mean post-test alertness ratings (visual analogue) 
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Figure 7.10 Graph showing mean pre-test hedonic tone ratings (visual 
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Figure 7.11 Graph showing mean post-test hedonic tone ratings (visual 
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Figure 7.12 Graph showing mean post-test anxiety ratings (visual analogue) 
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Figure 7.13 
Graph showing session means for Total Withdrawal 
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Figure 7.14 Graph showing mean total ratings in the nicotine and lofexidine 
study weeks on the WSC and OWS. 
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Table 7.1 Tabulated procedure for one experimental week (these were 
identical for lofexidine and nicotine Drocedures). 
Monday Tuesday Wednesday Thursday Friday 
9.00 a. rn. BASELINE PRE- N/A N/A PRE- 
SESSION TREATMENT TREATMENT 
SESSION SESSION 
TREATMENT N/A DRUG/PLACEBO N/A N/A PLACEBO/DRUG 
10.30 a. nL N/A POST_ N/A N/A POST_ 
TREATMENT TREATMENT 
SESSION SESSION 
INSTRUCTION ASKED ASKED TO ASKED TO N/A ASKED TO 
TO SMOKE ABSTAIN SMOKE 
ABSTAIN NORMALLY FROM NORMALLY or 
FROM UNTIL SMOKING DEBRIEFED 
SMOKING FURTHER FOR 24- 
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Table 7.3 Mean accuracy of responses to targets presented alone or with 
asterisks on the focused attention task during the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN ACCURACY 
(STANDARD ERROR) 3.89(0.02) 3.86(0.03) 3.79 (0.05) 3.85 (0.01) 3.77 (0.03)* 
number of correct 
responses 
Significance levels of differences to Baseline (without Bonferroni correction) * p<001, * p<05 
Table 7.4 Mean accuracy of responses to targets alternating from previous 
trial on the focused attention task during the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN ACCURACY 
(STANDARD ERROR) 3.86(0.03) 3.80(0.04) 3.77(0.05) 3.79 (0.03) 3.70 (0.04)* 
number of correct 
responses 
Nignificance levels of differences to Baseline (with Bonferroni correction) * p<01,9 p<05 
Table 7.5 Mean reaction time taken to encode a new response on the focused 
attention task. duriniz the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN REACTION TIME 
(STANDARD ERROR) 19.94 (6.57) 22.73 (6.50)* 35.58 (5.24)* 26.08 (3.87) 20.78 (5.06) 
milliseconds 
Significance levels of differences (without Bonferroni correction) * p<005 
Table 7.6 Mean reaction time on trials in categoric search task where target 
is reneated from nrevious trial. durinLy the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN REACTION 71ME 482.55 472.85 460.54* 459.65* 446.19* 
(STANDARD ERROR) (16.13) (14.24) (13.18) (15.17) (15.15) 
milliseconds 
Significance levels of differences to Baseline (without Bonferroni correction) * p<Ol, e p<05 
Table 7.7 Mean effect on reaction time of presenting a distracter in trials 
where the target is in the 'far' and 'compatible' condition in the 
cateLloric qearch task. durine the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN REACTION TIME 51.84 (9.77) 55.33* 24.17* 28.18 (9.57) 40.54 (10.48) 
(STANDARD ERROR) (10.52) (9.44) 
milliseconds 
Significance levels of differences (without Bonferroni correction) * p<05 
Table 7.8 Mean reaction time on trials where the target is presented in the 
same location as the previous trial in the categoric search task; 
nicotine week. 
SESSION Baseline Pre-placebo Post-placebo Pre-nicotine Post-nicotine 
MEAN REACUON TIME 478.48 474.26 752.25 470.26* 451.09* 
(STANDARD ERROR) (10.45) (9.77) (10.72) (12.86) (10.11) 
milliseconds 
Significance levels of differences (without Bonferroni correction) * p<05 
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Table 7.9 Mean total number of 'hits' made in the repeated digits vigilance 
ta. qk dnrinp the nicotine week. 
SESSION Baseline Pre-placebo Post-placebo Pre-nicotine Post-nicotine 
MEAN TOTAL HITS 
(STANDARD ERROR) 17.42 (1.18) 16.08 (1.42)* 13.25 (1.26)* 15.08 (1.00) 15.83(l. 5) 
number of correct 
responses 
, mgniticance levels of differences (without Bonferroni correction) * p<001 
Table 7.10 Mean pre-test alertness ratings on the visual analogue mood scales 
durinLy the nicotine week. 
SESSION Baseline Pre-placebo Post-placebo Pre-nicotine Post-nicotine 
MEAN RATING 240.17 185.58* 195.08 171.17* 181.75 
(STANDARD ERROR) (19.15) (14.54) (12.10) (14.50) (15.20) 
factor score 
Significance levels of differences to baseline (without Bonferroni correction) * p<Ol, * p<025 
Table 7.11 Mean post-test alertness ratings on the visual analogue mood 
scales durinLy the nicotine week. 
SESSION Baseline Pre-placebo Post-placebo Pre-nicotine Post-nicotine 
MEAN RATING 214.58 155.75 189.0 150.67* 179.33* 
(STANDARD ERROR) (18.07) (9.46) (11.9) (13.50) (17.88) 
factor score 
Nigniticance levels of differences (without Bonferrom correction) "' p<. U25 
Table 7.12 Mean pre-test hedonic tone ratings on the visual analogue mood 
scales. dnrinp the lofexidine week. 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN RATING 204.42 172.25* 164.42 165.50* 163.42 
(STANDARD ERROR) (12.94) (8.67) (9.60) (17.13) (17.26) 
factor score 
Significance levels of differences to baseline (without Bonferroni correction) * p<025, * p<05 
Table 7.13 Mean post-test hedonic tone ratings on the visual analogue mood 
scales durine the nicotine week. 
SESSION Baseline Pre-1)] acebo Post-placebo Pre-nicotine Post-nicotine 
MEAN RATING 194.50 149.17* 169.50* 143.92 159.83 
(STANDARD ERROR) (14.75) (12.96) (11.76) (16.07) (18.64) 
factor score 
Significance levels of differences (without Bonferrom correction) "I p<U I 
Table 7.14 Mean post-test anxiety ratings on the visual analogue mood scales 
during the lofexidine week (HIGHER score represents LOWER 
anxietv). 
SESSION Baseline Pre-lofexidine Post- Pre-placebo Post-placebo 
lofexidine 
MEAN RATING 
(STANDARD ERROR) 90.42 (4.85) 78.75 (6.78) 89.75 (6.22) 87.83 (5.86) 88.33 (7.86) 
factor score 
Table 7.15 Mean (Standard error) WSC/OWS total scores for all conditions 
in lofexidine and nicotine weeks. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drua 
NICOTINE 6.67(2.03) 38.0(7.02) 30.0(8.03) 38.92(8.23) 28.75 (7.48) 
LOFEXIDINE 9.58(l. 84) 33.08 (4.57) 21.92 (4.64) 43.33 (7.63) 28.08 (7.14) 
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Table 7.16 Spearman's Rho correlation coefficients between WSC and OWS 
for each session during the two experimental weeks. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drug 
NICOTINE r--0.238 r--0.646* r--0.724** r--0.868* r--0.395 
LOFEXIDINE r--0.576* r--0.71 I ** r--O. 458 r--0.483 r=0.744** 
*P<001, **p<. O I, op<. 05 - all 1 -tailed significance levels 
Table 7.17 Means (std. error) of QSU Factor 1 scores in all sessions. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drug 
NICOTINE -18.5(4.4) 10.1(3.2) 5.9(3.5) 9.8(2.7) 5.5(3.8) 
LOFEXIDINE -16.3(3.2) 10.0(3.1) 0.0(4.7) 12.1 (2.2)* 7.3 (3.0)* 
*- means differ significantly p<05 
Table 7.18 Means (std. error) of OSU Factor 2 scores in all sessions. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drug 
NICOTINE 27.2 (3ý1 -49.3 (3.7) 46.7(4.4) 51.3(3.9) 48.6(4.2) 
LOFEXIDINE 3 1.172.5) 48.8(4.3) 43.4 (4.8) 52.8(4.1) 48.5(4.5) 
Table 7.19 Mean (std. error) POMS 'Tension' factor scores in all sessions. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drug 
NICOTINE 3.9(0.8) 12.9(2.9) 9.2(2.9) 10.2(2.3) 8.8(2.7) 
LOFEXIDINE 5. O(l. l)-- T8-. 3(l. 6) 
15.4(l. 
3) 11.1 (2.0)* 8.0 (2.2)* 
*- means differ significantly p<05 
Table 7.20 Mean (std. error) POMS 'Vigour' factor scores in all sessions. 
Baseline Pre-placebo Post-pl cebo Pre-drug Post-drug 
NICOTINE 10.7(l. 4) 6.5(2.2) 5.6(l. 5) 5.6(l. 1) 6.1(1.4) 
LOFEXIDINE 10.9 (1.9) 
+ 
8.8 (1.5) 6.6 (1.2) 7.8 (1.5)* 4.7 (1.4)* 
*- means differ significantly p<05 
Table 7.21 Mean (std. error) POMS 'Confusion' factor scores in all sessions. 
Baseline Pre-placebo Post-placebo Pre-drug Post-drug 
NICOTINE 3.8(0.8) 8.0(1.4) 7.2 (1. )- 
-6.8 
(1.5) 6.3(l. 2) 
LOFEXIDINE 5.2(0.9) 6.5(l. 2) 6.6(l. 2) 7.4(l. 4) 7.90.7) 
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Chapter 8- Discussion 
8.1 Synopsis of major findings 
The primary aim of this research was to generate a multi-disciplinary picture of 
tobacco dependence, with a particular focus on the associated withdrawal syndrome. 
This is important since tobacco smoking is a highly complex addictive behaviour 
comprising a variety of social and biological components. Using psychological, 
psychopharmacological, psychosocial and genetic data different subtypes of smoker 
were characterised, and their responses to withdrawal and reinstatement were 
investigated. Finally, the involvement of noradrenergic activity on tobacco 
withdrawal was examined. 
Addicted and non-addicted smoker subgroups were profiled by creating a composite 
Addiction Index score. This was achieved by combining nicotine tolerance data and 
dependence-related smoking motivation data. It was believed that measuring the 
combined motivation and tolerance aspects of smoking would provide a more 
cffcctivc characterisation of tobacco addiction than eithcr mcasure would 
individually. This reflects both the physical and psychological dependence attributes 
of nicotine addiction. The observed association between Addiction Index scores and 
the latency to first cigarette of the day effectively demonstrated this. 
How soon people smoke their first cigarette after waking is considered a measure of 
dependence, with those who smoke very soon after waking theoretically 
demonstrating high nicotine tolerance. Although all addicted smokers had their first 
Cigarette in the first hour of the day, several non-addicted smokers also reported this 
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pattern of behaviour. This finding demonstrates the nature of the problem in addiction 
research, particularly with smoking; what are the defining features? What 
psychopharmacological phenomena best discriminate between addicted and non- 
addicted smokers? Clearly tolerance is important, but cannot perfectly describe the 
behavioural and motivational aspects of smoking. Therefore, the two groups might be 
different in other ways. What happens to smokers following abstinence is of particular 
interest, due to the tobacco withdrawal syndrome. 
Since smokers often report using tobacco to help them either relax or concentrate, 
addicted and non-addicted smokers' changes in mood and cognitive performance 
following withdrawal and subsequent reinstatement was examined. Twenty-four hour 
withdrawal caused increases in anxiety in the addicted but not non-addicted smokers. 
An unpredicted finding was that addicted smokers cognitive performance was 
improved on several tasks following withdrawal. Reinstatement improved all 
smokers' alertness and hedonic tone, whilst the addicted group derived some 
reduction in anxiety. The non-addicted smokers performance on a categoric search 
task was improved by reinstatement. 
These results could be interpreted as demonstrating that non-addicted smokers may be 
deriving more attentional benefits from smoking, whereas addicted smokers might be 
modulating levels of anxiety. Whether the anxiety fluctuations experienced by 
addicted smokers in tobacco withdrawal and reinstatement were simply caused by 
withdrawal and removed by reinstatement, or were related to independent levels of 
trait anxiety was not clear. If these findings are concretely related to withdrawal 
sensitivity, addicted smokers may display neurobiological differences to non-addicted 
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smokers. The different mood and performance effects derived by the two groups may 
reflect differences in nAChR distribution or activity, or differences in doparninergic 
reward systems. 
Potential differences in dopamine receptor morphology were examined. Since 
previous work has shown genetic differences in DRD2, DRD3 and DRD4 between 
drug users and non-users (in some cases specifically with nicotine), genetic 
polymorphisms of these receptors were exarnined. D2 and D3 polymorphisms were 
not shown to differ significantly between addicted and non-addicted smokers. 
However, a greater proportion of addicted smokers possessed the D4 L allele than 
non-addicted smokers. 
Furthennore, the D4 L allele was associated with the Novelty Seeking personality 
trait, and particularly the Impulsiveness subscale of this trait. The results suggest that 
DRD4 polymorphisms, may impact on nicotine dependence, although perhaps via 
associated personality variables rather than through different neurobiological reward 
or reinforcement systems. Since psychological factors such as anxiety and 
impulsiveness were emerging as powerful discriminatory parameters between the 
addicted and non-addicted smokers, a more wide-ranging psychosocial contrast 
between the groups was perfon-ned. 
All smokers reported greater perceived stress and more cognitive failures (absent- 
mindedness) than non-smokers. It is difficult to conclude whether this reflects the 
multiple episodes of tobacco withdrawal and reinstatement throughout the day, or is a 
true representation of baseline differences between the groups. Smokers may even 
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potentially be attempting to self-medicate these difficulties and were it not for 
nicotine use the differences may be even more marked. 
Unsurprisingly, smokers had different health orientations to non-smokers; greater 
anxiety about health, lower health confidence and reasons to be healthy. Addicted 
smokers reported more anxious and depressive symptoms than non-addicted smokers. 
Again, this is difficult to interpret, since it may reflect either anxiety or dysphoria 
associated with episodes of acute tobacco withdrawal for the addicted smokers, or 
represent true baseline differences between the groups. The severity of tobacco 
withdrawal syndrome could possibly account for some of the major differences 
emerging thus far in the research. Therefore, differences between addicted and non- 
addicted smokers craving and symptornatological responses to abstinence and 
reinstatement were profiled. 
Twenty-four hour abstinence was shown to increase ratings of withdrawal symptoms 
in all smokers. Addicted smokers experienced greater increases in craving for 
tobacco, restlessness and sleep disturbance than non-addicted smokers. It is plausible 
that these three symptoms could be linearly related. Increased craving for tobacco not 
treated by smoking may lead directly to restlessness, either through 
psychophannacological withdrawal or through suspension of stereotypical 
psychornotor routines. This restlessness could then persist after the individual has 
gone to bed leading to disturbed sleep, most likely characterised by increased sleep 
latency. 
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Although all urges to smoke measured by the Questionnaire of Smoking Urges 
(Tiffany, & Drobes, 1991) were rated higher in withdrawal by all smokers, non- 
addicted smokers reported greater increases in urges pertaining to positive 
reinforcement whereas addicted smokers urges to smoke relating to negative 
reinforcement were significantly increased. This can be summarised as addicted 
smokers experiencing a more severe withdrawal syndrome than non-addicted 
smokers, and the subsequent urges to smoke were essentially based on removing or 
ameliorating those withdrawal symptoms. 
Notably, increases in anxiety following withdrawal were not significantly different 
between addicted and non-addicted smokers. This contrasts with mood findings 
earlier in the thesis showing anxiety selectively significantly increasing in addicted 
smokers following abstinence. This may reflect the different methodologies, as the 
"Anxiety" mood measure discussed in Chapter 3 was a factorised construct 
amalgamating several bi-polar visual analogue scales, whereas the "Anxiety" 
symptornatology measure in Chapter 6 was a singular uni-polar item measured by 
Likert-scale. Alternatively, the temporal proximity of the mood ratings in Chapter 3 to 
the cognitive performance tests may have confounded results. If subjects were 
concerned about their performance on the tasks (either before or after the battery), this 
may have interacted with the greater severity of withdrawal state in the addicted 
smokers to produce the observed increases in anxiety ratings. 
Nicotine reinstatement through ad libitum smoking reduced all those urges to smoke 
and ratings of withdrawal symptoms intensified by abstinence. This is consistent with 
previous work in most drugs of abuse with a withdrawal syndrome, in that 
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reinstatement of that drug rapidly ameliorates the perceived negative symptoms of 
withdrawal. Addicted smokers derived greater relief from craving for tobacco than 
non-addicted smokers, although this was because addicted smokers had higher 
craving ratings in the withdrawn session. 
Lofexidine, an a2-adrenoceptor agonist used successfully to treat opiate withdrawal 
was compared to NRT in terms of effects on impairments in mood and cognitive 
performance associated with the tobacco withdrawal syndrome. The cognitive tasks 
selected were those demonstrating significant withdrawal effects in Chapter 3. 
Although few of the observed effects survived Bonferroni correction, nicotine and 
lofexidine were shown to alleviate some deficits associated with withdrawal, but each 
drug affected different mood and performance variables. This may suggest that 
different withdrawal symptoms are mediated by different neurotransn-iitters. Some 
problems may be a result of decreased cholinergic function, and these may be directly 
alleviated by nicotine, whereas others may be a result of increased noradrenergic 
activity, and thus mitigated by lofexidine. 
Addicted smokers experienced decreased accuracy but also decreased reaction times 
on several performance tasks following tobacco withdrawal. These effects were 
ascribed either to direct psychophannacological effects of withdrawal or to reflect 
subjects' performing tasks faster and less accurately in order to smoke sooner. 
Accuracy and reaction time variables on the categoric search task were improved by 
lofexidine, but had no positive effect on cognitive performance in other tasks. 
Nicotine inhalator was shown to improve reaction times on the focused attention and 
categoric search tasks. In contrast with previous research, there was no nicotine effect 
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on RVIP performance. Ratings of alertness and hedonic tone were lower in tobacco 
withdrawal compared to non-deprived. These ratings were increased by nicotine, but 
not by lofexidine. 
Ratings of severity of withdrawal symptoms measured by tobacco and opiate 
withdrawal checklists were increased following 24-hour abstinence. Many of the 
items on the two questionnaires were similar, suggesting that there are comrnon 
components of withdrawal syndromes for several drugs of abuse. Ratings of urges to 
smoke were also increased by withdrawal, consistent with findings in Chapter 6. 
Withdrawal lead to increased ratings on confusion and tension factors, and reduced 
vigour. These are consistent with more specific symptoms of the withdrawal 
syndrome, particularly difficulty concentrating, anxiety, irritability and restlessness, 
and drowsiness. After lofexidine was adrninistered, subjects rated the overall severity 
of their withdrawal symptoms lower, rated urges to smoke pertaining to positive 
reinforcement lower, and rated tension and vigour lower. The latter demonstrated the 
predicted anxiolytic and sedative effects of lofexidine. 
Nicotine inhalator was also shown to reduce severity ratings of withdrawal symptoms 
on the checklists, but interestingly did not reduce ratings of urges to smoke. Nicotine 
also had no effect on the impaired mood factors. These lack of effects were ascribed 
to the very low dose of nicotine delivered by this procedure. It was calculated post 
hoc that the nicotine delivered by eight puffs on an inhalator equates to half a puff on 
a cigarette. This may have been simply insufficient to effectively ameliorate the 
tobacco withdrawal syndrome. 
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Lofexidine showed some interesting effects on the tobacco withdrawal syndrome, and 
might require further investigation. If the sedative effects of the drug could be 
mitigated, the drug may have some anxiolytic benefit in ameliorating nicotine 
withdrawal. Lofexidine could potentially be used adjunctively with NRT to broaden 
the psychopharmacological management of symptoms associated with smoking 
cessation. 
The implications of the positive effects of lofexidine on tobacco withdrawal should 
also be investigated. Noradrenergic involvement in opiate withdrawal is well 
documented, but little human work has been performed in relation to tobacco 
withdrawal. The noradrenergic action of bupropion may be one important mechanism 
of the drug's efficacy in promoting smoking cessation. There may be scope for 
examining neurobiological differences in noradrenergic structures, such as 
distribution of receptor subtypes, relative densities or affinities of receptors. 
8.2 Addicted and non-addicted smokers 
One of the major achievements of this research was to create a composite score for 
tobacco dependence taking both physical (tolerance) and psychological (motivational) 
factors into account. Following some post-hoc refinement of the computational 
model, the Addiction Index score created allowed the sample of smokers to be 
characterised as either addicted or non-addicted, as evidenced by a modest bi-modal 
distribution of these scores. 
The ability to divide a continuous variable into two functional groups in this way 
suggests that although there may be a continuum for levels of tobacco dependence, 
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smokers are effectively either addicted, or not. There was evidence for this throughout 
the thesis as evidenced by a variety of predicted differences between the groups. 
The Addiction Index represents one way of characterising levels of nicotine 
dependence rather than a definitive figure. It is relatively resistant to self-report bias. 
By example, although all smokers in the addicted group claimed to be addicted to 
smoking, there were several smokers in the non-addicted group who also claimed to 
be addicted to smoking. Furthermore, the weighting of the components of the 
Addiction Index meant that tolerance scores did not overbear motivational scores, or 
vice versa. For example, although all the smokers in the addicted group consumed 
their first cigarette within an hour of waking, indicating high levels of tolerance, many 
non-addicted smokers also had short latencies to their first cigarette of the day. 
An individual's levels of tobacco dependence are likelY to fluctuate over time to some 
degree. The Addiction Index score provides a snapshot of dependence at a given 
moment, and could possibly be clinically useful to assess reductions in addiction 
perhaps in a phase of cutting down prior to cessation, or in terms of choosing the most 
effective NRT product. 
Due to this likely temporal sensitivity, the non-addicted smokers group may have 
included individuals who were progressing towards addiction to smoking. These 
individuals may have had smoking histories that were too short, or been too 
constrained by situational factors (e. g. living with parents) to develop full-blown 
nicotine dependence. This point is of particular relevance where genetic factors were 
investigated (Chapter 4). Neurobiological differences predicted to be associated with 
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tobacco addiction might be in evidence, but since the non-addicted smokers group 
was so heterogeneous the relationship is not confinned. Although a powerful tool, the 
Addiction Index score system should also take smoking history into account. 
The terminology of convenience and temporal sensitivity associated with groupings 
derived using the Addiction Index score means that chippers (Shiffman, 1979; 1989), 
a group demonstrating stable longstanding non-dependence may feature differences 
lost in the grouping methodology. Although certain differences found between 
addicted and non-addicted smokers might be valid, they could be different to contrasts 
between chippers and regular smokers. 
8.3 Craving, positive and negative reinforcement 
Both addicted and non-addicted smokers experienced increased cravings for tobacco 
and urges to smoke following periods of 24-hour abstinence. However, the 
fonnulations of these urges were different according to the groups. Non-addicted 
smokers cited increased urges pertaining to the positive reinforcement aspects of 
smoking following withdrawal, whereas addicted smokers reported increased urges 
pertaining to the negative reinforcement aspects of smoking. 
This exemplifies the importance of withdrawal symptornatology to the tobacco 
dependence phenomenon. Although all tobacco users will crave the positive 
reinforcement effects of nicotine (e. g. increased alertness), those exhibiting high 
levels of dependence will crave the negative reinforcing effects such as reduction of 
negative affect (see Chapter 6). This is explained by understanding that once tobacco 
dependence has developed fully, the mitigation of withdrawal symptoms caused by 
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periods of abstinence supersedes other factors to become perhaps the principal 
motivating factor driving smoking behaviour. Furthermore, it was found that with 
increased nicotine tolerance comes a depleted sensitivity to the positive reinforcing 
aspects of smoking, reducing the salience of these factors still further. 
Interestingly, when 24-hour withdrawn addicted smokers were administered 
lofexidine, only urges to smoke pertaining to positive reinforcement were 
significantly reduced. Since lofexidine is commonly used to mitigate withdrawal 
symptoms in opiate detoxification (Strang, Beam & Gossop, 1999) it was predicted 
that if any smoking urges were to be affected, those relating to negative reinforcement 
(broadly pertaining to withdrawal) would be moderated by the drug. This finding is 
made harder to explain by the concurrent result that lofexidine generally reduced 
severity of withdrawal symptoms, including craving for tobacco. Potentially, although 
lofexidine reduced some of the effects of tobacco withdrawal, subjects believed these 
effects could be reduced still further through smoking cigarettes. 
It can be hypothesised that the positive reinforcement effects of nicotine are important 
at the initiation phase of smoking behaviour, but the negative reinforcement effects 
are critical in the persistence of smoking behaviour. This theory still leaves the 
problem of explaining the behavioural patterns of chippers, who are able to smoke a 
number of cigarettes each day over a long period of time, without becoming 
dependent on tobacco. It could be explained simply by their smoking far fewer 
cigarettes, thus lower nicotine intake, resulting in persistently low levels of tolerance. 
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However, this only shifts the question. How are chippers able to moderate their 
cigarette use rather than escalate to the levels most dependent smokers reach? The 
best explanation for this is to view chippers in terms of Shiffman's (1991) sensitivity 
model of smoking behaviour. Chippers could have a low initial sensitivity to nicotine, 
therefore deriving relatively lower levels of positive reinforcement from early 
episodes of smoking. Rather than becoming non-smokers, other factors possibly 
social in nature result in the characteristic pattern of long-term low-level smoking. 
Steady escalation of number of cigarettes smoked daily is characteristic of 
development of tobacco dependence. The putative reduced positive reinforcement 
during these early episodes could explain the blunted incremental increases in intake 
observed with chippers. 
8.4 Cognitive performance and tobacco dependence 
The existence of absolute effects of nicotine on cognitive performance is still a highly 
contentious issue (Heishman, 1998). What is clearer is the existence of impairments in 
cognition associated with the tobacco withdrawal syndrome (Hatsukami et al. 1985; 
Snyder et al. 1989). The precise mechanism by which tobacco withdrawal generates 
these effects is still unknown, although the relative reduction in frontal ACh activity 
and withdrawal-induced mood problems are likely candidates. 
Findings in Chapter 3 were mixed in terms of consistency with previous research 
examining tobacco withdrawal and cognitive performance. Few clear differences were 
observed between addicted and non-addicted smokers, although the addicted group 
showed a general speeding up of reaction times from non-deprived to withdrawn 
sessions. These findings were interpreted as demonstrating a change, conscious or 
otherwise, in "response style" on the tasks; i. e. addicted subjects were responding as 
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quickly as possible in order to begin their period of ad libitum smoking as soon as 
possible. 
Similarly, in Chapter 7 addicted smokers' reaction times often improved from 
baseline (non-deprived) to withdrawn sessions. Again this was interpreted as 
demonstrating a change in response style potentially motivated or encouraged by the 
knowledge that smoking could recommence once the test session had been completed. 
The presence in both Chapters 3 and 7 of an imminent period where smoking would 
be allowed could be critical when contrasting current findings with those of Snyder et 
al. (1989). In general, withdrawal effects on cognitive performance in this thesis 
demonstrated improvements in reaction time and impairments in accuracy over a 
variety of tasks. Snyder et al. (1989) broadly found impairments in reaction times and 
little effect on accuracy in a comparable array of tasks. Importantly, Snyder et al. 's 
(1989) subjects were tested at regular intervals over a two-week period of abstinence. 
In other words, the rate of their task performance would have no impact on how soon 
they would be able to smoke. This contrasts with current research, whereby smokers 
may have believed that the sooner they completed the task batteries the sooner they 
would be able to resume smoking. This methodological difference may go some way 
toward explaining the difference between current findings and those of Snyder et al. 
(1989). 
If faster reaction times were merely a by-product of utilising a particular response 
style with the aim of smoking as soon as possible, it would be predicted that following 
nicotine reinstatement reaction times would become slower. In Chapter 3, ad libitum 
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smoking was shown to increase reaction times in addicted smokers, but also in non- 
addicted smokers. Furthen-nore, these longer reaction times observed in the smoking 
groups were less increased than in the non-smokers group. The non-smokers would 
not have been changing their response style in order to reduce smoking latency, hence 
the interpretation that smoking "protected" both groups of smokers from boredom or 
fatigue effects in the reinstatement session. 
The putative effects of tobacco deprivation on cognitive performance cannot be 
categorically ascribed to any one particular phenomenon on the strength of studies 
conducted as part of this thesis. However, it is possible that the accelerated reaction 
times observed in addicted smokers following withdrawal were due to changes in 
response style, perhaps driven by craving for tobacco. 
8.5 Mood and arousal in nicotine withdrawal 
The tobacco withdrawal syndrome described in DSM-IV includes important negative 
changes in mood and arousal. Symptoms such as irritability, restlessness and 
drowsiness are common following deprivation (Hughes & Hatsukami, 1986). A 
variety of instruments were used at various points in this thesis to examine the impact 
of withdrawal on mood and arousal. These included computer-administered visual 
analogue scales, and questionnaires such as Profile of Mood States (McNair et al. 
197 1; 198 1) and Withdrawal Symptoms Checklists (Hughes & Hatsukarni, 1986). 
The impact of tobacco withdrawal on sleep disturbance is potentially crucial to 
understanding the effects of nicotine deprivation on mood, arousal and daytime 
drowsiness. Although no clear differences were found between the addicted and non- 
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addicted smoker groups in terms of changes in mood or arousal following withdrawal, 
levels of nicotine dependence were correlated with magnitude of increases in "sleep 
disturbance" and "restlessness" (Chapter 6). These findings are interpreted as 
suggesting that when dependent smokers abstain from tobacco they have difficulty 
relaxing or "switching off'. Although sleep latency is acutely reduced following 
smoking cessation (Soldatos et al. 1980; Prosise et al. 1994), withdrawal has been 
found to increase the number of arousals, awakenings and sleep stage changes 
(Prosise et al. 1994; Wetter et al. 1995). As suggested, this withdrawal-induced sleep 
fragmentation could contribute to other withdrawal symptoms, particularly those 
pertaining to mood and arousal. 
In Chapter 7, addicted smokers were shown to rate their alertness and hedonic tone 
(visual analogue scales) and Tigour' (POMS factor) lower when tobacco withdrawn 
than when non-deprived. Increased ratings of 'impatience', 'excessive yawning' and 
'fitful sleep' were also observed following withdrawal. These can readily be presented 
as evidence of withdrawal-induced sleep disturbance. Ideally, studies should be 
carried out in order', to examine how much impact sleep disturbance has on the other 
symptoms of the tobacco withdrawal syndrome. If sleep were improved during 
smoking cessation, residual effects of poor sleep on alertness and mood mýight be 
reduced and the probability of continued smoking cessation increased. 
The precise mechanism by which nicotine withdrawal disrupts sleep is unknown, 
although fluctuations of neurotransmitter (particularly noradrenaline and doparnine) 
levels may be responsible. NRT has been shown to help with withdrawal-induced 
sleep disturbance (Wetter et al. 1995), but also to cause or exacerbate sleep problems 
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(Fagerstr6m et al, 1990; Glover, 1993). As discussed in section 8.6, it might be 
pertinent to examine the benefits of chronic a2-adrenoceptor agonist (e. g. lofexidine) 
administration. If the sedative side-effects of these drugs can be used with clinical 
effect and the damping down of excess frontal noradrenaline could mitigate the sleep 
fragmentation, a2-adrenoceptor agonists could be useful in ameliorating the tobacco 
withdrawal syndrome in a variety of ways. 
Although sleep disturbance may have an important role in many of the mood and 
arousal effects of nicotine withdrawal, the alerting effect of nicotine when 
administered via inhalator (Chapter 7) suggests that fragmented sleep resulting from 
abstinence does not explain the entire relationship. The relevance of this finding is 
undermined by the concomitant presence of a placebo effect, suggesting that oral 
stimulation or "sham smoking" may be alerting in itself, regardless of the presence of 
nicotine. 
Many of the negative affect and reduced hedonic tone symptoms associated with 
abstinence are likely to be direct effects of withdrawal. NRT is still probably the most 
effective way of treating mood problems caused by withdrawal. Addicted smokers in 
the current research did not rate hedonic tone significantly greater following the 
administration of a nicotine inhalator, but these findings were explained in terms of a 
dosage possibly insufficient to create that effect. 
8.6 The role of anxiety and stress in tobacco dependence 
The relationship between anxiety and smoking is perhaps one of the most interesting 
relationships to be addressed by this research. Although anxiety is included as an 
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established symptom of the tobacco withdrawal syndrome (Hughes & Hatsukarni, 
1986), more recent formulations of nicotine withdrawal argue that anxiety is 
ultimately reduced by smoking cessation (West & Hajek, 1997). 
Addicted smokers Anxiety factor scores on the Middlesex Health Questionnaire were 
higher than tho 7 of non-addicted smokers and non-smokers, suggesting that tobacco 
dependent subjects have greater trait anxiety than those who are not tobacco 
dependent (see Chapter 5). Examining how addicted smokers' anxiety levels change 
during periods of abstinence could elucidate whether this chronic anxiety may be a 
result of persistent smoking. It is possible that the observed higher "baseline" levels of 
anxiety are a result of repeated episodes of nicotine withdrawal and reinstatement 
throughout each day. 
Anxiety ratings measured by factorised visual analogue scales were higher in addicted 
smokers and 17 er in non-addicted smokers following twenty-four hour withdrawal 
(see Chapter 3). When anxiety was measured as an individual checklist item, addicted 
and non-addicted smokers responses to withdrawal did not differ. The visual analogue 
scales were completed contingently with cognitive performance tasks. This may 
suggest that addicted smokers are more neurotic than non-addicted smokers or non- 
smokers, and were therefore primarily anxious about their task performance in 
particular, rather than experiencing increased generalised anxiety as a result of their 
tobacco withdrawal. 
However, the addicted smokers examined in Chapter 7 rated their anxiety higher 
following withdrawal both as an individual checklist item and on the visual analogue 
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scales (the latter as a non-significant trend). Furthermore, the POMS 'Tension' factor 
was rated higher by these subjects following the 24-hour abstinence period. The 
findings from Chapter 7 suggest that addicted smokers' general anxiety levels 
increase in tobacco withdrawal. 
It is still unclear whether increases in anxiety observed in addicted smokers during a 
period of abstinence is definitively a symptom of tobacco withdrawal, or in fact a 
return to baseline (pre-smoking) high levels of anxiety which these individuals 
attempt to self-medicate using nicotine. Although nicotine has not been formally 
demonstrated\to have genuine anxiolytic effects, smokers' reports of their subjective 
experience often include the calming or anxiety-reducing abilities of cigarettes. 
Previous research has also shown an association between tobacco dependence and 
anxiety (Covey et al. 1998). Prospective studies are necessary to investigate whether 
anxious individuals are prone to developing tobacco dependence, or whether 
becoming a dependent smoker leads to increased levels of anxiety. 
Regardless of the aetiology, increased anxiety following smoking cessation is clearly 
a problem since it could lead to relapse. Even if, as West & Hajek (1997) suggest, 
anxiety eventually drops lower than "pre-quit" levels, there is still a 'danger period' 
where temporary increases in anxiety could affect smoking behaviour. Managing the 
anxiety component of withdrawal could be one potential explanation for the efficacy 
of bupropion as a smoking cessation aid. Other drugs with anxiolytic effects such as 
a2-adrenoceptor agonists could also have positive effects on tobacco withdrawal, and 
should be investigated. 
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On a related point, addicted and non-addicted smokers were shown not to differ in 
terms of levels of perceived stress. This is notable, particularly in light of the 
divergence between the groups in terms of both baseline and withdrawal levels of 
anxiety. When combined, the smoker groups had significantly higher levels of 
perceived stress than non-smokers. If Parrott's (2000) theory that smoking causes 
stress via the persistent cycle of withdrawal and reinstatement is correct, results 
presented in Chapter 5 would suggest that non-addicted as well as addicted smokers 
should experience increased anxiety and tension during tobacco withdrawal. As 
discussed earlier, results in Chapter 3 show that non-addicted smokers actually rate 
anxiety lower following withdrawal. Although unlikely, this could be explained by a 
foreshortened withdrawal syndrome in non-addicted smokers whereby several 
symptoms, including anxiety, have possibly been and gone before the 24-hour 
withdrawal period measures were taken. 
The relationship between stress or anxiety and tobacco dependence is clearly 
extremely important in understanding the tobacco withdrawal syndrome, and the 
addiction to smoking per se. Prospective studies are urgently required in order to fully 
elucidate the nature of this relationship. Future research of this kind could have 
important clinical relevance, since reducing smoking prevalence could reduce stress, 
or identifying groups at risk and reducing their stress or anxiety levels could reduce 
smoking prevalence. 
8.7 Noradrenergic involvement in nicotine addiction 
Recent research has shown that noradrenergic structures in dependent smokers are 
different to those of non-smokers (Klimek et al. 2001). The locus coeruleus' of long- 
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term smokers were shown to have significantly lower radioligand binding to a2- 
adrenoceptors than locus coeruleus' (LQ of non-smokers, suggesting lower receptor 
density in smokers. 
It is currently unclear whether these findings demonstrate that individuals with fewer 
a2-adrenoceptors are more prone to developing tobacco dependence and therefore 
become smokers, or whether long-term smoking somehow reduces the density of a2- 
adrenoceptors in the LC, possibly by receptor down-regulation. If the findings reflect 
long-term effects of smoking on noradrenergic biochemistry, smoking-induced 
changes in LC activity may strengthen the smoking habit, particularly in people with 
anxiety or depressive disorders (Klimek et al. 2001). 
If smokers are self-medicating with nicotine principally in order to manage negative 
affect, the modulation of noradrenergic function could be one method by which this is 
achieved. If chronic smoking down-regulates a2-adrenoceptors in the LC, it is most 
likely that there will be an increase in noradrenergic activity in this brain structure. In 
terms of direct effects, this could potentially indicate an acute anti-depressant effect of 
nicotine. 
How this theory relates to the cycle of withdrawal and reinstatement associated with 
habitual smoking is unclear. it is possible that altered noradrenergic biochemistry, 
particularly in the LC, is a long-term result of repeated episodes of withdrawal. Opiate 
withdrawal, for example, is associated with hyperactivity of noradrenergic cells 
(Brunning et al. 1986) and is successfully managed using a2-adrenoceptor agonists 
such as clonidine and lofexidine (Gerra et al. 2001). These drugs reduce noradrenergic 
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activity, particularly in the LC, and this in turn inhibits sympathetic outflow. 
Excessive sympathetic activity gives rise to many of the observed symptoms of opiate 
withdrawal. 
When abstinent (withdrawn) addicted smokers were administered lofexidine (see 
Chapter 7), withdrawal symptoms including anxiety and impatience were attenuated, 
and POMS 'Tension' factor items were rated lower. Furthermore, there was a trend 
for tobacco cravings to also be reduced following lofexidine. These findings suggest a 
potential role for lofexidine in managing some aspects of the tobacco withdrawal 
syndrome. 
There are obvious theoretical difficulties when comparing the findings of Klimek et 
al. (2001) and those of the current studies. If smokers are managing negative affect by 
using nicotine to increase noradrenergic activity in the LC, administering a drug such 
as lofexidine, which decreases noradrenergic activity in the LC, could in some 
instances intensify mood-based withdrawal symptoms. Resolution of this problem 
may lie in a putative selective action of lofexidine on some subtypes of a2- 
adrenoceptors (Aoki et al. 1994). This may mean that lofexidine can reduce the 
subjective perception of withdrawal symptoms and improve the affective reaction 
during drug withdrawal without the involvement of monoan-iinergic functions 
underlying arousal, mood and cardiovascular responses (Gerra et al. 2001). 
More research is needed to understand how noradrenergic function relates to both the 
direct mood and arousal effects of smoking and the tobacco withdrawal syndrome. 
Crucial to this advancement will be identifying whether the observed reduced a2- 
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adrenoceptor density in smokers' LC is (a) a result of chronic smoking, or (b) a 
genetically determined risk factor for tobacco dependence. For example, it could be 
investigated as to whether chippers, or non-addicted smokers, are protected from 
tobacco dependence by having relatively higher densities of a2-adrenoceptors prior to 
the initiation of smoking behaviour. 
8.8 Doparninergic involvement in nicotine addiction 
As with the majority of addictive or compulsive behaviours, dopamine has been 
afforded a central role in the development and maintenance of tobacco smoking 
behaviour. Specifically, the positive reinforcement aspects of nicotine dependence are 
ascribed to stimulation of the mesolimbic dopamine system. Although nicotine does 
not act directly on doparnine receptors, nAChRs found on dopaminergic neurons have 
been shown to enhance the release of dopamine when stimulated (Reavill, 1990). 
Shiffman (1991) proposed that individuals who were more sensitive to the effects of 
nicotine were more likely to go on to become dependent smokers. It is possible that 
those who are most sensitive to nicotine initially derive the greatest doparninergic 
activity from smoking tobacco. Individual differences in neurobiology of 
dopaminergic systems could represent one mechanism for variations in responses to 
nicotine. 
Genetic profiles of receptor subtypes provide one means of examining individual 
differences in human neurotransmitter function in vivo. The findings presented in 
Chapter 4 only support a moderate role for genetically mediated doparninergic 
neurobiology in predisposing individuals to nicotine addiction. Dopamine receptor 
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subtypes D2, D3 and D4 were profiled in non-smokers, addicted smokers and non- 
addicted smokers. In absolute terms, none of the receptor genotype polymorphisms 
differed significantly between the three groups of subjects. 
The absence of an association between DRD2 polymorphism and smoking behaviour 
was not consistent with some previous research (Noble et al. 1994), although an 
observable trend was emerging for addicted smokers to be more likely to possess the 
A2/A2 genotype. This association has only been previously demonstrated in a 
Japanese population, which is notable since genetic profiling studies are known to be 
highly sensitive to ethnic sampling. The fact that no Caucasian sample prior to this 
study has displayed an association between homozygous DRD2*A2 genotype and 
tobacco dependence suggests these findings may be a statistical artefact. 
However, possession of the DRD4 L-allele was associated with higher Novelty 
Seeking trait scores on Cloninger's (1993) Temperament and Character Inventory, 
consistent with much previous research (Ebstein et al. 1996). Novelty Seeking scores, 
and particularly the Impulsivity subscale thereof, were significantly higher in the 
addicted smokers group, again consistent with previous research (Mitchell, 1999). 
These results suggest that doparninergic neurobiology may have a predisposing effect 
on smoking behaviour, but it is subtle and the effect is expressed primarily through 
heritable biologically mediated personality characteristics. When examining the 
findings of the thesis as a whole, this is theoretically sound. Major differences in 
doparnine receptor morphology might explain differences in positive reinforcement, 
299 
Discussion Chapter 8 
perhaps mediated by relative differences in activity on the nucleus accumbens or 
another structure in the mesolimbic dopan-ýine pathway. 
However, as demonstrated in Chapter 6, non-addicted and addicted smokers differ 
more significantly in their negative reinforcement responses to tobacco withdrawal 
and reinstatement. Levels of positive reinforcement, possibly affected by dopamine 
receptor polymorphisms, are more likely to impact on initial sensitivity to nicotine 
and therefore be much more important to smoking initiation rather than smoking 
persistence (Shiffman, 1991). Although neurobiological parameters are important, 
personality characteristics such as novelty seeking or impulsive tendencies are less 
likely to be simplistically governed by variations in dopan-ýinergic function. Likewise, 
the mechanisms of negative reinforcement, i. e. withdrawal psychopharmacology, are 
more likely to be mediated by other neurotransmitters such as noradrenaline or 5-HT. 
In terms of differentiating who is likely to become tobacco dependent, heritable 
differences in doparninergic neurobiology may only have a limited role. Although 
dopan-iine may be important in the initiation of smoking, differences in heritable 
personality characteristics may be the only tangible way that dopamine impacts on 
smoking persistence, hence tobacco dependence. 
8.9 Methodological issues 
Several methodological limitations have been raised during the discussion sections of 
each individual chapter. Perhaps the most self-evident and ubiquitous of these issues 
has been the sample sizes used. Despite the large number of participants who 
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completed the initial questionnaire study used to develop the Addiction Index score, 
less than half these subjects went on to perform the exPerimental studies. 
Furthermore, the way that initial sample was split into addicted smokers and non- 
addicted smokers created unequal group sizes. Although this was a true reflection of 
the sample, it meant that the addicted smokers group was relatively small. This may 
have adversely affected statistical procedures by obscuring more subtle differences 
between the two groups of smokers. 
Recruiting addicted smokers for use in the study presented in Chapter 7 was also 
difficult. A larger number of subjects would have again been preferable for this study, 
although the within subjects design meant this was less of an issue than with between 
subjects comparisons featured in earlier chapters. 
Although the grouping strategy utilised in Chapters 2 to 6 may be valid for use with 
this sample, the cut-point of Addiction Index scores of 8 or higher indicating 
"addicted smoker" status might not be generalisable to other populations, in particular 
non-student populations. Further work is necessary to examine how robust this cut- 
point is, or indeed whether the emerging bi-modal distribution discussed in Chapter 2 
features in frequency profiles of Addiction Index scores in other samples. 
The expectation of smoking following experimental sessions may have affected 
subjects' performance on cognitive tasks and mood ratings in Chapters 3,6 and 7. In 
order to establish the impact of this expectation, further studies should be performed. 
These would have similar designs and aims, but with a further condition applied 
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whereby subjects are either infonned or uninformed as to whether they will be 
allowed to smoke following each test session. 
A final consideration is the use of the CO breathalyser to ascertain abstinence from 
smoking. Although readings of less than 10 parts per million breath CO was accepted 
as indicating compliance with the 24-hour abstinence protocol, these levels could 
easily be reached through overnight abstinence (approximately 8 hours) in lighter 
smokers. If subjects had only abstained overnight, withdrawal-induced cognitive 
performance deficits would not have peaked (Snyder, Davis & Henningfield, 1989), 
diminishing performance differences between sessions. The CO breathalyser method 
was chosen because of its convenience and simplicity, but future research should 
perhaps use plasma nicotine or salivary cotinine levels with appropriate baseline 
measures to determine abstinence. 
8.10 Conclusions 
Using a multi-disciplinary approach to studying addiction to smoking it has been 
possible to ascertain several crucial elements helping to understand the phenomenon. 
Tobacco dependence appears to be driven by negative rather than positive 
reinforcement, with the tobacco withdrawal syndrome central to motivating the 
persistence of the habit. Smokers who are not tobacco dependent show a variety of 
personality and behavioural differences to their addicted counterparts. These 
differences may protect them from becoming dependent, or may diminish or 
disappear if and when tobacco dependence develops. 
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Anxiety, both trait in terms of personality and state in terms of response to tobacco 
withdrawal is a crucial component of nicotine addiction. By extraction, addicted 
smokers appear to be using nicotine to manage anxious symptoms arising through 
periods of tobacco withdrawal, and possibly self-medicating anxious tendencies 
inherent in their personalities. The anxiety component of the tobacco withdrawal 
syndrome may be mediated by relative increases in frontal noradrenaline, particularly 
in the locus coeruleus, a brain structure implicated in fear and anxiety responses. 
Lofexidine, an a2-adrenoceptor agonist which reduces noradrenergic activity in this 
region can be used to mitigate symptoms associated with tobacco withdrawal. This 
drug could potentially be used as an adjunct or alternative to nicotine replacement 
therapy in managing the tobacco withdrawal syndrome and improving the chances of 
successful smoking cessation. 
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I. Reasons for Smoking Questionnaire (RFS) 
379 
RFS 
Please read the following statements and indicate your response by ticking one of the boxes to the right of the sentence. 
(]=never, 2=seldom, 3=occasionally, 4=frequently, 5=always) 
2 34 5 
I smoke cigarettes to stimulate me, to perk myself up- 
I've found a cigarette in my mouth and didn't 
remember putting it there 
When I am trying to solve a problem, I light up a cigarette- 
When I smoke a cigarette, part of the enjoyment is 
watching the smoke as I exhale it 
I am very much aware of the fact when I am not 
smoking a cigarette 
Part of the enjoyment of smoking a cigarette comes 
from the steps I take to light up 
When I feel "blue" or want to take my mind off cares and 
worries, I smoke cigarettes 
I smoke cigarettes automaticallY without even being 
aware of it 
I smoke cigarettes in order to keep from slowing down 
I get a real gnawing hunger for a cigarette when I 
haven't smoked for a while 
When I feel uncomfortable or upset about something, I 
light up a cigarette 
Handling a cigarette is part of the enjoyment of smoking it- 
Between cigarettes, I get a craving that only a 
cigarette can satisfy, 
I light up a cigarette when I feel angry about something- 
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(]=never, 2=. seldom, 3=occasionally, 4=frequently, S=always) 
I light up a cigarette without realising I still have one 
burning in the ash-tray 
I find cigarettes pleasurable 
When I feel ashamed or embarrassed about something, 
I light up a cigarette 
When I have run out of cigarettes I find it almost 
unbearable until I can get them 
Few things help better than cigarettes when I'm feeling 
upset 
I smoke cigarettes just from habit, without even really 
wanting the one I'm smoking 
Smoking cigarettes is pleasant and relaxing 
I do not feel contented for long unless I am smoking a 
cigarette 
I smoke cigarettes to give me a "lift" 
2 34 5 
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11. Smoking Motivation Questionnaire (SMQ) 
382 
SMO 
This questionnaire asks you to consider the various motives you might have for smoking. It asks you 
to think about different aspects of smoking, and rate them on how and when they apply to your 
individual smoking habits. Please tick one box for each item indicating your response. 
(O=not at all, ]=a little, 2=quite a bit, 3=very much so) 
0123 
I smoke in order to keep myself from slowing down 
Handling a cigarette is part of the enjoyment of smoking it 
I smoke for the pleasure of having something to put in 
my mouth 
I want to smoke most when I am comfortable and 
relaxed 
Part of the enjoyment of smoking is watching the 
smoke as I blow it out 
I smoke more when I am worried about something 
I like smoking while I am busy and working hard 
I smoke for the pleasure of offering and accepting 
cigarettes from other people 
When I run out of cigarettes I find it almost unbearable 
until I can get them 
I smoke automatically without even being aware of it 
I feel I look more mature and sophisticated when smoking 
Smoking helps me keep going when I'm tired 
Part of the enjoyment of smoking comes from the 
steps I take to light it up 
One reason I smoke is because it tastes so good 
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(O=not at all, ]=a little, 2=quite a bit, 3=very much so) 
0123 
After meals is the time I most enjoy smoking 
Smoking helps me to think and concentrate 
I am very much aware of the fact when I am not smoking 
It is easier to talk and get on with other 
people when smoking 
I light up a cigarette without realising I still have 
one burning in the ashtray 
Smoking cheers me up 
I like a cigarette best when I am having a quiet rest 
While smoking I feel more confident with other people 
I get a definite lift and feel more alert when smoking 
Without a cigarette I don't know what to do with 
my hands 
I only really enjoy smoking with a drink 
I smoke much more when I am with other people 
I smoke because I like the smell so much 
I usually only smoke when I can sit back and 
really enjoy it 
I light up a cigarette when I feel angry about something 
I find it a pleasure drawing the smoke into mY lungs 
I get a real gnawing hunger to smoke when I haven't 
smoked for a while 
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(0=; not at all, ]=; a little, 2=; quite a bit, 3=very much so) 
0123 
I find myself smoking without remembering lighting up 
I smoke more when I am rushed and have lots to do 
I feel more attractive to the opposite sex when smoking 
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111. Fagerstrom Tolerance Questionnaire (FTQ) 
386 
FTO 
Please answer the following questions as honestly as you possibly can. They are 
trying to establish how much smoking or nicotine has become integrated into your 
life. Please circle where appropriate, or write a short answer. Thank you. 
1. How many cigarettes a day do you smoke? ------------- 
2. What brand do you smoke? ---------------------- 
3. Do you inhale? Always / Sometimes / Never 
4. Do you smoke more during the morning than during the rest of the 
day? Yes / No / Depends 




6. If you had to give up one of your daily cigarettesq which cigarette 
would you hate to give up? ------------------------ 
7. Do you find it difflcult to refrain from smoking in places where it is 
forbidden, e. g. in libraries, cinemas, restaurants, religious buildingsq 
etc.? Yes / No / Depends 
8. Do you smoke if you are so ill that you are in bed most of the day? 
Yes / No / Depends 
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IV. Smoking Beliefs Inventory (SBI) 
388 
SBI 
This questionnaire asks you about some of the beliefs you might have about 
smoking. Think about the questions, and try to answer them according to what you 
yourself believe, rather than what you think the general consensus is. 
(O=strongly disagree, 1=slightIy disagree, 2=undecided, 3=slightly agree, 4=strongly 
agree) 
034 
Smoking can help people relax- 
Smoking is a dirty habit 
Smoking can help people when they 
feel nervous or embarrassed 
Smoking improves concentration 
Smoking does more harm than good 
Smoking improves memo 
Children should be discouraged from 
smoking 
Smoking is a nuisance 
Smoking is pleasurable 
Smoking can kill 
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V. ' Visual Analogue Mood Scales 
390 
Visual analogue mood scales 
Subjective mood is assessed using 18 computerised visual analogue mood scales. Each of 
the 18 bipolar scales are composed of a pair of adjectives, e. g. "drowsy - alert" or "happy 
- sad". Participants are required to move the cursor (using the response keys with arrows 
marked left and right) from a central position on the scale anywhere along the horizontal 
rule, towards either extreme of the scale, until the cursor rests at a position which is 
representative of their mood state at that exact time. The 18 scales are presented 
consecutively and always in the same order. The scales are as follows: 
1. Drowsy v Alert 
2. Relaxed v Excited 
3. Strong v Feeble 
4. Muzzy v Clear-headed 
5. Co-ordinated v Clumsy 
6. Lethargic v Energetic 
7. Contented v Discontented 
8. Troubled v Tranquil 
9. Mentally slow v Quick-witted 
10. Tense v Calm 
11. Attentive v Dreamy 
12. Incompetent v Proficient 
13. Happy v Sad 
14. Antagonistic v Friendly 
15. Interested v Bored 
16. Withdrawn v Sociable 
17. Depressed v Elated 
18. Self-centred v Outward-going 
For each of these scales a score is recorded between I and 5 1. Using a factor analysis 
three scores are derived from the 18 scales; alertness, sociability and anxiety. These are 
derived as follows: 
Factor I (Alertness) 
Scores for measures of feeble, dreamy and clumsy were reversed and then entered into the following 
equation with the 5 other items loading onto this factor. 
Drowsy + muzzy + feeble + clumsy + lethargic + mentally slow + dreamy + incompetent = Factor I 
Factor 2 (Hedonic Tone) 
Scores for measures of sad, bored and discontented were reversed and then entered into the following 
equation with the 3 other items loading onto this factor. 
Discontented + sad + antagonistic + bored + withdrawn + self-centred = Factor 2 
Factor 3 (Anxiety) 
Scores for the measure of excited were reversed and then entered into the following equation with the 2 
other items loading on this factor. 
Excited + troubled + tense = Factor 3 
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VI. Simple Reaction Time Task 
392 
Simple reaction time task 
In this task a frame of a box is displayed in the centre of the screen and at varying 
temporal intervals (I -8 seconds) a target square appears inside the box. As soon as the 
participant detects the square, they are required to press the response key marked SPACE 
using the forefinger of their dominant hand only. 
A reaction time is measured for each presentation. A mean 
reaction time is calculated for each minute of performance on the 
basis of the number of trials completed per minute. 
The total number of trials completed over the duration of the task 
is recorded. 
An overall mean reaction time is calculated from the total 
number of trials completed over the duration of the task. 
Analysing raw data using the appropriate data concatenation computer program 
eliminates any reaction times that are below 200ms and greater than 750ms, in doing so 
the number of trials completed is reduced correspondingly, i. e. if I trial has a reaction 
time of 760ms that trial will be eliminated from further analysis and will reduce the total 
number of trials by 1. 
Global analysis (measuring general speed of response): 
1. Total number of trials completed over the duration of the task. 
2. Total mean reaction time calculated across the duration of the test period. 
Further analysis: 
I. Reaction times for each minute can be looked at separately to observe time on 
task changes. 
2. A fatigue measures can be calculated by subtracting mean reaction time at I 
minute from the mean reaction time at the final minute. A positive fatigue score 
indicates that reaction times increase as the test progresses as a result of fatigue. 
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VII. Focused Attention Task 
394 
Focused attention task 
In this task target letters appear in upper case 'A's and 'B's in the centre of the screen. 
Participants are required to respond to the target letter presented in the centre of the 
screen, ignoring any distracters presented in the periphery, as quickly and as accurately as 
possible. The correct response to Wis to press the far left response key with the 
forefinger of the left hand, while the correct response to Wis to press the far right key 
with the forefinger of the right hand. Prior to each target presentation, three warning 
crosses are presented on the screen. These crosses appear for 5OOms and are then 
replaced by the target letter. The central (target) letter is either accompanied by 1) 
nothing, 2) asterisks, 3) letters that are the same as the target or 4) letters that are different 
to the target. The two distracters if and when presented are always identical and the 
targets and distracter letters are always A or B. 
Participants are presented with ten practice trials followed by 4 blocks of 64 trials. In 
each block there are equal numbers of near / far conditions (warning crosses and, if 
present, distracters either close or further away from target), 'A' and 'B' target 
presentations and equal numbers of the four distracter conditions. The condition of the 
trial order is also controlled. 
Preliminary analysis 
Raw data for this task provides a reaction time for each presentation and whether or not 
an accurate response was given. Additionally, number of correct responses with a 
reaction time less than 800ms, number of correct responses with reaction time greater 
than 800ms and overall number of errors made are also recorded in the raw data. The 
concatenation program creates several derived variables measuring different aspects of 
selective attention using the raw data. 
These variables include: 
Mean reaction time responding to targets presented alone or with asterisks. 
Mean reaction time when distracters are present, whether they agree/disagree. 
Speed of encoding of information - the difference in reaction time of response between conditions when the target is alternated from the previous trial and when the 
target is repeated from the previous trial. 
" The Eriksen effect -a measure of the focusing of attention - the difference in reaction 
time between responses with distracters near to the target and responses with 
distracters far from the target. If attention is focused then a big difference between 
near and far distracter conditions should be found. If attention is set at a wide angle 
then this difference should be reduced. 
" Mean reaction time when target is presented alone. 
" Mean accuracy responding to the target when presented alone or with asterisks 
(divide by number of blocks of 64 and multiply by 100 to calculate percentage). 
" Mean accuracy when distracters are present, whether they are agreeing (same letters 
as target) or disagreeing (different letters to target) or asterisks (divide by number of 
blocks of 64 and multiply by 100 to calculate percentage). 
" Number of long responses (reaction times >800ms). 
" Number of errors. 
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VIIL,, Categoric Search Task 
4 
396 
Categoric search task 
This task is similar to the focused attention task. Each trial begins with the appearance of 
two crosses either in the central positions occupied by the non-targets in the focused 
attention task or further apart, located towards either the left or right extremes of the 
screen. The target letter then appears in place of one of these crosses, however in this task 
the left/right location is unknown. On half the trials the target letter 'A' or'B' is presented 
alone and on the other half it is accompanied by a distracter (a digit between I and 7). As 
with the focused attention task, the number of near/far stimuli, 'A' versus '13' targets and 
distracter/no distracter conditions are controlled. Half of the trials lead to compatible 
responses (i. e. the letterA'on the left side of the screen, or letter'B'on the right: this 
means visual stimulus and correct motor response are on the same side) whereas the 
others are incompatible. The nature of the preceding trial is also controlled. In other 
respects (practice trials, blocks, number of trials, etc. ) the task is identical to the focused 
attention task. 
Preliminary analysis 
The raw data provides a reaction time for each presentation and records whether or not an 
accurate response was given. In addition, the number of correct responses with a reaction 
time less than 10OOms, the number of correct responses with reaction time greater than 
10OOms and the overall number of errors made are also recorded in the raw data. The 
concatenation program also uses the raw data and derives several scores measuring 
different aspects of selective attention. 
For the categoric search task the variables include: 
Mean reaction time when target is presented alone. 
Speed of encoding of information - the difference in reaction time of response between conditions when the target is alternated from the previous trial and when the 
target is repeated from the previous trial. 
The effect of spatial uncertainty on mean reaction time - difference in reaction time 
between far and near targets in blank and compatible conditions. 
The effect of compatibility of the target position and the response key on reaction 
time - the difference in reaction times between incompatible and compatible 
presentations. 
The effect of target location - the difference in reaction time between responses to 
targets presented in different locations and targets presented in the same locations. 
" Mean reaction time in blank, near and compatible conditions. 
" Mean accuracy when target is presented alone or with asterisk (divide by number of 
blocks of 64 and multiply by 100 to calculate percentage). 
" Number of long responses (>10OOms). 
" Number of errors. 
The focused attention and categoric search tasks are sophisticated in their ability to 
measure a number of aspects of selective attention, whilst the participant requires no 
change in test strategy or level of difficulty. The aim of the various derived scores is to 
examine the effects of various distracting stimuli in relation to the target letter, upon 
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reaction time and accuracy of response and therefore their effects upon attentional 
processes. 
Design specifications for focused attention and categoric search tasks 
'Near' and 'Far' refer to presentations of the target letter near the center of the screen or at 
the extreme edges of the screen (i. e. far from the centre). These are programmed as either 
2 character spaces from the centre, left and right (NEAR condition); or 34 character 
spaces from the centre, left and right (FAR condition). 
The font size of the characters presented is NORMAL character set for a DOS screen 
operating in 320x480 video mode. 
Reaction times <100ms are excluded during the concatenation process. Long responses 
are specified in the concatenation program (>800ms in focused attention; >10OOms in 
categoric search). The inter-stimulus time (i. e. time between presentation of warning 
crosses and target letter) is set at 120ms. 
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IX. Psychomotor (5-Choice) Task 
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Five-choice psvchomotor task 
This task is a measure of both speed and accuracy of movement to a choice of targets. 
Five buttons are arranged on the response box in a regular pentagon with a sixth button in 
the centre. A light appears in one of the peripheral buttons. The participant is required to 
extinguish the illuminated button simply by pressing it using the forefinger of the 
dominant hand only. Following this the centre key will illuminate. The participant is 
required to press the central light and continue to follow the light around the board in this 
periphery button, central button, periphery button sequence. 
For each minute of the task and over the duration of the task the following measures are 
recorded: 
" Total number of trials completed 
" Total percentage of trials performed correctly 
" Total number of long responses (reaction times >1500ms) 
Global analysis 
1. Total number of trials completed within the duration of the task. 
2. Total percentage of trials performed correctly within the duration of the task. 
3. Total number of long responses (reaction times >15OOms) within the duration of the 
task. 
Further analysis 
Number of trials completed in each minute of the task (can be used to observe changes in 
rate of task performance within task duration). 
Percentage of correct trials in each minute of the task (can be used to observe changes in 
accuracy of task performance within task duration). 
Number of long responses made in each minute of the task (can be used to observe 
changes in frequency of attentional lapses within task duration). 
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X. Rapid Visual Information Processing (RVIP)Nigilance Task 
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Ravid visual information processing/vi gi lance repeated digits detection task 
This visual cognitive vigilance task measures the ability to detect targets at irregular 
intervals. Participants are shown successive presentations of three-digit numbers in the 
centre of the screen (e. g. 473) at the rate of 100 per minute. Each three-digit number 
usually differs from the one preceding it, with one of the three digits being replaced with 
a different digit (e. g. 463,563,562). Occasionally (8 times per minute) the same three- 
digit number will be presented on successive trials. It is these repetitions that the 
participant needs to detect and respond to as quickly as possible by pressing the space 
key on the keyboard using the forefinger of the dominant hand. 
For each minute of the task and over the whole duration of the task the following 
measures are recorded: 
Total mean reaction time to targets 
Total percentage of targets correctly detected 
Total number of false alarms 
Global analysis 
I. Total mean reaction time calculated over the entire test period. 
2. Total hit rate is calculated by adding the number of hits for each trial period. 
I Total false alarm rate is calculated by adding the number of false alarms for each trial 
period. 
Further analysis 
I. Reaction times for each of the trial periods can be looked at separately to observe 
changes throughout the duration of the test. 
2. Hit rates for each of the trial periods can be looked at separately to observe changes in 
accuracy throughout the duration of the test. 
3. A fatigue measure can be calculated by subtracting mean reaction time at trial period 
I from the mean reaction time at the final trial period. A positive fatigue score 
indicates that reaction times increase as the test progresses as a result of fatigue. 
4. A second fatigue measure can be calculated by subtracting hit rate for trial period I 
from the hit rate for the final trial period. If the hit rate difference is found to be 
negative this also indicates that vigilance is being reduced by the effect of fatigue 
over the duration of the test. 
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Version 9- Revised 10-26-92 
TCI 
In this booklet you will find statements people might use to describe their 
attitudes, opinions, interests, and other personal feelings. 
Each statement can be answered TRUE or FALSE. Read the statement and decide 
which choice best describes you. Try to describe the way you USUALLY or generally act 
or feel, not just how you are feeling right now. 
We would like you to fill out this questionnaire on your own using a pencil. When 
you are finished, please return the questionnaire. 
HOW TO FILL OUT THIS QUESTIONNAIRE 
To answer you only need to circle either "T" or T" after each question. Here is an 
example: 
EXAMPLE TRUE FALSE 
I understand how to fill out this questionnaire ............ TF 
(If you understand how to fill out this questionnaire, circle "T" to show that the statement 
is true). 
Read each statement carefully, but don't spend too much time on deciding the 
answer. 
Please answer every statement, even if you are not completely sure of the answer. 
Remember there are no right or wrong answers - just describe your own personal 
opinions and feelings. 
Copyright(D 1987,1992byC. R. Cloninger 
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1.1 often try new things just for fun or thrills, 
even if most people think it is a waste of time ............................................... TF 
2.1 usually am confident that everything will go well, 
even in situations that worry most people . ................................................... 
TF 
3.1 am often moved deeply by a fine speech or 
poetry . ............................................................................................. 
TF 
4.1 often feel that I am the victim of 
circumstances . .................................................................................. 
TF 
5.1 can usually accept other people as they are, 
even when they are very different from me . ................................................ 
TF 
6.1 believe that miracles happen . ............................................................... 
TF 
7.1 enjoy getting revenge on people who hurt me ............................................ 
TF 
8. Often when I am concentrating on something, I lose 
awareness of the passage of time . ............................................................ 
TF 
9. Often I feel that my life has little purpose 
or meaning . ...................................................................................... 
TF 
10.1 like to help find a solution to problems so 
that everyone comes out ahead . .............................................................. 
TF 
11.1 could probably accomplish more than I do, 
but I don't see the point in pushing myself 
harder than is necessary to get by . ........................................................... 
TF 
12.1 often feel tense and worried in unfamiliar 
situations, even when others feel there is 
little to worry about . ............................................................................ 
TF 
13.1 often do things based on how I feel at the 
moment without thinking about how they were 
done in the past . ................................................................................ 
TF 
14.1 usually do things my own way - rather 
than giving in to the wishes of other people . ............................................... 
TF 
15.1 often feel so connected to the people around 
me that it is like there is no separation 
between us . ...................................................................................... 
TF 
16.1 generally don't like people who have different 
ideas from me . .................................................................................. 
TF 
17. In most situations my natural responses are based 
on good habits that I have developed . ....................................................... 
TF 
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18.1 would do almost anything legal in order to 
become rich and famous, even if I would lose the 
trust of many old friends . ...................................................................... 
T F 
19.1 am much more reserved and controlled than 
- most people . ..................................................................................... 
T F 
20.1 often have to stop what I am doing because 
I start worrying about what might go wrong . ............................................... 
T F 
2 1.1 like to discuss my experiences and feelings 
openly with friends instead of keeping them 
to myself . ........................................................................................ 
T F 
22.1 have less energy and get tired more quickly 
, than most people . ............................................................................... 
T F 
23.1 am often called "absent-minded" because I get so 
wrapped up in what I am doing that I lose track 
of everything else . .............................................................................. 
T F 
24.1 seldom feel free to choose what I want to do ............................................ 
T F 
25.1 often consider another person's feelings 
as much as my own . ............................................................................ 
T F 
26. Most of the time I would prefer to do some- 
thing a little risky (like riding in a 
automobile over steep hills and sharp turns) 
- rather than having to stay quiet and 
inactive for a few hours . ....................................................................... 
T 
27.1 often avoid meeting strangers because I 
lack confidence with people I do not know . ................................................ 
TF 
28.1 like to please other people as much as I can . ............................................ 
TF 
29.1 like old "tried and true" ways of doing things 
much better than trying "new and improved" ways ......................................... 
TF 
30. Usually I am not able to do things according to 
their priority of importance to me because of 
lack of time . ..................................................................................... 
TF 
31.1 often do things to help protect animals and 
plants from extinction . ......................................................................... 
TF 
32.1 often wish that I was smarter than everyone 
else . .............................................................................................. 
TF 
33. It gives me pleasure to see my enemies suffer . ........................................... 
TF 
34.1 like to be very organized and set up rules 
for people whenever I can ...................................................................... 
TF 
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35. It is difficult for me to keep the same 
interests for a long time because my 
attention often shifts to something else . ..................................................... 
TF 
36. Repeated practice has given me good habits that 
are stronger than most momentary impulses or 
persuasion . ....................................................................................... 
TF 
37.1 am usually so determined that I continue to 
work long after other people have given up . ................................................ 
TF 
38.1 am fascinated by the many things in life that 
cannot be scientifically explained . ........................................................... 
TF 
39.1 have many bad habits that I wish I could break . ........................................ 
TF 
40.1 often wait for someone else to provide a 
solution to my problems . ...................................................................... 
TF 
41.1 often spend money until I run out of cash or 
get into debt from using too much credit . ................................................... 
TF 
42.1 think I will have very good luck in the 
future . ............................................................................................ 
TF 
43.1 recover more slowly than most people from 
minor illnesses or stress . ...................................................................... 
TF 
44. It wouldn't bother me to be alone all the 
time . .............................................................................................. 
TF 
45. Often I have unexpected flashes of insight or 
understanding while relaxing . ................................................................ 
TF 
46.1 don't care very much whether other people 
like me or the way I do things . ................................................................ 
TF 
47.1 usually try to get just what I want for myself 
because it is not possible to satisfy everyone 
anyway . .......................................................................................... 
TF 
48.1 have no patience with people who don't accept 
my views . ........................................................................................ 
TF 
49.1 don't seem to understand most people very well . ....................................... 
TF 
50. You don't have to be dishonest to succeed in 
business . ......................................................................................... 
TF 
5 1.1 sometimes feel so connected to nature that 
everything seems to be part of one living 
organism . ........................................................................................ 
TF 
52. In conversations I am much better as a listener 
than as a talker . .................................................................................. 
TF 
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53.1 lose my temper more quickly than most 
people . ........................................................................................... TF 
54. When I have to meet a group of strangers, I 
am more shy than most people . ............................................................... TF 
55.1 am more sentimental than most people . ................................................. TF 
56.1 seem to have a "sixth sense" that sometimes 
allows me to know what is going to happen . ............................................... TF 
57. When someone hurts me in any way, I usually try 
to get even . ...................................................................................... TF 
58. My attitudes are determined largely by influences 
outside my control . ............................................................................ T F 
59. Each day I try to take another step toward 
my goals . ........................................................................................ T F 
60.1 often wish I was stronger than everyone else . .......................................... .T F 
61.1 like to think about things for a long time 
before I make a decision . ...................................................................... T F 
62.1 am more hard-working than most people . .............................................. .T 
F 
63.1 often need naps or extra rest periods 
because I get tired so easily . .................................................................. .T F 
64.1 like to be of service to others . ............................................................ .T F 
65. Regardless of any temporary problem that I 
have to overcome, I always think it will turn 
out well . .......................................................................................... T F 
66. It is hard for me to enjoy spending money on 
myself, even when I have saved plenty of money . ........................................ T F 
67.1 usually stay calm and secure in situations 
that most people would rind physically 
dangerous 
. ....................................................................................... T F 
68.1 like to keep my problems to myself . ...................................................... T F 
69.1 don't mind discussing my personal problems with 
people whom I have known briefly or slightly . ............................................ T F 
70.1 like to stay at home better than to travel 
or explore new places . ......................................................................... 
T F 
71.1 do not think it is smart to help weak 
people who cannot help themselves . ......................................................... T F 
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72.1 cannot have any peace of mind if I treat 
- other people unfairly, even if they are unfair 
to me . ............................................................................................ .TF 
73. People will usually tell me how they feel . ................................................ .TF 
74.1 often wish I could stay young forever . ................................................... TF 
75.1 am usually more upset than most people by 
the loss of a close friend . ..................................................................... .TF 
76. Sometimes I have felt like I was part of some- 
thing with no limits or boundaries in time 
and space . ........................................................................................ 
TF 
77.1 sometimes feel a spiritual connection to other 
people that I cannot explain in words . ....................................................... TF 
78.1 try to be considerate of other people's 
feelings, even when they have been unfair to me 
in the past . ....................................................................................... 
TF 
79.1 like it when people can do whatever they 
want without strict rules and regulations . ................................................... 
TF 
80.1 would probably stay relaxed and outgoing 
when meeting a group of strangers, even if 
I were told they are unfriendly . ............................................................... 
TF 
81. Usually I am more worried than most people 
that something might go wrong in the future . .............................................. TF 
82.1 usually think about all the facts in detail 
before I make a decision . ...................................................................... 
TF 
83.1 feel it is more important to be sympathetic 
and understanding of other people than to be 
practical and tough-minded . ................................................................... 
TF 
84.1 often feel a strong sense of unity with all the 
things around me . ............................................................................... 
TF 
85.1 often wish I had special powers like Superman . ........................................ 
TF 
86. Other people control me too much . ......................................................... 
TF 
87.1 like to share what I have learned with other 
people . ........................................................................................... 
TF 
88. Religious experiences have helped me understand 
the real purpose of my life . ................................................................... 
TF 
89.1 often learn a lot from people . .............................................................. 
TF 
90. Repeated practice has allowed me to become good 
at many things that help me to be successful . .............................................. TF 
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91.1 am usually able to get other people to 
believe me, even when I know that what I am 
saying is exaggerated or untrue . .............................................................. 
TF 
92.1 need much extra rest, support, or reassurance 
to recover from minor illnesses or stress . ................................................... 
TF 
93.1 know there are principles for living that no 
one can violate without suffering in the long 
run . ............................................................................................... 
TF 
94.1 don't want to be richer than everyone else . .............................................. 
TF 
95.1 would gladly risk my own life to make the 
world a better place . ............................................................................ 
TF 
96. Even after thinking about something a long time, 
I have learned to trust my feelings more than my 
logical reasons . .................................................................................. 
TF 
97. 'Sometimes I have felt my life was being directed 
by a spiritual force greater than any human 
being . ............................................................................................. 
TF 
98.1 usuafly enjoy being mean to anyone who has 
been mean to me . ............................................................................... 
TF 
99.1 have a reputation as someone who is very 
practical and does not act on emotion . ....................................................... 
TF 
100. It is easy for me to organize my thoughts while 
talking to someone . ............................................................................ 
TF 
10 1.1 often react so strongly to unexpected news that 
I say or do things that I regret. ................................................................ 
TF 
102.1 am strongly moved by sentimental appeals 
(like when asked to help crippled children) . ................................................ 
TF 
103.1 usually push myself harder than most 
people do because I want to do as well as 
I possibly can . .................................................................................. 
TF 
104.1 have so many faults that I don't like myself 
very much . ....................................................................................... 
TF 
105.1 have too little time to look for long-term 
solutions for my problems . .................................................................... 
TF 
106.1 often cannot deal with problems because I just 
don't know what to do . ......................................................................... 
TF 
107.1 often wish I could stop the passage of time . ............... ; ............................ TF 
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108.1 hate to make decisions based only on my 
first impressions . ............................................................................... 
TF 
109.1 prefer spending money rather than saving 
ý it . ................................................................................................. 
TF 
I 10.1 can usually do a good job of stretching the 
truth to tell a funnier story or to play a 
joke on someone . ............................................................................... 
TF 
I 11. Even after there are problems in a friendship, I 
nearly always try to keep it going anyway . ................................................. 
TF 
112. If I am embarassed or humiliated, I get over it 
very quickly . ..................................................................................... 
TF 
113. It is extremely difficult for me to adjust to 
changes in my usual way of doing things because 
I get so tense, tired, or worried . .............................................................. .TF 
114.1 usually demand very good practical reasons 
before I am willing to change my old ways of 
doing things . ..................................................................................... 
TF 
115.1 need a lot of help from other people to train 
me to have good habits . ........................................................................ 
TF 
116.1 think that extra-sensory perception (ESP, like 
telepathy or precognition) is really possible . ............................................... 
TF 
117.1 would like to have warm and close friends 
with me most of the time . ...................................................................... 
TF 
118.1 often keep trying the same thing over and over 
again, even when I have not had much success in 
a long time . ...................................................................................... 
TF 
119.1 nearly always stay relaxed and carefree, 
even when nearly everyone else is fearful . ................................................. 
TF 
120.1 find sad songs and movies pretty boring . ............................................... 
TF 
121. Circumstances often force me to do things 
against my will . ................................................................................. 
TF 
122. It is hard for me to tolerate people who are 
different from me . .............................................................................. 
TF 
123.1 think that most things that are called miracles 
are just chance . .................................................................................. 
TF 
124.1 would rather be kind than to get revenge when 
someone hurts me . .............................................................................. 
TF 
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125.1 often become so fascinated with what I'm doing 
that I get lost in the moment - like I'm detached from time and place . ............................................................................ TF 
126.1 do not think I have a real sense of purpose 
for my life . ....................................................................................... T 
127.1 try to cooperate with others as much as 
possible . .......................................................................................... TF 
128.1 am satisfied with my accomplishments, and 
have little desire to do better . ................................................................ .TF 
129.1 often feel tense and worried in unfamiliar 
situations, even when others feel there is 
no danger at all . ................................................................................ .TF 
130.1 often follow my instincts, hunches, or 
intuition without thinking through all the 
details . ........................................................................................... TF 
13 1. Other people often think that I am too independent 
ý because I won't do what they want . .......................................................... TF 
132.1 often feel a strong spiritual or emotional 
connection with all the people around me . ................................................. 
TF 
133. It is usually easy for me to like people who have 
different values from me . ...................................................................... TF 
134.1 try to do as little work as possible, even when 
other people expect more of me . ............................................................. TF 
135. Good habits have become "second nature" to me - 
they are automatic and spontaneous actions nearly 
all the time . ...................................................................................... TF 
136.1 don't mind the fact that other people often 
know more than I do about something. 
137.1 usually try to imagine myself "in other people's 
shoes", so I can really understand them . .................................................... 
TF 
138. Principles like fairness and honesty have little 
role in some aspects of my life . ............................................................... TF 
139.1 am better at saving money than most people . ........................................... TF 
140.1 seldom let myself get upset or frustrated: when 
things don't work out, I simply move on 
to other activities . ............................................................................... TF 
141. Even when most people feel it is not important, 
I often insist on things being done in a 
strict and orderly way . ......................................................................... TF 
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142.1 feel very confident and sure of myself in 
almost all social situations . .................................................................. .T F 
143. My friends find it hard to know my feelings 
because I seldom tell them about my private 
thoughts . ........................................................................................ .T F 
144.1 hate to change the way I do things, even 
if many people tell me there is a new and 
better way to do it. ............................................................................. .T F 
145.1 think it is unwise to believe in things that 
cannot be explained scientifically . ........................................................... 
T F 
146.1 like to imagine my enemies suffering . .................................................. .T F 
147.1 am more energetic and tire less quickly 
than most people . ............................................................................... T F 
148.1 like to pay close attention to detai Is in 
everything I do . ................................................................................. T F 
149.1 often stop what I am doing because I get 
worried, even when my friends tell me every- 
thing will go well . .............................................................................. T F 
150.1 often wish I was more powerful than everyone 
else . .............................................................................................. TF 
151.1 usually am free to choose what I will do . ............................................... T 
152. Often I become so involved in what I am doing 
that I forget where I am for a while . ......................................................... TF 
153. Members of a team rarely get their fair share . ........................................... TF 
154. Most of the time I would prefer to do something 
risky (like hang-gliding or parachute jumping) 
- rather than having to stay quiet and inactive 
for a few hours . ................................................................................. TF 
155. Because I so often spend too much money on 
impulse, it is hard for me to save money - even for special plans like a vacation . ............................................................. 
TF 
156.1 don't go out of my way to please other 
people . ........................................................................................... TF 
157.1 am not shy with strangers at all . .......................................................... 
TF 
158.1 often give in to the wishes of friends . .................................................... TF 
159.1 spend most of my time doing things that seem 
necessary but not really important to me . ................................................... TF 
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160.1 don't think that religious or ethical principles 
about what is right and wrong should have much 
influence in business decisions . .............................................................. TF 
16 1.1 often try to put aside my own judgments so 
that I can better understand what other people 
are experiencing . ............................................................................... TF 
162. Many of my habits make it hard for me to 
accomplish worthwhile goals . ................................................................ TF 
163.1 have made real personal sacrifices in order to 
make the world a better place - like trying to 
prevent war, poverty and injustice . .......................................................... 
TF 
164.1 never worry about terrible things that might 
happen in the future . ........................................................................... .TF 
165.1 almost never get so excited that I lose 
, control of myself . ............................................................................... 
TF 
166.1 often give up a job if it takes much 
longer than I thought it would . ................................................................ 
TF 
167.1 prefer to start conversations, rather than 
waiting for others to talk to me . .............................................................. 
TF 
168. Most of the time I quickly forgive anyone who 
I does me wrong . ................................................................................. 
TF 
169. My actions are determined largely by influences 
outside my control . .............................................................................. 
TF 
170.1 often have to change my decisions because I had 
a wrong hunch or mistaken first impression . ............................................... 
TF 
171.1 prefer to wait for someone else to take the 
lead in getting things done . ................................................................... 
TF 
172.1 usually respect the opinions of others . ................................................... 
TF 
173.1 have had experiences that made my role in life 
so clear to me that I felt very excited and happy . .......................................... 
TF 
174. It is fun for me to buy things for myself . ................................................. 
TF 
175.1 believe that I have experienced extra-sensory 
perception myself . .............................................................................. 
TF 
176.1 believe that my brain is not working properly . ......................................... 
TF 
177. My behavior is strongly guided by certain goals 
that I have set for my life . ..................................................................... 
TF 
178. It is usually foolish to promote the success of 
other people . ..................................................................................... 
TF 
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179.1 often wish I could live forever . ........................................................... 
T F 
180.1 usually like to stay cool and detached from 
other people . ..................................................................................... 
T F 
181.1 am more likely to cry at a sad movie than 
most people . ..................................................................................... 
T F 
182.1 recover more quickly than most people from 
minor illnesses or stress . ...................................................................... 
T F 
183.1 often break rules and regulations when I 
think I can get away with it. ................................................................... 
T F 
184.1 need much more practice in developing good 
habits before I will be able to trust myself in 
many tempting situations . ..................................................................... 
T F 
185.1 wish other people didn't talk as much as 
I they do . ........................................................................................... 
T F 
186. Everyone should be treated with dignity and respect, 
even if they seem to be unimportant or bad . ................................................ 
TF 
187.1 like to make quick decisions so I can get 
on with what has to be done . ................................................................. 
TF 
188.1 usually have good luck in whatever I try to 
- do . ................................................................................................. 
189.1 am usually confident that I can easily do 
things that most people would consider 
dangerous (such as driving an automobile 
fast on a wet or icy road) . ...................................................................... 
TF 
190.1 see no point in continuing to work on something 
unless there is a good chance of success . .................................................... 
T F 
191.1 like to explore new ways to do things . .................................................. 
T F 
192.1 enjoy saving money more than spending it on 
entertainment or thril Is . ........................................................................ 
T F 
193. Individual rights are more important than the 
needs of any group . ............................................................................ 
T F 
194.1 have had personal experiences in which I felt 
in contact with a divine and wonderful spiritual 
power . ............................................................................................ 
T F 
195.1 have had moments of great joy in which I 
suddenly had a clear, deep feeling of oneness 
with all that exists . ............................................................................. 
T F 
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196. Good habits make it easier for me to do things 
the way I want . .................................................................................. T 
197. Most people seem more resourceful than I am . ......................................... T F 
198. Other people and conditions are often to blame 
for my problems . ............................................................................... T F 
199. It gives me pleasure to help others, even if 
they have treated me badly . ................................................................... T F 
200.1 often feel like I am a part of the spiritual 
force on which all life depends . .............................................................. T F 
201. Even when I am with friends, I prefer not to 
flopen up" very much . .......................................................................... T F 
202.1 usually can stay "on the go" all day without 
having to push myself . ......................................................................... T 
203.1 nearly always think about all the facts in 
detail before I make a decision, even when 
other people demand a quick decision . ...................................................... T 
204.1 am not very good at talking my way out of 
trouble when I am caught doing something wrong . ........................................ T 1. 
205.1 am more of a perfectionist than most people . ........................................... T F 
206. Whether something is right or wrong is just a 
matter of opinion . ............................................................................. T 
207.1 think my natural responses now are usually 
consistent with my principles and long-term 
goals . ............................................................................................ T F 
208.1 believe that all life depends on some spiritual 
order or power that cannot be completely explained . ..................................... T F 
209.1 think I would stay confident and relaxed 
when meeting strangers, even if I were 
told they are angry at me . ..................................................................... T IT. 
2 10. People find it easy to come to me for help, 
sympathy, and warm understanding . ......................................................... T F 
211.1 am slower than most people to get excited 
about new ideas and activities . ................................................................ T F 
212.1 have trouble telling a lie, even when it is 
meant to spare someone else's feelings . ..................................................... T F 
213. There are some people I don't like . ........................................................ T 
214.1 don't want to be more admired than everyone 
else . .............................................................................................. T F 
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215. Often when I look at an ordinary thing, something 
wonderful happens -- I get the feeling that I am 
seeing it fresh for the first time . .............................................................. TF 
216. Most people I know look out only for themselves, 
no matter who else gets hurt . ............................................................... .. TF 
217.1 usually feel tense and worried when I have 
to do something new and unfamiliar . ...................................................... .. TF 
218.1 often push myself to the point of exhaustion 
or try to do more than I really can . ......................................................... .. T 
219. Some people think I am too stingy or tight with 
my money . ....................................................................................... TF 
220. Reports of mystical experiences are probably just 
wishful thinking . .............................................................................. .T 
221. My will power is too weak to overcome very strong 
temptations, even if I know I will suffer as a 
consequence . ................................................................................... .T 
222.1 hate to see anyone suffer . .................................................................. TF 
223.1 know what I want to do in my life . ...................................................... .TF 
224.1 regularly take time to consider whether 
what I am doing is right or wrong . .......................................................... .T 
225. Things often go wrong for me unless I 
am very careful . ................................................................................ .T 
226. If I am feeling upset, I usually feel better 
around friends than when left alone . ........................................................ .T 
227.1 don't think it is possible for one person 
to share feelings with someone else who hasn't 
had the same experiences . ..................................................................... TF 
228. It often seems to other people I ike I am in 
another world because I am so completely unaware 
of things going on around me . ................................................................ TF 
229.1 wish I were better looking than everyone else . ........................................ TF 
230.1 have lied a lot on this questionnaire . .................................................... TF 
23 1.1 usually stay away from social situations 
where I would have to meet strangers, even 
if I am assured that they will be friendly . ................................................... TF 
232.1 love the blooming of flowers in the spring as 
much as seeing an old friend again . .......................................................... TF 
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233.1 usually look at a difficult situation as a 
challenge or opportunity . ...................................................................... T F 
234. People involved with me have to learn how to do 
things my way . .................................................................................. T F 
235. Dishonesty only causes problems if you get 
caught . ........................................................................................... T P 
236.1 usually feel much more confident and energetic 
than most people, even after minor illnesses or 
stress . ............................................................................................. T IF 
237.1 like to read everything when I am asked 
to sign any papers . .............................................................................. T 
238. When nothing new is happening, I usually start 
looking for something that is thrilling or 
exciting . .......................................................................................... T 
239. Sometimes I get upset . ...................................................................... T F 
240. Occasionally I talk about people behind their 
backs . ............................................................................................. T F 
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XII. Genotyping Consent Form 
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SUBJECT CONSENT FORM 
I hereby consent to the use of genetic material obtained from the 
cheek cell sample I have volunteered being analysed. I understand 
that three genotypes only will be investigated: DRD2, DRD3 and 
DRD4 (all neurotransmitter receptors in the brain) polymorph i sins. 
If at any stage further data is needed from my DNA, I will receive 
a written request from the University to that end. I am within my 
rights to withdraw at any time, and may refuse further 















Your eating habits 
INSTRUCTIONS: Please circle the appropriate answer for each question 
1. Are you on a special diet of any sort for health reasons? 
No (0) Yes (1) 
If yes: What are the reasons? 
What is the special diet? 
2. Would you say that you usually eat the right amount of food for you? 
No (0) Yes (1) 
2. a If no: Do you eat too much or too little? 
I= too much 2= too little 
3. How often do you eat breakfast ? 
Every day Most days Once or twice a Less than once Never 
(3-6) week a week 
(4) (3) (2) (1) (0) 
4. Apart from breakfast, how many main or cooked meals (i. e. a mcal that has a main 
course with one or more vegetables) do you usually have during the day? 
5. Apart from breakfast, how many lighter meals do you usually have during the 
day? 
_ 
6. How often do you have a snack or something to cat between meals or before going to 
bed? 
Every day Most days Once or twice a Less than once Never 
(3-6) week a week 
(4) (3) (2) (1) (0) 
6. a If everv dav: How often ? 
I= once or twice 2=3 or4 3 =4+ 
7. Do you eat regularly; Le. have the same number of meals and snacks at roughly the same time 
each day? 
No (0) Yes (1) 
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8. How often do you eat fried foods (don't count chips)? 
Every day Most days Once or twice less than once Never 
(3-6) a week a week 
(4) (3) (2) (1) (0) 
9a. How many cups of caffeinated coffee do you usually drink in a day? 
I or2 3 or 4 5or6 6+ None 
(1) (3) (5) (6) (0) 
9b. How many cups of tea do you usually drink in a day? 
I or 23 or 4 5 or 6 6+ None 
(1) (3) (5) (6) (0) 
10. There will now follow a list of foods. Please indicate, by circling the appropriate 
answer, how often you eat each of them. 
More than Once a Most Once or Less than Never 
once a day day days twice a once a 
A Fresh fruit 
B Salads or raw veg. 
C Tinned fruit 
D Chips 
E Potatoes (NOT 
CHIPS) 
F Root vegetables like 
carrots, turnips and 
parsnips 
G Peas and beans (all 
kinds) 
H Green vegetables 
I Other cooked 
vegetables, inc. 
mushrooms and onions 
j Nuts 
(3-6) week week 
6 5 4 3 2 
6 5 4 3 2 
6 5 4 3 2 
6 5 4 3 2 
6 5 4 3 2 
6 5 4 3 2 
6 5 4 3 
6 5 4 3 
6 5 4 3 
5 
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K Potato crisps/similar 65 
snacks 
More than Once a 
once a day day 
432 
Most Once or Less 
days twice a than 




L Sweets, chocolates 6 5 4 3 2 
M Pasta and rice 6 5 4 3 2 
* Breakfast cereal 6 5 4 3 
2 
* Biscuits 6 5 4 3 2 
P Cakes of all kinds 6 5 4 3 2 
Q Sweets or puddings, 6 5 4 3 2 
fruit pies, and flans and 
tarts 
R Ice cream, mousse, 6 5 4 3 2 
yoghurt, milk puddings 
S Soft drinks; e. g. colas 6 5 4 3 2 
T Pure fruit juice 6 5 4 3 2 
U Jam/Marmalade/Honey 6 5 4 3 2 
V Cheese 6 5 4 3 2 
W Eggs 6 5 4 3 2 
X Cream 6 5 4 3 2 
Y Fish 6 5 4 3 2 
Z Poultry 6 5 4 3 2 
Sausages/Tinned meat/ 6 5 4 3 2 
PAt6, meat pies/pasties, 
etc. 
Beef/lamb/pork/ham/ 6 5 4 3 2 
bacon 
Can you think of any other sorts of food which you eat regularly? (Specify) 
a. 6 5 4 3 2 
b. 6543 21 
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C. 6 5 4 3 
d. 6 5 4 3 
The following questions are about your drinking habit. -;. 
11. Would you say that you are: 0=a non drinker 
I=a very occasional drinker 
2= an occasional drinker 




12. Would you say that you are: 0=a light drinker 
I=a moderate drinker 
2=a heavy drinker 
13. On how many days have you had an alcoholic drink in the last week? 
01234567 
14. We would like to know what you had to drink last week: 
Please indicate: 
the number of 1/2 pints of beer in the last week ....... 
the number of spirits in the last week 
the number of glasses of wine that you had 
15. Was last week's drinking: 0= reasonably typical of your usual pattern 
I= rather less than usual 
2= rather more than usual 
The following questions are about cigarette smoking. 
16. Do you smoke at least one cigarette a day? 
No (0) Yes (1) 
If yes: 
17. On average, how many cigarettes do you smoke each day? 
(Number of cigarettes; if less than I put 1) 
The following questions concern activities and exercise. 
18. How often do you take walks, runs or jogs In good weather? 
0= never or very infrequently 
I= sometimes 
2= frequently 
19. How often do you swim or do aerobic exercise? 




20. How often do you do physical work around the house or flat? 
0= never or very infrequently 
I= sometimes 
2= frequently 
21. How often do you participate in sports like an active ball game (not including sports 
like golf, bowling, pool or snooker)? 
0= never or very infrequently 
I= sometimes 
2= frequently 
22. How often do you take part in sports like golf, bowling or snooker? 
0= never or very infrequently 
I= sometimes 
2= frequently 
23. How often do you watch television? 
0= once a week or less 
I= several times 
2= daily, less than two hours 
3=2 to 4 hours 
4= more than four hours per day 
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ISEL 
INSTRUCTIONS: This scale is made up of a list of statements, each of which may or 
may not be true about you. For each statement circle 'definitely true' if you are sure it is 
true about you and 'probably true' if you think it is true but are not absolutely certain. 
Similarly, you should tick 'definitely false' if you are sure the statement is false and 
'probably false' if you think it is false but are not absolutely certain. 
I. There are several people I trust to help solve my problem. 
4= definitely true 3= probably true 2= probably false I= definitely false 
2. If I need help mending something, (e. g. an appliance, car, clothes, furniture), 
there is someone who would help me. 
4= definitely true 3= probably true 2= probably false I= definitely false 
3. Most of mY friends are more interesting than I am. 
4= definitely true 3= probably true 2= probably false I= definitely false 
4. There is someone who takes pride In my accomplishments. 
4= definitely true 3= probably true 2= probably false 1= definitely false 
5. When I feel lonely, there are several people I can talk to. 
4= definitely true 3= probably true 2= probably false I= definitely false 
6. There is no one that I feel comfortable talking to about Intimate personal 
problems. 
4= definitely true 3= probably true 2= probably false I= definitcly false 
7.1 often meet or talk with family or friends. 
4= definitely true 3= probably true 2= probably false I= definitely false 
8. Most people I know think highly of me. 
4= definitely true 3= probably true 2= probably false I= definitely false 
9. If I need a lift very early in the morning (e. g. to the tube station, train station, or 
airport), I would have a hard time finding anyone to take me. 
4= definitely true 3= probably true 2= probably false I= definitcly false 
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10.1 feel like I'm not always included in my circle of friends. 
4= definitely true 3= probably true 2= probably false I =definitely false 
11. There is really no one who can give me an objective view of how I'm handling 
my problems. 
4= definitely true 3= probably true 2= probably false I= definitely false 
12. There are several different people I enjoy spending time with. 
4= definitely true 3= probably true 2= probably false I= definitely false 
131 think that my friends feel that I'm not very good at helping them solve their 
problems. 
4= definitely true 3= probably true 2= probably false I= definitely false 
14. If I were ill and needed someone (friend, family member, or acquaintance) to 
take me to the doctor, I would have trouble finding someone. 
4= definitely true 3= probably true 2= probably false I= definitcly false 
15. If I wanted to go on a trip or outing for a day (e. g. to the seaside or countryside), 
I would have a hard time finding someone to go with me. 
4= definitely true 3= probably true 2= probably false I= definitcly false 
16. If I needed a place to stay for a week because of an emergency (e. g. water or 
electricity not working in my flat or house), I could easily find someone who 
would put me up. 
4= definitely true 3= probably true 2= probably false I= definitely false 
17.1 feel there is no one I can share my most private worries and fears with. 
4= definitely true 3= probably true 2= probably false 1= definitcly false 
18. If I were ill, I could easily find someone to help me with lily daily chores. 
4= definitely true 3= probably true 2= probably false I= definitely false 
19. There is someone I can turn to for advice about handling problems with illy 
family. 
4= definitely true 3= probably true 2= probably false I= definitely false 
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20. I'm as good at doing things as most people are. 
4= definitely true 3= probably true 2= probably false I= definitely false 
21. If I decide one afternoon that I would like to go out (e. g. to the cinema) that 
evening, I could rind someone to go with me. 
4= definitely true 3= probably true 2= probably false I= definitely false 
22. When I need suggestions on how to deal with a personal problem ,I know 
someone I can turn to. 
4= definitely true 3= probably true 2= probably false I= definitely false 
23. If I needed an emergency loan of 000, there Is someone (friend, relative or 
acquaintance) I could get it from. 
4= definitely true 3= probably true 2= probably false I= definitely false 
24. In general, people do not have much confidence In me. 
4= definitely true 3= probably true 2= probably false I= definitely false 
25. Most people I know do not enjoy the same things that I do. 
4= definitely true 3= probably true 2= probably false I= definitely false 
26. There is someone I could turn to for advice about making career plaits or about 
changing my job. 
4= definitely true 3= probably true 2= probably false I= definitely false 
27.1 don't get invited to do things with others. 
4= definitely true 3= probably true 2= probably false I= definitely false 
28. Most of my friends are more successful at making changes fit their lives (hall I 
am. 
4= definitely true 3= probably true 2= probably false I= definitely false 
29. If I had to go away from home for a few weeks, there Is someone I know who 
would look after my house or flat (the plants, pets, garden, etc. ). 
4= definitely true 3= probably true 2= probably false I= definitely false 
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30- 7"here Is really no one I can trust to give me good financial advice. 
4= definitely true 3= probably true 2= probably false 1= definitely false 
3 1. If I wanted to have lunch A ith someone, I could easily rind someone to join me. 
4= definitely true 3= probably true 2= probably false I= definitely false 
32.1 am more satisfied % ith my life than most people are with theirs. 
4= derinitcly true 3= probably true 2= probably false I= def i ni tely false 
33. If I was stranded 10 miles from home, there is someone I could call who would 
come and collect me. 
4= definitely true 3= probably true 2= probably false I definitely false 
34- No one I knowA ould throw a birthday party for me. 
4= definitely true 3= probably true 2= probably false I definitely false 
35. It A ould be difficult to rind someoneoho would lend me their car for a few 
hours. (If you don't drive, assume for the purpose of this question that you have 
someone to drive you, but no car). 
4= dcrinitely true 3= probably true 2= probably false I= definitely false 
36. If a family crisis arose, It would be difficult to rind someone who could give me 
good advice about how to handle it. 
4= def initcly tzuc 3= probably true 2= probably false I definitely false 
37.1 am closer to my friends than most people are to theirs. 
4= definitely true 3= probably true 2= probably false I definitely false 
38. Ilere Is at least one person I know whose advice I really trust. 
4= definitcly true 3= probably true 2= probably false I= definitely false 
39. if I needed some help In moving to a new house or nat, I would have a hard time 
finding someone to help me. 
4= definitcly true 3= probably true 2= probably false I= definitely false 
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A 
40.1 haie a hard time keeping pace %ith my friends. 
4= dcf initcly true 3= probably true 2= probably false I= def initcly false 
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SNI 
INSTRUCTIONS: Please circle the answer appropriate response. 
1. Marital status: 
a. Have you ever been married? 
yes (1) no (0) 
b. Are you now single, married, separated, divorced, widowed? 
single married separated divorced widowed 
(1) (2) (3) (4) (5) 
2. Friends and relatives: 
a: How many close friends do you have? 
none I or2 3 to 5 6 to 9 10 or more 
(0) (1) (2) (3) (4) 
b. How many relatives do you have that you feel close to? 
none I or2 3 to 5 6 to 9 10 or more 
(0) (1) (2) (3) (4) 
C. How many of these friends do you see at least once a month? 
none I or2 3to5 6 to 9 10 or more 
(0) (1) (2) (3) (4) 
d. How many of these relatives do you see at least once a month? 
none I or2 3 to5 6 to 9 10 or more 
(0) (1) (2) (3) (4) 
3. Church and group membership: 
Do you belong to any of these types of groups? if so please tick the 
appropriate box. 
a. A social or recreational group? 
b. A labour union, commercial group, professional organisation? 
C Church group? 
d. A group concerned with children (PTA, boy scout)? 
e. A group concerned with community betterment, charity or service? 
Any other group? 
Please give details 
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UCLA 
INSTRUCTIONS: Please indicate by circling one of the numbers how often you feel 
the way described in each of the statements. 
1. How often have you felt in harmony with people around you? 
never I= almost never 2= sometimes 3= fairly often 4= very often 
2. How often do you feel as though you lack companionship? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
3. How often do you feel that there is no one you can turn to? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
4. How often do you feel alone? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
5. How often do you feel part of a group? 
never I= almost never 2= sometimes 3= fairly often 4= very often 
6. How often do you feel that you have a lot in common with the people around 
you? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
7. How often do you feel that you are no longer close to anyone? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
8. How often do you feel that your interests and ideas are not shared by those 
around you? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
9. How often do you feel that you are an outgoing person? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
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10. How often do you feel that there are people you feel close to? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
11. How often do you feel left out? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
12. How often do you feel that your social relationships are superficial? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
13. How often do you feel that nobody really knows you? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
14. How often do you feel isolated from other people? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
15. How often do you feel that you find companionship when you want it? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
16. How often do you feel that there are people who really understand you? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
17. How often do you feel unhappy because of being so withdrawn? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
18. How often do you feel that people are around you but not with you? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
19. How often do you feel that there are people you can talk to? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
20. How often do you feel that there are people you can turn to? 
0= never I= almost never 2= sometimes 3= fairly often 4= very often 
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SE 
INSTRUCTIONS: The next group of questions has to do with your reactions and 
opinions about a number of situations. We would like to know how much you agree or 
disagree with each of the statements listed below. Please mark the number which 
expresses your answer, with numbers I and 6 being the extreme answers. We have 
covered many different points of view. You may find yourself agreeing strongly with 
some, disagreeing just as strongly with others, and perhaps uncertain about others. 
We want to learn about your responses to these situations, so it is important that each 
response reflects your own feelings. 
I worry about how well I get along with people. 
I agree very much 1234561 disagree very much 
2.1 often dislike myself. 
I agree very much 1234561 disagree very much 
3.1 often feel very self-conscious. 
I agree very much 1234561 disagree very much 
4.1 often feel inferior to most of the people I know. 
I agree very much 1234561 disagree very much 
5.1 feel confident that some day the people I know will look up to me and 
respect me. 
I agree very much 1234561 disagree very much 
6.1 feel afraid or anxious when I am going into a room by myself where other 
people have already gathered and are talking. 
I agree very much 1234561 disagree very much 
7.1 often have the feeling that there is nothing I can do well. 
I agree very much 1234561 disagree very much 
8.1 worry about whether other people like to be with me. 
I agree very much 1234561 disagree very much 
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9.1 am often troubled with shyness. 
I agree very much 1234561 disagree very much 
10.1 think that I am a worthless individual. 
I agree very much 1234561 disagree very much 
11.1 am worried that some of my friends may not have a good opinion of me. 
I agree very much 1234561 disagree very much 
12.1 am confident about my abilities. 
I agree very much 1234561 disagree very much 
13.1 sometimes feel so discouraged with myself that I wonder whether anything 
is worth while. 
I agree very much 1234561 disagree very much 
14.1 feel worried or bothered about what other people think about me. 
I agree very much 1234561 disagree very much 
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SRI 
INSTRUCTIONS: The next set of questions has to do with your reactions and opinions 
about a number of situations. Please indicate by circling the appropriate answer how 
much you agree or disagree with the statements below. You may find yourself agreeing 
strongly with some, disagreeing as strongly with others, and perhaps uncertain with 
others. 
We want to learn about your responses to these situations so it is important that your 
response reflects your feelings. 
When I get what I want it's usually because I have worked hard for it. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
2. Even when I'm feeling self-confident about most things, I still seem to lack 
the ability to control social situations. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
3.1 have no trouble making and keeping friends. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
4. When I make plans I am almost certain to make them work. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
5.1 am not good at guiding the course of a conversation with several others. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
1 disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
6.1 prefer games requiring some luck over games req uiring pure skill. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
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7.1 can learn almost anything if I set my mind to it. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
1 disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
8.1 can usually establish a close personal relationship with someone I rind 
attractive. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
9. My major accomplishments are entirely due to my hard work and skill. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
1 disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
10.1 usually don't set goals because I have a hard time following them through. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 





When talking with another person, I can usually steer the person toward the 
topic I want to talk about and away from those I wish to avoid. 
I agree very much (5) 1 mainly agree (4) 
1 disagree very much (0) 1 mainly disagree (1) 
Competition discourages excellence. 
I agree very much (5) 1 mainly agree (4) 
I disagree very much (0) 1 mainly disagree (1) 
Often people get ahead just by being lucky. 
I agree very much (5) 1 mainly agree (4) 
1 disagree very much (0) 1 mainly disagree (1) 
I slightly agree (3) 
1 slightly disagree (2) 
I slightly agree (3) 
I slightly disagree (2) 
I slightly agree (3) 
I slightly disagree (2) 
If I need help in carrying off a plan of mine, it's usually difficult to get others 
to help. 
I agree very much (5) 1 mainly agree (4) 
1 disagree very much (0) 1 mainly disagree (1) 
I slightly agree (3) 
I slightly disagree (2) 
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15. If there is someone I want to meet, I can usually arrange it. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
1 disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
16.1 often rind it hard to get my point of view across to others. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
1 disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
17. On any sort of competition (for example, an exam, board game, or athletic 
contest) I like to know how well I do relative to everybody else. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
18. It is pointless to keep working on something that's too difficult for me. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
19. In attempting to smooth over a disagreement, I usually make it worse. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
20.1 rind it easy to play an important part in most group situations. 
I agree very much (5) 1 mainly agree (4) 1 slightly agree (3) 
I disagree very much (0) 1 mainly disagree (1) 1 slightly disagree (2) 
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LE 
INSTRUCTIONS: Below are questions about a number of events that commonly 
happen in people's lives. Each question is concerned with whether the event has 
happened to you in the last 12 months. Please tick YES if the event happened and NO 
if it didn't. 
If you have responded YES, please indicate whether this was a good or a bad experience by placing a 
tick in the appropriate column. 
1. Have you moved during the 
last 12 months? 
2. Have you broken off an 
engagement to be married or 
ended an intimate relationship 
during the last 12 months? 
3. Did you get married during 
the last 12 months? 
4. Did someone close to you die 
in the last 12 months? 
5. Were you separated or 
divorced during the last 12 
months? 
6. Did you break up with a close 
friend during the last 6 
months? 
7. Has an important relationship 
(e. g. with a family member or 
friend) changed during the 
last 12 months? 
8. Have you (or your spouse/ 
partner ) had or adopted a 
baby during the 
last 12 months? 
No Yes Good Bad 
(0) (1) (2) 
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No Yes Good Bad 
(0) (1) (2) 
9. Have you or a close friend or 
family member had a serious 
accident during the last 12 
months? 
10. Have you or a close friend or 
family member had a serious 
illness during the last 12 
months? 
11. Have you (or your spouse/ 
partner) been pregnant during 
the last 12 months? 
12. Have you (or your wife) had 
an abortion or miscarriage 
during the last 12 months? 
13. Have you lost or changed jobs 
during the last 12 months? 
14. Have you been involuntarily 
unemployed during the last 12 
months? 
15. Have you suffered serious 
financial hardship during the 
last 12 months? 
16. Have you had any serious 
problems or disappointment 
in work or an educational 
course during the last 12 
months? 
17. Have you had a significant 
success in work or an 
educational course during the 
last 12 months? 
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18. Has your house been broken 
into or burgled during the last 
12 months? 
No Yes Good Bad 
(0) (1) (2) 
19. Have you, your wife or other 
member of your family been 
assaulted or mugged during 
the last 12 months? 
20. Has the behaviour of any 
member of your family or 
close friends been a 
significant problem for you 
during the last 12 months? 
21. Have you appeared in court 
during the last 12 months? 
22. Have you had a pet die or 
disappear during the last 12 
months? 
23 Have you (or your spouse/ 
partner) suffered a significant 
business or investment loss or 
had a business you own fail? 
24. If there have been other 
events that you consider to be 
important during the last 12 
months please list the three 
most significant below and 
note whether they were good 






The questions in this scale ask you about your feelings and thoughts during tile last 
month. In each case, please indicate by circlino a nuinher how ofien you I'Ch or thoujit 
a certain way. 
In the last month, ho", often have you been upset because ol'soniething that 
happened unexpectedly? 
flever I= almost never 2= sometimes 3= fairly often 4= very often 
In the last month, how often have you felt that you were nuable to confrof Ihe 
important things in your lire? 
never I= almost never 2= sometimes 3= fairly often 4= very often 
In the last nionth, how often have you felt nervous and 'stressed'? 
never I= ý111110. st never 2= sometimes 3= flurly often 4= very oflen 
4. In the last month, how often have you dealt successfully with day to day 
problems and annoyances? 
0= never I= almost never 2= sornetinies 3= fairly often 4= very ofien 
5. In the last month, how often have you 1'elt that you were elTectively coping 
with important changes that were occurring in your lil'e? 
0= never I= alnio,, t never 2 =. soinethnes 3= f1tirly of(en 4= Very ofIL-11 
6. In the last month, how often have you I*elt confident about your abilify to 
handle your personal problems? 
0= never I= alinost ncýer 2) = Sonletinle's .1=1,1111-1y Offen 4= vcrý OfICH 
7. In the last month, how often have you Nit that things Ivere going your way? 
* 
never I= almost never 2= sometimes 3= 1', tirly often 4= verv oflen 
8. In the last month, how often have you felt that you could not cope 'will) . 111 the 
things that you had to do? 
never I= almost never 2= soinctinics 3= fairly oftcn 4= vcry ofien 
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9. In the last month, how often have you been able to control irritations in yotir 
life? 
0 never I= almost never 2= sometimes 3= 111irly ol'ten 4= verv ot'len 
I In the last month, how often have you felt that you were on top ol'things! 
0 never I= almost never 2= sometimes 3= I'airly ohen 4= very ohen 
1111. In the last month, how often have you been angered because of* things that 
were outside your control? 
0= never I= almost never 2= sometimes 3= l'airly olIen -4 - \cry ohen 
12. In the last month, how often have you f'ound yoursell'thinking about filings 
that you have to accomplish? 
0= never I= almost never 2= sometimes 3= l'airly ofien 4ý vcry ohen 
13. In the last month, how often have you been able to control the way you spend 
your time? 
0= never I= almost never 2= sometimes 3= fairly ol'ten 4 -- very ol'ten 
14. In the last nionth, how often have you felt difTiculties were piling up so high 
that you could not overcorne thein? 
0= never I= almost never 2= sometimes 3= I'airly ol'ten 4= Very ohen 
*= reverse scoring (4-score) 
PSS = 'SuIll of all. 
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HPS 
INSTRUCTIONS: The items below assess your health-related behaviours. Please 
answer ALL questions by circling either 'YES' or NO' to describe your behaviour. 
Your answer will be kept confidential. 
(1) (0) 
1. Have you had your blood pressure read at least once in the past YES NO 
6 months? (do NOT include readings taken in this unit) 
2. Have you visited the dentist for treatment or check-up at least YES NO 
once in the past 6 months? 
I Do you try a lot to avoid eating too much salt? YES NO 
4. Do you try a lot to avoid eating too much fat? YES NO 
5. Do you try to eat sufficient ribre in your diet? YES NO 
6. Do you try to avoid eating too much cholesterol? YES NO 
7. Do you try to consume enough vitamins and minerals? YES NO 
8. Do you try to avoid eating too much sugar? YES NO 
9. Do you try to consume enough calcium? YES NO 
10. Do you try to keep your weight within the prescribed range for YES NO 
your age? 
11. Do you exercise at least three times a week so that you breathe YES NO 
heavily and your pulse is accelerated for at least 20 minutes? 
12. Do you smoke? YES NO 
13. Do you take steps to reduce stress? YES NO 
14. Do you socialise at least once a week with close friends or YES NO 
relatives? 
15. Do you usually sleep from 7 to 8 hours per night? YES NO 
16. Do you wear a seat belt when in the front seat of a car? YES NO 
17. Do you have a smoke detector? YES NO 
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18. Do you smoke in bed or live with someone who smokes in bed? YES NO 
19. Do you take speciaI precautions to avoid accidents in the home? YES NO 
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HOS 
INSTRUCTIONS: The items listed below refer to people's health, both physical and 
mental. Please read each item carefully and decide to what extent it is characteristic of 
you. Give each item a rating of how it applies to you by using the following: 
1= Not at all characteristic of me 
2= Slightly characteristic of me 
3= Somewhat characteristic of me 
4= Moderately characteristic of me 
5= Very characteristic of me 
Please circle the appropriate number. 
NOTE: Remember to respond to all items, even if you are not completely sure. Your 
answers will be kept in the strictest confidence. Also, please be honest in 
responding to these statements. 
am very aware of how healthy I feel 1 2 3 4 5 
2. 1 sometimes wonder what others think of my health 1 2 3 4 5 
3. 1 feel anxious when I think about my health 1 2 3 4 5 
4. 1 feel confident about the condition of my health 1 2 3 4 5 
5. 1 do things that keep me from becoming unhealthy 1 2 3 4 5 
6. I'm very motivated to be healthy 1 2 3 4 5 
7. 1 feel like my health is something that I myself am in 
charge of 
1 2 3 4 5 
8. My health is determined mostly by chance happenings 1 2 3 4 5 
9. 1 expect that my health will be excellent in the future 1 2 3 4 5 
10. 1 am in good health 1 2 3 4 5 
11. 1 notice immediately when I feel unhealthy 1 2 3 4 5 
12. I'm very concerned with how others evaluate my health 1 2 3 4 5 
13. I'm worried about my health 1 2 3 4 5 
14. 1 rarely become discouraged about my health 1 2 3 4 5 
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15. 1 am motivated to keep myself from becoming 
unhealthy 
1 2 3 4 5 
16. I'm strongly motivated to devote time and effort to my 
health 
1 2 3 4 5 
17. My health is something I alone am responsible for 1 2 3 4 5 
18. The condition of my health is controlled by accidental 
happenings 
1 2 3 4 5 
19. 1 believe that the future of my health will be positive 1 2 3 4 5 
20. My health is good 
- 
1 2 3 4 5 
21. P-msensitive to internal cues about my health 1 2 3 4 5 
22. I'm very aware of what others think of my health 1 2 3 4 5 
23. Thinking about my health leaves me with an uneasy 
feeling 
1 2 3 4 5 
24. 1 am pleased with how well and healthy I feel 1 2 3 4 5 
25. 1 try to avoid engaging in behaviours that undermine 
my health 
1 2 3 4 5 
26. 1 have a strong desire to keep myself healthy 1 2 3 4 5 
27. My health is determined largely by what I do (and don't 
do) 
1 2 3 4 5 
28. Being in good health is just a matter of luck 1 2 3 4 5 
29. 1 do expect to suffer health problems in the future 1 2 3 4 5 
30. 1 am a well exercised person 1 2 3 4 5 
31. 1 know immediately when I'm not in great health 1 2 3 4 5 
32. I'm concerned about how my health appears to others 1 2 3 4 5 
33. 1 usually worry about whether I am in good health 1 2 3 4 5 
34. 1 have positive feelings about my health 1 2 3 4 5 
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35. 1 really want to prevent myself from being unhealthy 1 2 3 4 5 
36. It's really important to me that I keep myself in proper 
health 
1 2 3 4 5 
37. What happens to my health is my responsibility 1 2 3 
1 
4 5 
38. Being healthy has nothing to do with luck 1 2 3 4 5 
39. 1 will probably experience a number of health problems 
in the future 
1 2 3 4 5 
40. My health needs a lot of attention to be in excellent 
condition 
1 2 3 4 5 
41. 
1 






42. I'm concerned about what other people think of my 
health 
1 2 3 4 5 
43. 1 feel nervous when I think about the state of my health 1 2 3 4 5 
44. 1 feel that I have handled my health very well 1 2 3 4 5 
45. 1 am really motivated to avoid being in bad health 1 2 3 4 5 
46. 1 strive to keep myself in the most healthy condition 1 2 3 4 5 
47. Being in good health is a matter of my own ability and 
effort 
1 2 3 4 5 
48. 1 don't believe that chance or luck play a role in my 
health 
1 2 3 4 5 
49. 1 anticipate that my health will deteriorate in the future 1 2 3 4 5 
50. My health is in need of attention 1 2 3 4 5 
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CFO 
The following questions are about minor mistakes which everyone makes from time to 
time, but some of which happen more often than others. We want to know how often 











1. Do you read something and fid you 4 3 2 1 0 
haven't been thinking about it and 
must read it again? 
2. Do you forget why you went from 4 3 2 1 0 
one part of the house to the other? 
I Do you fail to notice signposts on 4 3 2 1 0 
the road? 
4. Do you find you confuse left and 4 3 2 1 0 
right when giving directions? 
5. Do you bump into people? 4 3 2 1 0 
6. Do you find that forget whether 4 3 2 1 0 
you've turned off a light or a fire or 
locked the door? 
7. Do you fail to listen to people's 4 3 2 1 0 
names when you are meeting them? 
8. Do you say something and realise 4 3 2 1 0 
afterwards that it might be taken as 
insulting? 
9. Do you fail to hear people speaking 4 3 2 1 0 
to you when you are doing 
something else? 
10. Do you lose your temper and regret 4 3 2 1 0 
it? 
11. Do you leave important letters 4 3 2 1 0 
unanswered for days? 
12. Do you find you forget which way to 4 3 2 1 0 
turn on a road you know well but 
rarely use? 
13. Do you fail to see what you want in 4 3 2 1 0 
a supermarket (although it's there)? 
14. Do you find yourself suddenly 4 3 2 1 0 
wondering whether you've used a 
word correctly? 
15. Do you have trouble making your 4 3 2 1 0 
mind up? 











17. Do you forget where you put 4 3 2 1 0 
something like a newspaper or a 
book? 
18. Do you find you accidentally throw 4 3 2 1 0 
away the thing you want and keep 
what you meant to throw away - as 
in the example of throwing away the 
matchbox and putting the used 
match in your pocket? 
19. Do you daydream when you ought to 4 3 2 1 0 
be a listening to something? 
20. Do you forget people's names? 4 3 2 1 0 
21. Do you start doing one thing at home 4 3 2 1 0 
and get distracted into doing 
something else (unintentionally)? 
22. Do you find you can't quite 4 3 2 1 0 
remember something although it's 
'on the tip of your tongue'? 
23. Do you find that you forget what you 4 3 2 1 0 
came to the shops to buy? 
24. Do you drop things? 4 3 2 1 0 
25. Do you find you can't think of 4 3 2 1 0 
anything to say? 
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The next few questions ask about the way you personally feel; lots of them may have no 
application to you at all, but we are asking all kinds of people and want the results for 
comparison. Please circle the appropriate answer. 
During the past six weeks 
(0) (1) (2) 
1. Have you felt upset for no reason? Never Sometimes Often 
2. Have you been troubled by dizziness or Never Sometimes Often 
shortness of breath? 
3. Have you been able to think as quickly as Yes Rather less Much 
you used to? quickly less 
quickly 
4. Have you felt as though you might faint? Never Sometimes Often 
5. Have you felt sick or had indigestion? Never Sometimes Often 
6. Have you felt that life is too much effort? Never Sometimes Often 
7. Have you felt uneasy and restless? Never Sometimes Often 
8. Have you found that silly or unreasonable Never Sometimes Often 
thoughts kept recurring in your mind? 
9. Have you felt tickling or prickling Never Sometimes Often 
sensations in your body, arms or legs? 
10. Have you regretted much of your past? No Moderately Very 
much 
11. Have you felt really panicky? Never Sometimes Often 
12. Has your appetite been poor? No Moderately Very 
poor poor 
13. Have you woken unusually early in the Never Sometimes Often 
mornings? 
14. Have you felt 'strung up' inside? Never Sometimes Often 
15. Have you had to check things you do to Never Sometimes Often 
an unnecessary extent? 
16. Have you been able to get off to sleep Never Sometimes Often 
alright? not not not 
17. Have you had to make a special effort to Not Moderately Very 
face up to things (i. e. everyday more so much 
problems)? than so 
anyone 
else 
18. Have you had the feeling you are 'going Never Sometimes Often 
to pieces'? 
19. Has it irritated you if your normal routine Not at A little Greatly 
was disturbed? all 
20. Have you suffered from excessive Never Sometimes Often 
sweating or fluttering of the heart? 
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21. Have you experienced periods of sadness 
(more than half a day)? 
22. Have you had dreams which upset you 
when you woke up? 
23. Have you found yourself worrying about 
things that do not really matter? 
24. Have you felt unduly tired and exhausted 
25. Have you been able to feel warmth and 
affection for other people? 
Never Sometimes Often 
Never Sometimes Often 
Never Sometimes Often 
Never Sometimes Often 
Yes Not much Very 
little 
In general. (not referring only to the last sh weeks) 
Circle the answer which seems to describe 
how you generally feel or behave. 
2 1 0 
1 Do people say you are too conscientious ? Often Sometimes Never 
2 Do you think that "cleanliness is next to godliness" ? Definitely To a degree Not at a] I 
3 Are you a perfectionist ? Very 
much so 
To a degree No 
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CHIPS 
Using this scale, we'd like to ask you about some physical symptoms that people often experience. For 
each symptom we would like you to indicate how much that problem has bothered or distressed you during 
the past month, including today. For each we'd like you to answer by circling 'not at all', 'a little bit', 
'moderately', 'quite a bit', or 'extremely'. 
In the past 24 hours how often were you bothered by: 
1. Dizziness 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
2. Faintness 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
3. Constant fatigue 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
4. Nausea and/or vomiting 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
5. Stomach pains (e. g. cramps) 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
6. Hot or cold spells 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
7. Poor appetite 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
8. Felt weak all over 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
9. Feeling low in energy 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
10. Muscle tension or soreness 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
11. Muscle cramps 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
12. Severe aches and pains 
0= not at all I=a little bit 2= moderately 3= quite a bit 4= extremely 
458 
Symptom Checklist 
Please tick the boxes that describe any symptoms you are currently 
experiencing: 
(Y if ticked, otherwise N) 
Physical weakness 0 
Excessive fatigue 0 
Legs feel heavy 0 
Muscle pain in back, arms or legs 0 
Pain in chest 0 
Painful joints 0 
Nausea 0 
Indigestion 0 
Bloated stomach 0 
Wind 0 
Sore throat 0 
Headache 0 
Earache 0 
Sore eyes 0 
Sensitive to noise 0 
Sensitive to light 0 
Feeling hot/cold 0 
Sweating 0 
Shivering 0 
Swollen glands 0 
Racing heart 0 
Insomnia 0 
Depression 0 
Anxiety/panic fMings 0 
Loss of concentration 0 
Loss of memory 0 
Allergies 0 
Other 0 




XIV. Withdrawal Symptoms Checklist (WSC) 
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NAME: SUBJECT NO. 
WITHDRAWAL SYMPTOMS CHECKLIST 
(O=notpresent, ]=; mild, 2=moderate, 3=severe) 
0123 
CRAVWG FOR TOBACCO F-1 El Fl Fý 
IRRUABILITY r-I El Fl F-1 
ANXIETY El El F-1 Fý 
DIFTICULTY CONCENTRATING El Fý F-I Fý 
USTLESSNESS El 17 Fý El 
IMADACHES El F-I F-I [71 
DROWSINESS El El Fý [71 
GASTROINTESTINAL TRACT PROBLEMS El El F-1 Fl 
IMPATMNCE El Fý F-1 F-I 
SOMATIC COMPLAWTS F-1 El F-I El 
INCREASED EATING Fý Fý F-1 Fý 
HUNGER El F-1 F-1 Fý 
UNUSUAL ALCOHOL INTAU- F-I D Fý F-1 
UNUSUAL CAFFEINE INTAKE- F-1 El F-1 F-1 
SLEEP DISTU"ANCE 
El El Fý Fý 
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XV. Questionnaire of Smoking Urges (QSU) 
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NAME: SUBJECT NO. 
QUESTIONNAIRE OF SMOKING URGES 
Strongly Strongly 
disagree Unsure agree 
I ----------- I ------------ I 
1234567 
Smoking would make me feel very good 11 1: 1 El El El D El 11r:, 11L 11VW 
I would be less irritable right now if I El 1: 1 1: 1 11 0 [3 0 could smoke 
Nothing would be better than smoking 13 El 1: 1 1: 1 El El a cigarette right now 
I am not missing smoking right now El 1: 1 13 11 E3 0 0 
I will smoke as soon as I get the chance 1-: 1 11 El 13 1: 1 El El 
I don't want to smoke right now El 1: 1 El E] 11 El Cl 
Smoking would make me less depressed 
1: 1 1: 1 11 1-3 1: 1 El 0 
Smoking would not help me calm D 1 :1 D 1: 1 13 D El downnow - 
If I were offered a cigarette, I would El 11 0 1-: 1 11 0 El smoke it immediately 
Starting now, I could go without a 0 El 13 1 :1 0 0 
cigarette for a long time - 
Smoking a cigarette would not be 13 pleasant 
If I were smoking this minute, I would El D El 13 1: 1 1: 1 feel less bored 
All I want right now is a cigarette 1: 1 13 El 11 1: 1 13 1: 1 
Smoking right now would make me ri 
feel less tired 
Smoking would make me happier now- El El D 1: 1 1: 1 1: 1 11 
Even if it were possible, I probably 13 
wouldn't smoke now 
I have no desire for a cigarette right o El [: 1 n [I now 
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Strongly Strongly 




----- -- -1 
1234567 
My desire to smoke seems 
overpowerine El El El El El El El 
Smoking now would make things 
seem just perfect 
I crave a cigarette right now 
I would not enjoy a cigarette right now- 
A cigarette would taste good right now- 
I have an urge for a cigarette 
I could control things better right 
now if I could smoke 
I am going to smoke as soon as possible 
I would not feel better physically if 
I were smoking 
A Cigarette would not be very 
satisfying right now 
If I had a lit cigarette in my hand I 
probably wouldn't smoke it 
If I were smoking now I could 
think more clearly 
I would do almost anything for 
a cigarette right now- 
I need to smoke now 
Right now, I am not making 
plans to smoke 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
464 
XVI. Pre-Test Questionnaire (PTQ) 
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NAME: SUBJECT NUMBER: 0 
PRE-TEST QUESTIONNAIRE 
(please circle where appropriate) 
Have you smoked anything in the last 24 hours? Yes / No 
If yes, was it: a) cigarettes, b) cigars, c) pipes, d) cannabis with tobacco, or 
e) cannabis without tobacco? 
How many did you smoke? 
What time did you smoke the last thing you smoked? (24-hour 
clock) 
Did you consume any alcohol last night? Yes / No 
If yes, can you please write here what it was that you drank, how much you 




Did you have breakfast this moming? 
(If applicable) 
Would you describe your breakfast as: 
Yes / No 
Light / Medium / Large 
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XVII. Other Withdrawal Symptoms Scale (OWS) 
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Name Subiect No. 
OTH ER WITHDRAWAL SYMPTOMS 
Please circle one number for each item, indicati ng whether the stated symptom is present, and if so how inten sely it is 
felt. If the stated symptom is not present, please circle "0". If the symptom is present. but only felt very mfldly. please 
circle "I". If the symptom is present and extreme, please circl e "9". Of course, feel free to circle any between these 
guides if that better describes the severity. 
Not 
present Mild Moderate Severe 
Muscle cramps 0 1 2 3 4 5 6 7 8 9 
Depressed/sad 0 1 2 3 4 5 6 7 8 9 
Painful joints 0 1 2 3 4 5 6 7 8 9 
Excessive yawning 0 1 2 3 4 5 6 7 8 9 
Hot/cold flushes 0 1 2 3 4 5 6 7 8 9 
Trouble getting to sleep 0 1 2 3 4 5 6 7 8 9 
Sick to stomach 0 1 2 3 4 5 6 7 8 9 
Irritable 0 1 2 3 4 5 6 7 8 9 
Runny nose 0 1 2 3 4 5 6 7 8 9 
Poor appetite 0 1 2 3 4 5 6 7 8 9 
Weak knees 0 1 2 3 4 5 6 7 8 9 
Excessive sweating 0 1 2 3 4 5 6 7 8 9 
Tense and jittery 0 1 2 3 4 5 6 7 8 9 
Watery eyes 0 1 2 3 4 5 6 7 8 9 
Abdominal cramps 0 1 2 3 4 5 6 7 8 9 
Fitful sleep 0 1 2 3 4 5 6 7 8 9 
Chills and goose flesh 0 1 2 3 4 5 6 7 8 9 
Backache 0 1 2 3 4 5 6 7 8 9 
Bothered by noises 0 1 2 3 4 5 6 7 8 9 
Skin clammy and damp 0 1 2 3 4 5 6 7 8 9 
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XVIII. Profile Of Mood States (POMS) 
469 
Initials Date 
Below is a list of words that describe feelings people have. Please read each one carefully. Then place 
a circle around the answer which best describes HOW YOU ARE FEELING AT THE MOMENT. 
The Numbers refer to these phrases: EXAMPLE 
Friendly 01234 
Not at all A little Moderately Quite a Extremely 
bit 
1. Friendly 0 1 2 3 4 
2. Tense 0 1 2 3 4 
3. Angry 0 1 2 3 4 
4. Worn out 0 1 2 3 4 
5. Unhappy 0 1 2 3 4 
6. Clear-headed 0 1 2 3 4 
7. Lively 0 1 2 3 4 
8. Confused 0 1 2 3 4 
9. Sorry for things done 0 1 2 3 4 
wrong 
10. Shaky 0 1 2 3 4 
11. Listless 0 1 2 3 4 
12. Peeved 0 1 2 3 4 
13. Considerate 0 1 2 3 4 
14. Sad 0 1 2 3 4 
15. Active 0 1 2 3 4 
16. On edge 0 1 2 3 4 
17. Grouchy 0 1 2 3 4 
18. Blue 0 1 2 3 4 
19. Energetic 0 1 2 3 4 
20. Panicky 0 1 2 3 4 
21. Hopeless 0 1 2 3 4 
22. Relaxed 0 1 2 3 4 
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23. Unworthy 0 1 2 3 4 
24. Spiteful 0 1 2 3 4 
25. Sympathetic 0 1 2 3 4 
26. Uneasy 0 1 2 3 4 
27. Restless 0 1 2 3 4 
28. Unable to 0 1 2 3 4 
concentrate 
29. Fatigued 0 1 2 3 4 
30. Helpful 0 1 2 3 4 
31. Annoyed 0 1 2 3 4 
32. Discouraged 0 1 2 3 4 
33. Resentful 0 1 2 3 4 
34. Nervous 0 1 2 3 4 
35. Lonely 0 1 2 3 4 
36. Miserable 0 1 2 3 4 
37. Muddled 0 1 2 3 4 
38. Cheerful 0 1 2 3 4 
39. Bitter 0 1 2 3 4 
40. Exhausted 0 1 2 3 4 
41. Anxious 0 1 2 3 4 
42. Ready to right 0 1 2 3 4 
43. Good natured 0 1 2 3 4 
44. Gloomy 0 1 2 3 4 
45. Desperate 0 1 2 3 4 
46. Sluggish 0 1 2 3 4 
47. Rebellious 0 1 2 3 4 
48. Helpless 0 1 2 3 4 
49. Weary 0 1 2 3 4 
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50. Bewildered 0 1 2 3 4 
51. Alert 0 1 2 3 4 
52. Deceived 0 1 2 3 4 
53. Furious 0 1 2 3 4 
54. Efficient 0 1 2 3 4 
55. Trusting 0 1 2 3 4 
56. Full of pep 0 1 2 3 4 
57. Bad-tempered 0 1 2 3 4 
58. Worthless 0 1 2 3 4 
59. Forgetful 0 1 2 3 4 
60. Carefree 0 1 2 3 4 
61. Terrified 0 1 2 3 4 
62. Guilty 0 1 2 3 4 
63. Vigorous 0 1 2 3 4 
64. Uncertain about 0 1 2 3 4 
things 
65. Bushed 0 1 2 3 4 
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XIX. Infonnation Sheet for Lofexidine Study 
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(University of Bristol headed paper) 
Patient Information Sheet - version 1.3 (10/05/01) 
TAKING PART IN RESEARCH 
Study No: E4912 
Study title: A study of the effects of lofexidine on tobacco withdrawal syndrome. 
Researcher: Mr. Robert Hayward, University of Bristol; Telephone (0117) 928 8607 
You are being invited to take part in a research project. Here is some information 
to help you decide whether or not to take part. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything you do not understand or if you would like 
more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
1. You may or may not receive any direct benefit from taking part in this study. However, information obtained during the course of this study may help us to understand better your condition or illness. It may also help us in selecting treatment for future patients. 
2. It is up to you to decide whether to take part or not. If you decide to take part 
you will be given an information sheet and consent form. Even if you do 
decide to take part, you are free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you will receive. Your doctor 
will not be upset if you decide not to take part. 
3. You may be paid travelling expenses for taking part in this study. The study 
may require you to attend more frequently. You should ask the study doctor 
or nurse about this. 
4. All the information collected about you during the course of the study will be 
kept strictly confidential. If the study is of a new drug or we need your 
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permission to allow representatives of the drug companies or perhaps officials 
from Government or Health Boards/Health Authorities to look at your health 
records. This is to check the study is being carried out correctly. Any 
information taken away by these officials will not have your name on it. Any 
published report of the research will not identify you. 
5. Depending on the type of study, your GP will normally be informed that you 
are taking part. If this is a problem for you, you should discuss it with your 
study researcher. 
6. Sometimes during the course of the study new information becomes 
available. Your study doctor will talk to you about this and discuss with you 
whether you want to continue with the study. If you decide to withdraw, the 
study doctor will make arrangements for your care to continue. If you decide 
to continue in the study you may be asked to sign an updated consent form. 
7. If the study is about medical treatment, the study doctor will tell you about the 
known side effects which are listed on the attached sheet. if you suffer from 
any of these or any other symptoms you should tell the study doctor next time 
you meet. If you are at all worried you should contact the study doctor 
immediately. 
8. Some tests could affect your ability to obtain insurance. You should be sure to 
ask your study doctor about this. 
9. If you have private medical insurance you should let the insurers know that 
you intend to take part in a research project. They will be able to tell you if this 
will affect your medical insurance. 
IO. Consumers for ethics in research (CERES) publish a leaflet entitled 'Medical Research and You'. This leaflet gives more information about medical research and looks at some questions you may want to ask. A copy may be obtained from CERES, PO Box 1365, London N16 OBW. 
1. Study title 
A repeated measures placebo-controlled study of the effect of lofexidine on the tobacco 
withdrawal syndrome compared with nicotine replacement. 
Repeated measures means that there are no distinct groups in the study - each participant will 
perform all parts of the study. Placebo means a dummy medication such as a pill which looks like 
the real thing but contains no active ingredient. 
2. What Is the purpose of the study? 
This study will attempt to examine whether a drug - lofexidine - can help ease withdrawal 
symptoms associated with stopping smoking and perhaps therefore make cigarette smoking 
easier to give up. Smoking 'is difficult to give up because people can become addicted to the 
nicotine delivered in cigarettes. When your body and brain becomes accustomed to a particular 
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level of nicotine, it can often give you signals (e. g. craving) when your blood nicotine levels fall 
t)4310w that to which it has become accustomed. TNs is known as withdrawal 
These Symptoms can be unpleasant. and tend to drive people to seek nicotine: i. e. smoke. This is 
referred to as tVcotine dependence. The most common withdrawal symptoms associated with 
sn'Oking cessation are: craving for tobacco, irritability, arodety, . difficulty , concentrating, restessness, headaches, drowsiness, gastrointestinal tract [digestive] problems, impatience, 
somatic [bodily) complaints, increased eating, hunger, unusual alcohol intake, unusual caffeine, irdake and sleep disturbance. 
The most effective way of treating these effects is with nicotine - but this maintains the dependence. thereby proving problernafic when attempting to quit smoking. Alternative ways of 
assisting People trying to give up smoking are therefore important, and several substances have- 
been looked at in this capacity. Clonidne. a drug that works in a similar way to lofexidine, has 
been Shown by some studies to help relieve the withdrawal symptoms of smoking cessation. Lofe)ddine itself has been successfully used to treat the withdrawal symptoms of other addictive 
drugs. 
We wish to investigate whether the effects of lofeyjcfine can relieve nicotine withdrawal symptoms 
like those mentioned. We hope that. should our findings be positive, lofexidine could then be 
developed as a useful tool allowing people a more effective passage to stopping smoking, and 
thereby reduce people's likelihood of contracting lung cancer, heart disease, and other smoking- 
related illnesses. We will achieve this by comparing how abstinent - smokers administered 
lofexidine differ from abstinent smokers treated with placebo, and whether these effect s can 
compare favOurably with nicotine replacement. 
3. Why have I been chosen? You have been invited to participate because you are a smoker that has either: a) expressed an interest in doing research of tNs kind in the past or b) because you have responded to an 
advertisement asking for volunteers for tNs study. You should not take part in this study if you have a history of serious medical or psycNatric illness, or if you are a non-smoker or "part-time" 
-. rnoker. 
4. Who Is organising the study The study is being orgar9sed by the Psychopharmacology Unit at the University of Bristol, School'-,, 
of 
- 
Medical Sciences. It is expected to run for a total of approximately 4 months, during which time' 
we Would like you to attend during two experimental weeks. ' During these weeks you will be 
asked to attend on a Monday (9.00am-9.30am), Tuesday (9: 00am-1 1: 00am) and Friday, (9: 00am- 
I 1: 00am) 
5. What Will happen to me If I take part? 
. 
11nitially we will ask you to complete a questionnaire asking you about yourself, your health and 
Your smoking behaviours - you may complete this is your own time. - Providing you fulfil, the criteria for taking part in this studyý you will then be asked to attend the Clinic six times during 2 (not necessarily consecutive) experimental weeks, for a period of either 30 minutes or 2 hours. If 
you are able and willing to commit these times. you will be invited to attend the Clinic at 9.00am 
on a Monday (Week 1) for your first experimental session. 
You will be asked to srnoke as you would normally right up to the time you arrive at the Clinic. Upon arrival you will be asked to complete questionnaires regarding your mood, smoking urges, 
various Psychological and physical items relating to tobacco withdrawal. Once these are 
completed, You will be asked to complete a battery of mental performance tests (measuring 
attention, reaction times and visual vigilance) which will be presented on a computer screen. You 
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will then be free to leave the Clinic at approximately 9.30am, but directed to NOT SMOKE for the 
following 24 hours. 
You will be asked to return the Clinic the following day (Tuesday, Week 1) where you will 
complete the same questionnaires and computer tasks again. Following these, you have an hour 
break in which to read, etc. during which time you will be given your medication. In the first week 
you will receive either lofexidine (or a placebo) in tablet form or nicotine (or a placebo) in an 
inhalator. If you receive a tablet, you will be receiving pill containing 0.2mg lofexidine or a lactose 
placebo at approximately 9.30am. If you receive the inhalator you will be infusing approximately 
10mg nicotine or a menthol placebo at approximately 10.00am. At 10.30am, you will again be 
asked to complete the same questionnaires and perform the computer tasks again. 
You will then be free to leave the Clinic at approximately 1 1.00am. You may then smoke normally 
until 9.00am on Thursday morning after which time you must again NOT SMOKE for 24 hours. 
You will then be asked to return to the Clinic on Friday at 9.00arn where you will perform the 
same procedure as the Tuesday, with the exception of receiving the placebo/drug reverse of that 
administered earlier in the week. 
Week 2 will be the same procedure as Week 1 except that if you received lofexidine in Week 1 
you will receive nicotine in Week 2 and vice versa. 
6. What Is the drug? 
Lofexidine is a drug that acts in the brain, reducing the amount released of a particular chemical messenger [noradrenaline]. Currently its only clinical use is for the alleviation of symptoms in patients undergoing a detoxification from opiate drugs. It is unlikely that you would suffer any side effects from the single tablet containing a low dose we are using. 
Possible side effects are drowsiness, dry mucous membranes [particularly mouth, nose and throat], lowered blood pressure, slowed heart rate, and slight possibility of rebound hypertension on withdrawal. We would also advise you NOT TO DRIVE while taking this medication. 
7. Are there other ways of treating my condition? 
A number of medications are currently utilised in the treatment of tobacco withdrawal. Nicotine 
replacement therapy (NRT) such as patches, gum and inhalators/nasal sprays are readily 
available, and a new drug - Zyban (bupropion) - are established tools used for alleviating 
withdrawal symptoms associated with stopping smoking. 
8. Are there any disadvantages In taking part In this study? 
Possible side effects of lofexidine are drowsiness, dry mucous membranes (particularly mouth, 
nose and throat], lowered blood pressure, slowed heart rate, and slight possibility of rebound 
hypertension on withdrawal. Subjects are advised not drive following administration of lofexidine. 
A doctor will be readily accessible in case of any adverse event. The most common withdrawal 
symptoms associated with smoking cessation are: craving for tobacco, irritability, anxiety, 
difficulty concentrating, restlessness, headaches, drowsiness, gastrointestinal tract [digestive] 
problems, impatience, somatic [bodily] complaints, increased eating, hunger, unusual alcohol 
intake, unusual caffeine intake and sleep disturbance. 
9. What are the possible risks of taking part? 
It is possible that lofexidine-induced lowered blood pressure may result in slight dizziness or 
feeling faint. 
10. What are the possible benefits of taking part? 
You will receive C75 upon satisfactory completion. If you partially complete the study to some 
useful degree (e. g. only complete 1 experimental week) you will receive C30. Aside from the 
financial reward for taking part, we hope that both nicotine and lofexidine can be shown to 
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alleviate tobacco withdrawal symptoms. However, this cannot be guaranteed. The information we 
get from this study may help understand nicotine withdrawal better, and may suggest a possible 
for use for lofexidine as a too[ for helping people trying to quit smoking. 
11. Is my doctor being paid for including me in the study? 
No. 
12. What happens when the trial stops? 
Lofexidine will not be available, however NRT is available over-the-counter from pharmacies. 
13. Are there any restrictions on what I might eat or do? 
Avoid alcohol in the 24 hours prior to attending the Clinic on each day. 
14. What if something goes wrong? 
Compensation for any injury caused by taking part in this study will be in accordance with the 
guidelines of the University of Bristol "No Fault" Compensation scheme. Copies of these 
guidelines are available on request. 
15. Confidentiality - who will know I am taking part In the study? 
Any confidential or personal information will only be made available to researchers who are 
involved in this study. 
16. GP Notification 
As you are a healthy volunteer, there is no reason why your GP should be notified of your 
involvement in this project, although you may wish to inform him or her yourself. 
17. LREC Approval 
The United Bristol Healthcare Trust Ethics Committee has approved this study. 
18. What will happen to the results of the study? 
Subjects will be fully debriefed on completion of the study, and results will be made available as 
and when requested for individual subjects, or later in the year (August/September) for results of the study in general. 
19. Contact for further information 
If you, your friends or relatives have any questions about this project, please contact Mr Robert Hayward on (0117) 925 3066. 
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XX. Consent Form for Lofexidine study 
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(University of Bristol headed paper) 
Centre number 
Study number E4912 
Patient information number for this trial: 
CONSENTFORM 
Title of Project: A repeated measures placebo-controlled study of the effect of lofexidine on the tobacco 
withdrawal syndrome compared with nicotine replacement. 
Name of Researcher Mr Robert Hayward 
Please initial box 
I. I confirm I have read and understand the information sheet dated 10/05/01 
(versionl. 3) for the above study 
2.1 understand that my participation is voluntary and that I am free to withdraw 
at any time without my medical care or legal rights being affected 
3.1 am willing to allow access to my medical records but understand that strict 
confidentiality will be maintained. The purpose of this is to check that the study 
is being carried out correctly. 
4.1 agree to take part in the above study. 
Name of patient Date Signature 
Name of person taking consent Date 
(if different to researcher) 
Researcher Date 
I for patient, 1 for researcher, 1 to be kept with hospital notes. 
Signature 
Signature 
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